PMID- 25842774 OWN - NLM STAT- MEDLINE DA - 20150406 DCOM- 20150417 IS - 0350-6134 (Print) IS - 0350-6134 (Linking) VI - 38 IP - 4 DP - 2014 Dec TI - Nutrition in cancer patients. PG - 1271-5 AB - Cachexia is defined as an unintended loss of stable weight exceeding 10%. Patients with advanced cachexia express anorexia, early satiety, severe weight loss, weakness, anemia, and edema. Anorexia represents the result of a failure of the usual appetite signals whereas cachexia is the debilitating state of involuntary weight loss. This syndrome, referred to as the cancer anorexia-cachexia syndrome, (CACS) and usually consists of a combination of anorexia, tissue wasting, malnutrition, weight loss and loss of compensatory increase in feeding. CACS represents the result of a complex interaction between cancer growth and host response and is associated with a poor response to chemotherapy and with an increase in drug-related toxicity. In advanced cachexia (mostly in metastatic cancer and terminally disease) any interventions with nutritional suplements are ineffective. Therefore, nutritional support in the reversion of tumor cachexia and in the importance of maintaining patient weight, muscle mass, quality of life, has the exceptional importance, becouse good nutritional status of patients leads to the possibility of more aggressive and longer treatment and thus to longer survival. FAU - Dintinjana, Renata Dobrila AU - Dintinjana RD FAU - Redzovic, Arnela AU - Redzovic A FAU - Cubranic, Aleksandar AU - Cubranic A FAU - Dintinjana, Marijan AU - Dintinjana M FAU - Vanis, Nenad AU - Vanis N LA - eng PT - Journal Article PL - Croatia TA - Coll Antropol JT - Collegium antropologicum JID - 8003354 SB - IM MH - Cachexia/complications/*physiopathology/therapy MH - Humans MH - Neoplasms/complications/*physiopathology MH - *Nutritional Status EDAT- 2015/04/07 06:00 MHDA- 2015/04/18 06:00 CRDT- 2015/04/07 06:00 PST - ppublish SO - Coll Antropol. 2014 Dec;38(4):1271-5. PMID- 25740757 OWN - NLM STAT- MEDLINE DA - 20150305 DCOM- 20150424 IS - 0964-7058 (Print) IS - 0964-7058 (Linking) VI - 24 IP - 1 DP - 2015 TI - Effects of different parenteral nutrition infusions in a patient with short bowel syndrome. PG - 184-7 LID - 10.6133/apjcn.2015.24.1.06 [doi] AB - In this case study, we demonstrate the effects of different lipid emulsions on liver function in a 52-year-old woman with short bowel syndrome who was totally dependent on parenteral nutrition. Over a 13-month period after small bowel resection and jejunostomy, we followed the patient's plasma triglycerides and liver enzyme levels as well as body weight and discomfort levels. During the first 3 months when parenteral nutrition including a lipid emulsion containing 50% soybean oil/50% medium-chain triglyerides was administered daily, the patient reported feeling unwell (experiencing dizziness and palpitations) and her triglycerides and liver enzyme levels rose to 366 mg/dL and 145 U/L (alanine aminotransferase [ALT]), respectively; these levels recovered when this emulsion was discontinued. For the following 9 months, an emulsion containing 80% olive oil and 20% soybean oil was administered, and the patient's triglycerides (182 mg/dL) did not increase to abnormal levels and liver enzyme levels were only mildly elevated (109 U/L). The patient felt well and her body weight increased from 51 kg to 55 kg during this period. These results suggest that parenteral nutrition with a reduced soybean oil content may better preserve liver function in patients with short bowel syndrome. FAU - Weng, Chia-Chee AU - Weng CC AD - Department of Surgery, Far Eastern Memorial Hospital, Taipei, Taiwan. FAU - Chen, Yun AU - Chen Y AD - Department of Surgery, Far Eastern Memorial Hospital, Taipei, Taiwan. Email: ychen@mail.femh.org.tw. AD - Department of Chemical Engineering and Materials Science, Yuan Ze University, Taoyuan, Taiwan. LA - eng PT - Case Reports PT - Comparative Study PT - Journal Article PL - Australia TA - Asia Pac J Clin Nutr JT - Asia Pacific journal of clinical nutrition JID - 9440304 RN - 0 (Fat Emulsions, Intravenous) RN - 0 (Parenteral Nutrition Solutions) RN - 0 (Plant Oils) RN - 0 (Triglycerides) RN - 8001-22-7 (Soybean Oil) RN - 8001-25-0 (olive oil) RN - EC 2.6.1.2 (Alanine Transaminase) SB - IM MH - Alanine Transaminase/blood MH - Colonic Neoplasms/surgery MH - Fat Emulsions, Intravenous MH - Female MH - Humans MH - Ileum/surgery MH - Jejunostomy MH - Jejunum/surgery MH - Liver/enzymology/physiopathology MH - Middle Aged MH - Parenteral Nutrition/methods MH - Parenteral Nutrition Solutions/*administration & dosage/adverse effects MH - Plant Oils/administration & dosage MH - Short Bowel Syndrome/physiopathology/*therapy MH - Soybean Oil/administration & dosage MH - Triglycerides/administration & dosage/blood OAB - Publisher: Abstract available from the publisher. OABL- chi EDAT- 2015/03/06 06:00 MHDA- 2015/04/25 06:00 CRDT- 2015/03/06 06:00 PST - ppublish SO - Asia Pac J Clin Nutr. 2015;24(1):184-7. doi: 10.6133/apjcn.2015.24.1.06. PMID- 25740737 OWN - NLM STAT- MEDLINE DA - 20150305 DCOM- 20150424 IS - 0964-7058 (Print) IS - 0964-7058 (Linking) VI - 24 IP - 1 DP - 2015 TI - Omega-3 polyunsaturated fatty acids and non-communicable diseases: meta-analysis based systematic review. PG - 10-5 LID - 10.6133/apjcn.2015.24.1.21 [doi] AB - The aim of this updated systematic review is to summarize the evidence of the effect of omega-3 polyunsaturated fatty acids (n-3 PUFA) on non-communicable diseases (NCDs). Publications of meta-analysis up to August 2014 were systematically searched from PubMed, the Cochrane and EMBASE databases. N-3 PUFAs have the following beneficial effects; cardio-protective effects, reduce ischemic stroke risk in both men and women and total stroke risk in women, increase insulin sensitivity in Asians, decrease risk of breast cancer and colorectal cancer in men. However, n-3 PUFAs may have unfavourable effects on type 2 diabetes in Caucasians. In conclusion, n-3 PUFA plays a crucial role in the prevention of NCDs, however, unfavourable effects should be considered in subjects with certain clinical conditions. Cross-cultural studies on the effect of n-3 PUFA on type 2 diabetes are needed to verify why diabetic patients with different ancestries have a different response to n-3 PUFA. FAU - Li, Duo AU - Li D AD - Department of Food Science and Nutrition, Zhejiang University, 866 Yu-hang-tang Road, Hangzhou, 310058, China, . Email: duoli@zju.edu.cn. AD - Department of Nutrition and Dietetics, Monash University, Melbourne, Australia. AD - School of Public Health, Ningxia University, Ningxia, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PL - Australia TA - Asia Pac J Clin Nutr JT - Asia Pacific journal of clinical nutrition JID - 9440304 RN - 0 (Fatty Acids, Omega-3) SB - IM MH - Breast Neoplasms/prevention & control MH - Colorectal Neoplasms/prevention & control MH - Diabetes Mellitus, Type 2 MH - Fatty Acids, Omega-3/adverse effects/*therapeutic use MH - Female MH - *Health Promotion MH - Heart Diseases/prevention & control MH - Humans MH - Insulin Resistance MH - Male MH - Risk Factors MH - Stroke/prevention & control OAB - Publisher: Abstract available from the publisher. OABL- chi EDAT- 2015/03/06 06:00 MHDA- 2015/04/25 06:00 CRDT- 2015/03/06 06:00 PST - ppublish SO - Asia Pac J Clin Nutr. 2015;24(1):10-5. doi: 10.6133/apjcn.2015.24.1.21. PMID- 25723692 OWN - NLM STAT- MEDLINE DA - 20150228 DCOM- 20150422 IS - 1478-7083 (Electronic) IS - 0035-8843 (Linking) VI - 97 IP - 2 DP - 2015 Mar TI - Emergency oesophagectomy for oesophageal perforation after chemoradiotherapy for oesophageal cancer. PG - 140-5 LID - 10.1308/003588414X14055925060631 [doi] AB - INTRODUCTION: Oesophageal perforation following chemoradiotherapy for oesophageal cancer is a devastating condition but there have been no studies investigating the role of emergency oesophagectomy for this life threatening situation. METHODS: This retrospective study comprised all cases of emergency oesophagectomy for oesophageal perforation after chemoradiotherapy for oesophageal carcinoma at a major centre for oesophageal surgery in Germany between 2004 and 2013. RESULTS: A total of 13 patients (mean age: 58.9 years) were identified. During the same time period, 356 elective oesophagectomies were performed. Tumour entities were squamous cell carcinoma (n=12) and adenocarcinoma of the oesophagus (n=1). Alcoholism (odds ratio [OR]: 25.79, 95% confidence interval [CI]: 6.70-121.70, p<0.0001) and chronic pulmonary disease (OR: 3.76, 95% CI: 1.06-14.96, p=0.027) were more common among the emergency cases. Oesophageal rupture was caused by perforation of an oesophageal stent (10 cases) or perforation during implantation of a percutaneous endoscopic gastrostomy tube (3 cases). Emergency oesophagectomy was carried out either as discontinuity resection (10/13) or oesophagectomy with immediate reconstruction (3/13). Compared with the elective cases, patients undergoing emergency oesophagectomy had significantly higher odds for sustaining perioperative sepsis (OR: 4.42, 95% CI: 1.23-16.45, p=0.01), acute renal failure (OR: 6.49, 95% CI: 1.57-24.15, p=0.005) and pneumonia (OR: 24.33, 95% CI: 3.52-1,046.65, p<0.0001). Furthermore, slow respiratory weaning was more common and there was a significantly higher tracheostomy rate (OR: 4.64, 95% CI: 1.14-16.98, p=0.02). Oesophageal discontinuity was eventually reversed in eight patients. Emergency oesophagectomy patients had odds that were three times higher for fatal outcome (OR: 3.59, 95% CI: 0.77-13.64, p=0.05). The overall mortality was 4/13. The remaining nine patients had a mean survival of 25.1 months (range: 5-46 months). The two-year-survival-rate was 38.5% (5/13). CONCLUSIONS: Despite the most unfavourable preconditions, the results of emergency oesophagectomy for oesophageal perforation after chemoradiotherapy are not desperate. The procedure is not only justified but life saving. FAU - Schweigert, M AU - Schweigert M AD - Klinikum Nurnberg, Germany. FAU - Solymosi, N AU - Solymosi N FAU - Dubecz, A AU - Dubecz A FAU - Posada Gonzalez, M AU - Posada Gonzalez M FAU - Stadlhuber, R J AU - Stadlhuber RJ FAU - Ofner, D AU - Ofner D FAU - Stein, H J AU - Stein HJ LA - eng PT - Comparative Study PT - Journal Article PL - England TA - Ann R Coll Surg Engl JT - Annals of the Royal College of Surgeons of England JID - 7506860 SB - IM MH - Acute Kidney Injury/epidemiology MH - Adenocarcinoma/therapy MH - Aged MH - Alcoholism/epidemiology MH - Carcinoma, Squamous Cell/therapy MH - Chemoradiotherapy/*adverse effects MH - Chronic Disease MH - *Emergencies MH - Empyema, Pleural/epidemiology MH - Esophageal Neoplasms/*therapy MH - Esophageal Perforation/etiology/*surgery MH - *Esophagectomy/mortality/statistics & numerical data MH - Female MH - Gastrostomy/adverse effects/instrumentation MH - Germany/epidemiology MH - Humans MH - Lung Diseases/epidemiology MH - Male MH - Middle Aged MH - Pneumonia/epidemiology MH - Reoperation/statistics & numerical data MH - Retrospective Studies MH - Salvage Therapy/statistics & numerical data MH - Sepsis/epidemiology MH - Stents/adverse effects MH - Tracheostomy/statistics & numerical data MH - Ventilator Weaning EDAT- 2015/02/28 06:00 MHDA- 2015/04/23 06:00 CRDT- 2015/02/28 06:00 AID - 10.1308/003588414X14055925060631 [doi] PST - ppublish SO - Ann R Coll Surg Engl. 2015 Mar;97(2):140-5. doi: 10.1308/003588414X14055925060631. PMID- 25699356 OWN - NLM STAT- MEDLINE DA - 20150220 DCOM- 20150409 IS - 0172-6390 (Print) IS - 0172-6390 (Linking) VI - 61 IP - 136 DP - 2014 Nov-Dec TI - Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer. PG - 2222-6 AB - BACKGROUND/AIMS: KRAS mutation is an important prognostic factor for patients with metastatic colorectal cancer receiving anti-epidermal growth factor receptor therapy. However, the influence of KRAS mutation on the response to mFOLFOX6 +/- bevacizumab remains unclear. METHODOLOGY: We retrospectively analyzed 49 patients who received modified FOLFOX6 (mFOLFOX6) +/- bevacizumab as first-line therapy. Genetic analysis showed that 30 patients had wild-type (WT) KRAS and 19 patients hadKRAS mutations (MT). These two groups were compared with regard to the response rate (RR), progression-free survival (PFS), and overall survival (OS). RESULTS: The RR was not significantly different between the WT and MT groups, but PFS and OS were significantly better in the WT group than the MT group (PFS: 11.8 months vs. 8.7 months, p<0.01; OS: 37.8 months vs. 29.3 months, p<0.0385). A similar analysis of 27 patients who were treated with mFOLFOX6 + bevacizumab showed a better prognosis for WT patients. Multivariate analysis also revealed that KRAS mutation was an independent factor with a significant relation to PFS. CONCLUSIONS: These results suggest that KRAS mutation may be a useful prognostic marker for patients with metastatic colorectal cancer receiving mFOLFOX6 +/- bevacizumab therapy, especially for patients treated with mFOLFOX6 + bevacizumab. FAU - Koike, Junichi AU - Koike J FAU - Ushigome, Mitsunori AU - Ushigome M FAU - Funahashi, Kimihiko AU - Funahashi K FAU - Shiokawa, Hiroyuki AU - Shiokawa H FAU - Kaneko, Tomoaki AU - Kaneko T FAU - Arai, Kenichiro AU - Arai K FAU - Matsuda, Satoshi AU - Matsuda S FAU - Kagami, Satoru AU - Kagami S FAU - Suzuki, Takayuki AU - Suzuki T FAU - Kurihara, Akiharu AU - Kurihara A FAU - Shimada, Hideaki AU - Shimada H FAU - Kaneko, Hironori AU - Kaneko H LA - eng PT - Journal Article PL - Greece TA - Hepatogastroenterology JT - Hepato-gastroenterology JID - 8007849 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (KRAS protein, human) RN - 0 (Organoplatinum Compounds) RN - 0 (Proto-Oncogene Proteins) RN - 2S9ZZM9Q9V (bevacizumab) RN - EC 3.6.5.2 (ras Proteins) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Folfox protocol SB - IM MH - Aged MH - Antibodies, Monoclonal, Humanized/*administration & dosage MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use MH - Colorectal Neoplasms/*drug therapy/genetics/mortality/pathology MH - Female MH - Fluorouracil/administration & dosage MH - Humans MH - Leucovorin/administration & dosage MH - Male MH - Middle Aged MH - *Mutation MH - Neoplasm Metastasis MH - Organoplatinum Compounds/administration & dosage MH - Proto-Oncogene Proteins/*genetics MH - Retrospective Studies MH - ras Proteins/*genetics EDAT- 2015/02/24 06:00 MHDA- 2015/04/10 06:00 CRDT- 2015/02/21 06:00 PST - ppublish SO - Hepatogastroenterology. 2014 Nov-Dec;61(136):2222-6. PMID- 25688115 OWN - NLM STAT- MEDLINE DA - 20150217 DCOM- 20150413 LR - 20150408 IS - 1460-2105 (Electronic) IS - 0027-8874 (Linking) VI - 107 IP - 4 DP - 2015 Apr TI - Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235. LID - 10.1093/jnci/djv004 [doi] LID - djv004 [pii] AB - BACKGROUND: ACRIN 6668/RTOG 0235 evaluated the prognostic value of positron emission tomography with (18)F-fluorodeoxyglucose (FDG-PET) uptake before and after definitive, concurrent, platinum-based chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC). In this secondary analysis, we evaluate volumetric pretreatment PET measures as predictors of clinical outcomes. METHODS: Patients with stage III NSCLC underwent FDG-PET prior to treatment. A commercially available gradient-based segmentation tool was used to contour all visible hypermetabolic lesions on each scan. For each patient, the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total glycolytic activity (TGA) for all contoured lesions were recorded. Cox proportional hazards regression models were used to evaluate clinical variables and PET metrics as predictors of overall survival (OS) and locoregional control (LRC). Time-dependent covariables were added to the models when necessary to address nonproportional hazards. All statistical tests were two-sided. RESULTS: Complete data were available for 214 patients in the OS analysis and 189 subjects in the LRC analysis. In multivariable analysis incorporating clinical and imaging data available prior to treatment, MTV was an independent predictor of OS (HR = 1.04 per 10 cm(3) increase, 95% CI = 1.03 to 1.06, P < .001). High MTV was also associated with increased risk of locoregional failure at baseline (HR = 1.16 per 10 cm(3) increase, 95% CI = 1.08 to 1.23, P < .001) and at six months (HR = 1.05 per 10 cm(3) increase, 95% CI = 1.02 to 1.07, P < .001) but not at 12 months or later time points. CONCLUSION: Pretreatment MTV is a predictor of clinical outcomes for NSCLC patients treated with chemoradiotherapy. Quantitative PET measures may serve as stratification factors in clinical trials for this patient population and may help guide novel trial designs. CI - (c) The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. FAU - Ohri, Nitin AU - Ohri N AD - Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (NO); Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (FD, JJG, BSS); Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH (MM); Department of Radiology, University of Pennsylvania, Philadelphia, PA (AA); Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (BAS); Baptist Cancer Institute, Jacksonville, FL (DWJ); Department of Radiation Oncology and the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (JDB); Lankenau Medical Center and Lankenau Institute for Medical Research, Lower Merion, PA (AD); Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (MWW). ohri.nitin@gmail.com. FAU - Duan, Fenghai AU - Duan F AD - Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (NO); Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (FD, JJG, BSS); Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH (MM); Department of Radiology, University of Pennsylvania, Philadelphia, PA (AA); Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (BAS); Baptist Cancer Institute, Jacksonville, FL (DWJ); Department of Radiation Oncology and the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (JDB); Lankenau Medical Center and Lankenau Institute for Medical Research, Lower Merion, PA (AD); Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (MWW). FAU - Machtay, Mitchell AU - Machtay M AD - Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (NO); Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (FD, JJG, BSS); Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH (MM); Department of Radiology, University of Pennsylvania, Philadelphia, PA (AA); Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (BAS); Baptist Cancer Institute, Jacksonville, FL (DWJ); Department of Radiation Oncology and the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (JDB); Lankenau Medical Center and Lankenau Institute for Medical Research, Lower Merion, PA (AD); Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (MWW). FAU - Gorelick, Jeremy J AU - Gorelick JJ AD - Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (NO); Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (FD, JJG, BSS); Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH (MM); Department of Radiology, University of Pennsylvania, Philadelphia, PA (AA); Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (BAS); Baptist Cancer Institute, Jacksonville, FL (DWJ); Department of Radiation Oncology and the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (JDB); Lankenau Medical Center and Lankenau Institute for Medical Research, Lower Merion, PA (AD); Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (MWW). FAU - Snyder, Bradley S AU - Snyder BS AD - Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (NO); Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (FD, JJG, BSS); Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH (MM); Department of Radiology, University of Pennsylvania, Philadelphia, PA (AA); Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (BAS); Baptist Cancer Institute, Jacksonville, FL (DWJ); Department of Radiation Oncology and the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (JDB); Lankenau Medical Center and Lankenau Institute for Medical Research, Lower Merion, PA (AD); Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (MWW). FAU - Alavi, Abass AU - Alavi A AD - Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (NO); Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (FD, JJG, BSS); Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH (MM); Department of Radiology, University of Pennsylvania, Philadelphia, PA (AA); Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (BAS); Baptist Cancer Institute, Jacksonville, FL (DWJ); Department of Radiation Oncology and the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (JDB); Lankenau Medical Center and Lankenau Institute for Medical Research, Lower Merion, PA (AD); Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (MWW). FAU - Siegel, Barry A AU - Siegel BA AD - Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (NO); Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (FD, JJG, BSS); Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH (MM); Department of Radiology, University of Pennsylvania, Philadelphia, PA (AA); Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (BAS); Baptist Cancer Institute, Jacksonville, FL (DWJ); Department of Radiation Oncology and the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (JDB); Lankenau Medical Center and Lankenau Institute for Medical Research, Lower Merion, PA (AD); Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (MWW). FAU - Johnson, Douglas W AU - Johnson DW AD - Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (NO); Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (FD, JJG, BSS); Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH (MM); Department of Radiology, University of Pennsylvania, Philadelphia, PA (AA); Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (BAS); Baptist Cancer Institute, Jacksonville, FL (DWJ); Department of Radiation Oncology and the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (JDB); Lankenau Medical Center and Lankenau Institute for Medical Research, Lower Merion, PA (AD); Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (MWW). FAU - Bradley, Jeffrey D AU - Bradley JD AD - Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (NO); Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (FD, JJG, BSS); Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH (MM); Department of Radiology, University of Pennsylvania, Philadelphia, PA (AA); Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (BAS); Baptist Cancer Institute, Jacksonville, FL (DWJ); Department of Radiation Oncology and the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (JDB); Lankenau Medical Center and Lankenau Institute for Medical Research, Lower Merion, PA (AD); Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (MWW). FAU - DeNittis, Albert AU - DeNittis A AD - Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (NO); Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (FD, JJG, BSS); Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH (MM); Department of Radiology, University of Pennsylvania, Philadelphia, PA (AA); Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (BAS); Baptist Cancer Institute, Jacksonville, FL (DWJ); Department of Radiation Oncology and the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (JDB); Lankenau Medical Center and Lankenau Institute for Medical Research, Lower Merion, PA (AD); Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (MWW). FAU - Werner-Wasik, Maria AU - Werner-Wasik M AD - Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (NO); Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (FD, JJG, BSS); Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH (MM); Department of Radiology, University of Pennsylvania, Philadelphia, PA (AA); Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (BAS); Baptist Cancer Institute, Jacksonville, FL (DWJ); Department of Radiation Oncology and the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO (JDB); Lankenau Medical Center and Lankenau Institute for Medical Research, Lower Merion, PA (AD); Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (MWW). LA - eng GR - U01 CA079778/CA/NCI NIH HHS/United States GR - U01 CA079778/CA/NCI NIH HHS/United States GR - U01 CA080098/CA/NCI NIH HHS/United States GR - U01 CA080098/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20150216 PL - United States TA - J Natl Cancer Inst JT - Journal of the National Cancer Institute JID - 7503089 RN - 0 (Radiopharmaceuticals) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Adult MH - Aged MH - Carcinoma, Non-Small-Cell Lung/*metabolism/pathology/radionuclide imaging/therapy MH - *Chemoradiotherapy MH - Female MH - Fluorodeoxyglucose F18/*diagnostic use MH - Glucose/*metabolism MH - Glycolysis MH - Humans MH - Lung Neoplasms/*metabolism/pathology/radionuclide imaging/therapy MH - Male MH - Middle Aged MH - Neoplasm Staging MH - *Positron-Emission Tomography/methods MH - Proportional Hazards Models MH - Radiopharmaceuticals/diagnostic use MH - Time Factors EDAT- 2015/02/18 06:00 MHDA- 2015/04/14 06:00 CRDT- 2015/02/18 06:00 PHST- 2015/04 [ppublish] AID - djv004 [pii] AID - 10.1093/jnci/djv004 [doi] PST - epublish SO - J Natl Cancer Inst. 2015 Feb 16;107(4). pii: djv004. doi: 10.1093/jnci/djv004. Print 2015 Apr. PMID- 25674733 OWN - NLM STAT- MEDLINE DA - 20150214 DCOM- 20150423 IS - 1536-5964 (Electronic) IS - 0025-7974 (Linking) VI - 94 IP - 6 DP - 2015 Feb TI - Incidental microscopic bile duct tumor thrombi in hepatocellular carcinoma after curative hepatectomy: a matched study. PG - e450 LID - 10.1097/MD.0000000000000450 [doi] AB - In patients with hepatocellular carcinoma (HCC), the presence of bile duct tumor thrombi (BDTT) in the major bile ducts indicates poor prognosis compared with that of HCC patients without BDTT. However, the prognostic significance of incidental microscopic BDTT in the peripheral bile ducts after curative liver resection is not known. We compared the outcomes of HCC patients with and without microscopic BDTT in the peripheral bile ducts who underwent hepatectomy.The electronic medical records of 31 patients with microscopic BDTT (BDTT group) were retrospectively reviewed. To compare the surgical outcomes, 62 patients (No BDTT group) were randomly chosen from the remaining HCC patients without BDTT based on age, sex, etiology of HCC, tumor size, tumor number, and modified Union for International Cancer Control T staging.The 1-year, 2-year, and 3-year disease-free survival rates and overall survival rates were 54.8%, 34.0%, 34.0% and 90.1%, 69.2%, 61.0% in the BDTT group and 66.8%, 59.2%, 42.3% and 86.4%, 84.4%, 84.4% in the No BDTT group (P = 0.089 and P = 0.014, respectively). The overall survival curve in the No BDTT group was higher than that in the BDTT group. Multivariate analysis revealed that predisposing factors for tumor recurrence after curative liver resection included increased levels of the protein induced by vitamin K antagonist-II (PIVKA-II), tumor grades 3 and 4, and the presence of BDTT.This study demonstrates that HCC prognosis is worse in patients with incidental microscopic BDTT in the peripheral bile ducts than it is in those without BDTT. The presence of BDTT should therefore be considered when evaluating a patient's HCC prognosis after curative hepatectomy. FAU - Kim, Jong M AU - Kim JM AD - From the Department of Surgery (JMK, CHDK, J-WJ, JBP, SJK); Department of Medicine, Division of Gastroenterology (DHS, JHL, SWP, BCY); and Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (CKP). FAU - Kwon, Choon H D AU - Kwon CH FAU - Joh, Jae-Won AU - Joh JW FAU - Sinn, Dong H AU - Sinn DH FAU - Park, Jae B AU - Park JB FAU - Lee, Joon H AU - Lee JH FAU - Kim, Sung J AU - Kim SJ FAU - Paik, Seung W AU - Paik SW FAU - Park, Cheol K AU - Park CK FAU - Yoo, Byung C AU - Yoo BC LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - AIM SB - IM MH - Adult MH - Aged MH - Bile Duct Neoplasms/*pathology MH - Carcinoma, Hepatocellular/mortality/*pathology/*surgery MH - Female MH - *Hepatectomy MH - Humans MH - Incidental Findings MH - Liver Neoplasms/mortality/*pathology/*surgery MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplastic Cells, Circulating/*pathology MH - Postoperative Complications MH - Prognosis MH - Retrospective Studies MH - Thrombosis/*pathology EDAT- 2015/02/13 06:00 MHDA- 2015/04/24 06:00 CRDT- 2015/02/13 06:00 AID - 10.1097/MD.0000000000000450 [doi] AID - 00005792-201502020-00006 [pii] PST - ppublish SO - Medicine (Baltimore). 2015 Feb;94(6):e450. doi: 10.1097/MD.0000000000000450. PMID- 25670081 OWN - NLM STAT- MEDLINE DA - 20150211 DCOM- 20150424 LR - 20150215 IS - 1878-3686 (Electronic) IS - 1535-6108 (Linking) VI - 27 IP - 2 DP - 2015 Feb 9 TI - Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. PG - 257-70 LID - 10.1016/j.ccell.2014.12.006 [doi] LID - S1535-6108(14)00515-7 [pii] AB - How mitochondrial glutaminolysis contributes to redox homeostasis in cancer cells remains unclear. Here we report that the mitochondrial enzyme glutamate dehydrogenase 1 (GDH1) is commonly upregulated in human cancers. GDH1 is important for redox homeostasis in cancer cells by controlling the intracellular levels of its product alpha-ketoglutarate and subsequent metabolite fumarate. Mechanistically, fumarate binds to and activates a reactive oxygen species scavenging enzyme glutathione peroxidase 1. Targeting GDH1 by shRNA or a small molecule inhibitor R162 resulted in imbalanced redox homeostasis, leading to attenuated cancer cell proliferation and tumor growth. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Jin, Lingtao AU - Jin L AD - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Li, Dan AU - Li D AD - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Alesi, Gina N AU - Alesi GN AD - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Fan, Jun AU - Fan J AD - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Kang, Hee-Bum AU - Kang HB AD - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Lu, Zhou AU - Lu Z AD - Department of Chemistry and Institute for Biophysical Dynamics, The University of Chicago, Chicago, IL 60637, USA. FAU - Boggon, Titus J AU - Boggon TJ AD - Department of Pharmacology, Yale University, New Haven, CT 06520, USA. FAU - Jin, Peng AU - Jin P AD - Department of Human Genetics, Emory University, Atlanta, GA 30322, USA. FAU - Yi, Hong AU - Yi H AD - Robert P. Apkarian Integrated Electron Microscopy Core, Emory University, Atlanta, GA 30322, USA. FAU - Wright, Elizabeth R AU - Wright ER AD - Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Duong, Duc AU - Duong D AD - Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Seyfried, Nicholas T AU - Seyfried NT AD - Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Egnatchik, Robert AU - Egnatchik R AD - UT Southwestern Medical Center, Dallas, TX 75390, USA. FAU - DeBerardinis, Ralph J AU - DeBerardinis RJ AD - UT Southwestern Medical Center, Dallas, TX 75390, USA. FAU - Magliocca, Kelly R AU - Magliocca KR AD - Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - He, Chuan AU - He C AD - Department of Chemistry and Institute for Biophysical Dynamics, The University of Chicago, Chicago, IL 60637, USA. FAU - Arellano, Martha L AU - Arellano ML AD - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Khoury, Hanna J AU - Khoury HJ AD - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Shin, Dong M AU - Shin DM AD - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Khuri, Fadlo R AU - Khuri FR AD - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Kang, Sumin AU - Kang S AD - Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: smkang@emory.edu. LA - eng GR - F31 CA183365/CA/NCI NIH HHS/United States GR - R01 CA140515/CA/NCI NIH HHS/United States GR - R01 CA174786/CA/NCI NIH HHS/United States GR - R01 CA175316/CA/NCI NIH HHS/United States GR - R01 CA175316/CA/NCI NIH HHS/United States GR - R01 CA183594/CA/NCI NIH HHS/United States GR - S10 RR025679-01/RR/NCRR NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Cancer Cell JT - Cancer cell JID - 101130617 RN - 0 (Antioxidants) RN - 0 (Fumarates) RN - 0 (Ketoglutaric Acids) RN - 0 (Reactive Oxygen Species) RN - 328-50-7 (alpha-ketoglutaric acid) RN - EC 1.11.1.- (glutathione peroxidase GPX1) RN - EC 1.11.1.9 (Glutathione Peroxidase) RN - EC 1.4.1.2 (Glutamate Dehydrogenase) RN - EC 1.4.1.3 (GLUD1 protein, human) RN - GAN16C9B8O (Glutathione) SB - IM MH - Antioxidants/metabolism MH - Carcinogenesis MH - Fumarates/metabolism MH - Gene Expression Regulation, Neoplastic MH - Glutamate Dehydrogenase/antagonists & inhibitors/*biosynthesis/genetics MH - Glutathione/*metabolism MH - Glutathione Peroxidase/*biosynthesis/genetics MH - Humans MH - Ketoglutaric Acids/metabolism MH - Leukemia/enzymology/*genetics/pathology MH - Mitochondria/*enzymology/pathology MH - Oxidation-Reduction MH - Primary Cell Culture MH - Reactive Oxygen Species/metabolism MH - Signal Transduction/genetics PMC - PMC4325424 MID - NIHMS660472 OID - NLM: NIHMS660472 [Available on 02/09/16] OID - NLM: PMC4325424 [Available on 02/09/16] EDAT- 2015/02/12 06:00 MHDA- 2015/04/25 06:00 CRDT- 2015/02/12 06:00 PMCR- 2016/02/09 00:00 PHST- 2014/06/16 [received] PHST- 2014/09/29 [revised] PHST- 2014/12/15 [accepted] AID - S1535-6108(14)00515-7 [pii] AID - 10.1016/j.ccell.2014.12.006 [doi] PST - ppublish SO - Cancer Cell. 2015 Feb 9;27(2):257-70. doi: 10.1016/j.ccell.2014.12.006. PMID- 25667509 OWN - NLM STAT- MEDLINE DA - 20150210 DCOM- 20150409 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 35 IP - 2 DP - 2015 Feb TI - Vitamin D status and cancer prevalence of hemodialysis patients in Germany. PG - 1181-7 AB - AIM: To describe Vitamin D (VitD) status and prevalence of cancer in a large cohort of ambulatory hemodialysis patients in Germany. PATIENTS AND METHODS: In a registry study adult patients starting dialysis between 2006 and 2012 were analyzed for VitD blood levels and International classification of diseases (ICD)-10 cancer diagnoses. RESULTS: Almost one third (32.7%) of patients initiating dialysis, had VitD levels<12.5 ng/ml and 79.7% had levels<30 ng/ml (n=8,377). Average VitD at dialysis initiation increased from 18.0 to 23.2 ng/ml between 2006 and 2012. Prevalence of cancer in this cohort was 22.1% with genital, renal and gastro-intestinal cancers being most common. Cancer frequencies were similar in patients with high and low vitamin D levels. CONCLUSION: Most chronic hemodialysis patients were vitamin D-deficient in spite of concurrent vitamin D supplementation. The burden of cancer was high in these patients. Future studies should address the role of vitamin D treatment on the course and progression of cancer in chronic kidney disease (CKD) patients. CI - Copyright(c) 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. FAU - Marquardt, Philipp AU - Marquardt P AD - Department of Medicine II - QiN-Group, University Hospital Cologne, Cologne, Germany. FAU - Krause, Rolfdieter AU - Krause R AD - Research Group Heliotherapy, Department of Clinical Natural Medicine, Charite University Medical Center Berlin, Berlin, Germany. FAU - Schaller, Mathias AU - Schaller M AD - Department of Medicine II - QiN-Group, University Hospital Cologne, Cologne, Germany. FAU - Bach, Dieter AU - Bach D AD - KfH-Curatorium for Dialysis and Kidney Transplantation, Neu-Isenburg, Germany. FAU - Von Gersdorff, Gero AU - Von Gersdorff G AD - Department of Medicine II - QiN-Group, University Hospital Cologne, Cologne, Germany gero.von-gersdorff@uk-koeln.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 1406-16-2 (Vitamin D) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Germany/epidemiology MH - Humans MH - Male MH - Middle Aged MH - Neoplasms/*epidemiology/metabolism MH - Prevalence MH - Renal Dialysis/*adverse effects MH - Vitamin D/*metabolism OTO - NOTNLM OT - CKD OT - CKD-MBD OT - ESRD OT - Vitamin D OT - cancer OT - chronic kidney disease OT - dialysis OT - epidemiology OT - mineral and bone disease OT - renal replacement therapy (RRT) EDAT- 2015/02/11 06:00 MHDA- 2015/04/10 06:00 CRDT- 2015/02/11 06:00 AID - 35/2/1181 [pii] PST - ppublish SO - Anticancer Res. 2015 Feb;35(2):1181-7. PMID- 25667508 OWN - NLM STAT- MEDLINE DA - 20150210 DCOM- 20150409 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 35 IP - 2 DP - 2015 Feb TI - Vitamin D levels and dietary intake among patients with benign soft tissue tumors and sarcomas. PG - 1171-80 AB - BACKGROUND: Calcitriol [1,25(OH)2D] is hypothesized to lower the risk of cancer via binding to the vitamin D receptor (VDR). VDRs are also found in benign and malignant cells of mesenchymal origin. To our knowledge, vitamin D levels and dietary intake have not been previously evaluated in patients newly diagnosed with benign and malignant mesenchymal tumors. PATIENTS AND METHODS: Forty-eight patients with benign soft tissue tumors and 25 patients with sarcoma had their serum 25-hydroxyvitamin D [25(OH)D], 1,25(OH)2D and parathyroid hormone levels measured, vitamin D intake scored and body mass index [BMI] calculated. RESULTS: Vitamin D deficiency [25(OH)D level<50 nmol/l] was observed in 19% and 28% of patients with benign tumor and sarcoma, respectively. CONCLUSION: Serum 25(OH)D, 1,25(OH)2D and parathyroid hormone concentrations, BMI and daily vitamin D intake did not differ significantly between the two groups of patients. Higher vitamin D intake or UV exposure is needed to ensure that all patients achieve sufficient vitamin D levels. CI - Copyright(c) 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. FAU - Juzeniene, Asta AU - Juzeniene A AD - Department of Radiation Biology, Oslo University Hospital, The Norwegian Radium Hospital, Montebello, Oslo, Norway astaj@rr-research.no. FAU - Porojnicu, Alina Carmen AU - Porojnicu AC AD - Department of Radiation Biology, Oslo University Hospital, The Norwegian Radium Hospital, Montebello, Oslo, Norway. FAU - Baturaite, Zivile AU - Baturaite Z AD - Department of Radiation Biology, Oslo University Hospital, The Norwegian Radium Hospital, Montebello, Oslo, Norway. FAU - Lagunova, Zoya AU - Lagunova Z AD - Department of Radiation Biology, Oslo University Hospital, The Norwegian Radium Hospital, Montebello, Oslo, Norway. FAU - Aksnes, Lage AU - Aksnes L AD - Department of Paediatrics, Haukeland University Hospital, Bergen, Norway Department of Clinical Science, University of Bergen, Norway. FAU - Bruland, Oyvind Sverre AU - Bruland OS AD - Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Montebello, Oslo, Norway. FAU - Moan, Johan AU - Moan J AD - Department of Radiation Biology, Oslo University Hospital, The Norwegian Radium Hospital, Montebello, Oslo, Norway Institute of Physics, University of Oslo, Oslo, Norway. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 1406-16-2 (Vitamin D) SB - IM MH - *Diet MH - Female MH - Humans MH - Male MH - Middle Aged MH - Sarcoma/*blood MH - Soft Tissue Neoplasms/*blood MH - Vitamin D/administration & dosage/*blood OTO - NOTNLM OT - 1,25-dihydroxyvitamin D OT - 25-Hydroxyvitamin D OT - benign soft tissue tumor OT - daily vitamin D intake OT - parathyroid hormone OT - sarcoma EDAT- 2015/02/11 06:00 MHDA- 2015/04/10 06:00 CRDT- 2015/02/11 06:00 AID - 35/2/1171 [pii] PST - ppublish SO - Anticancer Res. 2015 Feb;35(2):1171-80. PMID- 25656533 OWN - NLM STAT- MEDLINE DA - 20150213 DCOM- 20150420 LR - 20150303 IS - 1476-6256 (Electronic) IS - 0002-9262 (Linking) VI - 181 IP - 4 DP - 2015 Feb 15 TI - Comparison of methods to account for implausible reporting of energy intake in epidemiologic studies. PG - 225-33 LID - 10.1093/aje/kwu308 [doi] AB - In a recent article in the American Journal of Epidemiology by Mendez et al. (Am J Epidemiol. 2011;173(4):448-458), the use of alternative approaches to the exclusion of implausible energy intakes led to significantly different cross-sectional associations between diet and body mass index (BMI), whereas the use of a simpler recommended criteria (<500 and >3,500 kcal/day) yielded no meaningful change. However, these findings might have been due to exclusions made based on weight, a primary determinant of BMI. Using data from 52,110 women in the Nurses' Health Study (1990), we reproduced the cross-sectional findings of Mendez et al. and compared the results from the recommended method with those from 2 weight-dependent alternative methods (the Goldberg method and predicted total energy expenditure method). The same 3 exclusion criteria were then used to examine dietary variables prospectively in relation to change in BMI, which is not a direct function of attained weight. We found similar associations using the 3 methods. In a separate cross-sectional analysis using biomarkers of dietary factors, we found similar correlations for intakes of fatty acids (n = 439) and carotenoids and retinol (n = 1,293) using the 3 methods for exclusions. These results do not support the general conclusion that use of exclusion criteria based on the alternative methods might confer an advantage over the recommended exclusion method. CI - (c) The Author 2015. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Rhee, Jinnie J AU - Rhee JJ FAU - Sampson, Laura AU - Sampson L FAU - Cho, Eunyoung AU - Cho E FAU - Hughes, Michael D AU - Hughes MD FAU - Hu, Frank B AU - Hu FB FAU - Willett, Walter C AU - Willett WC LA - eng GR - 5T32AG000158-23/AG/NIA NIH HHS/United States GR - 5T32DK007357-29/DK/NIDDK NIH HHS/United States GR - P01 CA87969/CA/NCI NIH HHS/United States GR - R01 CA49449/CA/NCI NIH HHS/United States GR - R01 HL088521/HL/NHLBI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. DEP - 20150205 PL - United States TA - Am J Epidemiol JT - American journal of epidemiology JID - 7910653 RN - 0 (Biological Markers) RN - 0 (Fatty Acids) RN - 11103-57-4 (Vitamin A) RN - 36-88-4 (Carotenoids) SB - IM CIN - Am J Epidemiol. 2015 Feb 15;181(4):234-6. PMID: 25656531 MH - Adult MH - Biological Markers/blood MH - *Body Mass Index MH - Body Weight MH - Breast Neoplasms/blood/diagnosis/*epidemiology MH - California/epidemiology MH - Cardiovascular Diseases/blood/diagnosis/*epidemiology MH - Carotenoids/*blood MH - Chronic Disease/epidemiology MH - Cross-Sectional Studies MH - Diet Surveys/statistics & numerical data MH - *Energy Intake MH - Epidemiologic Studies MH - *Exercise MH - Fatty Acids/*blood MH - Female MH - Humans MH - Incidence MH - Middle Aged MH - Nurses/*statistics & numerical data MH - Nutrition Assessment MH - Prospective Studies MH - Questionnaires MH - Reproducibility of Results MH - Risk Factors MH - Vitamin A/blood PMC - PMC4325679 OID - NLM: PMC4325679 [Available on 02/15/16] OTO - NOTNLM OT - biomarkers OT - body mass index OT - diet OT - energy intake OT - implausible reporting OT - selection bias EDAT- 2015/02/07 06:00 MHDA- 2015/04/22 06:00 CRDT- 2015/02/07 06:00 PMCR- 2016/02/15 00:00 PHST- 2015/02/05 [aheadofprint] AID - kwu308 [pii] AID - 10.1093/aje/kwu308 [doi] PST - ppublish SO - Am J Epidemiol. 2015 Feb 15;181(4):225-33. doi: 10.1093/aje/kwu308. Epub 2015 Feb 5. PMID- 25630415 OWN - NLM STAT- MEDLINE DA - 20150226 DCOM- 20150423 IS - 1432-0843 (Electronic) IS - 0344-5704 (Linking) VI - 75 IP - 3 DP - 2015 Mar TI - A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. PG - 639-43 LID - 10.1007/s00280-015-2688-9 [doi] AB - PURPOSE: This study was conducted to evaluate the efficacy and safety of the combination of capecitabine and oral leucovorin (LV) as a third-line chemotherapy for patients with metastatic colorectal cancer (CRC) showing resistance to irinotecan- and oxaliplatin-containing regimens. METHOD: Patients who showed disease progression while receiving or within 6 months of discontinuing irinotecan- and oxaliplatin-containing regimens received capecitabine 825 mg/m(2) in combination with oral LV at a fixed dose of 30 mg, twice a day for 2 weeks followed by a 1-week rest. RESULTS: Twenty-five patients were enrolled from July 2011 to June 2014. Three patients achieved PR, and 11 showed SD. The overall response rate was 12 %, and disease control rate was 56 %. With a median follow-up of 6.8 months, the median time to progression was 2.8 months and the median overall survival was 7.1 months. The most common non-hematologic toxicity was hand-foot syndrome (40 %), followed by mucositis (28 %) and diarrhea (12 %). Grade 3 hand-foot syndrome occurred in two patients (8 %), and grade 3 mucositis in one. Hematologic toxicities were mild, and only one patient developed grade 3 thrombocytopenia. CONCLUSION: The combination of capecitabine and oral LV showed a modest activity and tolerable toxicity profile in metastatic CRC patients pretreated with irinotecan- and oxaliplatin-containing regimens. Oral LV seems to be able to reduce the usual dose of capecitabine when the two drugs are combined. FAU - Choi, Dae Ro AU - Choi DR AD - Division of Hemato-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Shingilro1, Youngdeungpo-Gu, Seoul, 150-950, Republic of Korea. FAU - Yoon, Sang Nam AU - Yoon SN FAU - Kim, Hyeong Su AU - Kim HS FAU - Kim, Jung Han AU - Kim JH FAU - Kim, Kwang Yong AU - Kim KY FAU - Kim, Byung Chun AU - Kim BC FAU - Choi, Young Kyun AU - Choi YK FAU - Kim, Jin Bae AU - Kim JB FAU - Han, Boram AU - Han B FAU - Song, Hun Ho AU - Song HH FAU - Zang, Dae Young AU - Zang DY LA - eng PT - Clinical Trial, Phase II PT - Journal Article DEP - 20150129 PL - Germany TA - Cancer Chemother Pharmacol JT - Cancer chemotherapy and pharmacology JID - 7806519 RN - 0 (Organoplatinum Compounds) RN - 04ZR38536J (oxaliplatin) RN - 0W860991D6 (Deoxycytidine) RN - 6804DJ8Z9U (capecitabine) RN - 7673326042 (irinotecan) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - XT3Z54Z28A (Camptothecin) SB - IM MH - Administration, Oral MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use MH - Camptothecin/administration & dosage/analogs & derivatives MH - Colorectal Neoplasms/*drug therapy/pathology MH - Deoxycytidine/administration & dosage/analogs & derivatives MH - Disease Progression MH - Drug Resistance, Neoplasm MH - Female MH - Fluorouracil/administration & dosage/analogs & derivatives MH - Follow-Up Studies MH - Humans MH - Leucovorin/administration & dosage MH - Male MH - Middle Aged MH - Neoplasm Metastasis MH - Organoplatinum Compounds/administration & dosage MH - Survival Rate MH - Treatment Outcome EDAT- 2015/01/30 06:00 MHDA- 2015/04/24 06:00 CRDT- 2015/01/30 06:00 PHST- 2015/01/02 [received] PHST- 2015/01/18 [accepted] PHST- 2015/01/29 [aheadofprint] AID - 10.1007/s00280-015-2688-9 [doi] PST - ppublish SO - Cancer Chemother Pharmacol. 2015 Mar;75(3):639-43. doi: 10.1007/s00280-015-2688-9. Epub 2015 Jan 29. PMID- 25626807 OWN - NLM STAT- MEDLINE DA - 20150128 DCOM- 20150417 IS - 1529-4242 (Electronic) IS - 0007-1226 (Linking) VI - 135 IP - 2 DP - 2015 Feb TI - Assessment of patient factors, surgeons, and surgeon teams in immediate implant-based breast reconstruction outcomes. PG - 245e-52e LID - 10.1097/PRS.0000000000000912 [doi] AB - BACKGROUND: Outcome studies of immediate implant-based breast reconstruction have focused largely on patient factors, whereas the relative impact of the surgeon as a contributing variable is not known. As the procedure requires collaboration of both a surgical oncologist and a plastic surgeon, the effect of the surgeon team interaction can have a significant impact on outcome. This study examines outcomes in implant-based breast reconstruction and the association with patient characteristics, surgeon, and surgeon team familiarity. METHODS: A retrospective review of 3142 consecutive implant-based breast reconstruction mastectomy procedures at one institution was performed. Infection and skin necrosis rates were measured. Predictors of outcomes were identified by unadjusted logistic regression followed by multivariate logistic regression. Surgeon teams were grouped according to number of cases performed together. RESULTS: Patient characteristics remain the most important predictors for outcomes in implant-based breast reconstruction, with odds ratios above those of surgeon variables. The authors observed significant differences in the rate of skin necrosis between surgical oncologists with an approximately two-fold difference between surgeons with the highest and lowest rates. Surgeon teams that worked together on fewer than 150 procedures had higher rates of infection. CONCLUSIONS: Patient characteristics are the most important predictors for surgical outcomes in implant-based breast reconstruction, but surgeons and surgeon teams are also important variables. High-volume surgeon teams achieve lower rates of infection. This study highlights the need to examine modifiable risk factors associated with optimum implant-based breast reconstruction outcomes, which include patient and provider characteristics and the surgical team treating the patient. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III. FAU - Gfrerer, Lisa AU - Gfrerer L AD - Boston, Mass. From the Division of Plastic and Reconstructive Surgery, the Division of Surgical Oncology, and the Codman Center for Clinical Effectiveness in Surgery, Massachusetts General Hospital, Harvard Medical School; and the Center for Regenerative Medicine, Harvard Stem Cell Institute. FAU - Mattos, David AU - Mattos D FAU - Mastroianni, Melissa AU - Mastroianni M FAU - Weng, Qing Y AU - Weng QY FAU - Ricci, Joseph A AU - Ricci JA FAU - Heath, Martha P AU - Heath MP FAU - Lin, Alex AU - Lin A FAU - Specht, Michelle C AU - Specht MC FAU - Haynes, Alex B AU - Haynes AB FAU - Austen, William G Jr AU - Austen WG Jr FAU - Liao, Eric C AU - Liao EC LA - eng PT - Journal Article PT - Review PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 SB - AIM SB - IM MH - Acellular Dermis MH - Breast/pathology MH - Breast Implantation/methods/*statistics & numerical data MH - Breast Neoplasms/epidemiology/surgery/therapy MH - Combined Modality Therapy MH - Comorbidity MH - Cooperative Behavior MH - Female MH - Humans MH - Logistic Models MH - Mammaplasty/methods/*statistics & numerical data MH - Mastectomy/methods/*statistics & numerical data MH - Medical Oncology/*statistics & numerical data MH - Necrosis/pathology MH - Obesity/epidemiology MH - Odds Ratio MH - Patient Care Team/*statistics & numerical data MH - Patient Selection MH - Postoperative Complications/epidemiology/pathology MH - Prosthesis-Related Infections/epidemiology/surgery MH - Retrospective Studies MH - Smoking MH - Surgery, Plastic/*statistics & numerical data MH - Surgical Wound Infection/epidemiology/surgery MH - Tertiary Care Centers/statistics & numerical data MH - Treatment Outcome EDAT- 2015/01/30 06:00 MHDA- 2015/04/18 06:00 CRDT- 2015/01/29 06:00 AID - 10.1097/PRS.0000000000000912 [doi] AID - 00006534-201502000-00005 [pii] PST - ppublish SO - Plast Reconstr Surg. 2015 Feb;135(2):245e-52e. doi: 10.1097/PRS.0000000000000912. PMID- 25618901 OWN - NLM STAT- MEDLINE DA - 20150127 DCOM- 20150406 IS - 1460-2105 (Electronic) IS - 0027-8874 (Linking) VI - 107 IP - 3 DP - 2015 Mar TI - Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. LID - 10.1093/jnci/dju428 [doi] LID - dju428 [pii] AB - BACKGROUND: Adiposity, measured by body mass index, is implicated in carcinogenesis. While adult weight gain has diverse advantages over body mass index in measuring adiposity, systematic reviews on adult weight gain in relation to adiposity-related cancers are lacking. METHODS: PubMed and Embase were searched through September 2014 for prospective observational studies investigating the relationship between adult weight gain and the risk of 10 adiposity-related cancers. Dose-response meta-analyses were performed using a random-effects model to estimate summary relative risk (RR) and 95% confidence interval (CI) for each cancer type. All statistical tests were two-sided. RESULTS: A total of 50 studies were included. For each 5kg increase in adult weight gain, the summary relative risk was 1.11 (95% CI = 1.08 to 1.13) for postmenopausal breast cancer among no- or low-hormone replacement therapy (HRT) users, 1.39 (95% CI = 1.29 to 1.49) and 1.09 (95% CI = 1.02 to 1.16) for postmenopausal endometrial cancer among HRT nonusers and users, respectively, 1.13 (95% CI = 1.03 to 1.23) for postmenopausal ovarian cancer among no or low HRT users, 1.09 (95% CI = 1.04 to 1.13) for colon cancer in men. The relative risk of kidney cancer comparing highest and lowest level of adult weight gain was 1.42 (95% CI = 1.11 to 1.81). Adult weight gain was unrelated to cancers of the breast (premenopausal women, postmenopausal HRT users), prostate, colon (women), pancreas, and thyroid. An increase in risk associated with adult weight gain for breast cancer was statistically significantly greater among postmenopausal women (P heterogeneity = .001) and HRT nonusers (P heterogeneity = .001); that for endometrial cancer was alike among HRT nonusers (P heterogeneity = .04). CONCLUSIONS: Avoiding adult weight gain itself may confer protection against certain types of cancers, particularly among HRT nonusers. CI - (c) The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. FAU - Keum, NaNa AU - Keum N AD - Departments of Nutrition and Epidemiology (NK, DHL, FBH, ELG) and Department of Social and Behavioral Sciences (RK), Harvard School of Public Health, Boston, MA; Division of Biostatistics, University of Leeds, Leeds, UK (DCG); Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (DA); Department of Epidemiology and Biostatistics, Imperial College London, London, UK (DA); Department of Obstetrics and Gynecology, Ewha Womans University, Seoul, Republic of Korea (WJ); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (FBH, ELG). nak212@mail.harvard.edu. FAU - Greenwood, Darren C AU - Greenwood DC AD - Departments of Nutrition and Epidemiology (NK, DHL, FBH, ELG) and Department of Social and Behavioral Sciences (RK), Harvard School of Public Health, Boston, MA; Division of Biostatistics, University of Leeds, Leeds, UK (DCG); Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (DA); Department of Epidemiology and Biostatistics, Imperial College London, London, UK (DA); Department of Obstetrics and Gynecology, Ewha Womans University, Seoul, Republic of Korea (WJ); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (FBH, ELG). FAU - Lee, Dong Hoon AU - Lee DH AD - Departments of Nutrition and Epidemiology (NK, DHL, FBH, ELG) and Department of Social and Behavioral Sciences (RK), Harvard School of Public Health, Boston, MA; Division of Biostatistics, University of Leeds, Leeds, UK (DCG); Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (DA); Department of Epidemiology and Biostatistics, Imperial College London, London, UK (DA); Department of Obstetrics and Gynecology, Ewha Womans University, Seoul, Republic of Korea (WJ); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (FBH, ELG). FAU - Kim, Rockli AU - Kim R AD - Departments of Nutrition and Epidemiology (NK, DHL, FBH, ELG) and Department of Social and Behavioral Sciences (RK), Harvard School of Public Health, Boston, MA; Division of Biostatistics, University of Leeds, Leeds, UK (DCG); Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (DA); Department of Epidemiology and Biostatistics, Imperial College London, London, UK (DA); Department of Obstetrics and Gynecology, Ewha Womans University, Seoul, Republic of Korea (WJ); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (FBH, ELG). FAU - Aune, Dagfinn AU - Aune D AD - Departments of Nutrition and Epidemiology (NK, DHL, FBH, ELG) and Department of Social and Behavioral Sciences (RK), Harvard School of Public Health, Boston, MA; Division of Biostatistics, University of Leeds, Leeds, UK (DCG); Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (DA); Department of Epidemiology and Biostatistics, Imperial College London, London, UK (DA); Department of Obstetrics and Gynecology, Ewha Womans University, Seoul, Republic of Korea (WJ); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (FBH, ELG). FAU - Ju, Woong AU - Ju W AD - Departments of Nutrition and Epidemiology (NK, DHL, FBH, ELG) and Department of Social and Behavioral Sciences (RK), Harvard School of Public Health, Boston, MA; Division of Biostatistics, University of Leeds, Leeds, UK (DCG); Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (DA); Department of Epidemiology and Biostatistics, Imperial College London, London, UK (DA); Department of Obstetrics and Gynecology, Ewha Womans University, Seoul, Republic of Korea (WJ); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (FBH, ELG). FAU - Hu, Frank B AU - Hu FB AD - Departments of Nutrition and Epidemiology (NK, DHL, FBH, ELG) and Department of Social and Behavioral Sciences (RK), Harvard School of Public Health, Boston, MA; Division of Biostatistics, University of Leeds, Leeds, UK (DCG); Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (DA); Department of Epidemiology and Biostatistics, Imperial College London, London, UK (DA); Department of Obstetrics and Gynecology, Ewha Womans University, Seoul, Republic of Korea (WJ); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (FBH, ELG). FAU - Giovannucci, Edward L AU - Giovannucci EL AD - Departments of Nutrition and Epidemiology (NK, DHL, FBH, ELG) and Department of Social and Behavioral Sciences (RK), Harvard School of Public Health, Boston, MA; Division of Biostatistics, University of Leeds, Leeds, UK (DCG); Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (DA); Department of Epidemiology and Biostatistics, Imperial College London, London, UK (DA); Department of Obstetrics and Gynecology, Ewha Womans University, Seoul, Republic of Korea (WJ); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (FBH, ELG). LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20150124 PL - United States TA - J Natl Cancer Inst JT - Journal of the National Cancer Institute JID - 7503089 SB - IM MH - *Adiposity MH - Adult MH - Body Mass Index MH - Breast Neoplasms/epidemiology/etiology MH - Colonic Neoplasms/epidemiology/etiology MH - Endometrial Neoplasms/epidemiology/etiology MH - Estrogen Replacement Therapy/statistics & numerical data MH - Female MH - Humans MH - Incidence MH - Male MH - Neoplasms/*epidemiology/*etiology MH - Obesity/*complications MH - Observational Study as Topic MH - Ovarian Neoplasms/epidemiology/etiology MH - Prospective Studies MH - Prostatic Neoplasms/epidemiology/etiology MH - Risk Factors MH - *Weight Gain EDAT- 2015/01/27 06:00 MHDA- 2015/04/07 06:00 CRDT- 2015/01/26 06:00 PHST- 2015/03 [ppublish] AID - dju428 [pii] AID - 10.1093/jnci/dju428 [doi] PST - epublish SO - J Natl Cancer Inst. 2015 Jan 24;107(3). pii: dju428. doi: 10.1093/jnci/dju428. Print 2015 Mar. PMID- 25599323 OWN - NLM STAT- MEDLINE DA - 20150120 DCOM- 20150406 IS - 1528-1140 (Electronic) IS - 0003-4932 (Linking) VI - 261 IP - 1 DP - 2015 Jan TI - Neoadjuvant therapy for localized pancreatic cancer: support is growing? PG - 18-20 LID - 10.1097/SLA.0000000000000996 [doi] FAU - Evans, Douglas B AU - Evans DB AD - From the Pancreatic Cancer Program, Departments of Surgery, Medicine, and Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI. FAU - Ritch, Paul S AU - Ritch PS FAU - Erickson, Beth A AU - Erickson BA LA - eng PT - Comment PT - Editorial PL - United States TA - Ann Surg JT - Annals of surgery JID - 0372354 RN - 0 (Organoplatinum Compounds) RN - 04ZR38536J (oxaliplatin) RN - 7673326042 (irinotecan) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - XT3Z54Z28A (Camptothecin) SB - AIM SB - IM CON - Ann Surg. 2015 Jan;261(1):12-7. PMID: 25599322 MH - Adenocarcinoma/*therapy MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Camptothecin/administration & dosage/*analogs & derivatives MH - Female MH - Fluorouracil/*administration & dosage MH - Humans MH - Leucovorin/*administration & dosage MH - Male MH - *Neoadjuvant Therapy MH - Organoplatinum Compounds/*administration & dosage MH - Pancreatic Neoplasms/*therapy EDAT- 2015/01/20 06:00 MHDA- 2015/04/07 06:00 CRDT- 2015/01/20 06:00 AID - 10.1097/SLA.0000000000000996 [doi] AID - 00000658-201501000-00005 [pii] PST - ppublish SO - Ann Surg. 2015 Jan;261(1):18-20. doi: 10.1097/SLA.0000000000000996. PMID- 25599322 OWN - NLM STAT- MEDLINE DA - 20150120 DCOM- 20150406 LR - 20150423 IS - 1528-1140 (Electronic) IS - 0003-4932 (Linking) VI - 261 IP - 1 DP - 2015 Jan TI - Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. PG - 12-7 LID - 10.1097/SLA.0000000000000867 [doi] AB - PURPOSE: On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims of this study are to evaluate the accuracy of imaging in determining the resectability of PDAC and to determine the surgical and clinicopathologic outcomes of pancreatic resections after neoadjuvant FOLFIRINOX therapy. PATIENTS AND METHODS: Clinicopathologic data were retrospectively collected for surgical PDAC patients receiving neoadjuvant FOLFIRINOX or no neoadjuvant therapy between April 2011 and February 2014. Americas Hepato-Pancreato-Biliary Association/Society of Surgical Oncology/Society for Surgery of the Alimentary Tract consensus guidelines defined LA and borderline. Imaging was reviewed by a blinded senior pancreatic surgeon. RESULTS: Of 188 patients undergoing resection for PDAC, 40 LA/borderline received FOLFIRINOX and 87 received no neoadjuvant therapy. FOLFIRINOX resulted in a significant decrease in tumor size, yet 19 patients were still classified as LA and 9 as borderline. Despite post-FOLFIRINOX imaging suggesting continued unresectability, 92% had an R0 resection. When compared with no neoadjuvant therapy, FOLFIRINOX resulted in significantly longer operative times (393 vs 300 minutes) and blood loss (600 vs 400 mL), but significantly lower operative morbidity (36% vs 63%) and no postoperative pancreatic fistulas. Length of stay (6 vs 7 days), readmissions (20% vs 30%), and mortality were equivalent (1% vs 0%). On final pathology, the FOLFIRINOX group had a significant decrease in lymph node positivity (35% vs 79%) and perineural invasion (72% vs 95%). Median follow-up was 11 months with a significant increase in overall survival with FOLFIRINOX. CONCLUSIONS: After neoadjuvant FOLFIRINOX imaging no longer predicts unresectability. Traditional pathologic predictors of survival are improved, and morbidity is decreased in comparison to patients with clearly resectable cancers at the time of presentation. FAU - Ferrone, Cristina R AU - Ferrone CR AD - *Department of Surgery daggerDepartment of Radiation Oncology; and double daggerDepartment of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. FAU - Marchegiani, Giovanni AU - Marchegiani G FAU - Hong, Theodore S AU - Hong TS FAU - Ryan, David P AU - Ryan DP FAU - Deshpande, Vikram AU - Deshpande V FAU - McDonnell, Erin I AU - McDonnell EI FAU - Sabbatino, Francesco AU - Sabbatino F FAU - Santos, Daniela Dias AU - Santos DD FAU - Allen, Jill N AU - Allen JN FAU - Blaszkowsky, Lawrence S AU - Blaszkowsky LS FAU - Clark, Jeffrey W AU - Clark JW FAU - Faris, Jason E AU - Faris JE FAU - Goyal, Lipika AU - Goyal L FAU - Kwak, Eunice L AU - Kwak EL FAU - Murphy, Janet E AU - Murphy JE FAU - Ting, David T AU - Ting DT FAU - Wo, Jennifer Y AU - Wo JY FAU - Zhu, Andrew X AU - Zhu AX FAU - Warshaw, Andrew L AU - Warshaw AL FAU - Lillemoe, Keith D AU - Lillemoe KD FAU - Fernandez-del Castillo, Carlos AU - Fernandez-del Castillo C LA - eng GR - K12 CA087723/CA/NCI NIH HHS/United States GR - P50 CA127003/CA/NCI NIH HHS/United States PT - Journal Article PL - United States TA - Ann Surg JT - Annals of surgery JID - 0372354 RN - 0 (Organoplatinum Compounds) RN - 04ZR38536J (oxaliplatin) RN - 7673326042 (irinotecan) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - XT3Z54Z28A (Camptothecin) SB - AIM SB - IM CIN - Chirurg. 2015 Feb;86(2):183. PMID: 25673227 CIN - Ann Surg. 2015 Jan;261(1):18-20. PMID: 25599323 MH - Adenocarcinoma/mortality/pathology/radiography/*therapy MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Camptothecin/administration & dosage/*analogs & derivatives MH - Chemoradiotherapy MH - Disease-Free Survival MH - Female MH - Fluorouracil/*administration & dosage MH - Humans MH - Imaging, Three-Dimensional MH - Leucovorin/*administration & dosage MH - Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - *Neoadjuvant Therapy MH - Neoplasm Metastasis MH - Neoplasm Staging MH - Organoplatinum Compounds/*administration & dosage MH - Pancreatectomy MH - Pancreatic Neoplasms/mortality/pathology/radiography/*therapy MH - Pancreaticoduodenectomy MH - Retrospective Studies MH - Spiral Cone-Beam Computed Tomography MH - Treatment Outcome PMC - PMC4349683 MID - NIHMS657599 OID - NLM: NIHMS657599 [Available on 01/01/16] OID - NLM: PMC4349683 [Available on 01/01/16] EDAT- 2015/01/20 06:00 MHDA- 2015/04/07 06:00 CRDT- 2015/01/20 06:00 PMCR- 2016/01/01 00:00 AID - 10.1097/SLA.0000000000000867 [doi] AID - 00000658-201501000-00004 [pii] PST - ppublish SO - Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867. PMID- 25593034 OWN - NLM STAT- MEDLINE DA - 20150116 DCOM- 20150403 IS - 1538-7445 (Electronic) IS - 0008-5472 (Linking) VI - 75 IP - 2 DP - 2015 Jan 15 TI - Breast cancer risk in metabolically healthy but overweight postmenopausal women. PG - 270-4 LID - 10.1158/0008-5472.CAN-14-2317 [doi] AB - Adiposity is an established risk factor for postmenopausal breast cancer. Recent data suggest that high insulin levels in overweight women may play a major role in this relationship, due to insulin's mitogenic/antiapoptotic activity. However, whether overweight women who are metabolically healthy (i.e., normal insulin sensitivity) have elevated risk of breast cancer is unknown. We investigated whether overweight women with normal insulin sensitivity [i.e., homeostasis model assessment of insulin resistance (HOMA-IR) index, or fasting insulin level, within the lowest quartile (q1)] have increased breast cancer risk. Subjects were incident breast cancer cases (N = 497) and a subcohort (N = 2,830) of Women's Health Initiative (WHI) participants with available fasting insulin and glucose levels. In multivariate Cox models, metabolically healthy overweight women, defined using HOMA-IR, were not at elevated risk of breast cancer compared with metabolically healthy normal weight women [HRHOMA-IR, 0.96; 95% confidence interval (CI), 0.64-1.42]. In contrast, the risk among women with high (q3-4) HOMA-IRs was elevated whether they were overweight (HRHOMA-IR, 1.76; 95% CI, 1.19-2.60) or normal weight (HRHOMA-IR, 1.80; 95% CI, 0.88-3.70). Similarly, using fasting insulin to define metabolic health, metabolically unhealthy women (insulin q3-4) were at higher risk of breast cancer regardless of whether they were normal weight (HRinsulin, 2.06; 95% CI, 1.01-4.22) or overweight (HRinsulin, 2.01; 95% CI, 1.35-2.99), whereas metabolically healthy overweight women did not have significantly increased risk of breast cancer (HRinsulin, 0.96; 95% CI, 0.64-1.42) relative to metabolically healthy normal weight women. Metabolic health (e.g., HOMA-IR or fasting insulin) may be more biologically relevant and more useful for breast cancer risk stratification than adiposity per se. CI - (c)2014 American Association for Cancer Research. FAU - Gunter, Marc J AU - Gunter MJ AD - Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, United Kingdom. m.gunter@imperial.ac.uk. FAU - Xie, Xianhong AU - Xie X AD - Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, New York. FAU - Xue, Xiaonan AU - Xue X AD - Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, New York. FAU - Kabat, Geoffrey C AU - Kabat GC AD - Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, New York. FAU - Rohan, Thomas E AU - Rohan TE AD - Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, New York. FAU - Wassertheil-Smoller, Sylvia AU - Wassertheil-Smoller S AD - Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, New York. FAU - Ho, Gloria Y F AU - Ho GY AD - Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, New York. FAU - Wylie-Rosett, Judith AU - Wylie-Rosett J AD - Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, New York. FAU - Greco, Theresa AU - Greco T AD - Stanford University, Stanford, California. FAU - Yu, Herbert AU - Yu H AD - University of Hawaii Cancer Center, Honolulu, Hawaii. FAU - Beasley, Jeannette AU - Beasley J AD - Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, New York. FAU - Strickler, Howard D AU - Strickler HD AD - Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, New York. LA - eng GR - N01WH22110/WH/WHI NIH HHS/United States GR - N01WH24152/WH/WHI NIH HHS/United States GR - N01WH32100-2/WH/WHI NIH HHS/United States GR - N01WH32105-6/WH/WHI NIH HHS/United States GR - N01WH32108-9/WH/WHI NIH HHS/United States GR - N01WH32111-13/WH/WHI NIH HHS/United States GR - N01WH32115/WH/WHI NIH HHS/United States GR - N01WH32118-32119/WH/WHI NIH HHS/United States GR - N01WH32122/WH/WHI NIH HHS/United States GR - N01WH42107-26/WH/WHI NIH HHS/United States GR - N01WH42129-32/WH/WHI NIH HHS/United States GR - N01WH44221/WH/WHI NIH HHS/United States GR - R01-CA93881-01/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - Cancer Res JT - Cancer research JID - 2984705R RN - 0 (Blood Glucose) RN - 0 (Insulin) SB - IM MH - Age Factors MH - Aged MH - Blood Glucose/metabolism MH - Breast Neoplasms/*blood/*epidemiology MH - Female MH - Humans MH - Insulin/blood MH - Insulin Resistance MH - Middle Aged MH - Multivariate Analysis MH - Overweight/*blood/*epidemiology MH - Postmenopause/*blood MH - Proportional Hazards Models MH - Risk MH - United States/epidemiology EDAT- 2015/01/17 06:00 MHDA- 2015/04/04 06:00 CRDT- 2015/01/17 06:00 AID - 75/2/270 [pii] AID - 10.1158/0008-5472.CAN-14-2317 [doi] PST - ppublish SO - Cancer Res. 2015 Jan 15;75(2):270-4. doi: 10.1158/0008-5472.CAN-14-2317. PMID- 25575764 OWN - NLM STAT- MEDLINE DA - 20150226 DCOM- 20150423 IS - 1432-0843 (Electronic) IS - 0344-5704 (Linking) VI - 75 IP - 3 DP - 2015 Mar TI - A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. PG - 569-77 LID - 10.1007/s00280-015-2676-0 [doi] AB - PURPOSE: Biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (LV) enhances antitumor activity. LV is thus often added to 5-FU-based regimens for the treatment of metastatic colorectal cancer (mCRC). A combination of S-1, oxaliplatin, and LV (SOL) was shown to be feasible, effective, and safe in a previous phase I trial. We therefore conducted a randomized phase II trial to evaluate efficacy and safety of SOL compared with mFOLFOX6. METHODS: Patients with mCRC and no prior chemotherapy were randomly assigned to receive either SOL or mFOLFOX6. SOL consisted of S-1 (40-60 mg bid) plus oral LV (25 mg bid) for 1 week and oxaliplatin (85 mg/m(2)) on day 1, repeated every 2 weeks. RESULTS: Among 107 patients enrolled from July 2008 through July 2009, 105 (56 in the SOL group and 49 in the mFOLFOX6 group) were eligible and evaluated. The median progression-free survival was 9.6 months in the SOL group and 6.9 months in the mFOLFOX6 group [hazard ratio (HR) 0.83, 95 % confidence interval (CI) 0.49-1.40]. The median overall survival was 29.9 and 25.9 months, respectively (HR 0.91, 95 % CI 0.55-1.49). The response rate was 55 % in both groups. Grade 3 or 4 adverse drug reactions were neutropenia (20 % with SOL vs 41 % with mFOLFOX6), sensory neuropathy (20 vs 2.0 %), anorexia (13 vs 7.8 %), fatigue (11 vs 5.9 %), and diarrhea (11 vs 3.9 %). CONCLUSIONS: SOL demonstrated promising efficacy and acceptable toxicity as first-line chemotherapy for mCRC. Further studies of SOL combined with molecular target agents are warranted. FAU - Yamazaki, Kentaro AU - Yamazaki K AD - Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan, k.yamazaki@scchr.jp. FAU - Kuwano, Hiroyuki AU - Kuwano H FAU - Ojima, Hitoshi AU - Ojima H FAU - Otsuji, Toshio AU - Otsuji T FAU - Kato, Takeshi AU - Kato T FAU - Shimada, Ken AU - Shimada K FAU - Hyodo, Ichinosuke AU - Hyodo I FAU - Nishina, Tomohiro AU - Nishina T FAU - Shirao, Kuniaki AU - Shirao K FAU - Esaki, Taito AU - Esaki T FAU - Ohishi, Takashi AU - Ohishi T FAU - Denda, Tadamichi AU - Denda T FAU - Takeuchi, Masahiro AU - Takeuchi M FAU - Boku, Narikazu AU - Boku N LA - eng PT - Clinical Trial, Phase II PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20150110 PL - Germany TA - Cancer Chemother Pharmacol JT - Cancer chemotherapy and pharmacology JID - 7806519 RN - 0 (Drug Combinations) RN - 0 (Organoplatinum Compounds) RN - 04ZR38536J (oxaliplatin) RN - 150863-82-4 (S 1 (combination)) RN - 1548R74NSZ (Tegafur) RN - 5VT6420TIG (Oxonic Acid) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Folfox protocol SB - IM MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use MH - Colorectal Neoplasms/*drug therapy/pathology MH - Disease-Free Survival MH - Drug Combinations MH - Female MH - Fluorouracil/administration & dosage/adverse effects/therapeutic use MH - Humans MH - Leucovorin/administration & dosage/adverse effects/therapeutic use MH - Male MH - Middle Aged MH - Neoplasm Metastasis MH - Organoplatinum Compounds/administration & dosage/adverse effects/therapeutic use MH - Oxonic Acid/administration & dosage MH - Survival Rate MH - Tegafur/administration & dosage MH - Treatment Outcome EDAT- 2015/01/13 06:00 MHDA- 2015/04/24 06:00 CRDT- 2015/01/11 06:00 PHST- 2014/11/27 [received] PHST- 2015/01/03 [accepted] PHST- 2015/01/10 [aheadofprint] AID - 10.1007/s00280-015-2676-0 [doi] PST - ppublish SO - Cancer Chemother Pharmacol. 2015 Mar;75(3):569-77. doi: 10.1007/s00280-015-2676-0. Epub 2015 Jan 10. PMID- 25572362 OWN - NLM STAT- MEDLINE DA - 20150226 DCOM- 20150423 IS - 1432-0843 (Electronic) IS - 0344-5704 (Linking) VI - 75 IP - 3 DP - 2015 Mar TI - Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. PG - 547-57 LID - 10.1007/s00280-014-2656-9 [doi] AB - PURPOSE: Endostar is a recombinant human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. This study aimed to evaluate the drug safety and tolerability of continuous intravenous infusion (CIV) of endostar in combination with modified FOLFOX6 (mFOLFOX6) as an initial therapy in advanced colorectal cancer patients. METHODS: This was a single-center, single-arm, open, dose-escalation study in patients with advanced colorectal cancer at Fudan University Shanghai Cancer Center between August 2010 and January 2012. A total of 21 patients were included. Standard dosage of mFOLFOX6 was used. CIV endostar commenced on day 4 to day 14 ascending from 7.5 to 15, 30, 45, 60, and 75 mg/m(2)/day. Primary outcomes were dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CIV endostar in combination with mFOLFOX6. Secondary outcomes were pharmacokinetic parameters. Physical examination, performance status, standard blood tests and electrocardiograms were performed. RESULTS: MTD was 75 mg/m(2)/day. Adverse events included leucopenia (n = 17, 81 %), neutropenia (n = 12, 57.1 %), anemia (n = 5, 23.8 %), anorexia (n = 6, 28.6 %) and constipation (n = 4, 19.0 %). One patient with an allergic reaction stopped chemotherapy. Two patients stopped endostar treatment, one with level 3 ventricular premature beat (DLT at 15 mg/m(2)/day) and one with a level 1 ventricular arrhythmia (30 mg/m(2)/day). The main ECG changes were ST-segment and T wave changes. Exposure to endostar and CIV dose was linear between 7.5 and 30 mg/m(2)/day (R (2) = 0.974). CONCLUSIONS: Endostar in combination with mFOLFOX6 was generally safe and well tolerated. FAU - Chen, Zhiyu AU - Chen Z AD - Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. FAU - Guo, Weijian AU - Guo W FAU - Cao, Junning AU - Cao J FAU - Lv, Fangfang AU - Lv F FAU - Zhang, Wen AU - Zhang W FAU - Qiu, Lixin AU - Qiu L FAU - Li, Wenhua AU - Li W FAU - Ji, Dongmei AU - Ji D FAU - Zhang, Sheng AU - Zhang S FAU - Xia, Zuguang AU - Xia Z FAU - Wang, Jiachen AU - Wang J FAU - Li, Jin AU - Li J LA - eng PT - Clinical Trial, Phase I PT - Journal Article DEP - 20150109 PL - Germany TA - Cancer Chemother Pharmacol JT - Cancer chemotherapy and pharmacology JID - 7806519 RN - 0 (Endostatins) RN - 0 (Organoplatinum Compounds) RN - 0 (endostar protein) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Folfox protocol SB - IM MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects/therapeutic use MH - Colorectal Neoplasms/*drug therapy/pathology MH - Dose-Response Relationship, Drug MH - Endostatins/administration & dosage MH - Female MH - Fluorouracil/administration & dosage/adverse effects/therapeutic use MH - Humans MH - Infusions, Intravenous MH - Leucovorin/administration & dosage/adverse effects/therapeutic use MH - Male MH - Maximum Tolerated Dose MH - Middle Aged MH - Organoplatinum Compounds/administration & dosage/adverse effects/therapeutic use EDAT- 2015/01/13 06:00 MHDA- 2015/04/24 06:00 CRDT- 2015/01/10 06:00 PHST- 2014/10/10 [received] PHST- 2014/12/16 [accepted] PHST- 2015/01/09 [aheadofprint] AID - 10.1007/s00280-014-2656-9 [doi] PST - ppublish SO - Cancer Chemother Pharmacol. 2015 Mar;75(3):547-57. doi: 10.1007/s00280-014-2656-9. Epub 2015 Jan 9. PMID- 25560505 OWN - NLM STAT- MEDLINE DA - 20150106 DCOM- 20150331 IS - 1221-9118 (Print) IS - 1221-9118 (Linking) VI - 109 IP - 6 DP - 2014 Nov-Dec TI - Involvement of reactive oxygen species in the mechanisms associated with cervical cancer specific treatment. PG - 806-11 LID - 12 [pii] AB - Cervical cancer represents a genuine health issue in Romania.The courses of treatment applied are complex, and the accompanying biochemical mechanisms are yet to be fully understood. Thus, radiotherapy, which induces reactive oxygen species, can lead to failure of treatment in hypoxic tissues,tissues which are difficult to identify due to the small quantity in which these cytotoxic species are produced. As a result, the aim of this paper is to identify the production and role of reactive oxygen species, as well as the manner of activation of endogenous antioxidant defense mechanisms in cervical cancer patients admitted to the Oncologic Institute of Bucharest. To this purpose the biochemical parameters of oxidative stress were identified in 30 patients with cervical tumour localization, prior to surgery. The results obtained have showed that a production of reactive oxygen species is identifiable in these patients, having lipids as a primary target and leading to their peroxidation. The extension of protein oxidative degradation takes place at a much lower value, as well as the activation of endogenous antioxidant defence systems, comparing to our expectations. To conclude,we consider that when the production of active oxygen metabolites takes place in small concentrations, associated with hypoxia, the signals transmitted are towards modifying the phenotype under anaerobic conditions into one activating neo vascularization, angiogenesis initiation, new cell growth and proliferation. The moment that this phase is overcome anew oxidative stress is installed, one potentially destructive for biomolecules essential to life, but also useful for further treatment, such as radiotherapy. CI - Celsius. FAU - Marinescu, S AU - Marinescu S FAU - Anghel, R AU - Anghel R FAU - Gruia, M I AU - Gruia MI FAU - Beuran, M AU - Beuran M LA - eng PT - Journal Article PL - Romania TA - Chirurgia (Bucur) JT - Chirurgia (Bucharest, Romania : 1990) JID - 9213031 RN - 0 (Antioxidants) RN - 0 (Biological Markers) RN - 0 (Lipid Peroxides) RN - 0 (Reactive Oxygen Species) RN - 4Y8F71G49Q (Malondialdehyde) RN - EC 1.16.3.1 (Ceruloplasmin) SB - IM MH - Antioxidants/metabolism MH - Biological Markers/*blood MH - Ceruloplasmin/metabolism MH - Female MH - Humans MH - Lipid Peroxides/blood MH - Malondialdehyde/blood MH - Neoplasm Staging MH - Oxidation-Reduction MH - *Oxidative Stress MH - Preoperative Care MH - Reactive Oxygen Species/*metabolism MH - Uterine Cervical Neoplasms/blood/enzymology/*metabolism/pathology/*therapy EDAT- 2015/01/07 06:00 MHDA- 2015/04/01 06:00 CRDT- 2015/01/07 06:00 PHST- 2014/12/01 [accepted] AID - 12 [pii] PST - ppublish SO - Chirurgia (Bucur). 2014 Nov-Dec;109(6):806-11. PMID- 25560187 OWN - NLM STAT- MEDLINE DA - 20150209 DCOM- 20150416 IS - 1879-0038 (Electronic) IS - 0378-1119 (Linking) VI - 558 IP - 2 DP - 2015 Mar 10 TI - Vitamin D receptor gene polymorphisms and steroid receptor status among Saudi women with breast cancer. PG - 215-9 LID - 10.1016/j.gene.2014.12.065 [doi] LID - S0378-1119(14)01491-7 [pii] AB - The vitamin D receptor (VDR) is a mediator for the cellular effects of vitamin D and interacts with other cell signaling pathways that influence cancer development. We evaluated the associations of the FOK1 and Taq1 VDR polymorphisms and breast cancer risk and possible effect modification by steroid receptor status of the tumor. This case-control study includes 95 breast cancer patients and 100 age-matched controls. Genotyping for VDR FOK1 and Taq1 polymorphisms was performed using polymerase chain reaction-based restriction fragment length polymorphism. Level of 25(OH)D in serum was determined using ELISA. Immunohistochemical studies were performed for estrogen receptors (ER) and progesterone receptors (PR). The frequencies of ff genotype were significantly increased in the breast cancer group compared to the control group. Carriers of the f allele were significantly more likely to develop BC. We observed a statistically significant interaction for the Fok1 polymorphism and ER status. Our results demonstrated that FOK1 f. genotype and f allele have an important role in breast cancer risk in Saudi patients. CI - Copyright (c) 2015 Elsevier B.V. All rights reserved. FAU - Nemenqani, Dalal M AU - Nemenqani DM AD - Department of Pathology and Cytopathology, College of Medicine, Taif University, Saudi Arabia; Laboratory and Blood Bank, King Abdul Aziz Hospital, Taif, Saudi Arabia. FAU - Karam, Rehab A AU - Karam RA AD - Department of Biochemistry, college of Medicine, Taif University, Al Taif, Saudi Arabia; Departments of Biochemistry, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: rehab_atta@yahoo.com. FAU - Amer, Mona G AU - Amer MG AD - Department of Anatomy and Histology, College of Medicine, Taif University, Al Taif, Saudi Arabia; Departments of Histology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Abd El Rahman, Tamer M AU - Abd El Rahman TM AD - Department of surgery, College of Medicine, Taif University, Al Taif, Saudi Arabia; Department of surgery, Benha Teaching Hospital, Benha, Egypt. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150102 PL - Netherlands TA - Gene JT - Gene JID - 7706761 RN - 0 (Receptors, Calcitriol) RN - 0 (Receptors, Estrogen) RN - 0 (Receptors, Progesterone) RN - 0 (VDR protein, human) RN - EC 3.1.21.- (endodeoxyribonuclease FokI) RN - EC 3.1.21.4 (Deoxyribonucleases, Type II Site-Specific) RN - EC 3.1.21.4 (TCGA-specific type II deoxyribonucleases) RN - P6YZ13C99Q (Calcifediol) SB - IM MH - Adult MH - Breast Neoplasms/epidemiology/*genetics MH - Calcifediol/blood MH - Case-Control Studies MH - Deoxyribonucleases, Type II Site-Specific/metabolism MH - Female MH - Genetic Predisposition to Disease MH - Humans MH - Middle Aged MH - *Polymorphism, Restriction Fragment Length MH - Receptors, Calcitriol/*genetics MH - Receptors, Estrogen/*metabolism MH - Receptors, Progesterone/*metabolism MH - Saudi Arabia/epidemiology OTO - NOTNLM OT - Breast cancer OT - Single nucleotide polymorphisms OT - Vitamin D receptor EDAT- 2015/01/07 06:00 MHDA- 2015/04/17 06:00 CRDT- 2015/01/07 06:00 PHST- 2014/09/26 [received] PHST- 2014/12/13 [revised] PHST- 2014/12/27 [accepted] PHST- 2015/01/02 [aheadofprint] AID - S0378-1119(14)01491-7 [pii] AID - 10.1016/j.gene.2014.12.065 [doi] PST - ppublish SO - Gene. 2015 Mar 10;558(2):215-9. doi: 10.1016/j.gene.2014.12.065. Epub 2015 Jan 2. PMID- 25524803 OWN - NLM STAT- MEDLINE DA - 20150202 DCOM- 20150401 IS - 1474-5488 (Electronic) IS - 1470-2045 (Linking) VI - 16 IP - 1 DP - 2015 Jan TI - Skeletal muscle anabolism in patients with advanced cancer. PG - 13-4 LID - 10.1016/S1470-2045(14)71185-4 [doi] LID - S1470-2045(14)71185-4 [pii] FAU - Baracos, Vickie E AU - Baracos VE AD - Department of Oncology, University of Alberta, 11560 University Avenue, Edmonton, Canada T6G1Z2. Electronic address: vickie.baracos@ualberta.ca. LA - eng PT - Comment PT - Journal Article DEP - 20141216 PL - England TA - Lancet Oncol JT - The Lancet. Oncology JID - 100957246 RN - 0 (Anabolic Agents) RN - 0 (Appetite Stimulants) RN - 0 (Hydrazines) RN - 0 (Oligopeptides) RN - 0 (anamorelin) SB - IM CON - Lancet Oncol. 2015 Jan;16(1):108-16. PMID: 25524795 MH - Anabolic Agents/*therapeutic use MH - Appetite Stimulants/*therapeutic use MH - Cachexia/*drug therapy MH - Female MH - Humans MH - Hydrazines/*therapeutic use MH - Male MH - Neoplasms/*complications MH - Oligopeptides/*therapeutic use EDAT- 2014/12/20 06:00 MHDA- 2015/04/02 06:00 CRDT- 2014/12/20 06:00 PHST- 2014/12/16 [aheadofprint] AID - S1470-2045(14)71185-4 [pii] AID - 10.1016/S1470-2045(14)71185-4 [doi] PST - ppublish SO - Lancet Oncol. 2015 Jan;16(1):13-4. doi: 10.1016/S1470-2045(14)71185-4. Epub 2014 Dec 16. PMID- 25524795 OWN - NLM STAT- MEDLINE DA - 20150202 DCOM- 20150401 IS - 1474-5488 (Electronic) IS - 1470-2045 (Linking) VI - 16 IP - 1 DP - 2015 Jan TI - Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. PG - 108-16 LID - 10.1016/S1470-2045(14)71154-4 [doi] LID - S1470-2045(14)71154-4 [pii] AB - BACKGROUND: Cancer anorexia-cachexia syndrome is associated with increased morbidity and mortality. Anamorelin is an oral ghrelin-receptor agonist with appetite-enhancing and anabolic activity. We assessed the effects of anamorelin on body composition, strength, quality of life, biochemical markers, and safety in patients with cancer anorexia-cachexia. METHODS: Data were pooled, a priori, from two completed phase 2, multicentre, placebo-controlled, double-blind trials in patients with advanced or incurable cancer and weight loss of 5% or more. Patients were stratified by weight loss severity (5-15%, >15%) and randomly allocated (1:1) with a computer-generated randomisation schedule to anamorelin hydrochloride 50 mg or placebo once-daily for 12 weeks. Primary outcome was lean body mass by dual-energy x-ray absorptiometry over the 12 week treatment period in eligible patients who had at least one dose of study drug and post-treatment efficacy assessment. We assessed safety in all patients who received at least one dose of study drug. The trials are registered with ClinicalTrials.gov, numbers NCT00219817 and NCT00267358. FINDINGS: Between June 29, 2005, and Oct 26, 2006, we enrolled 44 patients in the anamorelin group and 38 patients in the placebo group. 74 patients were eligible for the efficacy analyses. Over 12 weeks, lean body mass increased in 38 patients in the anamorelin group by a least-squares mean of 1.89 kg (95% CI 0.84 to 2.95) compared with a decrease of a least-squares mean of -0.20 kg (-1.23 to 0.83) for 36 patients in the placebo group (difference 2.09 kg [0.94-3.25]; p=0.0006). 42 (95%) of 44 patients treated with anamorelin and 33 (87%) of 38 patients treated with placebo had adverse events. The most common grade 3-4 adverse events (treatment-related or not) in the anamorelin group were fatigue, asthenia, atrial fibrillation, and dyspnoea (two [5%] each); in the placebo group, such events were pneumonia (three [8%]) and anaemia, thrombocytopenia, abdominal pain, anxiety, and dyspnoea (two [5%] each). INTERPRETATION: Anamorelin treatment for 12 weeks had a favourable clinical response profile in patients with cancer anorexia-cachexia syndrome. These findings support further investigation in this setting. FUNDING: Helsinn Therapeutics (US), Helsinn Healthcare SA. CI - Copyright (c) 2015 Elsevier Ltd. All rights reserved. FAU - Garcia, Jose M AU - Garcia JM AD - Division of Endocrinology, Diabetes and Metabolism, Center for Translational Research on Inflammatory Diseases, Michael E DeBakey VA Medical Center, and Baylor College of Medicine, Houston, TX, USA. Electronic address: jgarcia1@bcm.edu. FAU - Boccia, Ralph V AU - Boccia RV AD - Georgetown University, Center for Cancer and Blood Disorders, Bethesda, MD, USA. FAU - Graham, Charles D AU - Graham CD AD - Charleston Cancer Center, Charleston, SC, USA. FAU - Yan, Ying AU - Yan Y AD - Helsinn Therapeutics (US), Bridgewater, NJ, USA. FAU - Duus, Elizabeth Manning AU - Duus EM AD - Helsinn Therapeutics (US), Bridgewater, NJ, USA. FAU - Allen, Suzan AU - Allen S AD - Helsinn Therapeutics (US), Bridgewater, NJ, USA. FAU - Friend, John AU - Friend J AD - Helsinn Therapeutics (US), Bridgewater, NJ, USA. LA - eng SI - ClinicalTrials.gov/NCT00219817 SI - ClinicalTrials.gov/NCT00267358 GR - AG040583/AG/NIA NIH HHS/United States GR - NIA T32AG000183/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20141216 PL - England TA - Lancet Oncol JT - The Lancet. Oncology JID - 100957246 RN - 0 (Anabolic Agents) RN - 0 (Appetite Stimulants) RN - 0 (Hydrazines) RN - 0 (Oligopeptides) RN - 0 (anamorelin) SB - IM CIN - Lancet Oncol. 2015 Jan;16(1):13-4. PMID: 25524803 MH - Absorptiometry, Photon MH - Adult MH - Aged MH - Aged, 80 and over MH - Anabolic Agents/adverse effects/*therapeutic use MH - Analysis of Variance MH - Appetite Stimulants/adverse effects/*therapeutic use MH - Body Composition/drug effects MH - Cachexia/diagnosis/*drug therapy/etiology/physiopathology MH - Clinical Trials, Phase II as Topic MH - Female MH - Humans MH - Hydrazines/adverse effects/*therapeutic use MH - Least-Squares Analysis MH - Male MH - Middle Aged MH - Muscle Strength/drug effects MH - Neoplasms/*complications MH - Oligopeptides/adverse effects/*therapeutic use MH - Quality of Life MH - Randomized Controlled Trials as Topic MH - Time Factors MH - Treatment Outcome MH - United States MH - Weight Gain/drug effects MH - Young Adult EDAT- 2014/12/20 06:00 MHDA- 2015/04/02 06:00 CRDT- 2014/12/20 06:00 PHST- 2014/12/16 [aheadofprint] AID - S1470-2045(14)71154-4 [pii] AID - 10.1016/S1470-2045(14)71154-4 [doi] PST - ppublish SO - Lancet Oncol. 2015 Jan;16(1):108-16. doi: 10.1016/S1470-2045(14)71154-4. Epub 2014 Dec 16. PMID- 25499998 OWN - NLM STAT- MEDLINE DA - 20150131 DCOM- 20150406 IS - 1532-1967 (Electronic) IS - 0305-7372 (Linking) VI - 41 IP - 2 DP - 2015 Feb TI - Metallic taste in cancer patients treated with chemotherapy. PG - 179-86 LID - 10.1016/j.ctrv.2014.11.006 [doi] LID - S0305-7372(14)00192-3 [pii] AB - BACKGROUND: Metallic taste is a taste alteration frequently reported by cancer patients treated with chemotherapy. Attention to this side effect of chemotherapy is limited. This review addresses the definition, assessment methods, prevalence, duration, etiology, and management strategies of metallic taste in chemotherapy treated cancer patients. METHODS: Literature search for metallic taste and chemotherapy was performed in PubMed up to September 2014, resulting in 184 articles of which 13 articles fulfilled the inclusion criteria: English publications addressing metallic taste in cancer patients treated with FDA-approved chemotherapy. An additional search in Google Scholar, in related articles of both search engines, and subsequent in the reference lists, resulted in 13 additional articles included in this review. Cancer patient forums were visited to explore management strategies. FINDINGS: Prevalence of metallic taste ranged from 9.7% to 78% among patients with various cancers, chemotherapy treatments, and treatment phases. No studies have been performed to investigate the influence of metallic taste on dietary intake, body weight, and quality of life. Several management strategies can be recommended for cancer patients: using plastic utensils, eating cold or frozen foods, adding strong herbs, spices, sweetener or acid to foods, eating sweet and sour foods, using 'miracle fruit' supplements, and rinsing with chelating agents. INTERPRETATION: Although metallic taste is a frequent side effect of chemotherapy and a much discussed topic on cancer patient forums, literature regarding metallic taste among chemotherapy treated cancer patients is scarce. More awareness for this side effect can improve the support for these patients. CI - Copyright (c) 2014 Elsevier Ltd. All rights reserved. FAU - IJpma, I AU - IJpma I AD - Top Institute Food and Nutrition, Wageningen, The Netherlands; Neuroimaging Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: i.ijpma@umcg.nl. FAU - Renken, R J AU - Renken RJ AD - Top Institute Food and Nutrition, Wageningen, The Netherlands; Neuroimaging Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: r.j.renken@umcg.nl. FAU - Ter Horst, G J AU - Ter Horst GJ AD - Top Institute Food and Nutrition, Wageningen, The Netherlands; Neuroimaging Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: g.j.ter.horst@umcg.nl. FAU - Reyners, A K L AU - Reyners AK AD - Top Institute Food and Nutrition, Wageningen, The Netherlands; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: a.k.l.reyners@umcg.nl. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20141205 PL - Netherlands TA - Cancer Treat Rev JT - Cancer treatment reviews JID - 7502030 RN - 0 (Platinum Compounds) RN - 80168379AG (Doxorubicin) RN - 8N3DW7272P (Cyclophosphamide) RN - U3P01618RT (Fluorouracil) RN - CAF protocol SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects MH - Cyclophosphamide/adverse effects MH - Doxorubicin/adverse effects MH - Fluorouracil/adverse effects MH - Humans MH - Interviews as Topic MH - Neoplasms/*drug therapy MH - Platinum Compounds/adverse effects MH - Prevalence MH - Quality of Life MH - Questionnaires MH - Taste Disorders/*chemically induced/epidemiology/physiopathology/*prevention & control MH - Time Factors OTO - NOTNLM OT - Cancer patients OT - Chemotherapy OT - Metallic taste EDAT- 2014/12/17 06:00 MHDA- 2015/04/07 06:00 CRDT- 2014/12/16 06:00 PHST- 2014/10/15 [received] PHST- 2014/11/24 [revised] PHST- 2014/11/27 [accepted] PHST- 2014/12/05 [aheadofprint] AID - S0305-7372(14)00192-3 [pii] AID - 10.1016/j.ctrv.2014.11.006 [doi] PST - ppublish SO - Cancer Treat Rev. 2015 Feb;41(2):179-86. doi: 10.1016/j.ctrv.2014.11.006. Epub 2014 Dec 5. PMID- 25489965 OWN - NLM STAT- MEDLINE DA - 20150218 DCOM- 20150421 IS - 1557-7430 (Electronic) IS - 1044-5498 (Linking) VI - 34 IP - 3 DP - 2015 Mar TI - DNA damage and oxidant-antioxidant status in blood of patients with head and neck cancer. PG - 213-9 LID - 10.1089/dna.2014.2706 [doi] AB - Oxidative stress induces a cellular redox imbalance that has been found to be present in various cancer cells, and overproduction of free radicals may be related to oncogenic stimulation. We investigated the activity of the following antioxidant enzymes: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and malondialdehyde (MDA) concentrations in blood of patients with head and neck squamous cell carcinoma (HNSCC) compared with the control group. A comet assay was used to assess DNA damage. A nonsignificant increase of MDA and a decrease of SOD, CAT, and GPx (p>0.05) were seen in HNSCC patients compared with controls. It was found that the level of oxidative DNA damage in HNSCC patients was significantly higher compared with the control group (p /= 28.0 kg/m(2); P < .001) and five categories of %WL (-2.5% to -5.9%, -6.0% to -10.9%, -11.0% to -14.9%, >/= -15.0%, and weight stable (+/- 2.4%); P < .001). A 5 x 5 matrix representing the five %WL categories within each of the five BMI categories was graded based on median survival and prognostic significance. Weight-stable patients with BMI >/= 25.0 kg/m(2) (grade 0) had the longest survival (20.9 months; 95% CI, 17.9 to 23.9 months), and %WL values associated with lowered categories of BMI were related to shorter survival (P < .001), as follows: grade 1, 14.6 months (95% CI, 12.9 to 16.2 months); grade 2, 10.8 months (95% CI, 9.7 to 11.9 months); grade 3, 7.6 months (95% CI, 7.0 to 8.2 months); and grade 4, 4.3 months (95% CI, 4.1 to 4.6 months). Survival discrimination by grade was observed within specific cancers, stages, ages, and performance status and in an independent validation sample (n = 2,963). CONCLUSION: A robust grading system incorporating the independent prognostic significance of both BMI and %WL was developed. CI - (c) 2014 by American Society of Clinical Oncology. FAU - Martin, Lisa AU - Martin L AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Senesse, Pierre AU - Senesse P AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Gioulbasanis, Ioannis AU - Gioulbasanis I AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Antoun, Sami AU - Antoun S AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Bozzetti, Federico AU - Bozzetti F AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Deans, Chris AU - Deans C AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Strasser, Florian AU - Strasser F AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Thoresen, Lene AU - Thoresen L AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Jagoe, R Thomas AU - Jagoe RT AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Chasen, Martin AU - Chasen M AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Lundholm, Kent AU - Lundholm K AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Bosaeus, Ingvar AU - Bosaeus I AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Fearon, Kenneth H AU - Fearon KH AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Baracos, Vickie E AU - Baracos VE AD - Lisa Martin and Vickie E. Baracos, University of Alberta, Edmonton, Alberta; R. Thomas Jagoe, McGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec; Martin Chasen, University of Ottawa, Ottawa, Ontario, Canada; Pierre Senesse, Institut Regional du Cancer de Montpellier, Montpellier; Sami Antoun, Institut Gustave Roussy, Villejuif, France; Ioannis Gioulbasanis, Larissa General Clinic, Larissa, Thessaly, Greece; Federico Bozzetti, University of Milan, Milan, Italy; Chris Deans and Kenneth H. Fearon, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, United Kingdom; Florian Strasser, Cantonal Hospital, St Gallen, Switzerland; Lene Thoresen, St Olavs University Hospital, Trondheim, Norway; Kent Lundholm, Institute of Clinical Sciences, Gothenburg University; and Ingvar Bosaeus, Sahlgrenska University Hospital, Gothenburg, Sweden. vickie.baracos@ualberta.ca. LA - eng GR - Canadian Institutes of Health Research/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141124 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 SB - IM EIN - J Clin Oncol. 2015 Mar 1;33(7):814. PMID: 25721580 MH - Aged MH - *Body Mass Index MH - Cachexia/classification/*diagnosis/etiology MH - Canada MH - Databases, Factual/statistics & numerical data MH - Europe MH - Female MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Staging MH - Neoplasms/complications/pathology/*physiopathology MH - Population Surveillance/methods MH - Prognosis MH - Prospective Studies MH - Survival Analysis MH - Weight Loss/*physiology EDAT- 2014/11/26 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/11/26 06:00 PHST- 2014/11/24 [aheadofprint] AID - JCO.2014.56.1894 [pii] AID - 10.1200/JCO.2014.56.1894 [doi] PST - ppublish SO - J Clin Oncol. 2015 Jan 1;33(1):90-9. doi: 10.1200/JCO.2014.56.1894. Epub 2014 Nov 24. PMID- 25375930 OWN - NLM STAT- MEDLINE DA - 20150116 DCOM- 20150407 IS - 2168-619X (Electronic) IS - 2168-6181 (Linking) VI - 141 IP - 1 DP - 2015 Jan TI - Sites of origin of oral cavity cancer in nonsmokers vs smokers: possible evidence of dental trauma carcinogenesis and its importance compared with human papillomavirus. PG - 5-11 LID - 10.1001/jamaoto.2014.2620 [doi] AB - IMPORTANCE: The relatively high and possibly rising incidence of mouth squamous cell carcinoma in nonsmokers, especially women, without obvious cause has been noted by previous authors. Is chronic dental trauma and irritation a carcinogen, and what is its importance compared with human papillomavirus (HPV) oropharyngeal cancer in nonsmokers? OBJECTIVE: To determine whether oral cavity cancers occurred more commonly at sites of dental trauma and how the position of these cancers varied between nonsmokers lacking major identified carcinogens and smokers. If these cancers occurred more frequently at sites of chronic trauma, especially in nonsmokers, it would suggest chronic dental trauma as a possible carcinogen. DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis of 881 patients with oral cavity or oropharyngeal cancers seen through a tertiary referral hospital between 2001 and 2011 was performed. MAIN OUTCOMES AND MEASURES: Patient medical records were analyzed to determine the location of the tumor within the oral cavity and oropharynx and how it relates to patient demographics, smoking and alcohol histories, and comorbidities. Dental histories were also sought, including use of dentures. RESULTS: Nonsmokers comprised 87 of 390 patients with mouth cancer (22%) and 48 of 334 patients with oropharyngeal cancer (14%). Female nonsmoking patients included 53 with oral cancer (61%) but only 12 with oropharyngeal squamous cell carcinoma (25%). Oral cancers occurred on the lateral tongue, a potential site of chronic dental trauma, in 57 nonsmokers (66%) compared with 107 smokers/ex-smokers (33%) (P < .001). Gingival and floor of mouth lesions occurred in older patients, possibly from chronic denture rubbing. Twenty-six patients had dental abnormalities recorded in close proximity to where their tumor developed. CONCLUSIONS AND RELEVANCE: Oral cavity cancers occur predominantly at sites of potential dental and denture trauma, especially in nonsmokers without other risk factors. Recognizing teeth irritation as a potential carcinogen would have an impact on prevention and treatment strategies. FAU - Perry, Brendan J AU - Perry BJ AD - Princess Alexandra Hospital, Brisbane, Queensland, Australia. FAU - Zammit, Andrew P AU - Zammit AP AD - University of Queensland School of Medicine, Brisbane, Queensland, Australia. FAU - Lewandowski, Andrew W AU - Lewandowski AW AD - University of Queensland School of Medicine, Brisbane, Queensland, Australia. FAU - Bashford, Julia J AU - Bashford JJ AD - Princess Alexandra Hospital, Brisbane, Queensland, Australia. FAU - Dragovic, Adrian S AU - Dragovic AS AD - Princess Alexandra Hospital, Brisbane, Queensland, Australia. FAU - Perry, Emily J AU - Perry EJ AD - Princess Alexandra Hospital, Brisbane, Queensland, Australia. FAU - Hayatbakhsh, Reza AU - Hayatbakhsh R AD - University of Queensland School of Population Health, Brisbane, Queensland, Australia. FAU - Perry, Christopher F L AU - Perry CF AD - Princess Alexandra Hospital, Brisbane, Queensland, Australia. LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - JAMA Otolaryngol Head Neck Surg JT - JAMA otolaryngology-- head & neck surgery JID - 101589542 SB - AIM SB - IM MH - Alcohol Drinking/adverse effects MH - Carcinoma, Squamous Cell/*etiology MH - Dental Care/*adverse effects MH - Dentures/adverse effects MH - Female MH - Humans MH - Male MH - Medical Records MH - Middle Aged MH - Mouth/*injuries MH - Mouth Neoplasms/*etiology MH - Oropharyngeal Neoplasms/etiology MH - Papillomavirus Infections/complications MH - Retrospective Studies MH - *Smoking/adverse effects EDAT- 2014/11/07 06:00 MHDA- 2015/04/08 06:00 CRDT- 2014/11/07 06:00 AID - 1921367 [pii] AID - 10.1001/jamaoto.2014.2620 [doi] PST - ppublish SO - JAMA Otolaryngol Head Neck Surg. 2015 Jan;141(1):5-11. doi: 10.1001/jamaoto.2014.2620. PMID- 25369236 OWN - NLM STAT- MEDLINE DA - 20150110 DCOM- 20150417 IS - 1476-8321 (Electronic) IS - 0887-0446 (Linking) VI - 30 IP - 3 DP - 2015 TI - Perceptions of the roles of behaviour and genetics in disease risk: are they associated with behaviour change attempts. PG - 336-53 LID - 10.1080/08870446.2014.972958 [doi] AB - The aims of the present study were to (i) examine the prevalence of perceived behavioural and genetic causal beliefs for four chronic conditions (i.e. obesity, heart disease, diabetes and cancer); (ii) to examine the association between these causal beliefs and attempts at behaviour change (i.e. physical activity, weight management, fruit intake, vegetable intake and soda intake). The data come from the Health Information National Trends Survey, a nationally representative population-based survey of adults (N = 3407). Results indicated that participants held both behavioural and genetic causal beliefs for all four chronic conditions. Multivariate analyses indicated that behavioural causal beliefs were significantly associated with attempts to increase physical activity and vegetable intake and to decrease weight. Genetic causal beliefs for cancer were significantly associated with reported attempts to maintain weight. Behaviour and genetic causal beliefs were not associated with changes in either fruit or soda intake. In conclusion, while behavioural causal beliefs are associated with behavioural change, measurement must capture disease-specific behavioural causal beliefs as they are associated with different health behaviours. FAU - Nguyen, Anh B AU - Nguyen AB AD - a Division of Cancer Control and Population Sciences , The National Cancer Institute , Rockville , MD , USA. FAU - Oh, April AU - Oh A FAU - Moser, Richard P AU - Moser RP FAU - Patrick, Heather AU - Patrick H LA - eng PT - Journal Article DEP - 20141121 PL - England TA - Psychol Health JT - Psychology & health JID - 8807983 SB - IM MH - Adolescent MH - Adult MH - Diabetes Mellitus/*psychology MH - Female MH - Genetic Predisposition to Disease/*psychology MH - *Health Behavior MH - *Health Knowledge, Attitudes, Practice MH - Heart Diseases/*psychology MH - Humans MH - Male MH - Middle Aged MH - Neoplasms/*psychology MH - Obesity/*psychology MH - Risk Assessment MH - Young Adult OTO - NOTNLM OT - behaviour change OT - causal beliefs OT - chronic conditions EDAT- 2014/11/05 06:00 MHDA- 2015/04/18 06:00 CRDT- 2014/11/05 06:00 PHST- 2014/11/21 [aheadofprint] AID - 10.1080/08870446.2014.972958 [doi] PST - ppublish SO - Psychol Health. 2015;30(3):336-53. doi: 10.1080/08870446.2014.972958. Epub 2014 Nov 21. PMID- 25349295 OWN - NLM STAT- MEDLINE DA - 20141231 DCOM- 20150420 LR - 20150326 IS - 1527-7755 (Electronic) IS - 0732-183X (Linking) VI - 33 IP - 1 DP - 2015 Jan 1 TI - Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. PG - 36-41 LID - 10.1200/JCO.2014.57.2826 [doi] AB - PURPOSE: The optimal end point for randomized phase II trials of anticancer therapies remains controversial. We simulated phase II trials by resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of various end points to detect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin]). METHODS: Tumor measurements and progression-free survival (PFS) data were obtained for 1,471 patients; 1,002 had consistently measured tumors and were resampled (5,000 replicates) to simulate two-arm, randomized phase II trials with alpha = 0.10 (one sided) and 20 to 80 patients per arm. End points included log ratio of tumor size at 6, 12, and 18 weeks relative to baseline; time to tumor growth (TTG), estimated using a nonlinear mixed-effects model; and PFS. Arms were compared using rank sum tests for log ratio and TTG and a log-rank test for PFS. RESULTS: For FOLFOX versus IFL, TTG and PFS had similar power, with both exceeding the power of log ratio at 18 weeks; for FOLFOX versus IROX, TTG and log ratio at 18 weeks had similar power, with both exceeding the power of PFS. The best end points exhibited > 80% power with 60 to 80 patients per arm. CONCLUSION: TTG is a powerful end point for randomized phase II trials of cytotoxic therapies in metastatic colorectal cancer; it was either comparable or superior to PFS and log ratio at 18 weeks. Additional studies will be needed to clarify the potential of TTG as a phase II end point. CI - (c) 2014 by American Society of Clinical Oncology. FAU - Sharma, Manish R AU - Sharma MR AD - Manish R. Sharma, Elizabeth Gray, and Theodore G. Karrison, University of Chicago, Chicago, IL; Richard M. Goldberg, Ohio State University, Columbus, OH; and Daniel J. Sargent, Mayo Clinic, Rochester, MN. msharma@medicine.bsd.uchicago.edu. FAU - Gray, Elizabeth AU - Gray E AD - Manish R. Sharma, Elizabeth Gray, and Theodore G. Karrison, University of Chicago, Chicago, IL; Richard M. Goldberg, Ohio State University, Columbus, OH; and Daniel J. Sargent, Mayo Clinic, Rochester, MN. FAU - Goldberg, Richard M AU - Goldberg RM AD - Manish R. Sharma, Elizabeth Gray, and Theodore G. Karrison, University of Chicago, Chicago, IL; Richard M. Goldberg, Ohio State University, Columbus, OH; and Daniel J. Sargent, Mayo Clinic, Rochester, MN. FAU - Sargent, Daniel J AU - Sargent DJ AD - Manish R. Sharma, Elizabeth Gray, and Theodore G. Karrison, University of Chicago, Chicago, IL; Richard M. Goldberg, Ohio State University, Columbus, OH; and Daniel J. Sargent, Mayo Clinic, Rochester, MN. FAU - Karrison, Theodore G AU - Karrison TG AD - Manish R. Sharma, Elizabeth Gray, and Theodore G. Karrison, University of Chicago, Chicago, IL; Richard M. Goldberg, Ohio State University, Columbus, OH; and Daniel J. Sargent, Mayo Clinic, Rochester, MN. LA - eng GR - K12CA139160/CA/NCI NIH HHS/United States GR - P30CA014599/CA/NCI NIH HHS/United States GR - U10 CA180850/CA/NCI NIH HHS/United States GR - UL1 TR000430/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20141027 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 RN - 0 (Organoplatinum Compounds) RN - 04ZR38536J (oxaliplatin) RN - 7673326042 (irinotecan) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - XT3Z54Z28A (Camptothecin) SB - IM CIN - J Clin Oncol. 2015 Jan 1;33(1):4-6. PMID: 25366687 MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Camptothecin/administration & dosage/analogs & derivatives MH - *Clinical Trials, Phase II as Topic MH - *Clinical Trials, Phase III as Topic MH - Colorectal Neoplasms/*drug therapy/pathology MH - Disease Progression MH - Fluorouracil/administration & dosage MH - Humans MH - Kaplan-Meier Estimate MH - Leucovorin/administration & dosage MH - Neoplasm Metastasis MH - Organoplatinum Compounds/administration & dosage MH - *Randomized Controlled Trials as Topic MH - Treatment Outcome MH - Tumor Burden/drug effects PMC - PMC4268251 OID - NLM: PMC4268251 [Available on 01/01/16] EDAT- 2014/10/29 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/10/29 06:00 PMCR- 2016/01/01 00:00 PHST- 2014/10/27 [aheadofprint] AID - JCO.2014.57.2826 [pii] AID - 10.1200/JCO.2014.57.2826 [doi] PST - ppublish SO - J Clin Oncol. 2015 Jan 1;33(1):36-41. doi: 10.1200/JCO.2014.57.2826. Epub 2014 Oct 27. PMID- 25314053 OWN - NLM STAT- MEDLINE DA - 20150107 DCOM- 20150423 IS - 1532-1827 (Electronic) IS - 0007-0920 (Linking) VI - 112 IP - 1 DP - 2015 Jan 6 TI - Lactose intolerance and risk of lung, breast and ovarian cancers: aetiological clues from a population-based study in Sweden. PG - 149-52 LID - 10.1038/bjc.2014.544 [doi] AB - BACKGROUND: Individuals with lactose intolerance are recommended to avoid milk or dairy products, which may affect the development of cancer. METHODS: We identified individuals with lactose intolerance from several Swedish Registers linked to the Swedish Cancer Registry to calculate standardised incidence ratios (SIRs) for cancers in the breast, lung, and ovary. RESULTS: A total of 22,788 individuals with lactose intolerance were identified, and their risks of lung (SIR=0.55), breast (SIR=0.79), and ovarian (SIR=0.61) cancers were significantly decreased. Cancer incidences in the siblings and parents of individuals with lactose intolerance were similar to those in the general population. CONCLUSIONS: In this large cohort study, people with lactose intolerance, characterised by low consumption of milk and other dairy products, had decreased risks of lung, breast, and ovarian cancers, but the decreased risks were not found in their family members, suggesting that the protective effects against these cancers may be related to their specific dietary pattern. FAU - Ji, J AU - Ji J AD - Center for Primary Health Care Research, Lund University, Malmo, Sweden. FAU - Sundquist, J AU - Sundquist J AD - 1] Center for Primary Health Care Research, Lund University, Malmo, Sweden [2] Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA. FAU - Sundquist, K AU - Sundquist K AD - 1] Center for Primary Health Care Research, Lund University, Malmo, Sweden [2] Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141014 PL - England TA - Br J Cancer JT - British journal of cancer JID - 0370635 SB - IM MH - Adult MH - Breast Neoplasms/*epidemiology MH - Cohort Studies MH - Female MH - Humans MH - Lactose Intolerance/*epidemiology MH - Lung Neoplasms/*epidemiology MH - Male MH - Ovarian Neoplasms/*epidemiology MH - Risk MH - Sweden/epidemiology EDAT- 2014/10/15 06:00 MHDA- 2015/04/24 06:00 CRDT- 2014/10/15 06:00 PHST- 2014/05/19 [received] PHST- 2014/09/14 [revised] PHST- 2014/09/20 [accepted] PHST- 2014/10/14 [aheadofprint] AID - bjc2014544 [pii] AID - 10.1038/bjc.2014.544 [doi] PST - ppublish SO - Br J Cancer. 2015 Jan 6;112(1):149-52. doi: 10.1038/bjc.2014.544. Epub 2014 Oct 14. PMID- 25273282 OWN - NLM STAT- MEDLINE DA - 20141002 DCOM- 20150330 IS - 1440-1746 (Electronic) IS - 0815-9319 (Linking) VI - 29 IP - 7 DP - 2014 TI - PNPLA3 in end-stage liver disease: alcohol consumption, hepatocellular carcinoma development, and transplantation-free survival. PG - 1477-84 LID - 10.1111/jgh.12540 [doi] AB - BACKGROUND AND AIMS: The rs738409 variant (I148M) of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene is associated with several liver malfunctions. Its impact on end-stage liver disease has not been addressed yet. METHODS: The I148M polymorphism was genotyped in a well-characterized cohort of 421 Caucasian patients and retrospectively analyzed from the time of enrollment at Eurotransplant. RESULTS: The G allele of the I148M variant was significantly overrepresented in patients with alcoholic liver disease (ALD, P < 0.001) and associated with hepatocellular carcinoma (HCC) development (odds ratio [OR] = 2.399; 95% confidence interval [CI]: 1.292-4.455; P = 0.008) while not affecting the other liver disease entities. Time until hydropic decompensation (P = 0.04) and hepatic encephalopathy (P = 0.043) was significantly impaired for ALD patients carrying either one or two mutated G alleles. Actuarial survival free of liver transplantation was further reduced for ALD carriers of the I148M variant (CC = 30.7 months +/- 7.9, 95% CI: 15.1-46.2 vs CG/GG: 17.1 months +/- 3.3, 95% CI: 3.3-10.6; P = 0.012) compared with wild-type patients. Cox multivariate analysis identified the PNPLA3 I148M genotype as an independent predictor actuarial survival free of liver transplantation (OR = 1.77; 95% CI: 1.27-2.47; P = 0.001). CONCLUSIONS: In end-stage liver disease patients, we identified ALD to be predominantly affected by the PNPLA3 I148M variant resulting in an increased risk of HCC and reduced transplantation free survival. Genetic testing of the I148M genotype in ALD patients awaiting liver transplantation might be beneficial for these patients. CI - (c) 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd. FAU - Friedrich, Kilian AU - Friedrich K AD - Department of Internal Medicine IV, University Hospital of Heidelberg, Heidelberg, Germany; Joint Division Molecular Metabolic Control, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Wannhoff, Andreas AU - Wannhoff A FAU - Kattner, Stefan AU - Kattner S FAU - Brune, Maik AU - Brune M FAU - Hov, Johannes Roksund AU - Hov JR FAU - Weiss, Karl Heinz AU - Weiss KH FAU - Antoni, Christoph AU - Antoni C FAU - Dollinger, Matthias AU - Dollinger M FAU - Neumann-Haefelin, Christoph AU - Neumann-Haefelin C FAU - Seufferlein, Thomas AU - Seufferlein T FAU - Schemmer, Peter AU - Schemmer P FAU - Schirmacher, Peter AU - Schirmacher P FAU - Stremmel, Wolfgang AU - Stremmel W FAU - Gotthardt, Daniel Nils AU - Gotthardt DN LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Australia TA - J Gastroenterol Hepatol JT - Journal of gastroenterology and hepatology JID - 8607909 RN - 0 (Membrane Proteins) RN - EC 3.1.1.3 (Lipase) RN - EC 3.1.1.3 (adiponutrin, human) SB - IM MH - Alleles MH - Carcinoma, Hepatocellular/*genetics/mortality MH - Cohort Studies MH - European Continental Ancestry Group/genetics MH - *Genetic Association Studies MH - Genotype MH - Humans MH - Lipase/*genetics MH - Liver Diseases, Alcoholic/*genetics/mortality MH - Liver Neoplasms/*genetics/mortality MH - Liver Transplantation MH - Membrane Proteins/*genetics MH - Mutation MH - Polymorphism, Genetic/*genetics MH - Retrospective Studies MH - Severity of Illness Index MH - Survival Rate OTO - NOTNLM OT - alcoholic liver disease OT - and therapy OT - cancers: biology OT - clinical OT - diagnosis OT - hepatocellular carcinoma OT - liver transplantation OT - metabolism. EDAT- 2014/10/03 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/10/03 06:00 PHST- 2014/01/26 [accepted] AID - 10.1111/jgh.12540 [doi] PST - ppublish SO - J Gastroenterol Hepatol. 2014;29(7):1477-84. doi: 10.1111/jgh.12540. PMID- 25264293 OWN - NLM STAT- MEDLINE DA - 20150210 DCOM- 20150416 LR - 20150210 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 136 IP - 8 DP - 2015 Apr 15 TI - Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark. PG - 1940-7 LID - 10.1002/ijc.29238 [doi] AB - There is no clear link between obesity and prostate cancer incidence but an association has been reported between obesity and fatal prostate cancer. We report on two prospective cohort analyses on (i) the incidence of prostate cancer in relation to obesity in a cohort of men with no previous cancer, and on (ii) the stage distribution and prostate cancer specific mortality in relation to obesity among men with prostate cancer. The "Diet, Cancer and Health" prospective cohort study was established in Denmark in 1993-1997 and accrued 26,944 men aged 50-64 years. Data were extracted on height, weight, body mass index (BMI), waist circumference and body fat percentage. Information on cancer incidence and deaths were obtained by record linkage with the Danish Cancer Register and the Danish Death Register. The incidence rate of prostate cancer was similar or slightly lower in obese men compared with nonobese men, but obese men tended to be diagnosed with more advanced prostate cancer. The proportion of Stage 3-4 cancers was 37% in the lowest BMI quartile and 48% in the highest (p = 0.006). Obese men with prostate cancer had higher prostate cancer specific mortality. The hazard ratio comparing the highest and the lowest quartiles of BMI was 1.48 (95% confidence interval: 1.06-2.05; p-value for trend: 0.002). The association was attenuated but not eliminated by statistical adjustment for stage, and the data are suggestive of a stage-independent causal pathway where prostate cancer in obese men has higher fatality, even in early-stage disease. CI - (c) 2014 UICC. FAU - Moller, Henrik AU - Moller H AD - King's College London, Section of Cancer Epidemiology and Population Health, London, United Kingdom; Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom; Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark. FAU - Roswall, Nina AU - Roswall N FAU - Van Hemelrijck, Mieke AU - Van Hemelrijck M FAU - Larsen, Signe Benzon AU - Larsen SB FAU - Cuzick, Jack AU - Cuzick J FAU - Holmberg, Lars AU - Holmberg L FAU - Overvad, Kim AU - Overvad K FAU - Tjonneland, Anne AU - Tjonneland A LA - eng GR - 16891/Cancer Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141009 PL - United States TA - Int J Cancer JT - International journal of cancer. Journal international du cancer JID - 0042124 SB - IM MH - Adipose Tissue/metabolism MH - Body Mass Index MH - Body Weight/physiology MH - Denmark MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Obesity/*complications MH - Prospective Studies MH - Prostatic Neoplasms/*etiology/metabolism/*pathology/physiopathology MH - Risk Factors MH - Waist Circumference/physiology OTO - NOTNLM OT - Denmark OT - cohort study OT - obesity OT - prostate cancer OT - survival EDAT- 2014/09/30 06:00 MHDA- 2015/04/17 06:00 CRDT- 2014/09/30 06:00 PHST- 2014/06/17 [received] PHST- 2014/08/26 [revised] PHST- 2014/09/18 [accepted] PHST- 2014/10/09 [aheadofprint] AID - 10.1002/ijc.29238 [doi] PST - ppublish SO - Int J Cancer. 2015 Apr 15;136(8):1940-7. doi: 10.1002/ijc.29238. Epub 2014 Oct 9. PMID- 25263171 OWN - NLM STAT- MEDLINE DA - 20141223 DCOM- 20150417 IS - 1365-3083 (Electronic) IS - 0300-9475 (Linking) VI - 81 IP - 1 DP - 2015 Jan TI - T cell reconstitution in allogeneic haematopoietic stem cell transplantation: prognostic significance of plasma interleukin-7. PG - 72-80 LID - 10.1111/sji.12244 [doi] AB - Infections and acute graft-versus-host disease (aGVHD) are major causes of treatment-related mortality and morbidity following allogeneic haematopoietic stem cell transplantation (HSCT). Both complications depend on reconstitution of the T-lymphocyte population based on donor T cells. Although it is well established that Interleukin-7 (IL-7) is a cytokine essential for de novo T cell development in the thymus and homoeostatic peripheral expansion of T cells, associations between circulating levels of IL-7 and T cell reconstitution following HSCT have not been investigated previously. We prospectively measured IL-7 levels in 81 patients undergoing myeloablative HSCT with either sibling donor or an unrelated donor. Plasma IL-7 levels peaked at day +7 post-transplant (1.3-82.4 pg/ml), at the time of maximal lymphopaenia. In multivariate analysis, peak levels of IL-7 were significantly higher in patients treated with anti-thymocyte globulin (ATG) compared with those not treated with ATG (P = 0.0079). IL-7 levels at day +7 were negatively associated with T cell counts at day +30 to +60 (at day +60: CD3(+) : beta = -10.6 x 10(6) cells/l, P = 0.0030; CD8(+) : beta = -8.4 x 10(6) cells/l, P = 0.061; CD4(+) : beta = -2.1 x 10(6) cells/l, P = 0.062) in multivariate analyses. In adults, high IL-7 levels were associated with increased risk of grade II-IV aGVHD (OR = 5.4, P = 0.036) and reduced overall survival (P = 0.046). The present data indicate that high plasma levels of IL-7 in the early post-transplant period are predictive for slow T cell reconstitution, increased risk of aGVHD and increased mortality following HSCT. CI - (c) 2014 John Wiley & Sons Ltd. FAU - Kielsen, K AU - Kielsen K AD - Institute for Inflammation Research, Department of Infectious Diseases and Rheumatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. FAU - Jordan, K K AU - Jordan KK FAU - Uhlving, H H AU - Uhlving HH FAU - Pontoppidan, P L AU - Pontoppidan PL FAU - Shamim, Z AU - Shamim Z FAU - Ifversen, M AU - Ifversen M FAU - Heilmann, C AU - Heilmann C FAU - Nielsen, C H AU - Nielsen CH FAU - Sengelov, H AU - Sengelov H FAU - Ryder, L P AU - Ryder LP FAU - Muller, K G AU - Muller KG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Scand J Immunol JT - Scandinavian journal of immunology JID - 0323767 RN - 0 (IL7 protein, human) RN - 0 (Interleukin-7) SB - IM MH - Adolescent MH - Adult MH - Bone Marrow Diseases/*therapy MH - CD4 Lymphocyte Count MH - CD4-Positive T-Lymphocytes/immunology MH - CD8-Positive T-Lymphocytes/immunology MH - Child MH - Child, Preschool MH - Female MH - Graft vs Host Disease/immunology/*mortality MH - Hematopoietic Stem Cell Transplantation/*mortality MH - Humans MH - Infant MH - Interleukin-7/*blood MH - Lymphopenia/*blood MH - Male MH - Middle Aged MH - Prognosis MH - Prospective Studies MH - Transplantation Conditioning MH - Transplantation, Homologous MH - Young Adult EDAT- 2014/09/30 06:00 MHDA- 2015/04/18 06:00 CRDT- 2014/09/30 06:00 PHST- 2014/08/01 [received] PHST- 2014/09/18 [accepted] AID - 10.1111/sji.12244 [doi] PST - ppublish SO - Scand J Immunol. 2015 Jan;81(1):72-80. doi: 10.1111/sji.12244. PMID- 25250505 OWN - NLM STAT- MEDLINE DA - 20150210 DCOM- 20150416 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 136 IP - 8 DP - 2015 Apr 15 TI - Anthropometric factors and ovarian cancer risk: a systematic review and nonlinear dose-response meta-analysis of prospective studies. PG - 1888-98 LID - 10.1002/ijc.29207 [doi] AB - In the World Cancer Research Fund/American Institute for Cancer Research report from 2007 the evidence relating body fatness to ovarian cancer risk was considered inconclusive, while the evidence supported a probably causal relationship between adult attained height and increased risk. Several additional cohort studies have since been published, and therefore we conducted an updated meta-analysis of the evidence as part of the Continuous Update Project. We searched PubMed and several other databases up to 20th of August 2014. Summary relative risks (RRs) were calculated using a random effects model. The summary relative risk for a 5-U increment in BMI was 1.07 (95% CI: 1.03-1.11, I(2) = 54%, n = 28 studies). There was evidence of a nonlinear association, pnonlinearity < 0.0001, with risk increasing significantly from BMI approximately 28 and above. The summary RR per 5 U increase in BMI in early adulthood was 1.12 (95% CI: 1.05-1.20, I(2) = 0%, pheterogeneity = 0.54, n = 6), per 5 kg increase in body weight was 1.03 (95% CI: 1.02-1.05, I(2) = 0%, n = 4) and per 10 cm increase in waist circumference was 1.06 (95% CI: 1.00-1.12, I(2) = 0%, n = 6). No association was found for weight gain, hip circumference or waist-to-hip ratio. The summary RR per 10 cm increase in height was 1.16 (95% CI: 1.11-1.21, I(2) = 32%, n = 16). In conclusion, greater body fatness as measured by body mass index and weight are positively associated risk of ovarian cancer, and in addition, greater height is associated with increased risk. Further studies are needed to clarify whether abdominal fatness and weight gain is associated with risk. CI - (c) 2014 UICC. FAU - Aune, Dagfinn AU - Aune D AD - Department of Epidemiology and Biostatistics, School of Public Health Imperial College London, London, United Kingdom; Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Navarro Rosenblatt, Deborah A AU - Navarro Rosenblatt DA FAU - Chan, Doris Sau Man AU - Chan DS FAU - Abar, Leila AU - Abar L FAU - Vingeliene, Snieguole AU - Vingeliene S FAU - Vieira, Ana Rita AU - Vieira AR FAU - Greenwood, Darren C AU - Greenwood DC FAU - Norat, Teresa AU - Norat T LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't DEP - 20140924 PL - United States TA - Int J Cancer JT - International journal of cancer. Journal international du cancer JID - 0042124 SB - IM MH - Adipose Tissue/metabolism MH - Adolescent MH - Adult MH - Anthropometry/methods MH - Body Composition/*physiology MH - Body Mass Index MH - Body Weight/physiology MH - Case-Control Studies MH - Female MH - Humans MH - Obesity/complications MH - Ovarian Neoplasms/*etiology/*physiopathology MH - Prospective Studies MH - Risk MH - Risk Factors MH - Waist Circumference/physiology MH - Waist-Hip Ratio/methods MH - Young Adult OTO - NOTNLM OT - body mass index OT - height OT - meta-analysis OT - ovarian cancer OT - weight EDAT- 2014/09/25 06:00 MHDA- 2015/04/17 06:00 CRDT- 2014/09/25 06:00 PHST- 2014/04/11 [received] PHST- 2014/08/13 [revised] PHST- 2014/08/19 [accepted] PHST- 2014/09/24 [aheadofprint] AID - 10.1002/ijc.29207 [doi] PST - ppublish SO - Int J Cancer. 2015 Apr 15;136(8):1888-98. doi: 10.1002/ijc.29207. Epub 2014 Sep 24. PMID- 25245018 OWN - NLM STAT- MEDLINE DA - 20140923 DCOM- 20150413 IS - 1479-6821 (Electronic) IS - 1351-0088 (Linking) VI - 21 IP - 5 DP - 2014 Oct TI - Thyroid tumors: are we unveiling the puzzle? PG - E7-8 LID - 10.1530/ERC-14-0407 [doi] FAU - Ward, Laura Sterian AU - Ward LS AD - Laboratory of Cancer Molecular GeneticsFaculty of Medical Sciences, University of Campinas (Unicamp), 126, Tessalia Vieira de Camargo Street, Cidade Universitaria, Campinas, Sao Paulo 13083-887, Brazil ward@fcm.unicamp.br. LA - eng PT - Editorial PL - England TA - Endocr Relat Cancer JT - Endocrine-related cancer JID - 9436481 RN - 0 (Gonadal Steroid Hormones) RN - 0 (MicroRNAs) SB - IM MH - Gonadal Steroid Hormones/metabolism MH - Humans MH - Incidence MH - MicroRNAs/metabolism MH - Obesity/epidemiology MH - *Thyroid Neoplasms/diagnosis/drug therapy/epidemiology/metabolism OTO - NOTNLM OT - oncology OT - thyroid EDAT- 2014/09/24 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/09/24 06:00 AID - ERC-14-0407 [pii] AID - 10.1530/ERC-14-0407 [doi] PST - ppublish SO - Endocr Relat Cancer. 2014 Oct;21(5):E7-8. doi: 10.1530/ERC-14-0407. PMID- 25231927 OWN - NLM STAT- MEDLINE DA - 20150112 DCOM- 20150420 IS - 1432-0584 (Electronic) IS - 0939-5555 (Linking) VI - 94 IP - 2 DP - 2015 Feb TI - Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. PG - 297-306 LID - 10.1007/s00277-014-2196-8 [doi] AB - Standard myeloablative conditioning regimens for children with acute lymphoblastic leukaemia are based on total body irradiation (TBI). However, TBI causes profound short-term and long-term side effects, provoking the necessity for alternative regimens. Treosulfan combines a potent immunosuppressive and antileukaemic effect with myeloablative activity and low toxicity profile. We retrospectively studied toxicity and outcome of 71 paediatric patients with acute lymphoblastic leukaemia (ALL) undergoing haematopoietic stem cell transplantation (HSCT) following treosulfan-based conditioning aiming to identify risk factors for treatment failure and dose-depending outcome differences. Early regimen-related toxicity was low. No case of veno-occlusive disease was reported. There was no association of toxicity with age or number of HSCT. Event-free survival (EFS) of infants was significantly better compared to older children. Overall survival (OS) at 3 years was 51 % and not significantly influenced by number of HSCT (first HSCT 54 %, >/=second HSCT 44 %, p = 0.71). In multivariate analysis, OS and EFS were significantly worse for patients transplanted without complete remission (p = 0.04 and 0.004). Treatment-related mortality was low at 14 %. We conclude that treosulfan-based conditioning is a safe and efficacious approach for paediatric ALL. FAU - Boztug, Heidrun AU - Boztug H AD - St. Anna Kinderspital and Children's Cancer Research Institute, Department of Paediatrics, Medical University of Vienna, Kinderspitalgasse 6, 1090, Vienna, Austria, heidrun.boztug@stanna.at. FAU - Zecca, Marco AU - Zecca M FAU - Sykora, Karl-Walter AU - Sykora KW FAU - Veys, Paul AU - Veys P FAU - Lankester, Arjan AU - Lankester A FAU - Slatter, Mary AU - Slatter M FAU - Skinner, Roderick AU - Skinner R FAU - Wachowiak, Jacek AU - Wachowiak J FAU - Potschger, Ulrike AU - Potschger U FAU - Glogova, Evgenia AU - Glogova E FAU - Peters, Christina AU - Peters C CN - EBMT paediatric diseases working party LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140919 PL - Germany TA - Ann Hematol JT - Annals of hematology JID - 9107334 RN - CO61ER3EPI (treosulfan) RN - G1LN9045DK (Busulfan) SB - IM MH - Adolescent MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Busulfan/administration & dosage/adverse effects/analogs & derivatives MH - Child MH - Child, Preschool MH - Diarrhea/etiology MH - Disease-Free Survival MH - Dose-Response Relationship, Drug MH - Female MH - Graft vs Host Disease/etiology MH - Hematopoietic Stem Cell Transplantation/adverse effects/*methods MH - Humans MH - Infant MH - Male MH - Multivariate Analysis MH - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy MH - Remission Induction MH - Retrospective Studies MH - Stomatitis/etiology MH - Transplantation Conditioning/adverse effects/*methods MH - Transplantation, Homologous MH - Treatment Outcome MH - Vomiting/etiology EDAT- 2014/09/19 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/09/19 06:00 PHST- 2014/06/01 [received] PHST- 2014/08/19 [accepted] PHST- 2014/09/19 [aheadofprint] AID - 10.1007/s00277-014-2196-8 [doi] PST - ppublish SO - Ann Hematol. 2015 Feb;94(2):297-306. doi: 10.1007/s00277-014-2196-8. Epub 2014 Sep 19. PMID- 25163649 OWN - NLM STAT- MEDLINE DA - 20140920 DCOM- 20150330 IS - 1476-511X (Electronic) IS - 1476-511X (Linking) VI - 13 DP - 2014 TI - The effects of virgin coconut oil (VCO) as supplementation on quality of life (QOL) among breast cancer patients. PG - 139 LID - 10.1186/1476-511X-13-139 [doi] AB - BACKGROUND: Breast cancer is the most common cancer amongst Malaysian women. Both the disease and its treatment can disrupt the lives of the woman and adversely affect all aspects of life and thus can alter a woman's quality of life. The aim of this study was to examine the effect of virgin coconut oil (VCO) on the quality of life (QOL) of patients diagnosed with breast cancer. METHODS: This was a prospective study of breast cancer patients admitted into the Oncology Unit of Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. The sample consisted of 60 patients with stage III and IV breast cancer allocated to either an intervention group (n = 30) or a control group (n = 30) using a simple random table. QOL was evaluated from the first cycle of chemotherapy to the sixth cycle, and data were collected using a validated Bahasa Malaysia version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-C30) and its breast-specific module (QLQ-BR 23). RESULTS: The mean age of breast cancer patients was 50.2 (SD = 13.5) years. There were significant mean score differences for functioning and global QOL between groups (alpha < 0.01). The intervention group also had better scores for symptoms including fatigue, dyspnea, sleep difficulties, and loss of appetite compared to the control group. Although there are deteriorations for sexual enjoyment, the intervention group exhibited improvement in breast functioning and symptom scores for body image, sexual function, future perspective, breast symptoms, and systemic therapy side effects. CONCLUSION: VCO consumption during chemotherapy helped improve the functional status and global QOL of breast cancer patients. In addition, it reduced the symptoms related to side effects of chemotherapy. FAU - Law, Kim Sooi AU - Law KS AD - Institut Perubatan dan Pergigian Termaju, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia. lawks@amdi.usm.edu.my. FAU - Azman, Nizuwan AU - Azman N FAU - Omar, Eshaifol Azam AU - Omar EA FAU - Musa, Muhammad Yusri AU - Musa MY FAU - Yusoff, Narazah Mohd AU - Yusoff NM FAU - Sulaiman, Siti Amrah AU - Sulaiman SA FAU - Hussain, Nik Hazlina Nik AU - Hussain NH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140827 PL - England TA - Lipids Health Dis JT - Lipids in health and disease JID - 101147696 RN - 0 (Plant Oils) RN - 8001-31-8 (coconut oil) SB - IM MH - Adult MH - Breast Neoplasms/*drug therapy MH - Dietary Supplements MH - Female MH - Humans MH - Middle Aged MH - Plant Oils/*administration & dosage MH - Prospective Studies MH - *Quality of Life MH - Questionnaires MH - Treatment Outcome PMC - PMC4176590 OID - NLM: PMC4176590 EDAT- 2014/08/29 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/08/29 06:00 PHST- 2014/04/08 [received] PHST- 2014/08/23 [accepted] PHST- 2014/08/27 [aheadofprint] AID - 1476-511X-13-139 [pii] AID - 10.1186/1476-511X-13-139 [doi] PST - epublish SO - Lipids Health Dis. 2014 Aug 27;13:139. doi: 10.1186/1476-511X-13-139. PMID- 25160073 OWN - NLM STAT- MEDLINE DA - 20140827 DCOM- 20150421 IS - 0272-4391 (Print) IS - 0272-4391 (Linking) VI - 75 IP - 5 DP - 2014 Aug TI - Redox regulation of cancer metastasis: molecular signaling and therapeutic opportunities. PG - 331-41 LID - 10.1002/ddr.21216 [doi] AB - Cancer metastasis is the major cause of cancer-related mortality. Accumulated evidence has shown that high-metastasis potential cancer cells have more reactive oxygen species (ROS) accumulation compared with low-metastasis potential cancer cells. ROS can function as second messengers to regulate multiple cancer metastasis-related signaling pathways via reversible oxidative posttranslational modifications of cysteine in key redox-sensitive proteins, which leads to the structural and functional change of these proteins. Because ROS can promote cancer metastasis, therapeutic strategies aiming at inducing/reducing cellular ROS level or targeting redox sensors involved in metastasis hold great potential in developing new efficient approaches for anticancer therapy. In this review, we summarize recent findings on regulation of tumor metastasis by key redox sensors and describe the potential of targeting redox signaling pathways for cancer therapy. CI - (c) 2014 Wiley Periodicals, Inc. FAU - Yang, Wenyong AU - Yang W AD - Department of Biochemistry and Molecular Biology, and Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing, 400016, China; College of Life Sciences, Sichuan University, Chengdu, 610065, China; The State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Zou, Linzhi AU - Zou L FAU - Huang, Canhua AU - Huang C FAU - Lei, Yunlong AU - Lei Y LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Drug Dev Res JT - Drug development research JID - 8204468 RN - 0 (Antineoplastic Agents) RN - 0 (Reactive Oxygen Species) SB - IM MH - Antineoplastic Agents/therapeutic use MH - Combined Modality Therapy MH - Humans MH - Neoplasm Metastasis/*drug therapy/radiotherapy MH - Neoplasms/drug therapy/metabolism/radiotherapy MH - Oxidation-Reduction MH - Oxidative Stress MH - Reactive Oxygen Species/*metabolism MH - Signal Transduction OTO - NOTNLM OT - cancer therapy OT - metastasis OT - reactive oxygen species OT - redox sensors EDAT- 2014/08/28 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/08/28 06:00 AID - 10.1002/ddr.21216 [doi] PST - ppublish SO - Drug Dev Res. 2014 Aug;75(5):331-41. doi: 10.1002/ddr.21216. PMID- 25145420 OWN - NLM STAT- MEDLINE DA - 20140822 DCOM- 20150420 IS - 1744-8301 (Electronic) IS - 1479-6694 (Linking) VI - 10 IP - 9 DP - 2014 TI - Dietary supplementation in cancer patients: a personal view of current status and future perspectives. PG - 1523-5 LID - 10.2217/fon.14.85 [doi] FAU - Sacco, Rodolfo AU - Sacco R AD - Cisanello Hospital, Pisa, Italy. FAU - Sivozhelezov, Victor AU - Sivozhelezov V FAU - Pellegrini, Luigi AU - Pellegrini L FAU - Giacomelli, Luca AU - Giacomelli L FAU - Longo, Vincenzo AU - Longo V LA - eng PT - Editorial PL - England TA - Future Oncol JT - Future oncology (London, England) JID - 101256629 RN - 0 (Anticarcinogenic Agents) RN - 0 (Vitamins) SB - IM MH - Anticarcinogenic Agents/*administration & dosage MH - *Dietary Supplements MH - Humans MH - Neoplasms/*prevention & control/therapy MH - Risk MH - Vitamins/*administration & dosage OTO - NOTNLM OT - Lisosan G OT - antioxidants OT - cancer OT - nutritional supplementation EDAT- 2014/08/26 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/08/23 06:00 AID - 10.2217/fon.14.85 [doi] PST - ppublish SO - Future Oncol. 2014;10(9):1523-5. doi: 10.2217/fon.14.85. PMID- 25145419 OWN - NLM STAT- MEDLINE DA - 20140822 DCOM- 20150420 IS - 1744-8301 (Electronic) IS - 1479-6694 (Linking) VI - 10 IP - 9 DP - 2014 TI - Inflammatory, insulin resistance metabolic markers and pancreatic cancer: quo vadis? [corrected]. PG - 1519-22 LID - 10.2217/fon.14.88 [doi] FAU - Toriola, Adetunji T AU - Toriola AT AD - Department of Surgery, Division of Public Health Sciences, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA. FAU - Fields, Ryan C AU - Fields RC LA - eng PT - Editorial PT - Research Support, Non-U.S. Gov't PL - England TA - Future Oncol JT - Future oncology (London, England) JID - 101256629 RN - 0 (Inflammation Mediators) RN - 0 (Tumor Markers, Biological) SB - IM EIN - Future Oncol. 2014;10(11):1888 MH - Adiposity MH - Humans MH - Inflammation Mediators/*metabolism MH - *Insulin Resistance MH - Obesity/immunology/metabolism MH - Pancreatic Neoplasms/immunology/*metabolism MH - Tumor Markers, Biological/*metabolism OTO - NOTNLM OT - IGF-I OT - IGFBP-3 OT - adiponectin OT - insulin resistance OT - metabolism OT - pancreatic cancer OT - risk OT - survival EDAT- 2014/08/26 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/08/23 06:00 AID - 10.2217/fon.14.88 [doi] PST - ppublish SO - Future Oncol. 2014;10(9):1519-22. doi: 10.2217/fon.14.88. PMID- 25142418 OWN - NLM STAT- MEDLINE DA - 20140829 DCOM- 20150420 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 14 DP - 2014 TI - A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. PG - 605 LID - 10.1186/1471-2407-14-605 [doi] AB - BACKGROUND: The VELOUR study demonstrated a survival benefit for FOLFIRI + aflibercept versus FOLFIRI + placebo in metastatic colorectal cancer (mCRC) patients who progressed on oxaliplatin-based chemotherapy. Continued divergence of overall survival (OS) curves in the intension to treat (ITT) population, with the survival advantage persisting beyond median survival time, suggested subpopulations might have different magnitudes of survival gain. Additionally, 10% of patients within VELOUR had recurrence during or within 6 months of completing oxaliplatin-based adjuvant therapy (adjuvant fast relapsers)--previously identified as having poorer survival outcomes. METHODS: To determine which patients received the greatest benefit from FOLFIRI-aflibercept, a post hoc multivariate analysis of the VELOUR ITT population was conducted. Prognostic factors identified were applied to the ITT population, excluding adjuvant fast relapsers, to derive OS prognostic profiles. RESULTS: The better efficacy subgroup was identified as patients within VELOUR exclusive of adjuvant fast relapsers and had performance status (PS) 0 with any number of metastatic site or PS 1 with <2 metastatic site. A significant improvement in efficacy outcome was observed with aflibercept in the better efficacy subgroup. Median OS for FOLFIRI-aflibercept and FOLFIRI-placebo:16.2 and 13.1 months (adjusted Hazard Ratio [HR] = 0.73; 95% confidence interval [CI]: 0.61-0.86); median progression free survival (PFS): 7.2 and 4.8 months (adjusted HR = 0.68; 95% CI: 0.57-0.80); and objective response rate (ORR): 24% versus 11% respectively. Poorer efficacy subgroup comprised of adjuvant fast relapsers or patients with PS2 or PS1 with >/= 2 metastatic sites. In poorer efficacy subgroup, no benefit was seen with aflibercept. Median OS for FOLFIRI-aflibercept and FOLFIRI-placebo: 10.4 and 9.6 months (adjusted HR = 0.97; 95% CI: 0.78-1.21) respectively with no improvement in PFS or ORR. CONCLUSION: This analysis suggests that within VELOUR, patients in the better efficacy subgroup may derive enhanced benefit from treatment with FOLFIRI-aflibercept. These prognostic criteria may guide practitioners toward optimal use of targeted biologicals in appropriate second-line mCRC patients. FAU - Chau, Ian AU - Chau I AD - Department of Medicine, Royal Marsden Hospital, London and Surrey, UK. ian.chau@rmh.nhs.uk. FAU - Joulain, Florence AU - Joulain F FAU - Iqbal, Sheikh Usman AU - Iqbal SU FAU - Bridgewater, John AU - Bridgewater J LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140820 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Recombinant Fusion Proteins) RN - 15C2VL427D (aflibercept) RN - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - XT3Z54Z28A (Camptothecin) RN - IFL protocol SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Camptothecin/adverse effects/*analogs & derivatives/therapeutic use MH - Colorectal Neoplasms/*drug therapy MH - Female MH - Fluorouracil/adverse effects/therapeutic use MH - Humans MH - Leucovorin/adverse effects/therapeutic use MH - Male MH - Middle Aged MH - Neoplasm Metastasis/*drug therapy MH - Receptors, Vascular Endothelial Growth Factor/adverse effects/*therapeutic use MH - Recombinant Fusion Proteins/adverse effects/*therapeutic use MH - Survival Analysis MH - Treatment Outcome PMC - PMC4149045 OID - NLM: PMC4149045 EDAT- 2014/08/22 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/08/22 06:00 PHST- 2013/12/11 [received] PHST- 2014/07/16 [accepted] PHST- 2014/08/20 [aheadofprint] AID - 1471-2407-14-605 [pii] AID - 10.1186/1471-2407-14-605 [doi] PST - epublish SO - BMC Cancer. 2014 Aug 20;14:605. doi: 10.1186/1471-2407-14-605. PMID- 25139100 OWN - NLM STAT- MEDLINE DA - 20141126 DCOM- 20150417 IS - 1423-0380 (Electronic) IS - 1010-4283 (Linking) VI - 35 IP - 11 DP - 2014 Nov TI - Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer. PG - 11613-20 LID - 10.1007/s13277-014-2495-7 [doi] AB - The purpose of the present study is to explore the relation between glycolytic metabolism assessed by (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) and final neoadjuvant chemotherapy (NC) response in locally advanced breast tumors. Of women with breast cancer, 126 were prospectively evaluated. All patients underwent (18)F-FDG PET/CT previous to NC. Standard uptake value (SUV) max was calculated in the primary tumor. After NC, residual primary tumor specimen was histopathologically classified according to Miller and Payne tumor regression grades (TRG), from G1 to G5 and in response groups as good responders (G4 or G5), partial responders (G2 or G3), and non-responders (G1). Furthermore, residual lesions were classified following a binary assessment as responders (G4 or G5) and non-responders (the rest of cases). The relationship between SUV max with TRG and response groups was evaluated. Of tumors, 127 were assessed (a patient had bilateral breast lesions). TRG were as follows: G1 (27), G2 (27), G3 (32), G4 (11), and G5 (30). Forty-one were classified as good responders, 59 as partial responders, and 27 as non-responders. For the binary assessment, 41 lesions were classified as responders and 86 as non-responders. We found statistical differences (p=0.02) between the mean SUV max and TRG with greater SUV values for G5 compared to the other TRG. Good responders showed greater mean SUV max +/- SD compared to partial responders and non-responders (10.51 +/- 6.64 for good responders, 6.94 +/- 5.81 for partial responders, and 5.23 +/- 2.76 for non-responders; p=0.001). Baseline tumor metabolism assessing by FDG PET/CT was associated with the final histopathologic status after neoadjuvant chemotherapy, with greater SUV max values for good responders compared to the less responder cancers. FAU - Garcia Vicente, Ana Maria AU - Garcia Vicente AM AD - Nuclear Medicine Department, University General Hospital, C/ Obispo Rafael Torija s/n, 13005, Ciudad Real, Spain, amgarcia@sescam.jccm.es. FAU - Cruz Mora, Miguel Angel AU - Cruz Mora MA FAU - Leon Martin, Antonio Alberto AU - Leon Martin AA FAU - Munoz Sanchez, Maria Del Mar AU - Munoz Sanchez Mdel M FAU - Relea Calatayud, Fernanda AU - Relea Calatayud F FAU - Van Gomez Lopez, Ober AU - Van Gomez Lopez O FAU - Espinosa Aunion, Ruth AU - Espinosa Aunion R FAU - Gonzalez Ageitos, Ana AU - Gonzalez Ageitos A FAU - Soriano Castrejon, Angel AU - Soriano Castrejon A LA - eng PT - Journal Article PT - Multicenter Study DEP - 20140820 PL - Netherlands TA - Tumour Biol JT - Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine JID - 8409922 RN - 0 (Radiopharmaceuticals) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Breast Neoplasms/*diagnosis/*drug therapy/metabolism MH - Carcinoma, Ductal, Breast/diagnosis/drug therapy/metabolism MH - Carcinoma, Lobular/diagnosis/drug therapy/metabolism MH - Female MH - Fluorodeoxyglucose F18/*diagnostic use MH - Follow-Up Studies MH - *Glycolysis MH - Humans MH - Middle Aged MH - Multimodal Imaging/*methods MH - *Neoadjuvant Therapy MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Positron-Emission Tomography MH - Prognosis MH - Prospective Studies MH - ROC Curve MH - Radiopharmaceuticals/diagnostic use MH - Tomography, X-Ray Computed EDAT- 2014/08/21 06:00 MHDA- 2015/04/18 06:00 CRDT- 2014/08/21 06:00 PHST- 2014/05/18 [received] PHST- 2014/08/13 [accepted] PHST- 2014/08/20 [aheadofprint] AID - 10.1007/s13277-014-2495-7 [doi] PST - ppublish SO - Tumour Biol. 2014 Nov;35(11):11613-20. doi: 10.1007/s13277-014-2495-7. Epub 2014 Aug 20. PMID- 25136668 OWN - NLM STAT- MEDLINE DA - 20140819 DCOM- 20150422 IS - 1537-744X (Electronic) IS - 1537-744X (Linking) VI - 2014 DP - 2014 TI - Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center. PG - 418694 LID - 10.1155/2014/418694 [doi] AB - BACKGROUND/AIM: To evaluate the clinical efficacy of FOLFOX4 (5-fluomumcil/leucovorin combined and oxaliplatin) neoadjuvant chemotherapy for advanced gastric cancer (AGC). PATIENTS AND METHODS: Fifty-eight AGC patients were enrolled in this retrospective cohort study, 23 in the neoadjuvant group and 35 in the adjuvant group. R0 resection, survival, and adverse events were compared. RESULTS: The two groups were well-matched, with no significant differences in R0 resection rate (82.6% versus 82.0%) and number of lymph nodes dissection (16 (0-49) versus 13 (3-40)) between the two groups (P > 0.05). The number of lymph node metastases in the neoadjuvant group (3 (0-14)) was significantly fewer than that in the adjuvant group (6 (0-27)) (P = 0.04). The neoadjuvant group had significantly better median overall survival (29.0 versus 22.0 months) and 3-year survival rate (73.9% versus 40.0%) than the adjuvant group (P = 0.013). The positive expression rate of Ki-67 in the neoadjuvant group (40.0%, 8/20) was lower than that in the adjuvant group (74.2%, 23/31; P = 0.015). CONCLUSION: The FOLFOX4 neoadjuvant chemotherapy could improve survival without increasing adverse events in patients with AGC. FAU - Sun, Zhen AU - Sun Z AUID- ORCID: 0000-0003-3901-6950 AD - Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, No. 169 Donghu Road, Wuchang District, Wuhan 430071, China. FAU - Zhu, Rui-Juan AU - Zhu RJ AD - Department of Pathology, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District, Wuhan 430071, China. FAU - Yang, Gui-Fang AU - Yang GF AD - Department of Pathology, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District, Wuhan 430071, China. FAU - Li, Yan AU - Li Y AD - Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, No. 169 Donghu Road, Wuchang District, Wuhan 430071, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140717 PL - United States TA - ScientificWorldJournal JT - TheScientificWorldJournal JID - 101131163 RN - 0 (Organoplatinum Compounds) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Folfox protocol SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Female MH - Fluorouracil/therapeutic use MH - Humans MH - Leucovorin/therapeutic use MH - Male MH - Middle Aged MH - Organoplatinum Compounds/therapeutic use MH - Retrospective Studies MH - Stomach Neoplasms/*drug therapy/*mortality MH - Treatment Outcome MH - Young Adult PMC - PMC4127276 OID - NLM: PMC4127276 EDAT- 2014/08/20 06:00 MHDA- 2015/04/23 06:00 CRDT- 2014/08/20 06:00 PHST- 2014/03/25 [received] PHST- 2014/06/28 [revised] PHST- 2014/07/01 [accepted] PHST- 2014/07/17 [epublish] AID - 10.1155/2014/418694 [doi] PST - ppublish SO - ScientificWorldJournal. 2014;2014:418694. doi: 10.1155/2014/418694. Epub 2014 Jul 17. PMID- 25128023 OWN - NLM STAT- MEDLINE DA - 20140820 DCOM- 20150420 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 14 DP - 2014 TI - A longitudinal study investigating quality of life and nutritional outcomes in advanced cancer patients receiving home parenteral nutrition. PG - 593 LID - 10.1186/1471-2407-14-593 [doi] AB - BACKGROUND: In cancer patients where gastrointestinal function is marginal and malnutrition significant enough to result in the requirement for intensive nutrition support, parenteral nutrition (PN) is indicated. This longitudinal study examined the quality of life (QoL) and nutritional outcomes in advanced cancer patients receiving home PN (HPN). METHODS: Fifty-two adult cancer patients (21 males, 31 females, average age 53 years) treated at a specialized cancer facility between April 2009 and November 2011 met criteria. QoL and nutritional status were measured at baseline and every month while on HPN using EORTC-QLQ-C30, Karnofsky Performance Status (KPS), and Subjective Global Assessment (SGA). Repeated measures ANOVA and Generalized Estimating Equations (GEE) were used to evaluate longitudinal changes in QoL and SGA. RESULTS: Cancer diagnoses included pancreatic (n = 14), colorectal (n = 11), ovarian (n = 6), appendix (n = 5), stomach (n = 4) and others (n = 12). Average weight loss 6-months prior to HPN was 13.2 kg (16.9%). Average weight at initiation of HPN was 62.2 kg. In patients with available follow-up data after 1 month (n = 39), there was a significant improvement in SGA, weight (61.5 to 63.1 kg; p = 0.03) and KPS (61.6 to 67.3; p = 0.01) from baseline. Similarly, after 2 months (n = 22), there was an improvement in global QoL (37.1 to 49.2; p = 0.02), SGA, weight (57.6 to 60 kg; p = 0.04) and KPS (63.2 to 73.2; p = 0.01) from baseline. Finally, after 3 months (n = 15), there was an improvement in global QoL (30.6 to 54.4; p = 0.02), SGA, weight (61.1 to 65.9 kg; p = 0.04) and KPS (64.0 to 78.7; p = 0.002) from baseline. Upon GEE analysis, every 1 month of HPN was associated with an increase of 6.3 points in global QoL (p<0.001), 1.3 kg in weight (p = 0.009) and 5.8 points in KPS (p<0.001). CONCLUSIONS: HPN is associated with an improvement in QoL, KPS and nutritional status in advanced cancer patients, irrespective of their tumor type, who have compromised enteral intake and malnutrition. The greatest benefit was seen in patients with 3 months of HPN, although patients receiving HPN for 1 or 2 months also demonstrated significant improvements. FAU - Vashi, Pankaj G AU - Vashi PG FAU - Dahlk, Sadie AU - Dahlk S FAU - Popiel, Brenten AU - Popiel B FAU - Lammersfeld, Carolyn A AU - Lammersfeld CA FAU - Ireton-Jones, Carol AU - Ireton-Jones C FAU - Gupta, Digant AU - Gupta D AD - Cancer Treatment Centers of America(R) (CTCA) at Midwestern Regional Medical Center, 2520 Elisha Avenue, Zion, IL 60099, USA. digant.gupta@ctca-hope.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140815 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Body Weight MH - Female MH - Humans MH - Karnofsky Performance Status MH - Longitudinal Studies MH - Male MH - Malnutrition/*diet therapy MH - Middle Aged MH - Neoplasms/*complications/therapy MH - *Nutritional Status MH - Parenteral Nutrition, Home/*methods MH - *Quality of Life MH - Treatment Outcome PMC - PMC4141117 OID - NLM: PMC4141117 EDAT- 2014/08/17 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/08/17 06:00 PHST- 2014/03/13 [received] PHST- 2014/08/12 [accepted] PHST- 2014/08/15 [aheadofprint] AID - 1471-2407-14-593 [pii] AID - 10.1186/1471-2407-14-593 [doi] PST - epublish SO - BMC Cancer. 2014 Aug 15;14:593. doi: 10.1186/1471-2407-14-593. PMID- 25117717 OWN - NLM STAT- MEDLINE DA - 20140902 DCOM- 20150413 IS - 1471-230X (Electronic) IS - 1471-230X (Linking) VI - 14 DP - 2014 TI - Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. PG - 143 LID - 10.1186/1471-230X-14-143 [doi] AB - BACKGROUND: Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a clear survival advantage over gemcitabine alone and has become a new standard in advanced Biliary Tract Carcinoma (aBTC). However, Gemcitabine/Oxaliplatin (GEMOX) combination and Gemcitabine/Carboplatin (Gem/Carb) combination regimens have shown efficacy in phase II trials and there is no comparative study between different platinum salts.We assessed the efficacy and safety of different platinum-based chemotherapies at first line in aBTC patients. We also analysed the second-line chemotherapy. METHODS: Sixty-four consecutive patients with aBTC diagnosed between 1998 and 2010 were included for analysis. At first line chemotherapy, 44 patients received one day GEMOX regimen (gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 Day 1, every 2 weeks), and 20 patients received Gem/Carb regimen (gemcitabine at 1000 mg/m2 Days 1 and 8 with carboplatin delivered according to an area-under-the-curve (AUC) 5 at day 1, every 3 weeks). At second line, a total of 16 patients received a fluoropyrimidine-based chemotherapy. RESULTS: With GEMOX regimen, median progression-free survival (PFS) was 3.7 months (95%CI, 2.4 to 5) and median overall survival (OS) was 10.5 months (95%CI, 6.4 to14.7). The main toxicity was peripheral neuropathy (20% grade 2 and 7% grade 3). Grade 3/4 haematological toxicities were rare.With Gem/Carb regimen, PFS was 2.5 months (95%CI, 2.1 to 3.7) and OS was 4.8 months (95%CI, 3.7 to 5.8). The main grade 3/4 toxicities were haematological: anaemia (45%), thrombocytopenia (45%), and neutropenia (40%).At second-line, fluoropyrimidine-based chemotherapy was feasible in only a fourth of the patients. The median OS was 5.3 months (95%CI, 4.1 to 6.6), and median PFS was 4.0 months (95%CI, 2.6 to 5.5). CONCLUSIONS: One day GEMOX regimen has a favourable toxicity profile and could be an alternative to standard Gem/CDDP regimen, in particular in unfit patients for CDDP.At second-line, selective patients may benefit from fluoropyrimidine-based chemotherapy. FAU - Fiteni, Frederic AU - Fiteni F FAU - Jary, Marine AU - Jary M FAU - Monnien, Franck AU - Monnien F FAU - Nguyen, Thierry AU - Nguyen T FAU - Beohou, Eric AU - Beohou E FAU - Demarchi, Martin AU - Demarchi M FAU - Dobi, Erion AU - Dobi E FAU - Fein, Francine AU - Fein F FAU - Cleau, Denis AU - Cleau D FAU - Fratte, Serge AU - Fratte S FAU - Nerich, Virginie AU - Nerich V FAU - Bonnetain, Franck AU - Bonnetain F FAU - Pivot, Xavier AU - Pivot X FAU - Borg, Christophe AU - Borg C FAU - Kim, Stefano AU - Kim S AD - Department of Medical Oncology, Jean Minjoz University Teaching Hospital, 3 Boulevard Alexander Fleming, Besancon F-25030, France. stefanokim@gmail.com. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20140813 PL - England TA - BMC Gastroenterol JT - BMC gastroenterology JID - 100968547 RN - 0 (Organoplatinum Compounds) RN - 04ZR38536J (oxaliplatin) RN - 0W860991D6 (Deoxycytidine) RN - 6804DJ8Z9U (capecitabine) RN - B76N6SBZ8R (gemcitabine) RN - BG3F62OND5 (Carboplatin) RN - Q20Q21Q62J (Cisplatin) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) SB - IM MH - Adenocarcinoma/*drug therapy/pathology MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Bile Duct Neoplasms/*drug therapy/pathology MH - *Bile Ducts, Extrahepatic/pathology MH - *Bile Ducts, Intrahepatic/pathology MH - Carboplatin/administration & dosage MH - Cisplatin/administration & dosage MH - Deoxycytidine/administration & dosage/analogs & derivatives MH - Disease-Free Survival MH - Female MH - Fluorouracil/administration & dosage/analogs & derivatives MH - Gallbladder Neoplasms/*drug therapy/pathology MH - Humans MH - Leucovorin/administration & dosage MH - Male MH - Middle Aged MH - Organoplatinum Compounds/administration & dosage MH - Retrospective Studies MH - Treatment Outcome PMC - PMC4236575 OID - NLM: PMC4236575 EDAT- 2014/08/15 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/08/14 06:00 PHST- 2013/08/09 [received] PHST- 2014/08/05 [accepted] PHST- 2014/08/13 [aheadofprint] AID - 1471-230X-14-143 [pii] AID - 10.1186/1471-230X-14-143 [doi] PST - epublish SO - BMC Gastroenterol. 2014 Aug 13;14:143. doi: 10.1186/1471-230X-14-143. PMID- 25115836 OWN - NLM STAT- MEDLINE DA - 20140813 DCOM- 20150423 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 9 IP - 8 DP - 2014 TI - A prospective study of gynecological cancer risk in relation to adiposity factors: cumulative incidence and association with plasma adipokine levels. PG - e104630 LID - 10.1371/journal.pone.0104630 [doi] AB - BACKGROUND: Associations of obesity and obesity-related metabolic factors (adiposity factors) with uterine corpus cancer (UCC) and ovarian cancer (OVC) risk have been described. Still, a cause-effect relationship and the underlying mediators remain unclear, particularly for low-incidence populations. We aimed to prospectively determine whether adiposity factors could predict the development of UCC and OVC in Taiwanese women. To explore the biological mediators linking adiposity factors to cancer risk, we examined the association of two adipokines, leptin and adiponectin, with the gynecological cancers. METHODS: Totally, 11,258 women, aged 30-65, were recruited into the Community-Based Cancer Screening Program (CBCSP) study during 1991-1993, and were followed for UCC and OVC cases until December 31, 2011. Cox proportional hazard models were used to estimate hazard ratios (HRs). Adiposity factors and risk covariates were assessed at recruitment. Newly-developed cancer cases were determined from data in the government's National Cancer Registry and Death Certification System. For adipokienes study, a nested case-control study was conducted within the cohort. Baseline plasma samples of 40 incident gynecological cancer cases and 240 age-menopause-matched controls were assayed for adipokines levels. FINDINGS: There were 38 and 30 incident cases of UCC and OVC, respectively, diagnosed during a median 19.9 years of follow-up. Multivariate analysis showed that alcohol intake (HR = 16.00, 95% = 4.83-53.00), high triglyceride levels (HR = 2.58, 95% = 1.28-5.17), and years of endogenous estrogen exposure per 5-year increment (HR = 1.91, 95% = 1.08-3.38) were associated with increased UCC risk. High body mass index (BMI >/= 27 kg/m(2), HR = 2.90, 95% = 1.30-6.46) was associated with increased OVC risk. Analysis further showed an independent effect of adipokines on UCC and OVC risk after adjustment of the risk covariates. CONCLUSION: We provided evidence that alcohol intake, high triglyceride levels and long endogenous estrogen exposure increase UCC risk, whereas obesity positively predicts OVC risk. Circulating adipokines may mediate the link of adiposity factors to gynecological cancer risk. FAU - Wu, Meei-Maan AU - Wu MM AD - Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Genomics Research Center, Academia Sinica, Taipei, Taiwan; School of Public Health, Taipei Medical University, Taipei, Taiwan. FAU - Chen, Hui-Chi AU - Chen HC AD - Genomics Research Center, Academia Sinica, Taipei, Taiwan. FAU - Chen, Chi-Ling AU - Chen CL AD - Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - You, San-Lin AU - You SL AD - Genomics Research Center, Academia Sinica, Taipei, Taiwan. FAU - Cheng, Wen-Fang AU - Cheng WF AD - Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan. FAU - Chen, Chi-An AU - Chen CA AD - Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan. FAU - Lee, Te-Chang AU - Lee TC AD - Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. FAU - Chen, Chien-Jen AU - Chen CJ AD - Genomics Research Center, Academia Sinica, Taipei, Taiwan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140812 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Adipokines) SB - IM MH - Adipokines/blood MH - *Adiposity MH - Adult MH - Aged MH - Aged, 80 and over MH - Case-Control Studies MH - Female MH - Follow-Up Studies MH - Genital Neoplasms, Female/blood/*epidemiology/*etiology MH - Humans MH - Incidence MH - Middle Aged MH - Obesity/*complications MH - Odds Ratio MH - Population Surveillance MH - Prospective Studies MH - Risk MH - Taiwan/epidemiology PMC - PMC4130554 OID - NLM: PMC4130554 EDAT- 2014/08/15 06:00 MHDA- 2015/04/24 06:00 CRDT- 2014/08/14 06:00 PHST- 2014 [ecollection] PHST- 2014/02/16 [received] PHST- 2014/07/11 [accepted] PHST- 2014/08/12 [epublish] AID - 10.1371/journal.pone.0104630 [doi] AID - PONE-D-14-07291 [pii] PST - epublish SO - PLoS One. 2014 Aug 12;9(8):e104630. doi: 10.1371/journal.pone.0104630. eCollection 2014. PMID- 25106406 OWN - NLM STAT- MEDLINE DA - 20141126 DCOM- 20150417 IS - 1423-0380 (Electronic) IS - 1010-4283 (Linking) VI - 35 IP - 11 DP - 2014 Nov TI - A4383C and C76G SNP in Cathepsin B is respectively associated with the high risk and tumor size of hepatocarcinoma. PG - 11193-8 LID - 10.1007/s13277-014-2004-z [doi] AB - Single nucleotide polymorphism (SNP) in some genes is a candidate for having or developing a cancer. Cathepsin B (CTSB) is considered to be the biomarker of cancers. The study aimed to evaluate the impacts of three SNPs in CTSB gene on the risk and progress of hepatocellular carcinoma (HCC). The SNPs of CTSB C76G (rs12338), CTSB A4383C (rs13332), and CTSB A8422G (rs8898) from 135 patients with HCC and 520 control participants in Taiwan were determined by real-time PCR. Through analyzing by statistics, we found that the polymorphism of rs13332 was significantly associated to the risk of HCC cancer; a significantly high frequent tumor size development was observed in HCC patients carrying rs12338 polymorphic genotype than those carrying ancestral genotype. The SNPs of rs12338, rs13332, and rs8898 were irrelevant to the frequencies of HCC clinical status and the levels of HCC clinicopathological markers. In conclusions, CTSB A4383C SNP is observed modestly more often in patients who developed HCC than in healthy controls and might be associated with the risk of HCC. The association between CTSB C76G SNP and greater tumor size may warrant further study in regards to the biology of HCC. FAU - Chen, Tsung-Po AU - Chen TP AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. FAU - Yang, Shun-Fa AU - Yang SF FAU - Lin, Chiao-Wen AU - Lin CW FAU - Lee, Hsiang-Lin AU - Lee HL FAU - Tsai, Chiung-Man AU - Tsai CM FAU - Weng, Chia-Jui AU - Weng CJ LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140810 PL - Netherlands TA - Tumour Biol JT - Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine JID - 8409922 RN - EC 3.4.22.1 (CTSB protein, human) RN - EC 3.4.22.1 (Cathepsin B) SB - IM MH - Alcohol Drinking/adverse effects MH - Carcinoma, Hepatocellular/*etiology/pathology MH - Case-Control Studies MH - Cathepsin B/*genetics MH - Female MH - Follow-Up Studies MH - Genetic Predisposition to Disease MH - Genotype MH - Humans MH - Liver Neoplasms/*etiology/pathology MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Polymorphism, Single Nucleotide/*genetics MH - Prognosis MH - Real-Time Polymerase Chain Reaction MH - Risk Factors MH - Tobacco Use/adverse effects EDAT- 2014/08/12 06:00 MHDA- 2015/04/18 06:00 CRDT- 2014/08/10 06:00 PHST- 2014/02/04 [received] PHST- 2014/04/22 [accepted] PHST- 2014/08/10 [aheadofprint] AID - 10.1007/s13277-014-2004-z [doi] PST - ppublish SO - Tumour Biol. 2014 Nov;35(11):11193-8. doi: 10.1007/s13277-014-2004-z. Epub 2014 Aug 10. PMID- 25104195 OWN - NLM STAT- MEDLINE DA - 20140808 DCOM- 20150406 IS - 1998-4774 (Electronic) IS - 0019-509X (Linking) VI - 51 IP - 2 DP - 2014 Apr-Jun TI - Can positron emission tomography-computed tomography predict response in locally advanced rectal cancer patients treated with induction folinic acid and 5-florouracil? PG - 138-41 LID - 10.4103/0019-509X.138234 [doi] AB - OBJECTIVE: The aim of this study was to determine the pathological complete response rates in a group of locally advanced rectal cancer patients who underwent chemoradiotherapy (CRT) after treatment with induction folinic acid and 5-florouracil (FOLFOX) chemotherapy and the relationship between the complete response and positron emission tomography-computed tomography (PET-CT). MATERIALS AND METHODS: The files of 239 patients who were diagnosed with rectal cancer between January 2008 and January 2012 were evaluated retrospectively. Of these, there were 24 locally advanced rectal cancer patients who met the following criteria: They were administered CRT after receiving four courses induction oxaliplatin, FOLFOX and they underwent PET-CT for staging and for the evaluation of their response to FOLFOX treatment. Of these 24 patients, 20 operable patients were included in the study. RESULTS: The pathological complete response was obtained in seven patients (35%) who were operated on and then given induction four courses FOLFOX chemotherapy and CRT. We determined that age, gender, clinical stage at diagnosis and PET-CT before and after induction chemotherapy were not predictive of the pathological complete response to tumor fluorodeoxyglucose uptake activity. CONCLUSION: The rates of pathological complete response were increased in locally advanced rectal cancer patients who underwent short-term induction chemotherapy. Although the PET-CT has retained its importance in predicting pathological complete response, there is still a need for studies with a larger number of patients and long-term follow-ups. FAU - Gunduz, S AU - Gunduz S AD - Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey. FAU - Coskun, H S AU - Coskun HS FAU - Arslan, D AU - Arslan D FAU - Goksu, S S AU - Goksu SS FAU - Tatli, A M AU - Tatli AM FAU - Uysal, M AU - Uysal M FAU - Ozdogan, M AU - Ozdogan M FAU - Savas, B AU - Savas B LA - eng PT - Journal Article PL - India TA - Indian J Cancer JT - Indian journal of cancer JID - 0112040 RN - 0 (Organoplatinum Compounds) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Folfox protocol SB - IM MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Chemoradiotherapy MH - Female MH - Fluorouracil/therapeutic use MH - Humans MH - Induction Chemotherapy/methods MH - Leucovorin/therapeutic use MH - Male MH - Middle Aged MH - *Multimodal Imaging MH - Organoplatinum Compounds/therapeutic use MH - Positron-Emission Tomography MH - Rectal Neoplasms/*drug therapy/*pathology/*radiotherapy MH - Retrospective Studies MH - Tomography, X-Ray Computed MH - Treatment Outcome EDAT- 2014/08/12 06:00 MHDA- 2015/04/07 06:00 CRDT- 2014/08/09 06:00 AID - IndianJournalofCancer_2014_51_2_138_138234 [pii] AID - 10.4103/0019-509X.138234 [doi] PST - ppublish SO - Indian J Cancer. 2014 Apr-Jun;51(2):138-41. doi: 10.4103/0019-509X.138234. PMID- 25103857 OWN - NLM STAT- MEDLINE DA - 20140813 DCOM- 20150413 IS - 1471-230X (Electronic) IS - 1471-230X (Linking) VI - 14 DP - 2014 TI - A multicentre case control study on complicated coeliac disease: two different patterns of natural history, two different prognoses. PG - 139 LID - 10.1186/1471-230X-14-139 [doi] AB - BACKGROUND: Coeliac disease is a common enteropathy characterized by an increased mortality mainly due to its complications. The natural history of complicated coeliac disease is characterised by two different types of course: patients with a new diagnosis of coeliac disease that do not improve despite a strict gluten-free diet (type A cases) and previously diagnosed coeliac patients that initially improved on a gluten-free diet but then relapsed despite a strict diet (type B cases). Our aim was to study the prognosis and survival of A and B cases. METHODS: Clinical and laboratory data from coeliac patients who later developed complications (A and B cases) and sex- and age-matched coeliac patients who normally responded to a gluten-free diet (controls) were collected among 11 Italian centres. RESULTS: 87 cases and 136 controls were enrolled. Complications tended to occur rapidly after the diagnosis of coeliac disease and cumulative survival dropped in the first months after diagnosis of complicated coeliac disease. Thirty-seven cases died (30/59 in group A, 7/28 in group B). Type B cases presented an increased survival rate compared to A cases. CONCLUSIONS: Complicated coeliac disease is an extremely serious condition with a high mortality and a short survival. Survival depends on the type of natural history. FAU - Biagi, Federico AU - Biagi F AD - Coeliac Centre/First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, P,le Golgi, 19, I-27100, Pavia, Italy. f.biagi@smatteo.pv.it. FAU - Marchese, Alessandra AU - Marchese A FAU - Ferretti, Francesca AU - Ferretti F FAU - Ciccocioppo, Rachele AU - Ciccocioppo R FAU - Schiepatti, Annalisa AU - Schiepatti A FAU - Volta, Umberto AU - Volta U FAU - Caio, Giacomo AU - Caio G FAU - Ciacci, Carolina AU - Ciacci C FAU - Zingone, Fabiana AU - Zingone F FAU - D'Odorico, Anna AU - D'Odorico A FAU - Carroccio, Antonio AU - Carroccio A FAU - Ambrosiano, Giuseppe AU - Ambrosiano G FAU - Mansueto, Pasquale AU - Mansueto P FAU - Gasbarrini, Antonio AU - Gasbarrini A FAU - Piscaglia, Anna Chiara AU - Piscaglia AC FAU - Andrealli, Alida AU - Andrealli A FAU - Astegiano, Marco AU - Astegiano M FAU - Segato, Sergio AU - Segato S FAU - Neri, Matteo AU - Neri M FAU - Meggio, Alberto AU - Meggio A FAU - de Pretis, Giovanni AU - de Pretis G FAU - De Vitis, Italo AU - De Vitis I FAU - Gobbi, Paolo AU - Gobbi P FAU - Corazza, Gino Roberto AU - Corazza GR LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20140807 PL - England TA - BMC Gastroenterol JT - BMC gastroenterology JID - 100968547 SB - IM MH - Adult MH - Aged MH - Carcinoma/etiology/mortality MH - Case-Control Studies MH - Celiac Disease/complications/*diet therapy/mortality MH - Collagenous Sprue/etiology/mortality MH - *Diet, Gluten-Free MH - Disease Progression MH - Enteritis/etiology/mortality MH - Enteropathy-Associated T-Cell Lymphoma/etiology/mortality MH - Female MH - Humans MH - Ileitis/etiology/mortality MH - Intestinal Neoplasms/etiology/mortality MH - Intestine, Small MH - Jejunal Diseases/etiology/mortality MH - Lymphoma, B-Cell/etiology/mortality MH - Male MH - Middle Aged MH - Prognosis MH - Treatment Failure PMC - PMC4127435 OID - NLM: PMC4127435 EDAT- 2014/08/12 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/08/09 06:00 PHST- 2014/01/03 [received] PHST- 2014/07/28 [accepted] PHST- 2014/08/07 [aheadofprint] AID - 1471-230X-14-139 [pii] AID - 10.1186/1471-230X-14-139 [doi] PST - epublish SO - BMC Gastroenterol. 2014 Aug 7;14:139. doi: 10.1186/1471-230X-14-139. PMID- 25102822 OWN - NLM STAT- MEDLINE DA - 20140808 DCOM- 20150407 IS - 1873-1244 (Electronic) IS - 0899-9007 (Linking) VI - 30 IP - 9 DP - 2014 Sep TI - Hypoglycemia, hypotriglyceridemia and starvation associated with cardiogenic shock. PG - 1093-4 LID - 10.1016/j.nut.2014.03.028 [doi] LID - S0899-9007(14)00190-7 [pii] FAU - Crook, Martin A AU - Crook MA AD - Department of Clinical Biochemistry and Metabolic Medicine, University Hospital Lewisham, London, United Kingdom; University of Greenwich, London, United Kingdom. LA - eng PT - Comment PT - Editorial DEP - 20140415 PL - United States TA - Nutrition JT - Nutrition (Burbank, Los Angeles County, Calif.) JID - 8802712 SB - IM CON - Nutrition. 2014 Sep;30(9):1090-2. PMID: 24927630 MH - *Anorexia Nervosa MH - *Esophageal Neoplasms MH - Female MH - Humans MH - Hypoglycemia/*etiology MH - Male MH - *Parkinson Disease MH - Refeeding Syndrome/*complications MH - Shock, Cardiogenic/*etiology MH - *Starvation EDAT- 2014/08/12 06:00 MHDA- 2015/04/08 06:00 CRDT- 2014/08/09 06:00 PHST- 2014/03/15 [received] PHST- 2014/03/31 [accepted] PHST- 2014/04/15 [aheadofprint] AID - S0899-9007(14)00190-7 [pii] AID - 10.1016/j.nut.2014.03.028 [doi] PST - ppublish SO - Nutrition. 2014 Sep;30(9):1093-4. doi: 10.1016/j.nut.2014.03.028. Epub 2014 Apr 15. PMID- 25102052 OWN - NLM STAT- MEDLINE DA - 20140820 DCOM- 20150421 IS - 1532-7914 (Electronic) IS - 0163-5581 (Linking) VI - 66 IP - 6 DP - 2014 TI - Artificial nutritional support in cancer patients after esophagectomy: 11 years of experience. PG - 1038-46 LID - 10.1080/01635581.2014.939292 [doi] AB - Esophageal cancer represents a high-risk group of patients. This study determines the association of artificial nutrition with morbidity, mortality, and survival and studies clinical situations that determine the choice between enteral (EN) and parenteral support (PN). This retrospective single-center study compared 2 periods: 1) treatment centered in surgical process with discretionary demand of support, and 2) elective therapeutic and nutritional interventions were systematized. Risks factors that determined use of PN and survival were included in 4 multivariate regression models: 2 logistic, 1 multinomial, and a survival Cox analysis. Significance determined with 95% confidence interval (CI) of 95%; inclusion criteria was P < 0.1. During an 11-yr period, 175 patients were studied. Artificial nutrition consisted of 45 jejunostomy EN, 28 PN, and 102 both. Risk factors that conditioned PN were first period (OR: 2.41; 95% CI: 1.13-5.14), stay in intensive care unit (ICU) >3 days (OR: 1.70; 95% CI: 0.93-3.71), and surgical reintervention (OR: 3.83; 95% CI: 0.94-16.95). Risk factors associated with mortality were first period (OR: 22.7; 95% CI: 2.31-172.05), respiratory infection (OR: 11.23; 95% CI: 2.33-55.5) and coloplasty surgery (OR: 13.16; 95% CI: 2.11-83.33). Longer survival was associated with second period (OR: 2.36; 95% CI: 1.38-4.05) and lower neoplasm staging (OR: 1.43; 95% CI: 1.21-1.69). A multidisciplinary management that includes nutritional support of esophagectomized patients is 1 of the factors that improves survival. Protocol implies greater use of EN; PN remains an important nutritional therapy. FAU - Llop-Talaveron, Josep Manel AU - Llop-Talaveron JM AD - a Department of Pharmacy, Institut d'Investigacio Biomedica de Bellvitge , Hospital Universitari Bellvitge, L'Hospitalet de Llobregat , Barcelona , Spain. FAU - Farran-Teixidor, Leandre AU - Farran-Teixidor L FAU - Badia-Tahull, Maria B AU - Badia-Tahull MB FAU - Virgili-Casas, Maria AU - Virgili-Casas M FAU - Leiva-Badosa, Elisabet AU - Leiva-Badosa E FAU - Galan-Guzman, Maria-Carmen AU - Galan-Guzman MC FAU - Miro-Martin, Monica AU - Miro-Martin M FAU - Aranda-Danso, Humberto AU - Aranda-Danso H LA - eng PT - Journal Article DEP - 20140807 PL - United States TA - Nutr Cancer JT - Nutrition and cancer JID - 7905040 SB - IM MH - Aged MH - *Enteral Nutrition MH - Esophageal Neoplasms/*therapy MH - Esophagectomy/*methods MH - Female MH - Humans MH - Intervention Studies MH - Logistic Models MH - Male MH - Middle Aged MH - Multivariate Analysis MH - *Parenteral Nutrition MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Treatment Outcome EDAT- 2014/08/08 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/08/08 06:00 PHST- 2014/08/07 [aheadofprint] AID - 10.1080/01635581.2014.939292 [doi] PST - ppublish SO - Nutr Cancer. 2014;66(6):1038-46. doi: 10.1080/01635581.2014.939292. Epub 2014 Aug 7. PMID- 25099765 OWN - NLM STAT- MEDLINE DA - 20140807 DCOM- 20150402 IS - 1559-131X (Electronic) IS - 1357-0560 (Linking) VI - 31 IP - 9 DP - 2014 Sep TI - Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. PG - 153 LID - 10.1007/s12032-014-0153-y [doi] AB - Gastric cancer is often diagnosed in advanced stage. Palliative chemotherapy or best supportive care is recommended for patients with metastatic gastric patients. In several clinical trials, palliative chemotherapy improved overall survival (OS) and progression-free survival (PFS), but the survival benefit of second-line chemotherapy was demonstrated in small cohort studies. The main aim of our study was to compare retrospectively the efficacy of second-line modified EOX (epirubicin, oxaliplatin and capecitabine) [mEOX] and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel-cisplatin-fluorouracil (DCF) regimen. Metastatic gastric cancer patients who progressed on modified DCF regimens were included. A total 105 patients were included to this study; 55 and 50 patients were treated with mEOX and FOLFIRI regimens, respectively. The clinicopathological and demographic characteristics of all patients were collected from the medical charts. Kaplan-Meier survival analysis was carried out for PFS and OS. The median follow-up of our study was 16 (4-85) months. In both groups, all of the patients were treated with first-line mDCF. Median cycle of second-line chemotherapy was 3 (1-8) and 3.5 (1-6) in EOX and FOLFIRI groups, respectively (P = 0.44). Overall response rate was observed in 34.6 % and 42.0 % of patients second-line chemotherapy in mEOX and FOLFIRI arms, respectively (P = 0.17). Median PFS was 5.5 and 6.3 months in mEOX and FOLFIRI arms, respectively (P = 0.98). Median OS was 6.9 and 7.0 months in mEOX and FOLFIRI arms, respectively, from the time of beginning second-line chemotherapy protocol (P = 0.89). As compared with FOLFIRI regimen, mEOX regimen was associated with less neutropenia, thrombocytopenia and anemia. Dose reduction and dose delay were significantly higher in FOLFIRI group compared to mEOX group (P < 0.001). In our trial, triplet regimens mEOX and FOLFIRI regimens have similar efficacy as second-line treatment for patients with metastatic gastric cancer. FOLFIRI regimen was associated with more hematological toxicity. FAU - Sendur, Mehmet Ali Nahit AU - Sendur MA AD - Department of Medical Oncology, Faculty of Medicine, Yildirim Beyazit University, 06800, Ankara, Turkey, masendur@yahoo.com.tr. FAU - Ozdemir, Nuriye AU - Ozdemir N FAU - Ozatli, Tahsin AU - Ozatli T FAU - Yazici, Ozan AU - Yazici O FAU - Aksoy, Sercan AU - Aksoy S FAU - Ekinci, Ahmet Siyar AU - Ekinci AS FAU - Yazilitas, Dogan AU - Yazilitas D FAU - Gunaydin, Yusuf AU - Gunaydin Y FAU - Oksuzoglu, Berna AU - Oksuzoglu B FAU - Benekli, Mustafa AU - Benekli M FAU - Zengin, Nurullah AU - Zengin N LA - eng PT - Comparative Study PT - Journal Article DEP - 20140807 PL - United States TA - Med Oncol JT - Medical oncology (Northwood, London, England) JID - 9435512 RN - 0 (Antineoplastic Agents) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - XT3Z54Z28A (Camptothecin) RN - IFL protocol SB - IM MH - Adult MH - Aged MH - Antineoplastic Agents/adverse effects/*therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Camptothecin/analogs & derivatives MH - Febrile Neutropenia MH - Female MH - Fluorouracil MH - Humans MH - Kaplan-Meier Estimate MH - Leucovorin MH - Male MH - Middle Aged MH - Retrospective Studies MH - *Stomach Neoplasms/drug therapy/epidemiology/pathology MH - Treatment Outcome EDAT- 2014/08/08 06:00 MHDA- 2015/04/04 06:00 CRDT- 2014/08/08 06:00 PHST- 2014/07/09 [received] PHST- 2014/07/28 [accepted] PHST- 2014/08/07 [aheadofprint] AID - 10.1007/s12032-014-0153-y [doi] PST - ppublish SO - Med Oncol. 2014 Sep;31(9):153. doi: 10.1007/s12032-014-0153-y. Epub 2014 Aug 7. PMID- 25099444 OWN - NLM STAT- MEDLINE DA - 20140807 DCOM- 20150413 IS - 1540-1413 (Electronic) IS - 1540-1405 (Linking) VI - 12 IP - 8 DP - 2014 Aug TI - Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. PG - 1123-30 AB - Appendiceal malignancies are rare and represent 1% of intestinal tumors in the United States. The role and efficacy of modern systemic therapy in advanced appendiceal adenocarcinoma has not been established. This study analyzed patients with recurrent or metastatic appendiceal adenocarcinoma in the database for Colorectal Cancer (CRC; 2005-2012). This database tracks longitudinal care for patients treated at 8 specialty centers across the Unites States. Study objectives were to describe and evaluate the efficacy of systemic therapy and investigate relationships with clinicopathologic features. Cox regression analysis was performed to identify predictors of progression-free survival (PFS) and overall survival (OS). Of 248 patients with advanced appendiceal carcinoma, 112 (45%) received systemic therapy for measurable disease and are the focus of this report. The most common chemotherapy regimens included FOLFOX with or without bevacizumab (n=39 and n=37, respectively), FOLFIRI (n=15), and single-agent fluoro-pyrimidine (n=10). Among 99 patients evaluable for best response, 39 experienced a response (response rate [RR], 39%) and 36 (36%) had stable disease. The median PFS was 1.2 years (95% CI, 1.0-1.8) and median OS was 2.1 years (95% CI, 1.6-2.3). Patients with non-mucinous histology or high-grade tumors and those who underwent nondebulking surgery had worse PFS and OS. Treatment of advanced appendiceal adenocarcinoma at NCCN Member Institutions commonly incorporates agents used for CRC. RR, PFS, and OS are comparable to those achieved in the treatment of metastatic CRC. Poor prognostic factors include nonmucinous histology or high-grade tumors and history of nondebulking surgery. CI - Copyright (c) 2014 by the National Comprehensive Cancer Network. FAU - Tejani, Mohamedtaki A AU - Tejani MA AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. FAU - ter Veer, Anna AU - ter Veer A AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. FAU - Milne, Dana AU - Milne D AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. FAU - Ottesen, Rebecca AU - Ottesen R AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. FAU - Bekaii-Saab, Tanios AU - Bekaii-Saab T AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. FAU - Benson, Al B 3rd AU - Benson AB 3rd AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. FAU - Schrag, Deborah AU - Schrag D AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. FAU - Shibata, Stephen AU - Shibata S AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. FAU - Skibber, John AU - Skibber J AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. FAU - Weiser, Martin AU - Weiser M AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. FAU - Wilkinson, Neal AU - Wilkinson N AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. FAU - Cohen, Steven J AU - Cohen SJ AD - From Fox Chase Cancer Center, Philadelphia, Pennsylvania; City of Hope Comprehensive Cancer Center, Duarte, California; Dana-Farber Cancer Institute, Boston, Massachusetts; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois; The University of Texas MD Anderson Cancer Center, Houston, Texas; Memorial Sloan Kettering Cancer Center, New York, New York; and Roswell Park Cancer Institute, Buffalo, New York. LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 RN - 0 (Organoplatinum Compounds) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Folfox protocol SB - IM MH - Adenocarcinoma/*drug therapy/pathology MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage MH - Appendiceal Neoplasms/*drug therapy/pathology MH - Colorectal Neoplasms/drug therapy/pathology MH - Disease-Free Survival MH - Female MH - Fluorouracil/administration & dosage MH - Humans MH - Kaplan-Meier Estimate MH - Leucovorin/administration & dosage MH - Male MH - Middle Aged MH - Organoplatinum Compounds/administration & dosage MH - *Treatment Outcome MH - United States EDAT- 2014/08/08 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/08/08 06:00 AID - 12/8/1123 [pii] PST - ppublish SO - J Natl Compr Canc Netw. 2014 Aug;12(8):1123-30. PMID- 25099439 OWN - NLM STAT- MEDLINE DA - 20140807 DCOM- 20150413 IS - 1540-1413 (Electronic) IS - 1540-1405 (Linking) VI - 12 IP - 8 DP - 2014 Aug TI - Current quandaries in cancer-associated anemia. PG - 1071-5 FAU - Gilreath, Jeffrey A AU - Gilreath JA FAU - Rodgers, George M AU - Rodgers GM LA - eng PT - Editorial PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 RN - 0 (Antineoplastic Agents) RN - 935E97BOY8 (Folic Acid) RN - E1UOL152H7 (Iron) RN - P6YC3EG204 (Vitamin B 12) SB - IM MH - Anemia/chemically induced/*drug therapy/pathology MH - Antineoplastic Agents/*adverse effects MH - Folic Acid/therapeutic use MH - Humans MH - Iron/therapeutic use MH - Neoplasms/drug therapy/*pathology MH - Vitamin B 12/therapeutic use EDAT- 2014/08/08 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/08/08 06:00 AID - 12/8/1071 [pii] PST - ppublish SO - J Natl Compr Canc Netw. 2014 Aug;12(8):1071-5. PMID- 25095889 OWN - NLM STAT- MEDLINE DA - 20140811 DCOM- 20150414 IS - 1471-2482 (Electronic) IS - 1471-2482 (Linking) VI - 14 DP - 2014 TI - Endoscopic thyroid surgery via a breast approach: a single institution's experiences. PG - 49 LID - 10.1186/1471-2482-14-49 [doi] AB - BACKGROUND: Thyroid carcinoma in young women is rapidly increasing, and cosmesis plays an important role in thyroid operations. Various endoscopic thyroid surgery approaches have been performed, and their application has recently been extended. We performed endoscopic thyroid surgeries via a breast approach since 1999. Herein, we evaluate the safety of this approach and identify the outcomes for differentiated thyroid carcinoma. METHODS: A total of 452 consecutive patients with thyroid and parathyroid disease underwent endoscopic thyroidectomy via a breast approach at Uijeongbu St. Mary's Hospital between November 1999 and December 2012. The inclusion criteria for endoscopic thyroidectomy included a benign tumour less than 4 cm in diameter, malignant thyroid nodules less than 2 cm, and no evidence of lymph node metastasis or local invasion. We analysed the clinicopathologic data and surgical factors of this approach. RESULTS: The mean age of the patients was 38.4 +/- 10.6 years (range 11-73 years). The mean tumour size was 2.12 +/- 1.17 cm (range 0.1-4 cm). The final tumour pathologies included papillary carcinoma (n = 120), follicular carcinoma (n = 8), nodular hyperplasia (n = 266), follicular adenoma (n = 43), and Huthle cell adenoma (n = 4). The mean postoperative hospital stay was 3.8 +/- 1.3 days (range 1-17 days). Temporary and permanent hypoparathyroidism requiring calcium and vitamin D supplementation developed in 32 (7.1%) and 4 (0.9%) patients, respectively. Transient vocal cord paresis occurred in 20 (4.4%) patients. CONCLUSIONS: For patients with benign and low-risk malignant thyroid disease, endoscopic thyroidectomy via a breast approach is a safe, feasible, and minimally invasive surgical method with minimal complications. FAU - Kim, Yong-Seok AU - Kim YS FAU - Joo, Kyu-Hwa AU - Joo KH FAU - Park, Sun-Cheol AU - Park SC FAU - Kim, Kee-Hwan AU - Kim KH FAU - Ahn, Chang-Hyuck AU - Ahn CH FAU - Kim, Jeong-Soo AU - Kim JS AD - Department of Surgery, Uijeongbu St, Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea. drbreast@catholic.ac.kr. LA - eng PT - Journal Article DEP - 20140805 PL - England TA - BMC Surg JT - BMC surgery JID - 100968567 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Child MH - *Endoscopy MH - Female MH - Follow-Up Studies MH - Humans MH - Length of Stay/trends MH - Male MH - Middle Aged MH - *Neoplasm Staging MH - Retrospective Studies MH - Thyroid Gland/pathology/*surgery MH - Thyroid Neoplasms/diagnosis/*surgery MH - Thyroidectomy/*methods MH - Treatment Outcome MH - Young Adult PMC - PMC4127080 OID - NLM: PMC4127080 EDAT- 2014/08/07 06:00 MHDA- 2015/04/15 06:00 CRDT- 2014/08/07 06:00 PHST- 2013/11/10 [received] PHST- 2014/07/28 [accepted] PHST- 2014/08/05 [aheadofprint] AID - 1471-2482-14-49 [pii] AID - 10.1186/1471-2482-14-49 [doi] PST - epublish SO - BMC Surg. 2014 Aug 5;14:49. doi: 10.1186/1471-2482-14-49. PMID- 25093336 OWN - NLM STAT- MEDLINE DA - 20140806 DCOM- 20150424 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 9 IP - 8 DP - 2014 TI - In-silico prediction of key metabolic differences between two non-small cell lung cancer subtypes. PG - e103998 LID - 10.1371/journal.pone.0103998 [doi] AB - Metabolism expresses the phenotype of living cells and understanding it is crucial for different applications in biotechnology and health. With the increasing availability of metabolomic, proteomic and, to a larger extent, transcriptomic data, the elucidation of specific metabolic properties in different scenarios and cell types is a key topic in systems biology. Despite the potential of the elementary flux mode (EFM) concept for this purpose, its use has been limited so far, mainly because their computation has been infeasible for genome-scale metabolic networks. In a recent work, we determined a subset of EFMs in human metabolism and proposed a new protocol to integrate gene expression data, spotting key 'characteristic EFMs' in different scenarios. Our approach was successfully applied to identify metabolic differences among several human healthy tissues. In this article, we evaluated the performance of our approach in clinically interesting situation. In particular, we identified key EFMs and metabolites in adenocarcinoma and squamous-cell carcinoma subtypes of non-small cell lung cancers. Results are consistent with previous knowledge of these major subtypes of lung cancer in the medical literature. Therefore, this work constitutes the starting point to establish a new methodology that could lead to distinguish key metabolic processes among different clinical outcomes. FAU - Rezola, Alberto AU - Rezola A AD - Department of Bioinformatics, CEIT and TECNUN, University of Navarra, San Sebastian, Spain. FAU - Pey, Jon AU - Pey J AD - Department of Bioinformatics, CEIT and TECNUN, University of Navarra, San Sebastian, Spain. FAU - Rubio, Angel AU - Rubio A AD - Department of Bioinformatics, CEIT and TECNUN, University of Navarra, San Sebastian, Spain. FAU - Planes, Francisco J AU - Planes FJ AD - Department of Bioinformatics, CEIT and TECNUN, University of Navarra, San Sebastian, Spain. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140805 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Algorithms MH - Carcinoma, Non-Small-Cell Lung/classification/genetics/*metabolism MH - Citric Acid Cycle/genetics MH - *Computational Biology MH - Computer Simulation MH - Databases, Genetic MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Gene Regulatory Networks MH - Glycolysis/genetics MH - Humans MH - Lung Neoplasms/classification/genetics/*metabolism MH - *Metabolic Networks and Pathways PMC - PMC4122379 OID - NLM: PMC4122379 EDAT- 2014/08/06 06:00 MHDA- 2015/04/25 06:00 CRDT- 2014/08/06 06:00 PHST- 2014 [ecollection] PHST- 2014/02/06 [received] PHST- 2014/07/09 [accepted] PHST- 2014/08/05 [epublish] AID - 10.1371/journal.pone.0103998 [doi] AID - PONE-D-14-05654 [pii] PST - epublish SO - PLoS One. 2014 Aug 5;9(8):e103998. doi: 10.1371/journal.pone.0103998. eCollection 2014. PMID- 25091359 OWN - NLM STAT- MEDLINE DA - 20140805 DCOM- 20150401 LR - 20150416 IS - 1871-403X (Print) IS - 1871-403X (Linking) VI - 8 IP - 4 DP - 2014 Jul-Aug TI - Association of body mass index and prostate cancer mortality. PG - e374-81 LID - 10.1016/j.orcp.2013.06.002 [doi] LID - S1871-403X(13)00047-1 [pii] AB - OBJECTIVES: Inconsistent evidence exists on whether obesity is associated with an increased risk of prostate cancer death post-radical prostatectomy. We examined data from three large health plans to evaluate if an increased body mass index (BMI) at prostate cancer diagnosis is related to prostate cancer mortality SUBJECTS AND METHODS: This population-based case-control study included 751 men with prostate cancer who underwent radical prostatectomy. Cases were men who died due to prostate cancer (N=323) and matched controls (N=428). We used multivariable logistic regression models to assess the association between BMI at diagnosis and prostate cancer mortality, adjusted for Gleason score, PSA, tumour characteristics, and matching factors. RESULTS: Study subjects were classified into the following BMI (kg/m2) categories: healthy (18.5-24.9), overweight (25-29.9) and obese (>/=30). Nearly 43% of the participants had a BMI >/=25 at diagnosis. A higher fraction of cases (30%) were obese compared to controls (22%). Overall, obese men had more than a 50% increase in prostate cancer mortality (adjusted odds ratio=1.50 [95% CI, 1.03-2.19]) when compared to men with healthy BMI. After stratifying by Gleason score, the odds of mortality generally rose with increasing BMI. The strongest effect was observed in the Gleason score 8+ category (2.37, 95% CI: 1.11-5.09). These associations persisted after adjusting for PSA at diagnosis and other tumour characteristics. CONCLUSIONS: These results suggest that BMI at diagnosis is strongly correlated with prostate cancer mortality, and that men with aggressive disease have a markedly greater odds of death if they are overweight or obese. CI - Copyright (c) 2013 Asian Oceanian Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved. FAU - Haque, Reina AU - Haque R AD - Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Reina.Haque@kp.org. FAU - Van Den Eeden, Stephen K AU - Van Den Eeden SK AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States. FAU - Wallner, Lauren P AU - Wallner LP AD - Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. FAU - Richert-Boe, Kathryn AU - Richert-Boe K AD - Center for Health Research, Kaiser Permanente Northwest, Portland, OR, United States. FAU - Kallakury, Bhaskar AU - Kallakury B AD - Georgetown University, Department of Pathology, Washington, DC, United States. FAU - Wang, Renyi AU - Wang R AD - Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. FAU - Weinmann, Sheila AU - Weinmann S AD - Center for Health Research, Kaiser Permanente Northwest, Portland, OR, United States. LA - eng GR - R01 CA100743/CA/NCI NIH HHS/United States GR - R01CA100743/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20130806 PL - Netherlands TA - Obes Res Clin Pract JT - Obesity research & clinical practice JID - 101303911 SB - IM MH - Aged MH - Aged, 80 and over MH - *Body Mass Index MH - Case-Control Studies MH - Humans MH - Logistic Models MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Obesity/complications/*mortality MH - Prostatectomy MH - Prostatic Neoplasms/complications/*mortality MH - Risk Factors PMC - PMC4122983 MID - NIHMS504607 OID - NLM: NIHMS504607 [Available on 07/01/15] OID - NLM: PMC4122983 [Available on 07/01/15] OTO - NOTNLM OT - BMI OT - Case–control OT - Population sciences OT - Prostate cancer OT - Survival EDAT- 2014/08/06 06:00 MHDA- 2015/04/02 06:00 CRDT- 2014/08/06 06:00 PMCR- 2015/07/01 00:00 PHST- 2013/04/26 [received] PHST- 2013/06/10 [revised] PHST- 2013/06/25 [accepted] PHST- 2013/08/06 [aheadofprint] AID - S1871-403X(13)00047-1 [pii] AID - 10.1016/j.orcp.2013.06.002 [doi] PST - ppublish SO - Obes Res Clin Pract. 2014 Jul-Aug;8(4):e374-81. doi: 10.1016/j.orcp.2013.06.002. Epub 2013 Aug 6. PMID- 25091355 OWN - NLM STAT- MEDLINE DA - 20140805 DCOM- 20150401 IS - 1871-403X (Print) IS - 1871-403X (Linking) VI - 8 IP - 4 DP - 2014 Jul-Aug TI - Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. PG - e339-49 LID - 10.1016/j.orcp.2013.10.005 [doi] LID - S1871-403X(13)00201-9 [pii] AB - BACKGROUND: Treatment of obesity with diet and exercise may have short-term success but longer-term maintenance of weight loss is less successful. Obesity is associated with a reduction of serum testosterone, and, vice versa, a reduction in serum testosterone is associated with obesity and features of the metabolic syndrome. OBJECTIVE: To investigate whether restoring serum testosterone to normal in hypo-gonadal obese men is beneficial with regard to weight loss and improvement of the metabolic syndrome. METHODS: A prospective registry accumulated to 181 men over five years (mean serum testosterone 10.06+/-1.3 nmol/L (N>12.1), body mass index (BMI) >/=30 kg/m2. Of these men, 72 had diabetes mellitus type 2. All received parenteral testosterone undecanoate 1000 mg/12 weeks for up to five years. RESULTS: Waist circumference (cm) decreased from 111.2+/-7.54 to 100.46+/-7.1, weight (kg) from 114.71+/-11.59 to 93.2+/-8.49, BMI (kg/m2) from 36.72+/-3.72 to 30.2+/-2.59 (all variables statistically significant vs. baseline (p<0.0001) and each year compared to the previous year (p<0.0001)). In the 72 diabetic men, waist circumference (cm) decreased from 112.93+/-7.16 to 101.48+/-7.24, weight (kg) from 116.94+/-11.62 to 94.42+/-9.42, BMI (kg/m2) from 37.71+/-3.5 to 30.95+/-2.69 (all variables statistically significant vs. baseline (p<0.0001) and each year compared to the previous year (p<0.0001)). In all men serum glucose, HbA1c, lipid profiles and blood pressure improved significantly. Testosterone treatment as assessed by hemoglobin, hematocrit, serum prostate specific antigen (PSA) and occurrence of prostate cancer was acceptably safe. CONCLUSIONS: Normalizing serum testosterone in obese hypogonadal men, also in those with diabetes type 2, improved their metabolic state. CI - Copyright (c) 2013 Asian Oceanian Association for the Study of Obesity. All rights reserved. FAU - Haider, Ahmad AU - Haider A AD - Private Urology Practice, Bremerhaven, Germany. FAU - Saad, Farid AU - Saad F AD - Bayer Pharma, Global Medical Affairs Andrology, Berlin, Germany; Gulf Medical University School of Medicine, Ajman, United Arab Emirates. Electronic address: farid.saad@bayer.com. FAU - Doros, Gheorghe AU - Doros G AD - Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. FAU - Gooren, Louis AU - Gooren L AD - Emeritus VU Medical Center, Amsterdam, The Netherlands; Androconsult, Chiang Mai, Thailand. LA - eng PT - Journal Article PT - Observational Study DEP - 20131105 PL - Netherlands TA - Obes Res Clin Pract JT - Obesity research & clinical practice JID - 101303911 RN - 0 (Blood Glucose) RN - 0 (Hemoglobin A, Glycosylated) RN - 0 (Hemoglobins) RN - 3XMK78S47O (Testosterone) RN - EC 3.4.21.77 (Prostate-Specific Antigen) RN - H16A5VCT9C (testosterone undecanoate) SB - IM MH - Adult MH - Aged MH - Blood Glucose/metabolism MH - Blood Pressure/drug effects MH - Body Mass Index MH - Cardiovascular Diseases/blood/*prevention & control MH - Diabetes Mellitus, Type 2/blood MH - Follow-Up Studies MH - Hematocrit MH - Hemoglobin A, Glycosylated/metabolism MH - Hemoglobins/metabolism MH - Humans MH - Hypogonadism/blood/*drug therapy MH - Male MH - Metabolic Syndrome X/blood/drug therapy MH - Middle Aged MH - Obesity/*drug therapy MH - Parenteral Nutrition MH - Prospective Studies MH - Prostate-Specific Antigen/blood MH - Prostatic Neoplasms/prevention & control MH - Risk Factors MH - Testosterone/*analogs & derivatives/blood/therapeutic use MH - Waist Circumference MH - *Weight Loss OTO - NOTNLM OT - Diabetes mellitus type 2 OT - Obesity OT - Testosterone OT - Waist circumference OT - Weight loss EDAT- 2014/08/06 06:00 MHDA- 2015/04/02 06:00 CRDT- 2014/08/06 06:00 PHST- 2013/05/25 [received] PHST- 2013/07/31 [revised] PHST- 2013/10/12 [accepted] PHST- 2013/11/05 [aheadofprint] AID - S1871-403X(13)00201-9 [pii] AID - 10.1016/j.orcp.2013.10.005 [doi] PST - ppublish SO - Obes Res Clin Pract. 2014 Jul-Aug;8(4):e339-49. doi: 10.1016/j.orcp.2013.10.005. Epub 2013 Nov 5. PMID- 25078601 OWN - NLM STAT- MEDLINE DA - 20140801 DCOM- 20150408 IS - 1676-5680 (Electronic) IS - 1676-5680 (Linking) VI - 13 IP - 3 DP - 2014 TI - Association of dietary intake of folate and MTHFR genotype with breast cancer risk. PG - 5446-51 LID - 10.4238/2014.July.24.24 [doi] AB - We conducted a hospital-based case-control study to investigate the associations of dietary intake of folate and MTHFR C677T and A1298C polymorphisms with breast cancer in a Chinese population. A 1:1-matched case-control study was conducted. Two hundred and thirty patients who were newly diagnosed and histologically confirmed breast cancer and 230 controls were enrolled from Xinxiang Central Hospital. Folate intake was calculated by standard portion size and relative size for each food item in the questionnaire. Genotyping of MTHFR C677T and A1298C was performed by PCR-RFLP. MTHFR 677TT (OR = 2.26, 95%CI = 1.09-4.87, P = 0.02) and T allele (OR = 1.40, 95%CI = 1.03-1.90, P = 0.03) had an increased risk of laryngeal cancer when compared with the CC genotype. We found any interaction between MTHFR C677T and folate intake (P for interaction = 0.02). In conclusion, our study demonstrated that MTHFR C677T polymorphism and folate are associated with risk of breast cancer. FAU - Wang, Z G AU - Wang ZG AD - Medical Image Center, Xinxiang Central Hospital, Xinxiang, China wzg_xch@163.com. FAU - Cui, W AU - Cui W AD - Special-Needed Hospital Ward, Xinxiang Central Hospital, Xinxiang, China. FAU - Yang, L F AU - Yang LF AD - Special-Needed Hospital Ward, Xinxiang Central Hospital, Xinxiang, China. FAU - Zhu, Y Q AU - Zhu YQ AD - Health Check Centre, Xinxiang Central Hospital, Xinxiang, China. FAU - Wei, W H AU - Wei WH AD - Special-Needed Hospital Ward, Xinxiang Central Hospital, Xinxiang, China. LA - eng PT - Journal Article DEP - 20140724 PL - Brazil TA - Genet Mol Res JT - Genetics and molecular research : GMR JID - 101169387 RN - 935E97BOY8 (Folic Acid) RN - EC 1.5.1.20 (MTHFR protein, human) RN - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2)) SB - IM MH - Adult MH - Alleles MH - Asian Continental Ancestry Group MH - Breast Neoplasms/ethnology/etiology/*genetics/pathology MH - Case-Control Studies MH - Eating/physiology MH - Female MH - Folic Acid/administration & dosage/*adverse effects MH - Gene Expression MH - *Genotype MH - Humans MH - Methylenetetrahydrofolate Reductase (NADPH2)/*genetics MH - Middle Aged MH - Questionnaires MH - Risk Factors EDAT- 2014/08/01 06:00 MHDA- 2015/04/09 06:00 CRDT- 2014/08/01 06:00 AID - gmr3673 [pii] AID - 10.4238/2014.July.24.24 [doi] PST - epublish SO - Genet Mol Res. 2014 Jul 24;13(3):5446-51. doi: 10.4238/2014.July.24.24. PMID- 25071331 OWN - NLM STAT- MEDLINE DA - 20140729 DCOM- 20150417 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 28 DP - 2014 Jul 28 TI - Cachexia and pancreatic cancer: are there treatment options? PG - 9361-73 LID - 10.3748/wjg.v20.i28.9361 [doi] AB - Cachexia is frequently described in patients with pancreatic ductal adenocarcinoma (PDAC) and is associated with reduced survival and quality of life. Unfortunately, the therapeutic options of this multi-factorial and complex syndrome are limited. This is due to the fact that, despite extensive preclinical and clinical research, the underlying pathological mechanisms leading to PDAC-associated cachexia are still not fully understood. Furthermore, there is still a lack of consensus on the definition of cachexia, which complicates the standardization of diagnosis and treatment as well as the analysis of the current literature. In order to provide an efficient therapy for cachexia, an early and reliable diagnosis and consistent monitoring is required, which can be challenging especially in obese patients. Although many substances have been tested in clinical and preclinical settings, so far none of them have been proven to have a long-term effect in ameliorating cancer-associated cachexia. However, recent studies have demonstrated that multidimensional therapeutic modalities are able to alleviate pancreatic cancer-associated cachexia and ultimately improve patients' outcome. In this current review, we propose a stepwise and pragmatic approach to facilitate and standardize the treatment of cachexia in pancreatic cancer patients. This strategy consists of nutritional, dietary, pharmacological, physical and psychological methods. FAU - Mueller, Tara C AU - Mueller TC AD - Tara C Mueller, Jeannine Bachmann, Marc E Martignoni, Department of Surgery, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany. FAU - Burmeister, Marc A AU - Burmeister MA AD - Tara C Mueller, Jeannine Bachmann, Marc E Martignoni, Department of Surgery, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany. FAU - Bachmann, Jeannine AU - Bachmann J AD - Tara C Mueller, Jeannine Bachmann, Marc E Martignoni, Department of Surgery, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany. FAU - Martignoni, Marc E AU - Martignoni ME AD - Tara C Mueller, Jeannine Bachmann, Marc E Martignoni, Department of Surgery, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 RN - 0 (Appetite Stimulants) SB - IM MH - Appetite Stimulants/therapeutic use MH - Cachexia/diagnosis/etiology/physiopathology/psychology/*therapy MH - Carcinoma, Pancreatic Ductal/*complications MH - Combined Modality Therapy MH - Dietary Supplements MH - Humans MH - Nutrition Therapy/*methods MH - Nutritional Status MH - Nutritional Support MH - Palliative Care MH - Pancreatic Neoplasms/*complications MH - Treatment Outcome PMC - PMC4110568 OID - NLM: PMC4110568 OTO - NOTNLM OT - Cachexia OT - Gastrointestinal neoplasms OT - Nutritional support OT - Pancreatic neoplasms EDAT- 2014/07/30 06:00 MHDA- 2015/04/18 06:00 CRDT- 2014/07/30 06:00 PHST- 2013/10/29 [received] PHST- 2014/01/14 [revised] PHST- 2014/02/16 [accepted] AID - 10.3748/wjg.v20.i28.9361 [doi] PST - ppublish SO - World J Gastroenterol. 2014 Jul 28;20(28):9361-73. doi: 10.3748/wjg.v20.i28.9361. PMID- 25065318 OWN - NLM STAT- MEDLINE DA - 20140802 DCOM- 20150331 IS - 1573-8221 (Electronic) IS - 0007-4888 (Linking) VI - 157 IP - 3 DP - 2014 Jul TI - The relationship between the pro-oxidant and antioxidant system status of patients with multiple myeloma and the disease stage. PG - 375-9 LID - 10.1007/s10517-014-2570-5 [doi] AB - Disturbances of the erythrocyte antioxidant system presented by LPO intensification were detected in patients with multiple myeloma. Plasma concentrations of MDA in these patients were close to normal due to effective work of the nonenzymatic antioxidant system. Activities of antioxidant enzymes in the plasma were reduced, while catalase activity was high, and ceruloplasmin content did not differ from the control, this indicating suppression of the enzymatic component of the antioxidant system. In erythrocytes, the level of reduced glutathione was low, especially at stage III of the disease. Changes in SOD and catalase activities were similar to those in the plasma, while activities of glutathione-dependent enzymes were comparable to those in normal human erythrocytes. FAU - Smirnova, O V AU - Smirnova OV AD - Research Institute of Medical Problems of the North, Siberian Division of the Russian Academy of Medical Sciences, Krasnoyarsk, Russia, ovsmirnova71@mail.ru. FAU - Titova, N M AU - Titova NM FAU - Elmanova, N G AU - Elmanova NG LA - eng PT - Journal Article DEP - 20140729 PL - United States TA - Bull Exp Biol Med JT - Bulletin of experimental biology and medicine JID - 0372557 RN - 0 (Antioxidants) RN - 0 (Oxidants) RN - 4Y8F71G49Q (Malondialdehyde) RN - EC 1.11.1.6 (Catalase) RN - EC 1.11.1.9 (Glutathione Peroxidase) RN - EC 1.15.1.1 (Superoxide Dismutase) RN - GAN16C9B8O (Glutathione) SB - IM MH - Adult MH - Antioxidants/*metabolism MH - Case-Control Studies MH - Catalase/blood MH - Female MH - Glutathione/blood MH - Glutathione Peroxidase/blood MH - Humans MH - Lipid Peroxidation MH - Male MH - Malondialdehyde/blood MH - Middle Aged MH - Multiple Myeloma/*blood MH - Oxidants/*blood MH - Oxidative Stress MH - Superoxide Dismutase/blood EDAT- 2014/07/30 06:00 MHDA- 2015/04/01 06:00 CRDT- 2014/07/29 06:00 PHST- 2013/03/02 [received] PHST- 2014/07/29 [aheadofprint] AID - 10.1007/s10517-014-2570-5 [doi] PST - ppublish SO - Bull Exp Biol Med. 2014 Jul;157(3):375-9. doi: 10.1007/s10517-014-2570-5. Epub 2014 Jul 29. PMID- 25057938 OWN - NLM STAT- MEDLINE DA - 20140725 DCOM- 20150421 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 9 IP - 7 DP - 2014 TI - Association of socioeconomic status with overall and cause specific mortality in the Republic of Seychelles: results from a cohort study in the African region. PG - e102858 LID - 10.1371/journal.pone.0102858 [doi] AB - BACKGROUND: Low socioeconomic status (SES) is consistently associated with higher mortality in high income countries. Only few studies have assessed this association in low and middle income countries, mainly because of sparse reliable mortality data. This study explores SES differences in overall and cause-specific mortality in the Seychelles, a rapidly developing small island state in the African region. METHODS: All deaths have been medically certified over more than two decades. SES and other lifestyle-related risk factors were assessed in a total of 3246 participants from three independent population-based surveys conducted in 1989, 1994 and 2004. Vital status was ascertained using linkage with vital statistics. Occupational position was the indicator of SES used in this study and was assessed with the same questions in the three surveys. RESULTS: During a mean follow-up of 15.0 years (range 0-23 years), 523 participants died (overall mortality rate 10.8 per 1000 person-years). The main causes of death were cardiovascular disease (CVD) (219 deaths) and cancer (142 deaths). Participants in the low SES group had a higher mortality risk for overall (HR = 1.80; 95% CI: 1.24-2.62), CVD (HR = 1.95; 1.04-3.65) and non-cancer/non-CVD (HR = 2.14; 1.10-4.16) mortality compared to participants in the high SES group. Cancer mortality also tended to be patterned by SES (HR = 1.44; 0.76-2.75). Major lifestyle-related risk factors (smoking, heavy drinking, obesity, diabetes, hypertension, hypercholesterolemia) explained a small proportion of the associations between low SES and all-cause, CVD, and non-cancer/non-CVD mortality. CONCLUSIONS: In this population-based study assessing social inequalities in mortality in a country of the African region, low SES (as measured by occupational position) was strongly associated with overall, CVD and non-cancer/non-CVD mortality. Our findings support the view that the burden of non-communicable diseases may disproportionally affect people with low SES in low and middle income countries. FAU - Stringhini, Silvia AU - Stringhini S AD - Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland. FAU - Rousson, Valentin AU - Rousson V AD - Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland. FAU - Viswanathan, Bharathi AU - Viswanathan B AD - Ministry of Health, Victoria, Republic of Seychelles. FAU - Gedeon, Jude AU - Gedeon J AD - Ministry of Health, Victoria, Republic of Seychelles. FAU - Paccaud, Fred AU - Paccaud F AD - Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland. FAU - Bovet, Pascal AU - Bovet P AD - Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland; Ministry of Health, Victoria, Republic of Seychelles. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140724 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - Aged MH - Binge Drinking/epidemiology MH - Cardiovascular Diseases/*mortality/pathology MH - Cause of Death MH - Cohort Studies MH - Developing Countries MH - Diabetes Mellitus/epidemiology MH - Female MH - Humans MH - Hypercholesterolemia/epidemiology MH - Hypertension/epidemiology MH - Male MH - Middle Aged MH - Neoplasms/*mortality/pathology MH - Obesity/epidemiology MH - Risk Factors MH - Seychelles/epidemiology MH - Smoking/epidemiology MH - *Social Class MH - Survival Analysis PMC - PMC4109956 OID - NLM: PMC4109956 EDAT- 2014/07/25 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/07/25 06:00 PHST- 2014 [ecollection] PHST- 2014/01/16 [received] PHST- 2014/06/24 [accepted] PHST- 2014/07/24 [epublish] AID - 10.1371/journal.pone.0102858 [doi] AID - PONE-D-14-01974 [pii] PST - epublish SO - PLoS One. 2014 Jul 24;9(7):e102858. doi: 10.1371/journal.pone.0102858. eCollection 2014. PMID- 25057316 OWN - NLM STAT- MEDLINE DA - 20140724 DCOM- 20150421 IS - 1838-7640 (Electronic) IS - 1838-7640 (Linking) VI - 4 IP - 9 DP - 2014 TI - Immuno nanoparticles integrated electrical control of targeted cancer cell development using whole cell bioelectronic device. PG - 919-30 LID - 10.7150/thno.8575 [doi] AB - Electrical properties of cells determine most of the cellular functions, particularly ones which occur in the cell's membrane. Manipulation of these electrical properties may provide a powerful electrotherapy option for the treatment of cancer as cancerous cells have been shown to be more electronegative than normal proliferating cells. Previously, we used an electrical impedance sensing system (EIS) to explore the responses of cancerous SKOV3 cells and normal HUVEC cells to low intensity (<2 V/cm) AC electric fields, determining that the optimal frequency for SKOV3 proliferation arrest was 200 kHz, without harming the non-cancerous HUVECs. In this study, to determine if these effects are cell type dependant, human breast adenocarcinoma cells (MCF7) were subjected to a range of frequencies (50 kHz-2 MHz) similar to the previously tested SKOV3. For the MCF7, an optimal frequency of 100 kHz was determined using the EIS, indicating a higher sensitivity towards the applied field. Further experiments specifically targeting the two types of cancer cells using HER2 antibody functionalized gold nanoparticles (HER2-AuNPs) were performed to determine if enhanced electric field strength can be induced via the application of nanoparticles, consequently leading to the killing of the cancerous cells without affecting non cancerous HUVECs and MCF10a providing a platform for the development of a non-invasive cancer treatment without any harmful side effects. The EIS was used to monitor the real-time consequences on cellular viability and a noticeable decrease in the growth profile of the MCF7 was observed with the application of the HER2-AuNPs and the electric fields indicating specific inhibitory effects on dividing cells in culture. To further understand the effects of the externally applied field to the cells, an Annexin V/EthD-III assay was performed to determine the cell death mechanism indicating apoptosis. The zeta potential of the SKOV3 and the MCF7 before and after incorporation of the HER2-AuNPs was also obtained indicating a decrease in zeta potential with the incorporation of the nanoparticles. The outcome of this research will improve our fundamental understanding of the behavior of cancer cells and define optimal parameters of electrotherapy for clinical and drug delivery applications. FAU - Hondroulis, Evangelia AU - Hondroulis E AD - 1. Nanobioengineering/Bioelectronics Laboratory, Department of Biomedical Engineering, Florida International University, 10555 West Flagler Street, Miami, FL 33174, USA. FAU - Zhang, Rui AU - Zhang R AD - 1. Nanobioengineering/Bioelectronics Laboratory, Department of Biomedical Engineering, Florida International University, 10555 West Flagler Street, Miami, FL 33174, USA. FAU - Zhang, Chengxiao AU - Zhang C AD - 2. Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of Education, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an 710062, China. FAU - Chen, Chunying AU - Chen C AD - 3. CAS Key Lab for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience & Technology of China, Beijing 100190, PR China. FAU - Ino, Kosuke AU - Ino K AD - 4. Graduate School of Environmental Studies, Tohoku University. FAU - Matsue, Tomokazu AU - Matsue T AD - 4. Graduate School of Environmental Studies, Tohoku University ; 5. WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan. FAU - Li, Chen-Zhong AU - Li CZ AD - 1. Nanobioengineering/Bioelectronics Laboratory, Department of Biomedical Engineering, Florida International University, 10555 West Flagler Street, Miami, FL 33174, USA ; 2. Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of Education, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an 710062, China ; 5. WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan. LA - eng GR - R15ES021079/ES/NIEHS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20140713 PL - Australia TA - Theranostics JT - Theranostics JID - 101552395 RN - 0 (Antibodies) RN - 7440-57-5 (Gold) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Antibodies/therapeutic use MH - Apoptosis MH - Breast Neoplasms/*therapy MH - Cell Proliferation MH - Electric Impedance MH - Electric Stimulation Therapy/*methods MH - Gold/chemistry MH - Human Umbilical Vein Endothelial Cells/physiology MH - Humans MH - MCF-7 Cells MH - *Metal Nanoparticles MH - Receptor, ErbB-2/immunology PMC - PMC4107292 OID - NLM: PMC4107292 OTO - NOTNLM OT - antibody OT - biosensor OT - cancer OT - electrotherapy OT - nanoparticles EDAT- 2014/07/25 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/07/25 06:00 PHST- 2014 [ecollection] PHST- 2014/01/13 [received] PHST- 2014/06/04 [accepted] PHST- 2014/07/13 [epublish] AID - 10.7150/thno.8575 [doi] AID - thnov04p0919 [pii] PST - epublish SO - Theranostics. 2014 Jul 13;4(9):919-30. doi: 10.7150/thno.8575. eCollection 2014. PMID- 25056184 OWN - NLM STAT- MEDLINE DA - 20140728 DCOM- 20150330 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 146 IP - 3 DP - 2014 Aug TI - Central adiposity after breast cancer diagnosis is related to mortality in the Health, Eating, Activity, and Lifestyle study. PG - 647-55 LID - 10.1007/s10549-014-3048-x [doi] AB - We examined whether waist circumference (WC) and waist-to-hip ratio (WHR) after breast cancer diagnosis are associated with all-cause or breast cancer-specific mortality and explored potential biological pathways mediating these relationships. Our analysis included 621 women diagnosed with local or regional breast cancer who participated in the Health, Eating, Activity, and Lifestyle study. At 30 (+/-4) months postdiagnosis, trained staff measured participants' waist and hip circumferences and obtained fasting serum samples for biomarker assays for assays of insulin, glucose, C-peptide, insulin growth factor-1 and binding protein-3, C-reactive protein (CRP), and adiponectin. We estimated multivariate hazard ratios (HR) and 95 % confidence intervals (CI) for death over ~9.5 years of follow-up. After adjustment for measured body mass index, treatment, comorbidities, race/ethnicity, diet quality, and postdiagnosis physical activity, WC was positively associated with all-cause mortality (HRq4:q1: 2.99, 95 % CI 1.14, 7.86) but its positive association with breast cancer-specific mortality was not statistically significant (HRq4:q1: 2.69, 95 % CI 0.69, 12.01). WHR was positively associated with all-cause mortality (HRq4:q1: 2.10, 95 % CI 1.08, 4.05) and breast cancer-specific mortality (HRq4:q1: 4.02, 95 % CI 1.31, 12.31). After adjustment for homeostatic model assessment (HOMA) score and C-reactive protein, risk estimates were attenuated and not statistically significant. In this diverse breast cancer survivor cohort, postdiagnosis WC and WHR were associated with all-cause mortality. Insulin resistance and inflammation may mediate the effects of central adiposity on mortality among breast cancer patients. FAU - George, Stephanie M AU - George SM AD - Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA, Stephanie.george@nih.gov. FAU - Bernstein, Leslie AU - Bernstein L FAU - Smith, Ashley W AU - Smith AW FAU - Neuhouser, Marian L AU - Neuhouser ML FAU - Baumgartner, Kathy B AU - Baumgartner KB FAU - Baumgartner, Richard N AU - Baumgartner RN FAU - Ballard-Barbash, Rachel AU - Ballard-Barbash R LA - eng GR - N01-CN-05228/CN/NCI NIH HHS/United States GR - N01-CN-75036-20/CN/NCI NIH HHS/United States GR - N01-PC-67010/PC/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20140724 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 0 (Adiponectin) RN - 0 (Blood Glucose) RN - 0 (C-Peptide) RN - 0 (Insulin) SB - IM MH - Adiponectin/blood MH - *Adiposity MH - Aged MH - Blood Glucose MH - Breast Neoplasms/blood/*mortality/pathology MH - C-Peptide/blood MH - Female MH - Food Habits MH - Humans MH - Insulin/blood MH - Insulin Resistance/genetics MH - Middle Aged MH - *Motor Activity MH - Obesity, Abdominal/blood/*mortality/pathology MH - Waist Circumference/physiology MH - Waist-Hip Ratio/psychology EDAT- 2014/07/25 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/07/25 06:00 PHST- 2014/06/24 [received] PHST- 2014/06/25 [accepted] PHST- 2014/07/24 [aheadofprint] AID - 10.1007/s10549-014-3048-x [doi] PST - ppublish SO - Breast Cancer Res Treat. 2014 Aug;146(3):647-55. doi: 10.1007/s10549-014-3048-x. Epub 2014 Jul 24. PMID- 25053606 OWN - NLM STAT- MEDLINE DA - 20140723 DCOM- 20150411 IS - 1541-3772 (Electronic) IS - 1048-2911 (Linking) VI - 24 IP - 1 DP - 2014 TI - Risks endemic to long-haul trucking in North America: strategies to protect and promote driver well-being. PG - 57-81 LID - 10.2190/NS.24.1.c [doi] AB - Long-haul truck drivers in North America function in a work context marked by excess physical and psychological workload, erratic schedules, disrupted sleep patterns, extreme time pressures, and these factors' far-reaching consequences. These work-induced stressors are connected with excess risk for cardiometabolic disease, certain cancers, and musculoskeletal and sleep disorders, as well as highway crashes, which in turn exert enormous financial burdens on trucking and warehousing companies, governments and healthcare systems, along with working people within the sector. This article: 1) delineates the unique work environment of long-haul truckers, describing their work characteristics and duties; (2) discusses the health hazards of long-haul trucking that impact drivers, the general population, and trucking enterprises, examining how this work context induces, sustains, and exacerbates these hazards; and (3) proposes comprehensive, multi-level strategies with potential to protect and promote the health, safety, and well-being of truckers, while reducing adverse consequences for companies and highway safety. FAU - Apostolopoulos, Yorghos AU - Apostolopoulos Y AD - Department of Public Health Education of the School of Health and Human Sciences, University of North Carolina Greensboro. FAU - Lemke, Michael AU - Lemke M AD - Community Psychology doctoral program, Wichita State University. FAU - Sonmez, Sevil AU - Sonmez S AD - Department of Marketing, Entrepreneurship, Hospitality, and Tourism, Bryan School of Business and Economics of the University of North Carolina Greensboro. LA - eng PT - Journal Article PL - United States TA - New Solut JT - New solutions : a journal of environmental and occupational health policy : NS JID - 9100937 RN - 0 (Air Pollutants, Occupational) SB - IM MH - Adult MH - Air Pollutants, Occupational/*adverse effects MH - *Automobile Driving MH - Cardiovascular Diseases/epidemiology MH - Causality MH - Fatigue/epidemiology MH - Female MH - *Health Status Indicators MH - Humans MH - Lung Diseases/epidemiology MH - Male MH - Mental Disorders/epidemiology MH - Middle Aged MH - *Motor Vehicles MH - Musculoskeletal Diseases/epidemiology MH - Neoplasms/epidemiology MH - North America/epidemiology MH - Obesity/epidemiology MH - Occupational Diseases/*chemically induced/epidemiology/*prevention & control MH - Sleep Disorders/epidemiology OTO - NOTNLM OT - excess driver morbidity OT - highway safety OT - long-haul truckers OT - prevention and protection strategies OT - work environment EDAT- 2014/07/24 06:00 MHDA- 2015/04/12 06:00 CRDT- 2014/07/24 06:00 AID - X431U7355NR44246 [pii] AID - 10.2190/NS.24.1.c [doi] PST - ppublish SO - New Solut. 2014;24(1):57-81. doi: 10.2190/NS.24.1.c. PMID- 25050322 OWN - NLM STAT- MEDLINE DA - 20140722 DCOM- 20150330 IS - 2314-6141 (Electronic) VI - 2014 DP - 2014 TI - Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer. PG - 132702 LID - 10.1155/2014/132702 [doi] AB - Ovarian cancer is the most lethal gynecologic malignancy among women worldwide and is presumed to result from the presence of ovarian cancer stem cells. To overcome the limitation of current anticancer agents, another anticancer strategy is necessary to effectively target cancer stem cells in ovarian cancer. In many types of malignancies, including ovarian cancer, metformin, one of the most popular antidiabetic drugs, has been demonstrated to exhibit chemopreventive and anticancer efficacy with respect to incidence and overall survival rates. Thus, the metabolic reprogramming of cancer and cancer stem cells driven by genetic alterations during carcinogenesis and cancer progression could be therapeutically targeted. In this review, the potential efficacy and anticancer mechanisms of metformin against ovarian cancer stem cells will be discussed. FAU - Kim, Tae Hun AU - Kim TH AD - Department of Obstetrics and Gynecology, Korean Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Republic of Korea. FAU - Suh, Dong Hoon AU - Suh DH AD - Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam 463-707, Republic of Korea. FAU - Kim, Mi-Kyung AU - Kim MK AD - Biomedical Science Project, Brain Korea 21 Program for Leading Universities & Students, Seoul National University, Seoul 110-799, Republic of Korea. FAU - Song, Yong Sang AU - Song YS AD - Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea ; Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Republic of Korea ; Major in Biomodulation, World Class University, Seoul National University, Seoul 151-921, Republic of Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20140624 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - 9100L32L2N (Metformin) SB - IM MH - Drug Resistance, Neoplasm/drug effects MH - Energy Metabolism/*drug effects MH - Female MH - Humans MH - Metformin/*pharmacology/therapeutic use MH - Models, Biological MH - Neoplastic Stem Cells/drug effects/*metabolism/pathology MH - Ovarian Neoplasms/drug therapy/*metabolism/*pathology PMC - PMC4094711 OID - NLM: PMC4094711 EDAT- 2014/07/23 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/07/23 06:00 PHST- 2014/02/28 [received] PHST- 2014/05/29 [accepted] PHST- 2014/06/24 [epublish] AID - 10.1155/2014/132702 [doi] PST - ppublish SO - Biomed Res Int. 2014;2014:132702. doi: 10.1155/2014/132702. Epub 2014 Jun 24. PMID- 25049439 OWN - NLM STAT- MEDLINE DA - 20140722 DCOM- 20150402 IS - 1875-8630 (Electronic) IS - 0278-0240 (Linking) VI - 2014 DP - 2014 TI - Serum levels of resistin, adiponectin, and apelin in gastroesophageal cancer patients. PG - 619649 LID - 10.1155/2014/619649 [doi] AB - The aim of the study was the investigation of relationship between cachexia syndrome and serum resistin, adiponectin, and apelin in patients with gastroesophageal cancer (GEC). MATERIAL AND METHODS: Adipocytokines concentrations were measured in sera of 85 GEC patients and 60 healthy controls. They were also evaluated in tumor tissue and appropriate normal mucosa of 38 operated cancer patients. RESULTS: Resistin and apelin concentrations were significantly higher in GEC patients than in the controls. The highest resistin levels were found in cachectic patients and in patients with distant metastasis. Serum adiponectin significantly decreased in GEC patients with regional and distant metastasis. Serum apelin was significantly higher in cachectic patients than in the controls. Apelin was positively correlated with hsCRP level. Resistin and apelin levels increased significantly in tumor tissues. Weak positive correlations between adipocytokines levels in serum and in tumor tissue were observed. CONCLUSIONS: Resistin is associated with cachexia and metastasis processes of GEC. Reduction of serum adiponectin reflects adipose tissue wasting in relation to GEC progression. Correlation of apelin with hsCRP can reflect a presumable role of apelin in systemic inflammatory response in esophageal and gastric cancer. FAU - Diakowska, Dorota AU - Diakowska D AUID- ORCID: 0000-0002-1377-5601 AD - Department of Gastrointestinal and General Surgery, University of Medicine, Sklodowska-Curie 66, 50-369 Wroclaw, Poland. FAU - Markocka-Maczka, Krystyna AU - Markocka-Maczka K AD - Department of Gastrointestinal and General Surgery, University of Medicine, Sklodowska-Curie 66, 50-369 Wroclaw, Poland. FAU - Szelachowski, Piotr AU - Szelachowski P AD - Department of Gastrointestinal and General Surgery, University of Medicine, Sklodowska-Curie 66, 50-369 Wroclaw, Poland. FAU - Grabowski, Krzysztof AU - Grabowski K AD - Department of Gastrointestinal and General Surgery, University of Medicine, Sklodowska-Curie 66, 50-369 Wroclaw, Poland. LA - eng PT - Journal Article DEP - 20140624 PL - United States TA - Dis Markers JT - Disease markers JID - 8604127 RN - 0 (APLN protein, human) RN - 0 (Adiponectin) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (Resistin) RN - 0 (Tumor Markers, Biological) SB - IM MH - Adiponectin/*blood MH - Aged MH - Cachexia/blood/diagnosis/pathology MH - Carcinoma/*blood/diagnosis/pathology MH - Case-Control Studies MH - Esophageal Neoplasms/*blood/diagnosis/pathology MH - Female MH - Gastric Mucosa/pathology MH - Humans MH - Intercellular Signaling Peptides and Proteins/*blood MH - Male MH - Middle Aged MH - Resistin/*blood MH - Stomach Neoplasms/*blood/diagnosis/pathology MH - Tumor Markers, Biological/*blood PMC - PMC4094727 OID - NLM: PMC4094727 EDAT- 2014/07/23 06:00 MHDA- 2015/04/04 06:00 CRDT- 2014/07/23 06:00 PHST- 2014/01/09 [received] PHST- 2014/05/30 [accepted] PHST- 2014/06/24 [epublish] AID - 10.1155/2014/619649 [doi] PST - ppublish SO - Dis Markers. 2014;2014:619649. doi: 10.1155/2014/619649. Epub 2014 Jun 24. PMID- 25040978 OWN - NLM STAT- MEDLINE DA - 20140721 DCOM- 20150407 IS - 1513-7368 (Print) IS - 1513-7368 (Linking) VI - 15 IP - 13 DP - 2014 TI - Fruit and vegetable intake in relation to prostate cancer in Iranian men: a case-control study. PG - 5223-7 AB - BACKGROUND: Findings of epidemiologic studies on the relationship between fruit and vegetable consumption and prostate cancer (PCa) risk have been inconclusive. We therefore examined the association between intake of fruits and vegetables and PCa risk in Iran. MATERIALS AND METHODS: In this hospital based, case-control study, a total of 50 patients with PCa and 100 controls underwent face-to-face interviews. Regression analysis was used to examine the relation between fruit and vegetable intake and PCa risk. RESULTS: A protective independent effect was observed for the highest tertile of total fruit and vegetable (OR: 0.33, CI: 0.04-0.30, p value<0.001), total fruit (OR: 0.30, CI: 0.06-0.4, p value=0.03) and total vegetable (OR: 0.31, CI: 0.02-0.21, p value<0.001) consumption. Within the group of fruits, a significant inverse association was observed for apple and pomegranate (p trends were 0.01 and 0.016, respectively). In the vegetable group, a significant inverse association was observed for tomatoes (p trend<0.001) and cabbage (p trend=0.021). CONCLUSIONS: The results of the present study suggested that fruits and vegetable intake might be negatively associated with PCa risk. FAU - Askari, Faezeh AU - Askari F AD - Department of Community Nutrition, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute (WHO Collaborating Center), Shahid Beheshti University of Medical Sciences, Tehran, Iran E-mail : b_rashidkhani@sbmu.ac.ir, Rashidkhani@yahoo.com. FAU - Parizi, Mehdi Kardoust AU - Parizi MK FAU - Jessri, Mahsa AU - Jessri M FAU - Rashidkhani, Bahram AU - Rashidkhani B LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 SB - IM MH - Brassica MH - Case-Control Studies MH - Diet MH - Disease Susceptibility/*etiology MH - Food Habits MH - Fruit MH - Humans MH - Iran MH - Lycopersicon esculentum MH - Male MH - Malus MH - Middle Aged MH - Prostatic Neoplasms/*etiology MH - Punicaceae MH - Risk MH - Risk Factors MH - Vegetables EDAT- 2014/07/22 06:00 MHDA- 2015/04/08 06:00 CRDT- 2014/07/22 06:00 PST - ppublish SO - Asian Pac J Cancer Prev. 2014;15(13):5223-7. PMID- 25037667 OWN - NLM STAT- MEDLINE DA - 20140719 DCOM- 20150407 LR - 20150213 IS - 1878-7541 (Electronic) IS - 1550-8307 (Linking) VI - 10 IP - 4 DP - 2014 Jul-Aug TI - Hot flashes severity, complementary and alternative medicine use, and self-rated health in women with breast cancer. PG - 241-7 LID - 10.1016/j.explore.2014.04.003 [doi] LID - S1550-8307(14)00068-8 [pii] AB - CONTEXT: Hot flashes (HF) are a common distressing symptom in women with breast cancer (BC). Current pharmacologic options are moderately effective and are associated with bothersome side effects. Complementary and alternative medicine is commonly used by cancer patients. However, information on the association of hot flashes severity with such use and self-rated health is lacking. OBJECTIVE: To examine the hot flashes severity in women with breast cancer and its association with complementary and alternative medicine use and self-rated health (SRH). DESIGN: Longitudinal multicenter study to assess information needs of cancer outpatients. PARTICIPANTS: Patients with a diagnosis of breast cancer who were scheduled to undergo chemotherapy and/or radiotherapy. OUTCOME MEASURES: Hot flashes severity (0 = not present and 10 = as bad as you can imagine), use of complementary and alternative medicine (yes/no), and self-rating of health (SRH) status post-treatment and six-months thereafter (1-5, higher score = better SRH). RESULTS: The majority of women with HF (mean age = 54.4 years) were Caucasian and married, with higher education, and 93% had received surgical treatment for BC. At the end of treatment, 79% women reported experiencing HF [mean severity = 5.87, standard deviation (SD) = 2.9]; significantly more severe HF were reported by younger women with poor SRH, poor performance status, and those reporting doing spiritual practices. At follow-up, 73% had HF (mean severity = 4.86, SD = 3.0), and more severe HF were reported by younger women with poor self-rated health who had undergone chemotherapy plus radiotherapy, used vitamins, and did not exercise. CONCLUSIONS: A high percentage of women experienced hot flashes at the end of treatment and at six-month follow-up. A significant association of hot flashes severity with spiritual practice, increased vitamin use, and reduced exercise emphasize the need for future studies to confirm the results. This can facilitate safe use of complementary and alternative medicine and favorable outcomes while managing cancer-related hot flashes. CI - Copyright (c) 2014 Elsevier Inc. All rights reserved. FAU - Chandwani, Kavita D AU - Chandwani KD AD - Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY. Electronic address: kavita_chandwani@urmc.rochester.edu. FAU - Heckler, Charles E AU - Heckler CE AD - Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY. FAU - Mohile, Supriya G AU - Mohile SG AD - Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY. FAU - Mustian, Karen M AU - Mustian KM AD - Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY. FAU - Janelsins, Michelle AU - Janelsins M AD - Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY. FAU - Peppone, Luke J AU - Peppone LJ AD - Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY. FAU - Bushunow, Peter AU - Bushunow P AD - Rochester General Hospital, Rochester, NY. FAU - Flynn, Patrick J AU - Flynn PJ AD - Metro-Minnesota CCOP, Minneapolis, MN. FAU - Morrow, Gary R AU - Morrow GR AD - Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY. LA - eng GR - K07 CA120025/CA/NCI NIH HHS/United States GR - K07CA120025/CA/NCI NIH HHS/United States GR - R25 CA102618/CA/NCI NIH HHS/United States GR - R25CA102618/CA/NCI NIH HHS/United States GR - U10 CA037420/CA/NCI NIH HHS/United States GR - U10 CA37420/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20140418 PL - United States TA - Explore (NY) JT - Explore (New York, N.Y.) JID - 101233160 RN - 0 (Vitamins) SB - IM MH - Adult MH - Age Factors MH - Aged MH - Aged, 80 and over MH - *Breast Neoplasms/therapy MH - *Complementary Therapies/utilization MH - Exercise MH - Female MH - *Health MH - Hot Flashes/epidemiology/etiology/*therapy MH - Humans MH - Longitudinal Studies MH - Middle Aged MH - Prevalence MH - Sedentary Lifestyle MH - *Severity of Illness Index MH - Spiritual Therapies MH - Survivors MH - Vitamins PMC - PMC4325272 MID - NIHMS606507 OID - NLM: NIHMS606507 [Available on 07/01/15] OID - NLM: PMC4325272 [Available on 07/01/15] OTO - NOTNLM OT - Breast cancer OT - complementary and alternative medicine OT - hot flashes OT - self-rated health EDAT- 2014/07/20 06:00 MHDA- 2015/04/08 06:00 CRDT- 2014/07/20 06:00 PMCR- 2015/07/01 00:00 PHST- 2013/02/14 [received] PHST- 2014/04/18 [aheadofprint] AID - S1550-8307(14)00068-8 [pii] AID - 10.1016/j.explore.2014.04.003 [doi] PST - ppublish SO - Explore (NY). 2014 Jul-Aug;10(4):241-7. doi: 10.1016/j.explore.2014.04.003. Epub 2014 Apr 18. PMID- 25036857 OWN - NLM STAT- MEDLINE DA - 20140820 DCOM- 20150421 IS - 1532-7914 (Electronic) IS - 0163-5581 (Linking) VI - 66 IP - 6 DP - 2014 TI - Untold nutrition. PG - 1077-82 LID - 10.1080/01635581.2014.927687 [doi] AB - Nutrition is generally investigated, and findings interpreted, in reference to the activities of individual nutrients. Nutrient composition of foods, food labeling, food fortification, and nutrient recommendations are mostly founded on this assumption, a practice commonly known as reductionism. While such information on specifics is important and occasionally useful in practice, it ignores the coordinated, integrated and virtually symphonic nutrient activity (wholism) that occurs in vivo. With reductionism providing the framework, public confusion abounds and huge monetary and social costs are incurred. Two examples are briefly presented to illustrate, the long time misunderstandings (1) about saturated and total fat as causes of cancer and heart disease and (2) the emergence of the nutrient supplement industry. A new definition of the science of nutrition is urgently needed. FAU - Campbell, T Colin AU - Campbell TC AD - a Division of Nutritional Sciences , Cornell University , Ithaca , New York , USA. LA - eng PT - Journal Article DEP - 20140718 PL - United States TA - Nutr Cancer JT - Nutrition and cancer JID - 7905040 RN - 0 (Dietary Fats) RN - 0 (Dietary Proteins) RN - 0 (Fatty Acids) RN - 0 (Micronutrients) SB - IM MH - Dietary Fats/adverse effects/analysis MH - Dietary Proteins/analysis MH - *Dietary Supplements MH - Fatty Acids/administration & dosage/adverse effects/analysis MH - Food Labeling MH - Heart Diseases/*epidemiology MH - Humans MH - Micronutrients/analysis MH - Neoplasms/*epidemiology MH - *Nutritional Status MH - Recommended Dietary Allowances EDAT- 2014/07/19 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/07/19 06:00 PHST- 2014/07/18 [aheadofprint] AID - 10.1080/01635581.2014.927687 [doi] PST - ppublish SO - Nutr Cancer. 2014;66(6):1077-82. doi: 10.1080/01635581.2014.927687. Epub 2014 Jul 18. PMID- 25034340 OWN - NLM STAT- MEDLINE DA - 20140728 DCOM- 20150330 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 146 IP - 3 DP - 2014 Aug TI - Adolescent physical activity and inactivity: a prospective study of risk of benign breast disease in young women. PG - 611-8 LID - 10.1007/s10549-014-3055-y [doi] AB - In previous investigations of adolescent activity recalled in adulthood, modest reductions in risk of benign breast disease (BBD) and premenopausal breast cancer were seen with moderate-strenuous activity during high school. We therefore investigated physical activity, walking, and recreational inactivity (watching TV-videos, playing computer-videogames) reported by adolescent girls in relation to their subsequent risk for BBD as young women. The Growing Up Today Study includes 9,039 females, 9-15 years at study initiation (1996), who completed questionnaires annually through 2001, then in 2003, 2005, 2007, 2010 and 2013. Annual surveys (1996-2001) obtained data on physical and sedentary activities during the past year. Beginning in 2005, women (>/=18 years) reported whether they had ever been diagnosed with BBD confirmed by breast biopsy (n = 133 cases, to 11/01/2013). Logistic regression (adjusted for baseline adiposity and age; additional factors in multivariable-adjusted models) estimated associations between adolescent activities (moderate-vigorous, walking, METS, inactivity) and biopsy-confirmed BBD in young women. Girls who walked the most had significantly lower risk of BBD (multivariable-adjusted OR = 0.61, >/=30 vs /=3 vs <2 h/day OR = 1.02, p = .92) or METS (top vs bottom tertile OR = 1.19, p = .42) were associated with BBD. Accounting for factors including family history, childhood adiposity, and other activities and inactivities, adolescent girls who walked the most were at lower risk for BBD. We found no evidence that high moderate-vigorous activity might reduce risk, nor did we observe any association with inactivity. Continued follow-up will re-evaluate these findings as more BBD cases, and ultimately breast cancer, are diagnosed. FAU - Berkey, Catherine S AU - Berkey CS AD - Channing Division of Network Medicine, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA, 02115, USA, catherine.berkey@channing.harvard.edu. FAU - Tamimi, Rulla M AU - Tamimi RM FAU - Willett, Walter C AU - Willett WC FAU - Rosner, Bernard AU - Rosner B FAU - Lindsay Frazier, A AU - Lindsay Frazier A FAU - Colditz, Graham A AU - Colditz GA LA - eng GR - DK046834/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20140718 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Adolescent MH - Breast/*pathology MH - Breast Diseases/complications/*epidemiology/pathology MH - Breast Neoplasms/complications/*epidemiology/pathology MH - Child MH - Female MH - Humans MH - *Motor Activity MH - Obesity/complications/epidemiology/pathology MH - Prospective Studies MH - Questionnaires MH - Risk Factors EDAT- 2014/07/19 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/07/19 06:00 PHST- 2014/07/02 [received] PHST- 2014/07/04 [accepted] PHST- 2014/07/18 [aheadofprint] AID - 10.1007/s10549-014-3055-y [doi] PST - ppublish SO - Breast Cancer Res Treat. 2014 Aug;146(3):611-8. doi: 10.1007/s10549-014-3055-y. Epub 2014 Jul 18. PMID- 25024628 OWN - NLM STAT- MEDLINE DA - 20140715 DCOM- 20150413 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 26 DP - 2014 Jul 14 TI - APE1 polymorphisms are associated with colorectal cancer susceptibility in Chinese Hans. PG - 8700-8 LID - 10.3748/wjg.v20.i26.8700 [doi] AB - AIM: To study the association between four base excision repair gene polymorphisms and colorectal cancer risk in a Chinese population. METHODS: Two hundred forty-seven colorectal cancer (CRC) patients and three hundred cancer-free controls were enrolled in this study. Four polymorphisms (OGG1 Ser326Cys, APE1 Asp148Glu, -141T/G in the promoter region, and XRCC1 Arg399Gln) in components of the base excision repair pathway were determined in patient blood samples using polymerase chain reaction with confronting two-pair primers. The baseline information included age, gender, family history of cancer, and three behavioral factors [smoking status, alcohol consumption, and body mass index (BMI)]. chi(2) tests were used to assess the Hardy-Weinberg equilibrium, the distributions of baseline characteristics, and the four gene polymorphisms between the cases and controls. Multivariate logistic regression analyses were conducted to analyze the correlations between the four polymorphisms and CRC risk, adjusted by the baseline characteristics. Likelihood ratio tests were performed to analyze the gene-behavior interactions of smoking status, alcohol consumption, and BMI on polymorphisms and CRC susceptibility. RESULTS: The APE1 148 Glu/Glu genotype was significantly associated with an increased risk of colorectal cancer (OR = 2.411, 95%CI: 1.497-3.886, P < 0.001 relative to Asp/Asp genotype). There were no associations between OGG1, XRCC1, or APE1 promoter polymorphisms and CRC risk. A multivariate analysis including three behavioral factors showed that the APE1 148 Glu/Glu genotype was associated with an increased risk for CRC among both smokers and non-smokers, non-drinkers and individuals with a BMI >/= 25 kg/m(2) (ORs = 2.356, 3.299, 2.654, and 2.581, respectively). The XRCC1 399 Arg/Gln genotype was associated with a decreased risk of CRC among smokers and drinkers (OR = 0.289, 95%CI: 0.152-0.548, P < 0.001, and OR = 0.327, 95%CI: 0.158-0.673, P < 0.05, respectively). The APE1 promoter polymorphism -141 T/G genotype was associated with a reduced risk of colorectal cancer among subjects with a BMI < 25 kg/m(2) (OR = 0.214, 95%CI: 0.069-0.660, P < 0.05 relative to T/T genotype). There were significant gene-behavior interactions between smoking status and XRCC1 Arg399Gln, as well as BMI and APE1 -141T/G polymorphism (all P < 0.05). CONCLUSION: APE1 Asp148Glu is associated with increased CRC risk and smoking alters the association between XRCC1 Arg399Gln and CRC risk in the Chinese Han population. FAU - Zhang, Shi-Heng AU - Zhang SH AD - Shi-Heng Zhang, Lin-Ang Wang, Zheng Li, Yu Peng, Yan-Ping Cun, Nan Dai, Yi Cheng, He Xiao, Yan-Li Xiong, Dong Wang, Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. FAU - Wang, Lin-Ang AU - Wang LA AD - Shi-Heng Zhang, Lin-Ang Wang, Zheng Li, Yu Peng, Yan-Ping Cun, Nan Dai, Yi Cheng, He Xiao, Yan-Li Xiong, Dong Wang, Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. FAU - Li, Zheng AU - Li Z AD - Shi-Heng Zhang, Lin-Ang Wang, Zheng Li, Yu Peng, Yan-Ping Cun, Nan Dai, Yi Cheng, He Xiao, Yan-Li Xiong, Dong Wang, Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. FAU - Peng, Yu AU - Peng Y AD - Shi-Heng Zhang, Lin-Ang Wang, Zheng Li, Yu Peng, Yan-Ping Cun, Nan Dai, Yi Cheng, He Xiao, Yan-Li Xiong, Dong Wang, Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. FAU - Cun, Yan-Ping AU - Cun YP AD - Shi-Heng Zhang, Lin-Ang Wang, Zheng Li, Yu Peng, Yan-Ping Cun, Nan Dai, Yi Cheng, He Xiao, Yan-Li Xiong, Dong Wang, Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. FAU - Dai, Nan AU - Dai N AD - Shi-Heng Zhang, Lin-Ang Wang, Zheng Li, Yu Peng, Yan-Ping Cun, Nan Dai, Yi Cheng, He Xiao, Yan-Li Xiong, Dong Wang, Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. FAU - Cheng, Yi AU - Cheng Y AD - Shi-Heng Zhang, Lin-Ang Wang, Zheng Li, Yu Peng, Yan-Ping Cun, Nan Dai, Yi Cheng, He Xiao, Yan-Li Xiong, Dong Wang, Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. FAU - Xiao, He AU - Xiao H AD - Shi-Heng Zhang, Lin-Ang Wang, Zheng Li, Yu Peng, Yan-Ping Cun, Nan Dai, Yi Cheng, He Xiao, Yan-Li Xiong, Dong Wang, Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. FAU - Xiong, Yan-Li AU - Xiong YL AD - Shi-Heng Zhang, Lin-Ang Wang, Zheng Li, Yu Peng, Yan-Ping Cun, Nan Dai, Yi Cheng, He Xiao, Yan-Li Xiong, Dong Wang, Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. FAU - Wang, Dong AU - Wang D AD - Shi-Heng Zhang, Lin-Ang Wang, Zheng Li, Yu Peng, Yan-Ping Cun, Nan Dai, Yi Cheng, He Xiao, Yan-Li Xiong, Dong Wang, Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 RN - 0 (DNA-Binding Proteins) RN - 0 (X-ray repair cross complementing protein 1) RN - EC 3.2.2.- (DNA Glycosylases) RN - EC 3.2.2.- (oxoguanine glycosylase 1, human) RN - EC 4.2.99.18 (APEX1 protein, human) RN - EC 4.2.99.18 (DNA-(Apurinic or Apyrimidinic Site) Lyase) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Alcohol Drinking/adverse effects/ethnology MH - Asian Continental Ancestry Group/*genetics MH - Body Mass Index MH - Case-Control Studies MH - Chi-Square Distribution MH - China/epidemiology MH - Colorectal Neoplasms/enzymology/ethnology/*genetics MH - DNA Glycosylases/genetics MH - DNA-(Apurinic or Apyrimidinic Site) Lyase/*genetics MH - DNA-Binding Proteins/genetics MH - Female MH - Gene-Environment Interaction MH - Genetic Association Studies MH - Genetic Predisposition to Disease MH - Humans MH - Logistic Models MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Odds Ratio MH - Phenotype MH - *Polymorphism, Single Nucleotide MH - Prospective Studies MH - Risk Factors MH - Smoking/adverse effects/ethnology MH - Young Adult PMC - PMC4093723 OID - NLM: PMC4093723 OTO - NOTNLM OT - Apurinic endonuclease 1 OT - Base excision repair OT - Colorectal cancer OT - Single nucleotide polymorphisms OT - X-ray repair cross-complementing groups EDAT- 2014/07/16 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/07/16 06:00 PHST- 2013/11/30 [received] PHST- 2014/03/27 [revised] PHST- 2014/04/21 [accepted] AID - 10.3748/wjg.v20.i26.8700 [doi] PST - ppublish SO - World J Gastroenterol. 2014 Jul 14;20(26):8700-8. doi: 10.3748/wjg.v20.i26.8700. PMID- 25024597 OWN - NLM STAT- MEDLINE DA - 20140715 DCOM- 20150413 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 26 DP - 2014 Jul 14 TI - Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. PG - 8393-406 LID - 10.3748/wjg.v20.i26.8393 [doi] AB - Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are serious health problems worldwide. These two diseases have similar pathological spectra, ranging from simple hepatic steatosis to steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. Although most subjects with excessive alcohol or food intake experience simple hepatic steatosis, a small percentage of individuals will develop progressive liver disease. Notably, both ALD and NAFLD are frequently accompanied by extrahepatic complications, including cardiovascular disease and malignancy. The survival of patients with ALD and NAFLD depends on various disease-associated conditions. This review delineates the clinical characteristics and outcomes of patients with ALD and NAFLD by comparing their epidemiology, the factors associated with disease susceptibility and progression, and the predictors and characteristics of outcomes. A comprehensive understanding of the characteristics and outcomes of ALD and NAFLD is imperative in the management of these chronic liver diseases. FAU - Toshikuni, Nobuyuki AU - Toshikuni N AD - Nobuyuki Toshikuni, Tomiyasu Arisawa, Department of Gastroenterology, Kanazawa Medical University, Ishikawa 920-0293, Japan. FAU - Tsutsumi, Mikihiro AU - Tsutsumi M AD - Nobuyuki Toshikuni, Tomiyasu Arisawa, Department of Gastroenterology, Kanazawa Medical University, Ishikawa 920-0293, Japan. FAU - Arisawa, Tomiyasu AU - Arisawa T AD - Nobuyuki Toshikuni, Tomiyasu Arisawa, Department of Gastroenterology, Kanazawa Medical University, Ishikawa 920-0293, Japan. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 SB - IM MH - Alcohol Drinking/adverse effects/epidemiology MH - Comorbidity MH - Diagnosis, Differential MH - Diet/adverse effects MH - Disease Progression MH - Disease Susceptibility MH - Humans MH - Life Style MH - Liver Cirrhosis/diagnosis/epidemiology MH - Liver Diseases, Alcoholic/*diagnosis/epidemiology MH - Liver Neoplasms/diagnosis/epidemiology MH - Non-alcoholic Fatty Liver Disease/*diagnosis/epidemiology MH - Predictive Value of Tests MH - Prognosis MH - Risk Assessment MH - Risk Factors MH - Severity of Illness Index PMC - PMC4093692 OID - NLM: PMC4093692 OTO - NOTNLM OT - Alcoholic liver disease OT - Chronic liver disease OT - Clinical characteristics OT - Nonalcoholic fatty liver disease OT - Outcomes EDAT- 2014/07/16 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/07/16 06:00 PHST- 2013/10/28 [received] PHST- 2014/01/29 [revised] PHST- 2014/03/19 [accepted] AID - 10.3748/wjg.v20.i26.8393 [doi] PST - ppublish SO - World J Gastroenterol. 2014 Jul 14;20(26):8393-406. doi: 10.3748/wjg.v20.i26.8393. PMID- 25023197 OWN - NLM STAT- MEDLINE DA - 20140820 DCOM- 20150421 IS - 1532-7914 (Electronic) IS - 0163-5581 (Linking) VI - 66 IP - 6 DP - 2014 TI - Combined genetic and nutritional risk models of triple negative breast cancer. PG - 955-63 LID - 10.1080/01635581.2014.932397 [doi] AB - Triple negative breast cancer (TNBC) presents clinical challenges due to unknown etiology, lack of treatment targets, and poor prognosis. We examined combined genetic and nutritional risk models of TNBC in 354 breast cancer cases. We evaluated 18 DNA-repair nonsynonymous single nucleotide polymorphisms (nsSNPs) and dietary/nutritional intakes. Multivariate Adaptive Regression Splines models were used to select nutrients of interest and define cut-off values for logistic regression models. Our results suggest that TNBC was associated with 6 DNA-repair nsSNPs, ERCC4 R415Q (rs1800067), MSH3 R940Q (rs184967), MSH6 G39E (rs1042821), POLD1 R119H (rs1726801), XRCC1 R194W (rs1799782), and XPC A499V (rs2228000) and/or deficiencies in 3 micronutrients (zinc, folate, and beta-carotene). Combined analyses of these 6 nsSNPs and 3 micronutrients showed significant association with TNBC: odds ratios = 2.77 (95% confidence interval = 1.01-7.64) and 10.89 (95% confidence interval = 3.50-33.89) for 2 and at least 3 risk factors, respectively. To the best of our knowledge, this is the first study to suggest that multiple genetic and nutritional factors are associated with TNBC, particularly in combination. Our findings, if validated in larger studies, will have important clinical implication that dietary modulations and/or micronutrient supplementations may prevent or reverse TNBC phenotype, so tumors can be treated with less toxic therapeutic strategies, particularly in genetically susceptible women. FAU - Lee, Eunkyung AU - Lee E AD - a Department of Public Health Sciences and Sylvester Comprehensive Cancer Center , University of Miami Miller School of Medicine , Miami , Florida , USA. FAU - Levine, Edward A AU - Levine EA FAU - Franco, Vivian I AU - Franco VI FAU - Allen, Glenn O AU - Allen GO FAU - Gong, Feng AU - Gong F FAU - Zhang, Yanbin AU - Zhang Y FAU - Hu, Jennifer J AU - Hu JJ LA - eng GR - R01 CA73629/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20140714 PL - United States TA - Nutr Cancer JT - Nutrition and cancer JID - 7905040 RN - 0 (Micronutrients) RN - 01YAE03M7J (beta Carotene) RN - 935E97BOY8 (Folic Acid) RN - J41CSQ7QDS (Zinc) SB - IM MH - Adult MH - Aged MH - Case-Control Studies MH - DNA Repair MH - *Diet MH - Energy Intake MH - Female MH - Folic Acid/blood MH - Folic Acid Deficiency MH - *Gene-Environment Interaction MH - Genetic Predisposition to Disease MH - Humans MH - Logistic Models MH - Malnutrition/blood/complications MH - Micronutrients/blood/deficiency MH - Middle Aged MH - Multivariate Analysis MH - Nutrition Assessment MH - Pilot Projects MH - Polymorphism, Single Nucleotide MH - Questionnaires MH - Risk Factors MH - Triple Negative Breast Neoplasms/blood/etiology/*genetics MH - Zinc/blood/deficiency MH - beta Carotene/blood/deficiency EDAT- 2014/07/16 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/07/16 06:00 PHST- 2014/07/14 [aheadofprint] AID - 10.1080/01635581.2014.932397 [doi] PST - ppublish SO - Nutr Cancer. 2014;66(6):955-63. doi: 10.1080/01635581.2014.932397. Epub 2014 Jul 14. PMID- 25022764 OWN - NLM STAT- MEDLINE DA - 20140730 DCOM- 20150330 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 12 DP - 2014 TI - Inflammation-based prognostic scores and nutritional prognostic index in patients with locally-advanced unresectable colorectal cancer. PG - 210 LID - 10.1186/1477-7819-12-210 [doi] AB - BACKGROUND: Unresectable colorectal cancer has a poor prognosis. However, some patients survive intensive chemotherapy, and complete resection of primary and metastatic tumors may even be possible. In the present study, we examined the prognostic factors associated with survival after intensive chemotherapy in patients with unresectable colorectal cancer. METHODS: This retrospective study enrolled 61 patients diagnosed with unresectable locally advanced colorectal cancer between January 2004 and December 2013. Among the prognostic parameters, we found that the prognoses of patients with abnormal performance status (PS) of 2 or 3, high Glasgow Prognostic Score (GPS) of 1 or 2, high neutrophil/lymphocyte ratio (NLR) >5, and low prognostic nutritional index (PNI) <40 were poor. Thus, we scored each patient according to our scoring system (abnormal PS, 2 or 3 = +1; high GPS, 1 or 2 = +1; high NLR, >5 = +1; and low PNI, <40 = +1). If the patient showed abnormalities in every parameter, the score would be +4. RESULTS: Sixteen patients had a score of 0, 17 scored +1, 10 scored +2, 17 scored +3, and one scored +4. The median survival time (MST) of the 61 patients was 9 months. Patients were divided into two groups, a low-score group (0 and +1) and a high-score group (+2, +3, and +4). The MST of the 33 patients in the low-score group was significantly longer than that of the 28 patients in the high-score group (15 months versus 4 months, P < 0.001). Also, conversion chemotherapy was performed in 4.9% (3/61) of patients. And these 3 patients were in a low-score group. CONCLUSIONS: This new prognostic scoring system may help to select patients with unresectable advanced colorectal cancer who are able to survive through intensive chemotherapy. FAU - Ikeguchi, Masahide AU - Ikeguchi M AD - Department of Surgery, Division of Surgical Oncology, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan. masaike@med.tottori-u.ac.jp. FAU - Urushibara, Sho-Ichi AU - Urushibara S FAU - Shimoda, Ryugo AU - Shimoda R FAU - Yamamoto, Manabu AU - Yamamoto M FAU - Maeta, Yoshihiko AU - Maeta Y FAU - Ashida, Keigo AU - Ashida K LA - eng PT - Journal Article DEP - 20140715 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Colorectal Neoplasms/*diagnosis/drug therapy/mortality MH - Female MH - Follow-Up Studies MH - Humans MH - Inflammation/*diagnosis/mortality MH - Lymphocytes/*pathology MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Neutrophils/*pathology MH - *Nutrition Assessment MH - Prognosis MH - Retrospective Studies MH - Survival Rate PMC - PMC4114089 OID - NLM: PMC4114089 EDAT- 2014/07/16 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/07/16 06:00 PHST- 2014/05/27 [received] PHST- 2014/07/04 [accepted] PHST- 2014/07/15 [aheadofprint] AID - 1477-7819-12-210 [pii] AID - 10.1186/1477-7819-12-210 [doi] PST - epublish SO - World J Surg Oncol. 2014 Jul 15;12:210. doi: 10.1186/1477-7819-12-210. PMID- 25017804 OWN - NLM STAT- MEDLINE DA - 20140811 DCOM- 20150413 IS - 1879-0593 (Electronic) IS - 1368-8375 (Linking) VI - 50 IP - 9 DP - 2014 Sep TI - Nutrition impact symptoms in a population cohort of head and neck cancer patients: multivariate regression analysis of symptoms on oral intake, weight loss and survival. PG - 877-83 LID - 10.1016/j.oraloncology.2014.06.009 [doi] LID - S1368-8375(14)00168-7 [pii] AB - OBJECTIVES: To evaluate the impact of 17 symptoms on reduced dietary intake, weight loss, and survival of patients with Head and Neck Cancer (HNC). METHODS: 635 Consecutive patients were screened (Patient- Generated Subjective Global Assessment(c), Head and Neck Symptom Checklist(c)) before radiation and/or chemotherapy. Multivariate regression analyses were used to relate severity of symptoms to reduced dietary intake and weight loss and identify prognostic individual symptoms impact on dietary intake. Cox proportional hazards model was used to find significant predictors of survival. RESULTS: Aggregate burden of symptoms was a significant independent predictor of reduced intake, weight loss and survival. Patients with a highest total symptom scores survived significantly less (205days, 95% CI=146-264) compared to patients with lowest total symptom score (577days, CI=429-725), log-rank P<0.001). Loss of appetite, difficulty chewing, dry mouth, thick saliva and pain were individual symptoms that significantly associated with reduced dietary intake in the entire cohort. In subgroup analyses, tumor location, disease stage, performance status, and presence of dysphagia altered the profile of individual symptoms that predict intake. However across all subgroups loss of appetite had the highest impact (OR=4.6; 95% CI=3.1-6.8), followed by difficulty chewing (OR=2.5; 95% CI=2.0-3.9). CONCLUSION: HNC patients experience significant symptom burden prior to radiation and chemotherapy. The nutritional impact of these symptoms on dietary intake is revealed by multivariate analysis and support the suggestion that unique individual symptom profiles require management to improve nutritional status. CI - Copyright (c) 2014 Elsevier Ltd. All rights reserved. FAU - Farhangfar, Arazm AU - Farhangfar A AD - Division of Palliative Care Medicine, Department of Oncology, University of Alberta, Canada. FAU - Makarewicz, Marcin AU - Makarewicz M AD - Division of Palliative Care Medicine, Department of Oncology, University of Alberta, Canada. FAU - Ghosh, Sunita AU - Ghosh S AD - Division of Medical Oncology, Department of Oncology, University of Alberta, Canada; Alberta Health Services - Cancer Control, Cross Cancer Institute, Edmonton, Alberta, Canada. FAU - Jha, Naresh AU - Jha N AD - Division of Radiation Oncology, Department of Oncology, University of Alberta, Canada. FAU - Scrimger, Rufus AU - Scrimger R AD - Division of Radiation Oncology, Department of Oncology, University of Alberta, Canada. FAU - Gramlich, Leah AU - Gramlich L AD - Department of Medicine, University of Alberta, Canada. FAU - Baracos, Vickie AU - Baracos V AD - Division of Palliative Care Medicine, Department of Oncology, University of Alberta, Canada. Electronic address: vickie.baracos@ualberta.ca. LA - eng PT - Journal Article DEP - 20140710 PL - England TA - Oral Oncol JT - Oral oncology JID - 9709118 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Cohort Studies MH - *Diet MH - *Energy Intake MH - Female MH - Head and Neck Neoplasms/*physiopathology MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - *Nutritional Status MH - Proportional Hazards Models MH - *Survival Analysis MH - *Weight Loss MH - Young Adult OTO - NOTNLM OT - Dysphagia OT - Head and neck cancer OT - Mucositis OT - Nutrition OT - Patient-Generated Subjective Global Assessment(©) OT - Symptoms EDAT- 2014/07/16 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/07/15 06:00 PHST- 2014/01/29 [received] PHST- 2014/06/10 [revised] PHST- 2014/06/11 [accepted] PHST- 2014/07/10 [aheadofprint] AID - S1368-8375(14)00168-7 [pii] AID - 10.1016/j.oraloncology.2014.06.009 [doi] PST - ppublish SO - Oral Oncol. 2014 Sep;50(9):877-83. doi: 10.1016/j.oraloncology.2014.06.009. Epub 2014 Jul 10. PMID- 25003682 OWN - NLM STAT- MEDLINE DA - 20140709 DCOM- 20150330 IS - 1300-4948 (Print) IS - 1300-4948 (Linking) VI - 25 IP - 2 DP - 2014 Apr TI - FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer. PG - 198-204 LID - 10.5152/tjg.2014.3609 [doi] AB - BACKGROUND/AIMS: We aimed to investigate the efficacy and tolerability of a FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer (mCRC) patients. MATERIALS AND METHODS: Patients were evaluated in two groups. Group A did not receive any treatment before, and group B had metastasectomy or metastasectomy plus primary tumor resection. RESULTS: In total, 132 mCRC patients had received FOLFOX7 regimen. The A group consisted of 117 (88.6%) patients, and group B consisted of 15 (11.4%) patients. In the A group, 52.1% had an objective response, 9.4% complete response, 42.7% partial response, 24.8% stable response, and 23.1% progression, and there was a 54.5% rate of primary tumor resection, 22.2% rate of metastasectomy, 80.7% rate of R0 metastasectomy, 19.1% rate of R1 metastasectomy, 15 (10-19) months median progression-free survival, and 32 (22-41) months median overall survival. In the B group, 40 (4-70) months median disease-free survival and 58 (21-94) months median overall survival were found. When toxicities were evaluated, grade 3/4 toxicity was observed in 35.6%. Grade 3/4 hematologic toxicity was the most frequently observed toxicity (29.5%). CONCLUSION: FOLFOX7 regimen was found to be an efficient and safe regimen for the first-line treatment of mCRC patients. FAU - Koca, Dogan AU - Koca D AD - Department of Medical Oncology, Van Regional Training and Research Hospital, Van, Turkey. FAU - Unal, Olcun Umit AU - Unal OU FAU - Oztop, Ilhan AU - Oztop I FAU - Yilmaz, Ugur AU - Yilmaz U LA - eng PT - Journal Article PL - Turkey TA - Turk J Gastroenterol JT - The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology JID - 9515841 RN - 0 (Organoplatinum Compounds) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Adenocarcinoid tumor RN - Folfox protocol SB - IM MH - Adenocarcinoma/*drug therapy/*secondary/surgery MH - Adolescent MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Colorectal Neoplasms/*pathology/surgery MH - Disease-Free Survival MH - Female MH - Fluorouracil/adverse effects/therapeutic use MH - Humans MH - Leucovorin/adverse effects/therapeutic use MH - Liver Neoplasms/drug therapy/secondary/surgery MH - Lung Neoplasms/drug therapy/secondary/surgery MH - Male MH - Metastasectomy MH - Middle Aged MH - Organoplatinum Compounds/adverse effects/therapeutic use MH - Survival Rate MH - Treatment Outcome MH - Young Adult EDAT- 2014/07/09 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/07/09 06:00 AID - 10.5152/tjg.2014.3609 [doi] PST - ppublish SO - Turk J Gastroenterol. 2014 Apr;25(2):198-204. doi: 10.5152/tjg.2014.3609. PMID- 24998696 OWN - NLM STAT- MEDLINE DA - 20140707 DCOM- 20150330 IS - 1665-2681 (Print) IS - 1665-2681 (Linking) VI - 13 Suppl 1 DP - 2014 May TI - Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. PG - S4-40 AB - Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third most common cause of cancer death, and accounts for 5.6% of all cancers. Nearly 82% of the approximately 550,000 liver cancer deaths each year occur in Asia. In some regions, cancer-related death from HCC is second only to lung cancer. The incidence and mortality of HCC are increasing in America countries as a result of an ageing cohort infected with chronic hepatitis C, and are expected to continue to rise as a consequence of the obesity epidemic. Clinical care and survival for patients with HCC has advanced considerably during the last two decades, thanks to improvements in patient stratification, an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and the introduction of novel therapies and strategies in prevention. Nevertheless, HCC remains the third most common cause of cancer-related deaths worldwide. These LAASL recommendations on treatment of hepatocellular carcinoma are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the optimal management of patients with liver cancer. FAU - Mendez-Sanchez, Nahum AU - Mendez-Sanchez N AD - Liver Research Unit. Medica Sur Clinic & Foundation. Mexico City, Mexico. FAU - Ridruejo, Ezequiel AU - Ridruejo E AD - Hepatology Section, Department of Medicine. Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno "CEMIC". Ciudad Autonoma de Buenos Aires, Argentina; Hepatology and Liver Transplant Unit. Hospital Universitario Austral, Pilar, Argentina. FAU - Alves de Mattos, Angelo AU - Alves de Mattos A AD - Federal University of Health Sciences Porto Alegre, Brazil. FAU - Chavez-Tapia, Norberto C AU - Chavez-Tapia NC AD - Digestive Diseases and Obesity Clinic, Medica Sur Clinic Foundation. Mexico City, Mexico. FAU - Zapata, Rodrigo AU - Zapata R AD - Hepatology and Liver Transplantation Unit. University of Chile School of Medicine, German Clinic. Santiago, Chile. FAU - Parana, Raymundo AU - Parana R AD - Associate Professor of School of Medicine - Federal University of Bahia Head of the Gastro-Hepatologist Unit of the University Bahia University Hospital. FAU - Mastai, Ricardo AU - Mastai R AD - Transplantation Unit. German Hospital.Buenos Aires, Argentina. FAU - Strauss, Edna AU - Strauss E AD - Clinical hepatologist of Hospital do Coracao - Sao Paulo - Brazil. Professor of the Post Graduate Course in the Department of Pathology at the School of Medicine, University of Sao Paulo. FAU - Guevara-Casallas, Luis Gonzalo AU - Guevara-Casallas LG AD - Department of Gastroenterology and Hepatology. San Vicente Foundation, University Hospital. Medellin, Colombia. FAU - Daruich, Jorge AU - Daruich J AD - Hepatology Department, Clinical Hospital San Martin. University of Buenos Aires Buenos Aires, Argentina. FAU - Gadano, Adrian AU - Gadano A AD - Section of Hepatology, Italian Hospital of Buenos Aires. Buenos Aires, Argentina. FAU - Parise, Edison Roberto AU - Parise ER AD - Professor Associado da Disciplina de Gastroenterologia da Universidade Federal de Sao Paulo, Presidente Eleito da Sociedade Brasileira de Hepatologia. FAU - Uribe, Misael AU - Uribe M AD - Digestive Diseases and Obesity Clinic, Medica Sur Clinic Foundation. Mexico City, Mexico. FAU - Aguilar-Olivos, Nancy E AU - Aguilar-Olivos NE AD - Digestive Diseases and Obesity Clinic, Medica Sur Clinic Foundation. Mexico City, Mexico. FAU - Dagher, Lucy AU - Dagher L AD - Consultant Hepatologist. Metropolitan Policlinic- Caracas- Venezuela. FAU - Ferraz-Neto, Ben-Hur AU - Ferraz-Neto BH AD - Director of Liver Institute - Beneficencia Portuguesa de Sao Paulo. Chief of Liver Transplantation Team. FAU - Valdes-Sanchez, Martha AU - Valdes-Sanchez M AD - Department of Pediatric Oncology National Medical Center "Siglo XXI". Mexico City, Mexico. FAU - Sanchez-Avila, Juan F AU - Sanchez-Avila JF AD - Hepatology and Liver Transplantation Department National Institute of Nutrition and Medical Sciences "Salvador Zubiran" Mexico City, Mexico. LA - eng PT - Journal Article PT - Review PL - Mexico TA - Ann Hepatol JT - Annals of hepatology JID - 101155885 SB - IM MH - Alcoholism/diagnosis/epidemiology MH - Carcinoma, Hepatocellular/diagnosis/*mortality/*therapy MH - Combined Modality Therapy MH - Developing Countries MH - Early Detection of Cancer MH - Female MH - Hepatitis C, Chronic/diagnosis/epidemiology MH - Humans MH - Latin America MH - Liver Cirrhosis/diagnosis/epidemiology MH - Liver Neoplasms/diagnosis/*mortality/*therapy MH - Male MH - *Practice Guidelines as Topic MH - Prognosis MH - Risk Assessment MH - Societies, Medical MH - Survival Analysis MH - Treatment Outcome EDAT- 2014/07/08 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/07/08 06:00 AID - 1112090 [pii] PST - ppublish SO - Ann Hepatol. 2014 May;13 Suppl 1:S4-40. PMID- 24994923 OWN - NLM STAT- MEDLINE DA - 20140704 DCOM- 20150416 IS - 1540-1413 (Electronic) IS - 1540-1405 (Linking) VI - 12 IP - 7 DP - 2014 Jul TI - Colon cancer, version 3.2014. PG - 1028-59 AB - The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference. CI - Copyright (c) 2014 by the National Comprehensive Cancer Network. FAU - Benson, Al B 3rd AU - Benson AB 3rd FAU - Venook, Alan P AU - Venook AP FAU - Bekaii-Saab, Tanios AU - Bekaii-Saab T FAU - Chan, Emily AU - Chan E FAU - Chen, Yi-Jen AU - Chen YJ FAU - Cooper, Harry S AU - Cooper HS FAU - Engstrom, Paul F AU - Engstrom PF FAU - Enzinger, Peter C AU - Enzinger PC FAU - Fenton, Moon J AU - Fenton MJ FAU - Fuchs, Charles S AU - Fuchs CS FAU - Grem, Jean L AU - Grem JL FAU - Hunt, Steven AU - Hunt S FAU - Kamel, Ahmed AU - Kamel A FAU - Leong, Lucille A AU - Leong LA FAU - Lin, Edward AU - Lin E FAU - Messersmith, Wells AU - Messersmith W FAU - Mulcahy, Mary F AU - Mulcahy MF FAU - Murphy, James D AU - Murphy JD FAU - Nurkin, Steven AU - Nurkin S FAU - Rohren, Eric AU - Rohren E FAU - Ryan, David P AU - Ryan DP FAU - Saltz, Leonard AU - Saltz L FAU - Sharma, Sunil AU - Sharma S FAU - Shibata, David AU - Shibata D FAU - Skibber, John M AU - Skibber JM FAU - Sofocleous, Constantinos T AU - Sofocleous CT FAU - Stoffel, Elena M AU - Stoffel EM FAU - Stotsky-Himelfarb, Eden AU - Stotsky-Himelfarb E FAU - Willett, Christopher G AU - Willett CG FAU - Gregory, Kristina M AU - Gregory KM FAU - Freedman-Cass, Deborah A AU - Freedman-Cass DA CN - National Comprehensive Cancer Network LA - eng PT - Guideline PT - Journal Article PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 RN - 0 (Angiogenesis Inhibitors) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antineoplastic Agents) RN - 0 (KRAS protein, human) RN - 0 (Membrane Proteins) RN - 0 (Organoplatinum Compounds) RN - 0 (Proto-Oncogene Proteins) RN - 0W860991D6 (Deoxycytidine) RN - 2S9ZZM9Q9V (bevacizumab) RN - EC 2.7.11.1 (BRAF protein, human) RN - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) RN - EC 3.6.1.- (GTP Phosphohydrolases) RN - EC 3.6.1.- (NRAS protein, human) RN - EC 3.6.5.2 (ras Proteins) RN - PQX0D8J21J (cetuximab) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - XT3Z54Z28A (Camptothecin) RN - Folfox protocol RN - IFL protocol RN - XELOX SB - IM MH - Angiogenesis Inhibitors/adverse effects/therapeutic use MH - Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use MH - Antineoplastic Agents/adverse effects/*therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use MH - Camptothecin/adverse effects/analogs & derivatives/therapeutic use MH - Colonic Neoplasms/*drug therapy/pathology/*surgery MH - Deoxycytidine/adverse effects/analogs & derivatives/therapeutic use MH - Disease Progression MH - Fluorouracil/adverse effects/analogs & derivatives/therapeutic use MH - GTP Phosphohydrolases/genetics MH - Humans MH - Leucovorin/adverse effects/therapeutic use MH - Liver Neoplasms/drug therapy/*secondary/surgery MH - Membrane Proteins/genetics MH - Organoplatinum Compounds/adverse effects/therapeutic use MH - Proto-Oncogene Proteins/genetics MH - Proto-Oncogene Proteins B-raf/genetics MH - Treatment Outcome MH - ras Proteins/genetics EDAT- 2014/07/06 06:00 MHDA- 2015/04/17 06:00 CRDT- 2014/07/05 06:00 AID - 12/7/1028 [pii] PST - ppublish SO - J Natl Compr Canc Netw. 2014 Jul;12(7):1028-59. PMID- 24991773 OWN - NLM STAT- MEDLINE DA - 20140704 DCOM- 20150330 IS - 1925-6523 (Electronic) IS - 1925-6515 (Linking) VI - 34 IP - 2-3 DP - 2014 Jul TI - Cancer risk factors and screening in the off-reserve First Nations, Metis and non-Aboriginal populations of Ontario. PG - 103-12 AB - INTRODUCTION: This study describes the prevalence of smoking, obesity, sedentary behaviour/physical activity, fruit and vegetable consumption and alcohol use as well as the uptake of breast, cervical and colorectal cancer screening among First Nations and Metis adults in Ontario and compares these to that of the non-Aboriginal population. METHODS: We used the Canadian Community Health Survey (2007 to 2011 combined) to calculate prevalence estimates for the 3 ethnocultural populations. RESULTS: First Nations and Metis adults were significantly more likely than non-Aboriginal adults to self-report smoking and/or to be classified as obese. Alcohol use exceeding cancer prevention recommendations and inadequate fruit and vegetable consumption were more common in First Nations people than in the non-Aboriginal population. First Nations women were more likely to report having had a Fecal Occult Blood Test in the previous 2 years than non-Aboriginal women. No significant differences across the 3 ethnocultural groups were found for breast and cervical screening among women or colorectal screening among men. CONCLUSION: Without intervention, we are likely to continue to see a significant burden of smoking- and obesity-related cancers in Ontario's Aboriginal population. FAU - Withrow, D R AU - Withrow DR AD - Surveillance and Prevention, Prevention and Cancer Control, Cancer Care Ontario, Toronto, Ontario, Canada; Department of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. FAU - Amartey, A AU - Amartey A AD - Surveillance and Prevention, Prevention and Cancer Control, Cancer Care Ontario, Toronto, Ontario, Canada. FAU - Marrett, L D AU - Marrett LD AD - Surveillance and Prevention, Prevention and Cancer Control, Cancer Care Ontario, Toronto, Ontario, Canada; Department of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. LA - eng LA - fre PT - Journal Article PL - Canada TA - Chronic Dis Inj Can JT - Chronic diseases and injuries in Canada JID - 101556266 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Breast Neoplasms/*diagnosis MH - Colorectal Neoplasms/*diagnosis MH - Diet MH - Early Detection of Cancer MH - Female MH - Fruit MH - Humans MH - Indians, North American/*statistics & numerical data MH - Inuits/*statistics & numerical data MH - Male MH - Middle Aged MH - Obesity/*ethnology MH - Ontario/epidemiology MH - Patient Acceptance of Health Care/*ethnology MH - Prevalence MH - Risk Factors MH - Sedentary Lifestyle/ethnology MH - Sex Factors MH - Smoking/*ethnology MH - Uterine Cervical Neoplasms/*diagnosis MH - Vegetables MH - Young Adult OAB - Publisher: Abstract available from the publisher. OABL- fre OTO - NOTNLM OT - American native continental ancestry group OT - First Nations OT - Métis OT - Ontario OT - cancer OT - chronic disease OT - indigenous population OT - mass screening OT - risk factors EDAT- 2014/07/06 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/07/04 06:00 PST - ppublish SO - Chronic Dis Inj Can. 2014 Jul;34(2-3):103-12. PMID- 24984804 OWN - NLM STAT- MEDLINE DA - 20140729 DCOM- 20150330 IS - 1573-7233 (Electronic) IS - 0167-7659 (Linking) VI - 33 IP - 2-3 DP - 2014 Sep TI - Extracellular acidity, a "reappreciated" trait of tumor environment driving malignancy: perspectives in diagnosis and therapy. PG - 823-32 LID - 10.1007/s10555-014-9506-4 [doi] AB - Tumors are ecosystems which develop from stem cells endowed with unlimited self-renewal capability and genetic instability, under the effects of mutagenesis and natural selection imposed by environmental changes. Abnormal vascularization, reduced lymphatic network, uncontrolled cell growth frequently associated with hypoxia, and extracellular accumulation of glucose metabolites even in the presence of an adequate oxygen level are all factors contributing to reduce pH in the extracellular space of tumors. Evidence is accumulating that acidity is associated with a poor prognosis and participates actively to tumor progression. This review addresses some of the most experimental evidences providing that acidity of tumor environment facilitates local invasiveness and metastatic dissemination, independently from hypoxia, with which acidity is often but not always associated. Clinical investigations have also shown that tumors with acidic environment are associated with resistance to chemotherapy and radiation-induced apoptosis, suppression of cytotoxic lymphocytes, and natural killer cells tumoricidal activity. Therefore, new technologies for functional and molecular imaging as well as strategies directed to target low extracellular pH and low pH-adapted tumor cells might represent important issues in oncology. FAU - Peppicelli, Silvia AU - Peppicelli S AD - Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy. FAU - Bianchini, Francesca AU - Bianchini F FAU - Calorini, Lido AU - Calorini L LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - Netherlands TA - Cancer Metastasis Rev JT - Cancer metastasis reviews JID - 8605731 RN - 0 (Antineoplastic Agents) SB - IM MH - *Acidosis MH - Antineoplastic Agents/therapeutic use MH - Diagnostic Imaging/methods MH - Energy Metabolism MH - Extracellular Space/*metabolism MH - Humans MH - Neoplasm Metastasis MH - Neoplasms/diagnosis/*metabolism/*pathology/therapy MH - *Tumor Microenvironment EDAT- 2014/07/06 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/07/03 06:00 AID - 10.1007/s10555-014-9506-4 [doi] PST - ppublish SO - Cancer Metastasis Rev. 2014 Sep;33(2-3):823-32. doi: 10.1007/s10555-014-9506-4. PMID- 24980767 OWN - NLM STAT- MEDLINE DA - 20140701 DCOM- 20150413 IS - 1812-9269 (Print) IS - 1812-9269 (Linking) VI - 36 IP - 2 DP - 2014 Jun TI - Correlation of nucleotides and carbohydrates metabolism with pro-oxidant and antioxidant systems of erythrocytes depending on age in patients with colorectal cancer. PG - 117-20 AB - AIM: To examine the relationship between metabolic features of purine nucleotides and antioxidant system depending on the age of patients with colorectal cancer. MATERIALS AND METHODS: The activity of adenosine deaminase, xanthine oxidase, glutathione peroxidase, superoxide dismutase and glucose-6-phosphate dehydrogenase, the NOx concentration and the oxidative modification of proteins were determined spectrophotometricaly in 50 apparently healthy people and 26 patients with colorectal cancer stage -III---IV, aged 40 to 79 years. RESULTS: Increase of pro-oxidant system of erythrocytes with the age against decrease in level of antioxidant protection in both healthy individuals and colorectal cancer patients was determined. A significant increase of pro-ducts of oxidative proteins modification in erythrocytes with ageing was shown. Statistically significant correlation between enzymatic and non enzymatic markers pro-oxidant system and the activity of antioxidant defense enzymes in erythrocytes of patient with colorectal cancer was determined. CONCLUSION: Obtained results have demonstrated the imbalance in the antioxidant system of erythrocytes in colorectal cancer patients that improve the survival of cancer cells that is more distinctly manifested in ageing. FAU - Zuikov, S A AU - Zuikov SA AD - Department of Chemistry, Maksim Gorky National Medical University, Donetsk 83003, Ukraine. FAU - Borzenko, B G AU - Borzenko BG AD - Department of Chemistry, Maksim Gorky National Medical University, Donetsk 83003, Ukraine. FAU - Shatova, O P AU - Shatova OP AD - Department of Chemistry, Maksim Gorky National Medical University, Donetsk 83003, Ukraine. FAU - Bakurova, E M AU - Bakurova EM AD - Department of Chemistry, Maksim Gorky National Medical University, Donetsk 83003, Ukraine. FAU - Polunin, G E AU - Polunin GE AD - Department of General Surgery and Surgical Diseases, Maksim Gorky National Medical University, Donetsk 83003, Ukraine. LA - eng PT - Journal Article PL - Ukraine TA - Exp Oncol JT - Experimental oncology JID - 101230541 RN - 0 (Antioxidants) RN - 0 (Biological Markers) RN - 0 (Nucleotides) RN - 0 (Oxidants) RN - 0 (Reactive Oxygen Species) SB - IM MH - Adult MH - Age Factors MH - Aged MH - Antioxidants/metabolism MH - Biological Markers MH - Colorectal Neoplasms/*metabolism/pathology MH - Erythrocytes/*metabolism MH - Female MH - Humans MH - *Lipid Metabolism MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Nucleotides/*metabolism MH - Oxidants/metabolism MH - *Oxidation-Reduction MH - Oxidative Stress MH - Reactive Oxygen Species EDAT- 2014/07/02 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/07/02 06:00 AID - 6937 [pii] PST - ppublish SO - Exp Oncol. 2014 Jun;36(2):117-20. PMID- 24976421 OWN - NLM STAT- MEDLINE DA - 20140808 DCOM- 20150407 IS - 1873-1244 (Electronic) IS - 0899-9007 (Linking) VI - 30 IP - 9 DP - 2014 Sep TI - Body composition following stem cell transplant: comparison of bioimpedance and air-displacement plethysmography. PG - 1000-6 LID - 10.1016/j.nut.2014.01.017 [doi] LID - S0899-9007(14)00083-5 [pii] AB - OBJECTIVE: The aim of this study was to assess the agreement between detected changes in body composition determined by bioimpedance spectroscopy (BIS) and air-displacement plethysmography (ADP) among patients with cancer undergoing peripheral blood stem cell transplantation (PBSCT); and to assess the agreement of absolute values of BIS with ADP and dual energy x-ray (DXA). METHODS: Forty-four adult hematologic cancer patients undergoing PBSCT completed both BIS and ADP assessment at preadmission and at 3 mo after transplantation. A subsample (n = 11) was assessed by DXA at 3 mo after transplantation. Results were examined for the BIS instrument's default setting and three alternative predictive equations from the literature. Agreement was assessed by the Bland-Altman limits of agreement analysis while correlation was examined using the Lin's concordance correlation. RESULTS: Changes in body composition parameters assessed by BIS were comparable with those determined by ADP regardless of the predictive equations used. Bias of change in fat-free mass was clinically acceptable (all <1 kg), although limits of agreement were wide (more than +/-6 kg). Overall, the BIS predictive equation accounting for body mass index performed the best. Absolute body composition parameters predicted by the alternative predictive equations agreed with DXA and ADP better than the BIS instrument's default setting. CONCLUSION: Changes predicted by BIS were similar to those determined by ADP on a group level; however, agreement of predicted changes at an individual level should be interpreted with caution due to wide limits of agreement. CI - Copyright (c) 2014 Elsevier Inc. All rights reserved. FAU - Hung, Yun-Chi AU - Hung YC AD - Centre for Dietetics Research, School of Human Movement Studies, The University of Queensland, Brisbane, Queensland, Australia. Electronic address: yui.hung@uqconnect.edu.au. FAU - Bauer, Judith D AU - Bauer JD AD - Centre for Dietetics Research, School of Human Movement Studies, The University of Queensland, Brisbane, Queensland, Australia; The Wesley Research Institute, Brisbane, Queensland, Australia. FAU - Horsely, Pamela AU - Horsely P AD - Nutrition Services Department, The Wesley Hospital, Brisbane, Queensland, Australia. FAU - Ward, Leigh C AU - Ward LC AD - School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia. FAU - Bashford, John AU - Bashford J AD - Haematology & Oncology Clinics of Australia, The Wesley Medical Centre, Brisbane, Queensland, Australia. FAU - Isenring, Elisabeth A AU - Isenring EA AD - Centre for Dietetics Research, School of Human Movement Studies, The University of Queensland, Brisbane, Queensland, Australia; Department of Nutrition & Dietetics, Princess Alexandra Hospital, Brisbane, Queensland, Australia. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140220 PL - United States TA - Nutrition JT - Nutrition (Burbank, Los Angeles County, Calif.) JID - 8802712 SB - IM MH - Absorptiometry, Photon MH - *Adipose Tissue MH - Adult MH - Aged MH - Air MH - *Body Composition MH - *Body Fluid Compartments MH - *Body Mass Index MH - *Electric Impedance MH - Female MH - Hematopoietic Stem Cells MH - Humans MH - Male MH - Middle Aged MH - Neoplasms/therapy MH - Plethysmography/*methods MH - *Stem Cell Transplantation MH - Young Adult OTO - NOTNLM OT - Air-displacement plethysmography OT - Bioelectrical impedance OT - Body composition OT - Cancer OT - Spectroscopy OT - Stem cell transplantation EDAT- 2014/07/01 06:00 MHDA- 2015/04/08 06:00 CRDT- 2014/07/01 06:00 PHST- 2013/08/08 [received] PHST- 2013/12/02 [revised] PHST- 2014/01/29 [accepted] PHST- 2014/02/20 [aheadofprint] AID - S0899-9007(14)00083-5 [pii] AID - 10.1016/j.nut.2014.01.017 [doi] PST - ppublish SO - Nutrition. 2014 Sep;30(9):1000-6. doi: 10.1016/j.nut.2014.01.017. Epub 2014 Feb 20. PMID- 24969887 OWN - NLM STAT- MEDLINE DA - 20140627 DCOM- 20150330 IS - 1513-7368 (Print) IS - 1513-7368 (Linking) VI - 15 IP - 11 DP - 2014 TI - Diabetes--increased risk for cancers through chromosomal aberrations? PG - 4571-3 AB - Diabetes, a comprehensive genetic disease, is principally due to the deregulation of glucose levels in the blood. In addition to contemporary epidemiological studies, systematic substantiation suggests that long-term diabetes leads to cancers due to a variety of reasons. In this study, blood samples were collected with informed consent from confirmed type I diabetic (T1DM, n=25) and type II Diabetic patients (T2DM, n=25) with equal numbers of controls. Further depending on the lifestyle habits they were subdivided into smokers/non-smokers and alcoholics/non-alcoholics. Chromosomal assays were performed for these cases and it was found that there was a significant increase in chromosomal aberration frequency in diabetic patient groups who are exposed to smoking and alcohol than that of normal diabetic groups (T1DM and T2DM). On the other hand, patient groups who were non-smoking and non-alcoholics also showed higher chromosomal aberrations when compared to that of controls. While the mechanisms for these increased chromosomal aberrations in diabetic groups are not clear, they may be due to increased oxidative stress leading to oxidative damage and resulting in genomic instability, which in turn may contribute to an increased risk for cancer. FAU - Anand, Sudhaa AU - Anand S AD - Biomedical Genetics Research Laboratory, SBST, VIT University, Vellore, India E-mail : r_saraswathy@yahoo.com. FAU - Nath, Badari AU - Nath B FAU - Saraswathy, Radha AU - Saraswathy R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 SB - IM MH - Alcohol Drinking/adverse effects MH - Chromosomal Instability/*genetics MH - Chromosome Aberrations MH - Diabetes Complications/*genetics MH - Diabetes Mellitus/*genetics MH - Genomic Instability/genetics MH - Humans MH - Life Style MH - Neoplasms/*etiology/*genetics MH - Oxidative Stress/genetics MH - Risk MH - Smoking/adverse effects EDAT- 2014/06/28 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/06/28 06:00 PST - ppublish SO - Asian Pac J Cancer Prev. 2014;15(11):4571-3. PMID- 24969869 OWN - NLM STAT- MEDLINE DA - 20140627 DCOM- 20150330 IS - 1513-7368 (Print) IS - 1513-7368 (Linking) VI - 15 IP - 11 DP - 2014 TI - Prevalence and risk factors of H. pylori from dyspeptic patients in northwest Ethiopia: a hospital based cross-sectional study. PG - 4459-63 AB - BACKGROUND: Gastric cancer is the second leading cause of cancer-related deaths worldwide and infection with H. pylori is considered essential for its development. Helicobacter pylori infects more than 50% of the world's population with higher prevalence in developing countries than developed countries. The prevalence of H. pylori varies in different societies and geographical locations. The objectives of this study were to estimate the seroprevalence and determine the risk factors of H. pylori infection in dyspeptic patents in Ethiopia. MATERIALS AND METHODS: A cross-sectional study involving 209 dyspeptic patients was carried out from February 15 to April 30, 2013. Five to ten ml venous blood was collected from each dyspeptic patient and analyzed for detection of Helicobacter pylori immunoglobulin (IgG). The socio-demographic characteristic, hygienic practices, alcohol consumption, sources of drinking water and types of latrine were also obtained with a pre-tested questionnaire. RESULTS: The overall seroprevalence of Helicobacter pylori was 72.2%. There was statistically significant difference in the prevalence of H. pylori among age groups (p=0.02). Seroprevalence of H. pylori was higher in those patients who used unprotected surface water (76.4%) than those with access to piped tap water (65.9%). There was also statistically significant differences in prevalence of H. pylori with the habit of hand washing before meal (p=0.01) and alcohol consumption (p=0.001). CONCLUSIONS: The prevalence of H. pylori was high in the study area and increased with age of dyspeptic patients. Alcohol consumption and the type of drinking water are risk factors that have associations with the prevalence of H. pylori. Molecular epidemiological techniques can show a true picture of H. pylori and improvement in the drinking water quality is recommended. FAU - Abebaw, Wubejig AU - Abebaw W AD - Department of Biology, Science College, Bahir Dar University, Ethiopia E-mail : mulugetanig@gmail.com. FAU - Kibret, Mulugeta AU - Kibret M FAU - Abera, Bayeh AU - Abera B LA - eng PT - Journal Article PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 RN - 0 (Drinking Water) RN - 0 (Immunoglobulin G) SB - IM MH - Adult MH - Age Factors MH - Alcohol Drinking/adverse effects MH - Cross-Sectional Studies MH - Drinking Water MH - Dyspepsia/immunology/*microbiology MH - Ethiopia/epidemiology MH - Female MH - Helicobacter Infections/*epidemiology/*etiology/immunology MH - Helicobacter pylori/immunology MH - Hospitals MH - Humans MH - Immunoglobulin G/immunology MH - Male MH - Middle Aged MH - Prevalence MH - Questionnaires MH - Risk Factors MH - Seroepidemiologic Studies MH - Stomach Neoplasms/immunology/microbiology MH - Young Adult EDAT- 2014/06/28 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/06/28 06:00 PST - ppublish SO - Asian Pac J Cancer Prev. 2014;15(11):4459-63. PMID- 24966600 OWN - NLM STAT- MEDLINE DA - 20140626 DCOM- 20150413 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 23 DP - 2014 Jun 21 TI - Impairment of innate immune responses in cirrhotic patients and treatment by branched-chain amino acids. PG - 7298-305 LID - 10.3748/wjg.v20.i23.7298 [doi] AB - It has been reported that host defense responses, such as phagocytic function of neutrophils and natural killer (NK) cell activity of lymphocytes, are impaired in cirrhotic patients. This review will concentrate on the impairment of innate immune responses in decompensated cirrhotic patients and the effect of the treatment by branched-chain amino acids (BCAA) on innate immune responses. We already reported that phagocytic function of neutrophils was significantly improved by 3-mo BCAA supplementation. In addition, the changes of NK activity were also significant at 3 mo of supplementation compared with before supplementation. Also, Fisher's ratios were reported to be significantly increased at 3 mo of BCAA supplementation compared with those before oral supplementation. Therefore, administration of BCAA could reduce the risk of bacterial and viral infection in patients with decompensated cirrhosis by restoring impaired innate immune responses of the host. In addition, it was also revealed that BCAA oral supplementation could reduce the risk of development of hepatocellular carcinoma in cirrhotic patients. The mechanisms of the effects will also be discussed in this review article. FAU - Nakamura, Ikuo AU - Nakamura I AD - Ikuo Nakamura, Department of Gastroenterology, Tokyo Medical University, Tokyo 160-0023, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 RN - 0 (Amino Acids, Branched-Chain) SB - IM MH - Administration, Oral MH - Amino Acids, Branched-Chain/administration & dosage/*therapeutic use MH - Carcinoma, Hepatocellular/immunology/prevention & control MH - *Dietary Supplements MH - Humans MH - Immunity, Innate/*drug effects MH - Killer Cells, Natural/drug effects/immunology MH - Liver Cirrhosis/complications/diagnosis/*drug therapy/immunology MH - Liver Neoplasms/immunology/prevention & control MH - Neutrophils/drug effects/immunology MH - Phagocytosis/drug effects MH - Risk Factors MH - Treatment Outcome PMC - PMC4064075 OID - NLM: PMC4064075 OTO - NOTNLM OT - Branched-chain amino acids OT - Innate immunity OT - Liver cirrhosis OT - Natural killer cell activity of lymphocytes OT - Phagocytic function of neutrophils EDAT- 2014/06/27 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/06/27 06:00 PHST- 2013/10/27 [received] PHST- 2013/12/19 [revised] PHST- 2014/04/30 [accepted] AID - 10.3748/wjg.v20.i23.7298 [doi] PST - ppublish SO - World J Gastroenterol. 2014 Jun 21;20(23):7298-305. doi: 10.3748/wjg.v20.i23.7298. PMID- 24951608 OWN - NLM STAT- MEDLINE DA - 20140806 DCOM- 20150410 LR - 20150422 IS - 1549-490X (Electronic) IS - 1083-7159 (Linking) VI - 19 IP - 8 DP - 2014 Aug TI - FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. PG - 845-50 LID - 10.1634/theoncologist.2014-0106 [doi] AB - PURPOSE: The standard treatment of peritoneal pseudomyxoma is based on cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). The establishment of newer systemic treatments is an unmet clinical need for unresectable or relapsed peritoneal pseudomyxoma. The aim of our study was to assess the activity of chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX-4 regimen) in terms of response rate in this subset of patients. MATERIALS AND METHODS: Patients were included in a single-center, observational study and treated with FOLFOX-4 administered every 2 weeks for up to 12 cycles or until progressive disease or unacceptable toxicity. RESULTS: Twenty consecutive patients were reviewed from July 2011 to September 2013. Only partial responses were observed, with an objective response rate of 20%. Median progression-free survival and overall survival were 8 months and 26 months, respectively. Two patients were able to undergo laparotomy with complete cytoreduction and HIPEC in one case. Safety data for FOLFOX-4 were consistent with the literature. By means of a mutant enriched polymerase chain reaction, KRAS mutation was found in 16 of 19 cases (84%), and MGMT promoter methylation was found in 8 (42%, all KRAS mutant). CONCLUSION: FOLFOX-4 chemotherapy is tolerable and active in patients with peritoneal pseudomyxoma when disease is deemed unresectable or relapsed after peritonectomy and HIPEC. The identification of predictive biomarkers, such as KRAS for resistance to anti-epidermal growth factor receptor monoclonal antibodies and MGMT for response to temozolomide, is a priority for the development of evidence-based treatment strategies for peritoneal pseudomyxoma. CI - (c)AlphaMed Press. FAU - Pietrantonio, Filippo AU - Pietrantonio F AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy filippo.pietrantonio@istitutotumori.mi.it. FAU - Maggi, Claudia AU - Maggi C AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Fanetti, Giuseppe AU - Fanetti G AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Iacovelli, Roberto AU - Iacovelli R AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Di Bartolomeo, Maria AU - Di Bartolomeo M AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Ricchini, Francesca AU - Ricchini F AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Deraco, Marcello AU - Deraco M AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Perrone, Federica AU - Perrone F AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Baratti, Dario AU - Baratti D AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Kusamura, Shigeki AU - Kusamura S AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Tamborini, Elena AU - Tamborini E AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Castano, Alessandra AU - Castano A AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Consonni, Paola Valentina AU - Consonni PV AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Bossi, Ilaria AU - Bossi I AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Gavazzi, Cecilia AU - Gavazzi C AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Milione, Massimo AU - Milione M AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Pelosi, Giuseppe AU - Pelosi G AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - de Braud, Filippo AU - de Braud F AD - Medical Oncology Department, Surgery Department, Pathology and Molecular Biology Department, Scientific Directorate, and Clinical Nutrition Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140620 PL - United States TA - Oncologist JT - The oncologist JID - 9607837 RN - 0 (KRAS protein, human) RN - 0 (Organoplatinum Compounds) RN - 0 (Proto-Oncogene Proteins) RN - 0 (Tumor Suppressor Proteins) RN - EC 2.1.1.- (DNA Modification Methylases) RN - EC 2.1.1.63 (MGMT protein, human) RN - EC 3.6.5.2 (ras Proteins) RN - EC 6.5.1.- (DNA Repair Enzymes) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Folfox protocol SB - IM CIN - Oncologist. 2015 Mar;20(3):e3-4. PMID: 25745054 CIN - Oncologist. 2015 Mar;20(3):e5. PMID: 25745055 MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects MH - DNA Methylation/genetics MH - DNA Modification Methylases/genetics MH - DNA Repair Enzymes/genetics MH - Disease-Free Survival MH - Female MH - Fluorouracil/administration & dosage/adverse effects MH - Follow-Up Studies MH - Humans MH - Leucovorin/administration & dosage/adverse effects MH - Male MH - Middle Aged MH - Organoplatinum Compounds/administration & dosage/adverse effects MH - Peritoneal Neoplasms/*drug therapy/genetics/pathology MH - Proto-Oncogene Proteins/genetics MH - Pseudomyxoma Peritonei/*drug therapy/genetics/pathology MH - Treatment Outcome MH - Tumor Suppressor Proteins/genetics MH - ras Proteins/genetics PMC - PMC4122474 OID - NLM: PMC4122474 [Available on 08/01/15] OTO - NOTNLM OT - Appendiceal cancer OT - Chemotherapy OT - FOLFOX-4 OT - Peritoneal pseudomyxoma EDAT- 2014/06/22 06:00 MHDA- 2015/04/11 06:00 CRDT- 2014/06/22 06:00 PMCR- 2015/08/01 00:00 PHST- 2014/06/20 [aheadofprint] AID - theoncologist.2014-0106 [pii] AID - 10.1634/theoncologist.2014-0106 [doi] PST - ppublish SO - Oncologist. 2014 Aug;19(8):845-50. doi: 10.1634/theoncologist.2014-0106. Epub 2014 Jun 20. PMID- 24950597 OWN - NLM STAT- MEDLINE DA - 20140722 DCOM- 20150402 IS - 1877-783X (Electronic) IS - 1877-7821 (Linking) VI - 38 IP - 4 DP - 2014 Aug TI - Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort - Differential effects by tumour subtype, NAT2 status, BMI and alcohol intake. PG - 419-26 LID - 10.1016/j.canep.2014.05.006 [doi] LID - S1877-7821(14)00098-8 [pii] AB - BACKGROUND: Inconsistent associations of smoking and breast cancer-specific mortality might be explained by subgroups of patients with different susceptibility to harmful effects of smoking. METHODS: We used a prospective cohort of 3340 postmenopausal breast cancer patients aged 50-74 and diagnosed with invasive tumours 2001-2005 in Germany, with a median follow-up time of 6 years. The effect of pre-diagnostic smoking behaviour on mortality outcomes and risk of recurrence was investigated using delayed entry Cox regression analysis. Differential effects according to N-acetyltransferase (NAT2) status, BMI, alcohol consumption, and tumour subtypes were assessed. RESULTS: Overall, smoking at time of breast cancer diagnosis versus never/former smoking was non-significantly associated with increased breast cancer-specific mortality and risk of recurrence (HR 1.23, 95% CI 0.93-1.64, and HR 1.29, 95% CI 0.95-1.75, respectively). Associations were consistently stronger in NAT2 slow than in fast acetylators for all mortality outcomes. Breast cancer-specific mortality was significantly increased in smokers with NAT2 slow acetylating status (HR 1.77, 95% CI 1.13-2.79) but not in those with fast acetylating status (HR 1.09, 95% CI 0.60-1.98; Pheterogeneity=0.19). Smoking was associated with significantly poorer outcomes for triple negative and luminal A-like tumours (e.g. all-cause mortality: HR 1.93, 95% CI 1.02-3.65, and HR 2.08, 95% CI 1.40-3.10, respectively). Risk of recurrence was significantly increased for women with HER2 positive tumours (HR 3.64, 95% CI 1.22-10.8). There was significant heterogeneity by BMI for non-breast cancer-specific mortality (<25 kg/m(2): HR 2.52, 95% CI 1.52-4.15 vs. >/=25 kg/m(2): HR 0.94, 95% CI 0.38-2.36; Pheterogeneity=0.04). CONCLUSION: The harmful effects of smoking may be particularly relevant for certain subgroups of breast cancer patients. This may include patients with NAT2 slow acetylation status or with tumour subtypes other than luminal B, such as luminal A tumours who usually have a rather good prognosis. Emphasis on smoking cessation programmes for all cancer patients should be strengthened. CI - Copyright (c) 2014 Elsevier Ltd. All rights reserved. FAU - Seibold, Petra AU - Seibold P AD - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. Electronic address: p.seibold@dkfz.de. FAU - Vrieling, Alina AU - Vrieling A AD - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany; Department for Health Evidence, Radboud University Medical Centre, Geert Grooteplein 21, 6525 EZ Nijmegen, The Netherlands. Electronic address: Alina.Vrieling@radboudumc.nl. FAU - Heinz, Judith AU - Heinz J AD - University Cancer Center Hamburg (UCCH) and University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Electronic address: j.heinz@uke.uni-hamburg.de. FAU - Obi, Nadia AU - Obi N AD - University Cancer Center Hamburg (UCCH) and University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Electronic address: n.obi@uke.de. FAU - Sinn, Hans-Peter AU - Sinn HP AD - Institute of Pathology, Heidelberg University, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany. Electronic address: peter.sinn@med.uni-heidelberg.de. FAU - Flesch-Janys, Dieter AU - Flesch-Janys D AD - University Cancer Center Hamburg (UCCH) and University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Electronic address: flesch@uke.uni-hamburg.de. FAU - Chang-Claude, Jenny AU - Chang-Claude J AD - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. Electronic address: j.chang-claude@dkfz.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140617 PL - Netherlands TA - Cancer Epidemiol JT - Cancer epidemiology JID - 101508793 RN - EC 2.3.1.5 (Arylamine N-Acetyltransferase) RN - EC 2.3.1.5 (NAT2 protein, human) SB - IM MH - Aged MH - Alcohol Drinking/adverse effects MH - Arylamine N-Acetyltransferase/genetics/*metabolism MH - Body Mass Index MH - Breast Neoplasms/genetics/metabolism/*pathology MH - Cohort Studies MH - European Continental Ancestry Group MH - Female MH - Genotype MH - Germany MH - Humans MH - Kaplan-Meier Estimate MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology MH - Polymorphism, Single Nucleotide MH - Prognosis MH - Proportional Hazards Models MH - Prospective Studies MH - Risk Factors MH - Smoking/*adverse effects OTO - NOTNLM OT - Acetylation status OT - Breast cancer survival OT - Effect modification OT - NAT2 OT - Smoking OT - Tobacco EDAT- 2014/06/22 06:00 MHDA- 2015/04/04 06:00 CRDT- 2014/06/22 06:00 PHST- 2014/02/10 [received] PHST- 2014/05/14 [revised] PHST- 2014/05/18 [accepted] PHST- 2014/06/17 [aheadofprint] AID - S1877-7821(14)00098-8 [pii] AID - 10.1016/j.canep.2014.05.006 [doi] PST - ppublish SO - Cancer Epidemiol. 2014 Aug;38(4):419-26. doi: 10.1016/j.canep.2014.05.006. Epub 2014 Jun 17. PMID- 24926819 OWN - NLM STAT- MEDLINE DA - 20140704 DCOM- 20150419 IS - 1473-5636 (Electronic) IS - 0960-8931 (Linking) VI - 24 IP - 4 DP - 2014 Aug TI - Increased risk of developing cutaneous malignant melanoma is associated with variation in pigmentation genes and VDR, and may involve epistatic effects. PG - 388-96 LID - 10.1097/CMR.0000000000000095 [doi] AB - Cutaneous malignant melanoma (CMM) is a malicious human skin cancer that primarily affects individuals with light pigmentation and heavy sun exposure, but also has a known familial association. Multiple genes and polymorphisms have been reported as low-penetrance susceptibility loci for CMM. Here, we examined 33 candidate polymorphisms located in 11 pigmentation genes and the vitamin D receptor gene (VDR) in a population of 130 cutaneous melanoma patients and 707 healthy controls. The genotypes obtained were evaluated for main association effects and potential gene-gene interactions. MC1R, TYR, VDR and SLC45A2 genes were found to be associated with CMM in our population. The results obtained for major function MC1R mutations were the most significant [with odds ratio (OR)=1.787, confidence interval (CI)=1.320-2.419 and P=1.715(-4)], followed by TYR (rs1393350) (with OR=1.569, CI=1.162-2.118, P=0.003), VDR (GCCC haplotype in rs2238136-rs4516035-rs7139166-rs11568820 block) (with OR=5.653, CI=1.794-17.811, P=0.003) and SLC45A2 (rs16891982) (with OR=0.238, CI=0.057-0.987, P=0.048). The study also detected significant intermolecular epistatic effects between MC1R and TYR, SLC45A2 and VDR, HERC2 and VDR, OCA2 and TPCN2, as well as intramolecular interactions between variants within the genes MC1R and VDR. In the final multivariate logistic regression model for CMM development, only the gene-gene interactions discovered remained significant, showing that epistasis may be an important factor in the risk of melanoma. FAU - Kosiniak-Kamysz, Agnieszka AU - Kosiniak-Kamysz A AD - aDepartment of Dermatology, Collegium Medicum of the Jagiellonian University bDepartment of Analytical Biochemistry, Jagiellonian University Medical College cDepartment of Genetics and Evolution, Institute of Zoology, Jagiellonian University dSection of Forensic Genetics, Institute of Forensic Research, Krakow, Poland. FAU - Marczakiewicz-Lustig, Anna AU - Marczakiewicz-Lustig A FAU - Marcinska, Magdalena AU - Marcinska M FAU - Skowron, Malgorzata AU - Skowron M FAU - Wojas-Pelc, Anna AU - Wojas-Pelc A FAU - Pospiech, Ewelina AU - Pospiech E FAU - Branicki, Wojciech AU - Branicki W LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Melanoma Res JT - Melanoma research JID - 9109623 RN - 0 (Receptors, Calcitriol) RN - 0 (VDR protein, human) RN - Melanoma, Cutaneous Malignant SB - IM MH - Case-Control Studies MH - Female MH - Genetic Predisposition to Disease MH - Genotype MH - Humans MH - Male MH - Melanoma/*genetics/pathology MH - Middle Aged MH - Polymorphism, Single Nucleotide MH - Questionnaires MH - Receptors, Calcitriol/*genetics MH - Risk Factors MH - Skin Neoplasms/*genetics/pathology MH - Skin Pigmentation/*genetics EDAT- 2014/06/14 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/06/14 06:00 AID - 10.1097/CMR.0000000000000095 [doi] PST - ppublish SO - Melanoma Res. 2014 Aug;24(4):388-96. doi: 10.1097/CMR.0000000000000095. PMID- 24906910 OWN - NLM STAT- MEDLINE DA - 20140812 DCOM- 20150415 IS - 1552-695X (Electronic) IS - 1534-7354 (Linking) VI - 13 IP - 5 DP - 2014 Sep TI - A clinical protocol demonstrating rapid, safe, and effective treatment of vitamin D deficiency: a potential role in oncology alongside conventional treatment. PG - 411-6 LID - 10.1177/1534735414537875 [doi] AB - Vitamin D status has importance in the prevention and treatment of many malignancies. Patients with breast, colon, and lung malignancies with higher vitamin D status at the onset of treatment have an improved prognosis compared with those patients with a lower vitamin D status. Methods to improve vitamin D status are often unreliable and take time, often months, to be successful. A method that improves and normalizes the vitamin D status safely, quickly (within 1-2 weeks), and reliably is described herein. The use of this method will allow testing of the hypothesis that improving the vitamin D status of patients with various malignancies before treatment is initiated will improve their outcome. CI - (c) The Author(s) 2014. FAU - Cantor, Ira AU - Cantor I AD - Steiner Medical and Therapeutic Center, Phoenixville, PA, USA isc@steinermed.com. LA - eng PT - Journal Article DEP - 20140605 PL - United States TA - Integr Cancer Ther JT - Integrative cancer therapies JID - 101128834 RN - 1406-16-2 (Vitamin D) RN - 1C6V77QF41 (Cholecalciferol) RN - 64719-49-9 (25-hydroxyvitamin D) SB - IM MH - Cholecalciferol/*therapeutic use MH - Humans MH - Neoplasms/*drug therapy/pathology MH - Reproducibility of Results MH - Retrospective Studies MH - Time Factors MH - Vitamin D/*analogs & derivatives/blood MH - Vitamin D Deficiency/*drug therapy OTO - NOTNLM OT - malignancies OT - treatment of vitamin D deficiency OT - vitamin D OT - vitamin D and oncology treatment OT - vitamin D replacement therapy EDAT- 2014/06/08 06:00 MHDA- 2015/04/16 06:00 CRDT- 2014/06/08 06:00 PHST- 2014/06/05 [aheadofprint] AID - 1534735414537875 [pii] AID - 10.1177/1534735414537875 [doi] PST - ppublish SO - Integr Cancer Ther. 2014 Sep;13(5):411-6. doi: 10.1177/1534735414537875. Epub 2014 Jun 5. PMID- 24905862 OWN - NLM STAT- MEDLINE DA - 20140809 DCOM- 20150407 IS - 1473-6519 (Electronic) IS - 1363-1950 (Linking) VI - 17 IP - 5 DP - 2014 Sep TI - Ghrelin: from discovery to cancer cachexia therapy. PG - 471-6 LID - 10.1097/MCO.0000000000000075 [doi] AB - PURPOSE OF REVIEW: Despite the high prevalence of cancer cachexia, a condition that negatively impacts patients' prognosis and quality of life, effective therapies are still lacking. Ghrelin is a peptide hormone involved in anabolic and homeostatic functions, whose mechanisms of action are still only partially clarified, but with promising positive effects in cancer cachexia. Recently, the therapeutic administration of ghrelin in cancer has been shown to counteract loss of body mass and function, including muscle, and we specifically focus on this novel evidence. RECENT FINDINGS: Recent research aimed at developing new pharmacological therapies to prevent muscle wasting has used ghrelin and molecules acting as synthetic ghrelin receptor agonists with different modalities of administration and with high selectivity for specific targeted tissues. Positive effects of these therapies were described in cancer cachexia and chemotherapy-induced muscle wasting. New insights into the mechanisms of action of ghrelin revealed how its pleiotropic effects should be ascribed both to systemic anti-inflammation effect and to muscle-specific action through the activation of the antiatrophic molecular cascade. SUMMARY: Growing interest arises from the identification of ghrelin as a valid and well tolerated therapeutic option to counteract structural and functional wasting derived from tumour growth. FAU - Molfino, Alessio AU - Molfino A AD - Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy. FAU - Formiconi, Alessandra AU - Formiconi A FAU - Rossi Fanelli, Filippo AU - Rossi Fanelli F FAU - Muscaritoli, Maurizio AU - Muscaritoli M LA - eng PT - Journal Article PT - Review PL - England TA - Curr Opin Clin Nutr Metab Care JT - Current opinion in clinical nutrition and metabolic care JID - 9804399 RN - 0 (Ghrelin) SB - IM MH - Cachexia/*drug therapy/etiology MH - Ghrelin/*therapeutic use MH - Humans MH - Muscular Atrophy/*drug therapy MH - Neoplasms/*complications MH - Wasting Syndrome/*drug therapy EDAT- 2014/06/07 06:00 MHDA- 2015/04/08 06:00 CRDT- 2014/06/07 06:00 AID - 10.1097/MCO.0000000000000075 [doi] PST - ppublish SO - Curr Opin Clin Nutr Metab Care. 2014 Sep;17(5):471-6. doi: 10.1097/MCO.0000000000000075. PMID- 24898895 OWN - NLM STAT- MEDLINE DA - 20140723 DCOM- 20150402 IS - 1432-1238 (Electronic) IS - 0342-4642 (Linking) VI - 40 IP - 8 DP - 2014 Aug TI - Acute respiratory distress syndrome in patients with malignancies. PG - 1106-14 LID - 10.1007/s00134-014-3354-0 [doi] AB - PURPOSE: Little attention has been given to ARDS in cancer patients, despite their high risk for pulmonary complications. We sought to describe outcomes in cancer patients with ARDS meeting the Berlin definition. METHODS: Data from a cohort of patients admitted to 14 ICUs between 1990 and 2011 were used for a multivariable analysis of risk factors for hospital mortality. RESULTS: Of 1,004 included patients (86 % with hematological malignancies and 14 % with solid tumors), 444 (44.2 %) had neutropenia. Admission SOFA score was 12 (10-13). Etiological categories were primary infection-related ARDS (n = 662, 65.9 %; 385 bacterial infections, 213 invasive aspergillosis, 64 Pneumocystis pneumonia); extrapulmonary septic shock-related ARDS (n = 225, 22.4 %; 33 % candidemia); noninfectious ARDS (n = 76, 7.6 %); and undetermined cause (n = 41, 4.1 %). Of 387 (38.6 %) patients given noninvasive ventilation (NIV), 276 (71 %) subsequently required endotracheal ventilation. Hospital mortality was 64 % overall. According to the Berlin definition, 252 (25.1 %) patients had mild, 426 (42.4 %) moderate and 326 (32.5 %) severe ARDS; mortality was 59, 63 and 68.5 %, respectively (p = 0.06). Mortality dropped from 89 % in 1990-1995 to 52 % in 2006-2011 (p < 0.0001). Solid tumors, primary ARDS, and later admission period were associated with lower mortality. Risk factors for higher mortality were allogeneic bone-marrow transplantation, modified SOFA, NIV failure, severe ARDS, and invasive fungal infection. CONCLUSIONS: In cancer patients, 90 % of ARDS cases are infection-related, including one-third due to invasive fungal infections. Mortality has decreased over time. NIV failure is associated with increased mortality. The high mortality associated with invasive fungal infections warrants specific studies of early treatment strategies. FAU - Azoulay, Elie AU - Azoulay E AD - Intensive Care Unit of the Saint-Louis University Hospital, Paris, France, elieazoulay.icm@sls.aphp.fr. FAU - Lemiale, Virginie AU - Lemiale V FAU - Mokart, Djamel AU - Mokart D FAU - Pene, Frederic AU - Pene F FAU - Kouatchet, Achille AU - Kouatchet A FAU - Perez, Pierre AU - Perez P FAU - Vincent, Francois AU - Vincent F FAU - Mayaux, Julien AU - Mayaux J FAU - Benoit, Dominique AU - Benoit D FAU - Bruneel, Fabrice AU - Bruneel F FAU - Meert, Anne-Pascale AU - Meert AP FAU - Nyunga, Martine AU - Nyunga M FAU - Rabbat, Antoine AU - Rabbat A FAU - Darmon, Michael AU - Darmon M LA - eng PT - Journal Article DEP - 20140605 PL - United States TA - Intensive Care Med JT - Intensive care medicine JID - 7704851 SB - IM CIN - Intensive Care Med. 2014 Aug;40(8):1168-70. PMID: 25023529 MH - Aged MH - Bone Marrow Transplantation/adverse effects MH - Female MH - Humans MH - Intensive Care Units MH - Leukemia/complications MH - Lung Diseases/complications MH - Lymphoma/complications MH - Male MH - Middle Aged MH - Mycoses/complications MH - Neoplasms/*complications MH - Neutropenia/complications MH - Respiratory Distress Syndrome, Adult/*etiology/mortality MH - Risk Factors EDAT- 2014/06/06 06:00 MHDA- 2015/04/04 06:00 CRDT- 2014/06/06 06:00 PHST- 2014/03/07 [received] PHST- 2014/05/23 [accepted] PHST- 2014/06/05 [aheadofprint] AID - 10.1007/s00134-014-3354-0 [doi] PST - ppublish SO - Intensive Care Med. 2014 Aug;40(8):1106-14. doi: 10.1007/s00134-014-3354-0. Epub 2014 Jun 5. PMID- 24898674 OWN - NLM STAT- MEDLINE DA - 20140716 DCOM- 20150413 IS - 1435-2451 (Electronic) IS - 1435-2443 (Linking) VI - 399 IP - 6 DP - 2014 Aug TI - Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy. PG - 773-81 LID - 10.1007/s00423-014-1217-3 [doi] AB - PURPOSE: With improved chemotherapeutic regimens, metastasized gastric cancer may show a good response rendering an initially unresectable tumor resectable. We performed a retrospective analysis on the outcome of stage IV gastric cancer patients treated by chemotherapy followed by oncologic resection in a western institution. METHODS: From August 1988 to December 2010, a total number of 1,817 patients underwent surgery for gastric cancer at the Department of Surgery, Technical University of Munich. A retrospective analysis of our prospective gastric cancer database identified 58 patients with stage IV gastric cancer having undergone induction chemotherapy followed by surgery in an individualized treatment concept. After induction chemotherapy usually consisting of 2 cycles of PLF (cisplatin, 5-fluorouracil, leucovorin), resection was performed with or without removal of metastases in patients without disease progression. Patients were followed up until death or loss to follow up. RESULTS: The three most common metastatic locations were liver (27.6 %), distant lymph nodes (22.4 %), and peritoneum (19.0 %). Of patients, 13.8 % had metastases in more than one location. Thirty-day mortality was 5.2 %, 90-day mortality was 13.8 %, while overall postoperative morbidity accounted for 24 %. In 19 (32.8 %) patients, a complete resection without any macroscopic tumor residues was achieved. In 39 (67.2 %) patients, tumors could not be completely removed with either local residual disease or residual disease at distant sites. Overall median survival was 20 months, while patients without residual tumor survived significantly longer (72 months) than patients with residual disease (12 months, p = 0.001). CONCLUSION: Secondary surgery of metastasized gastric cancer may be justified in selected cases without progression under induction chemotherapy. An achievable complete removal of the primary tumor and metastases appears the main selection criterion for patients benefitting from this approach. FAU - Novotny, Alexander R AU - Novotny AR AD - Department of Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany, alexander.novotny@tum.de. FAU - Reim, Daniel AU - Reim D FAU - Friess, Helmut M AU - Friess HM FAU - Schuhmacher, Christoph AU - Schuhmacher C LA - eng PT - Journal Article DEP - 20140605 PL - Germany TA - Langenbecks Arch Surg JT - Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie JID - 9808285 RN - 0 (Antineoplastic Agents) RN - 12001-76-2 (Vitamin B Complex) RN - Q20Q21Q62J (Cisplatin) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) SB - IM MH - Adenocarcinoma/drug therapy/pathology/*surgery MH - Aged MH - Antineoplastic Agents/administration & dosage MH - Cisplatin/administration & dosage MH - Esophageal Neoplasms/drug therapy/pathology/*surgery MH - Female MH - Fluorouracil/administration & dosage MH - *Gastrectomy MH - Humans MH - *Induction Chemotherapy MH - Leucovorin/administration & dosage MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Retrospective Studies MH - Stomach Neoplasms/drug therapy/pathology/*surgery MH - Treatment Outcome MH - Vitamin B Complex/administration & dosage EDAT- 2014/06/06 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/06/06 06:00 PHST- 2014/03/06 [received] PHST- 2014/05/26 [accepted] PHST- 2014/06/05 [aheadofprint] AID - 10.1007/s00423-014-1217-3 [doi] PST - ppublish SO - Langenbecks Arch Surg. 2014 Aug;399(6):773-81. doi: 10.1007/s00423-014-1217-3. Epub 2014 Jun 5. PMID- 24890168 OWN - NLM STAT- MEDLINE DA - 20140603 DCOM- 20150406 IS - 0366-6999 (Print) IS - 0366-6999 (Linking) VI - 127 IP - 11 DP - 2014 TI - Lycopene can reduce prostate-specific antigen velocity in a phase II clinical study in Chinese population. PG - 2143-6 AB - BACKGROUND: Epidemiological studies have shown that lycopene has anti-prostate cancer effect. In vitro tests also confirmed that it can promote apoptosis of prostate cancer cells. We investigated the effect of whole-tomato supplement lycopene on the prostate-specific antigen velocity in selected prostate cancer patients. METHODS: Twenty selected prostate cancer patients were given whole-tomato supplement lycopene 10 mg per day for about 6 months. Blood samples of patients were collected weekly to measure serum prostate-specific antigen (PSA) values. PSA velocity slope, which reflects the change of PSA, and the degree of change were also calculated. By comparing the values of average PSA velocity slope (rise or fall of PSA) before and after the administration of lycopene, the effect of lycopene can be evaluated. Blood chemistry analysis was regular followed as safety control. RESULTS: Three patients in the research group withdrew within 3 weeks because of inability to conform. The rest 17 patients continued for an average period of 6 months. Two patients withdrew because of cancer progression (PSA rise) who later received active treatment. The average fall in PSA was equivalent to 2.56% over (i.e. an average slope/d of -0.000 28) the first 3 months. In the last 3 months, average fall in PSA was equivalent to 31.58% (i.e. an average slope/d of -0.003 51). The Wilcoxon rank-sum test showed a statistically significant decrease of PSA velocity slope overall (P = 0.000 9). Analysis of the PSA doubling time (pre- vs. post-treatment) showed a median increase over 3 months but this was not statistically significant (P = 0.21). No toxic side effect was observed during the whole process. The results indicate that the average PSA change is "decline" in patients, and the degree of the decline is accelerated. CONCLUSION: Administration of lycopene was able to reduce PSA velocity in this study group. FAU - Zhang, Xin AU - Zhang X AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100020, China. FAU - Yang, Yong AU - Yang Y AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100020, China. FAU - Wang, Qi AU - Wang Q AD - Department of Urology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. Email: wangqi6@medmail.com.cn. LA - eng PT - Clinical Trial, Phase II PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - Chin Med J (Engl) JT - Chinese medical journal JID - 7513795 RN - 36-88-4 (Carotenoids) RN - EC 3.4.21.77 (Prostate-Specific Antigen) RN - SB0N2N0WV6 (lycopene) SB - IM MH - Aged MH - Carotenoids/*therapeutic use MH - Dietary Supplements MH - Female MH - Humans MH - Male MH - Prostate-Specific Antigen/*metabolism MH - Prostatic Neoplasms/*blood/*drug therapy EDAT- 2014/06/04 06:00 MHDA- 2015/04/07 06:00 CRDT- 2014/06/04 06:00 PST - ppublish SO - Chin Med J (Engl). 2014;127(11):2143-6. PMID- 24886695 OWN - NLM STAT- MEDLINE DA - 20140725 DCOM- 20150331 LR - 20150402 IS - 1878-5875 (Electronic) IS - 1357-2725 (Linking) VI - 53 DP - 2014 Aug TI - Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. PG - 514-9 LID - 10.1016/j.biocel.2014.05.033 [doi] LID - S1357-2725(14)00191-5 [pii] AB - Loss of function of the succinate dehydrogenase complex characterizes a rare group of human tumors including some gastrointestinal stromal tumors, paragangliomas, renal carcinomas, and pituitary adenomas, and these can all be characterized as SDH-deficient tumors. Approximately 7.5% of gastric gastrointestinal stromal tumors are SDH-deficient and not driven by KIT/PDGFRA mutations, as are most other GISTs. The occurrence of SDH-deficient GISTs is restricted to stomach, and they typically occur in children and young adults representing a spectrum of clinical behavior from indolent to progressive. Slow progression is a common feature even after metastatic spread has taken place, and many patients live years with metastases. SDH-deficient GISTs have characteristic morphologic features including multinodular gastric wall involvement, often multiple separate tumors, common lymphovascular invasion, and occasional lymph node metastases. Diagnostic is the loss of succinate dehydrogenase subunit B (SDHB) from the tumor cells and this can be practically assessed by immunohistochemistry. SDHA is lost in cases associated with SDHA mutations. Approximately half of the patients have SDH subunit gene mutations, often germline and most commonly A (30%), and B, C or D (together 20%), with both alleles inactivated in the tumor cells according to the classic tumor suppressor gene model. Half of the cases are not associated with SDH-mutations and epigenetic silencing of the SDH complex is the possible pathogenesis. Extensive genomic methylation has been observed in these tumors, which is in contrast with other GISTs. SDH-loss causes succinate accumulation and activation of pseudohypoxia signaling via overexpression of HIF-proteins. Activation of insulin-like growth factor 1-signaling is also typical of these tumors. SDH-deficient GISTs are a unique group of GISTs with an energy metabolism defect as the key oncogenic mechanism. This article is part of a Directed Issue entitled: Rare Cancers. CI - Published by Elsevier Ltd. FAU - Miettinen, Markku AU - Miettinen M AD - Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA. Electronic address: miettinenmm@mail.nih.gov. FAU - Lasota, Jerzy AU - Lasota J AD - Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA. LA - eng GR - ZID BC011291-04/Intramural NIH HHS/United States PT - Journal Article PT - Review DEP - 20140602 PL - Netherlands TA - Int J Biochem Cell Biol JT - The international journal of biochemistry & cell biology JID - 9508482 RN - 0 (Membrane Proteins) RN - 0 (SDHC protein, human) RN - 0 (SDHD protein, human) RN - 0 (Somatomedins) RN - EC 1.3.5.1 (Electron Transport Complex II) RN - EC 1.3.5.1 (SDHA protein, human) RN - EC 1.3.5.1 (SDHB protein, human) RN - EC 1.3.99.1 (Succinate Dehydrogenase) SB - IM MH - DNA Methylation/genetics MH - Electron Transport Complex II/deficiency/*genetics MH - Energy Metabolism/genetics MH - Gastrointestinal Stromal Tumors/enzymology/epidemiology/*genetics/pathology MH - Genetic Predisposition to Disease MH - Humans MH - Membrane Proteins/deficiency/*genetics MH - Mutation MH - Somatomedins/metabolism MH - Succinate Dehydrogenase/deficiency/*genetics PMC - PMC4112081 MID - NIHMS612951 OID - NLM: NIHMS612951 [Available on 08/01/15] OID - NLM: PMC4112081 [Available on 08/01/15] OTO - NOTNLM OT - GIST OT - Gastrointestinal stromal tumor OT - SDH-complex OT - SDHA OT - SDHB EDAT- 2014/06/03 06:00 MHDA- 2015/04/01 06:00 CRDT- 2014/06/03 06:00 PMCR- 2015/08/01 00:00 PHST- 2014/02/28 [received] PHST- 2014/05/20 [revised] PHST- 2014/05/21 [accepted] PHST- 2014/06/02 [aheadofprint] AID - S1357-2725(14)00191-5 [pii] AID - 10.1016/j.biocel.2014.05.033 [doi] PST - ppublish SO - Int J Biochem Cell Biol. 2014 Aug;53:514-9. doi: 10.1016/j.biocel.2014.05.033. Epub 2014 Jun 2. PMID- 24880091 OWN - NLM STAT- MEDLINE DA - 20140725 DCOM- 20150331 IS - 1878-5875 (Electronic) IS - 1357-2725 (Linking) VI - 53 DP - 2014 Aug TI - Extracellular-signal-regulated kinase 5 modulates the antioxidant response by transcriptionally controlling Sirtuin 1 expression in leukemic cells. PG - 253-61 LID - 10.1016/j.biocel.2014.05.026 [doi] LID - S1357-2725(14)00184-8 [pii] AB - Cancer cell metabolism differs from that of non-transformed cells in the same tissue. This specific metabolism gives tumor cells growing advantages besides the effect in increasing anabolism. One of these advantages is immune evasion mediated by a lower expression of the mayor histocompatibility complex class I molecules. The extracellular-signal-regulated kinase-5 regulates both mayor histocompatibility complex class I expression and metabolic activity. However, the mechanisms underlying are largely unknown. We show here that extracellular-signal-regulated kinase-5 regulates the transcription of the NADH(+)-dependent histone deacetylase silent mating type information regulation 2 homolog 1 (Sirtuin 1) in leukemic Jurkat T cells. This involves the activation of the transcription factor myocyte enhancer factor-2 and its binding to the sirt1 promoter. In addition, extracellular-signal-regulated kinase-5 is required for T cell receptor-induced and oxidative stress-induced full Sirtuin 1 expression. Extracellular-signal-regulated kinase-5 induces the expression of promoters containing the antioxidant response elements through a Sirtuin 1-dependent pathway. On the other hand, down modulation of extracellular-signal-regulated kinase-5 expression impairs the anti-oxidant response. Notably, the extracellular-signal-regulated kinase-5 inhibitor BIX02189 induces apoptosis in acute myeloid leukemia tumor cells without affecting T cells from healthy donors. Our results unveil a new pathway that modulates metabolism in tumor cells. This pathway represents a promising therapeutic target in cancers with deep metabolic layouts such as acute myeloid leukemia. CI - Copyright (c) 2014 Elsevier Ltd. All rights reserved. FAU - Lopez-Royuela, Nuria AU - Lopez-Royuela N AD - INSERM, U1040, Universite de Montpellier 1, UFR Medecine, 80 av. Augustin Fliche, 34295 Montpellier Cedex 5, France. FAU - Rathore, Moeez G AU - Rathore MG AD - INSERM, U1040, Universite de Montpellier 1, UFR Medecine, 80 av. Augustin Fliche, 34295 Montpellier Cedex 5, France. FAU - Allende-Vega, Nerea AU - Allende-Vega N AD - INSERM, U1040, Universite de Montpellier 1, UFR Medecine, 80 av. Augustin Fliche, 34295 Montpellier Cedex 5, France. FAU - Annicotte, Jean-Sebastien AU - Annicotte JS AD - European Genomic Institute for Diabetes (EGID), CNRS UMR 8199, Lille2 University, F-59000 Lille, France. FAU - Fajas, Lluis AU - Fajas L AD - Department of Physiology, Universite de Lausanne, Rue du Bugnon 7, CH1005 Lausanne, Switzerland. FAU - Ramachandran, Bindu AU - Ramachandran B AD - Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA. FAU - Gulick, Tod AU - Gulick T AD - Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA. FAU - Villalba, Martin AU - Villalba M AD - INSERM, U1040, Universite de Montpellier 1, UFR Medecine, 80 av. Augustin Fliche, 34295 Montpellier Cedex 5, France; Institut de Recherche en Biotherapie (IRB), CHU Montpellier, 34295 Montpellier, France. Electronic address: martin.villalba@inserm.fr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140528 PL - Netherlands TA - Int J Biochem Cell Biol JT - The international journal of biochemistry & cell biology JID - 9508482 RN - 0 (Antioxidants) RN - EC 2.7.11.24 (MAPK7 protein, human) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 7) RN - EC 3.5.1.- (Sirtuin 1) SB - IM MH - Antioxidant Response Elements/*genetics MH - Antioxidants/*metabolism MH - Apoptosis/genetics MH - Gene Expression Regulation, Leukemic MH - Humans MH - Jurkat Cells MH - Leukemia/*genetics/metabolism/pathology MH - Mitochondria/genetics/metabolism/pathology MH - Mitogen-Activated Protein Kinase 7/biosynthesis/*metabolism MH - Oxidative Phosphorylation MH - Signal Transduction/genetics MH - Sirtuin 1/*biosynthesis OTO - NOTNLM OT - Anti-oxidant response elements (ARE) OT - ERK5 OT - Mitochondria OT - Oxidative phosphorylation OT - Sirt1 EDAT- 2014/06/01 06:00 MHDA- 2015/04/01 06:00 CRDT- 2014/06/01 06:00 PHST- 2014/01/10 [received] PHST- 2014/04/17 [revised] PHST- 2014/05/19 [accepted] PHST- 2014/05/28 [aheadofprint] AID - S1357-2725(14)00184-8 [pii] AID - 10.1016/j.biocel.2014.05.026 [doi] PST - ppublish SO - Int J Biochem Cell Biol. 2014 Aug;53:253-61. doi: 10.1016/j.biocel.2014.05.026. Epub 2014 May 28. PMID- 24878452 OWN - NLM STAT- MEDLINE DA - 20141202 DCOM- 20150413 IS - 1532-7361 (Electronic) IS - 0039-6060 (Linking) VI - 156 IP - 5 DP - 2014 Nov TI - The incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices. PG - 1145-52 LID - 10.1016/j.surg.2014.04.020 [doi] LID - S0039-6060(14)00190-1 [pii] AB - BACKGROUND: The connection between high body mass index (BMI), risk of papillary thyroid carcinoma (PTC), and the aggressiveness of PTC is still debated. We aimed to establish the relationship between excess BMI and the risk of PTC in an operative population, and the impact of obesity on histopathologic aggressiveness of PTC and on the outcome of patients. METHODS: All consecutive patients who underwent thyroid operation from June 2002 to December 2009 were reviewed in this retrospective study. BMI groupings were based on standardized categories: normal-weight, overweight, and obesity. We performed a total thyroidectomy with lymph node dissection in patients with preoperative or operative diagnosis of PTC. Radioiodine ablation was performed in every N1 patient, in case of tumor size greater than 10 mm, and if there was extrathyroidal invasion. During a median follow-up of 6.2 years, patients who were retreated by operation or (131)I were considered to have a persistent (<18 months of the initial operative treatment) or recurrent (>/= 18 months) disease. RESULTS: Of 6,684 patients who had a thyroid gland resection, we identified 1,216 (18.2%) patients with PTC. Patients who were overweight or obese were not at greater risk of PTC than normal-weight subjects. Indications for operation or radioiodine therapy were similar in the three BMI groups. During follow-up, 86 patients (7.1%) experienced persistent (4.5%) or recurrent (2.5%) disease. When excluding micro-PTCs (/= BMI < 30 kg/m(2) (P = .03). This difference was clearly marked for persistence. When adjusted for other cofounder factors, we observed that BMI was an independent factor associated with the risk of postoperative locoregional event (odds ratio 3.8, 95% confidence interval 1.6-8.8), with sex, age, lymph node metastasis, and tumor bilaterality. CONCLUSION: In macro-PTC, obese patients had an increased risk of developing a locoregional event during the follow-up, specifically a persistence of the disease. According to these results, overweight and obese patients with macro-PTC should be monitored more carefully for early detection of cancer persistence. CI - Copyright (c) 2014 Elsevier Inc. All rights reserved. FAU - Tresallet, Christophe AU - Tresallet C AD - Department of General, Digestive and Endocrine Surgery, Pierre-et-Marie Curie University (Paris VI), Assistance Publique des Hopitaux de Paris (APHP), Paris, France. Electronic address: christophe.tresallet@psl.aphp.fr. FAU - Seman, Marie AU - Seman M AD - Department of General, Digestive and Endocrine Surgery, Pierre-et-Marie Curie University (Paris VI), Assistance Publique des Hopitaux de Paris (APHP), Paris, France. FAU - Tissier, Frederique AU - Tissier F AD - Department of Pathology, Pierre-et-Marie Curie University (Paris VI), Assistance Publique des Hopitaux de Paris (APHP), Paris, France. FAU - Buffet, Camille AU - Buffet C AD - Department of Nuclear Medicine, Pitie-Salpetriere Hospital, Pierre-et-Marie Curie University (Paris VI), Assistance Publique des Hopitaux de Paris (APHP), Paris, France. FAU - Lupinacci, Renato Micelli AU - Lupinacci RM AD - Department of General, Digestive and Endocrine Surgery, Pierre-et-Marie Curie University (Paris VI), Assistance Publique des Hopitaux de Paris (APHP), Paris, France. FAU - Vuarnesson, Helene AU - Vuarnesson H AD - Department of General, Digestive and Endocrine Surgery, Pierre-et-Marie Curie University (Paris VI), Assistance Publique des Hopitaux de Paris (APHP), Paris, France. FAU - Leenhardt, Laurence AU - Leenhardt L AD - Department of Nuclear Medicine, Pitie-Salpetriere Hospital, Pierre-et-Marie Curie University (Paris VI), Assistance Publique des Hopitaux de Paris (APHP), Paris, France. FAU - Menegaux, Fabrice AU - Menegaux F AD - Department of General, Digestive and Endocrine Surgery, Pierre-et-Marie Curie University (Paris VI), Assistance Publique des Hopitaux de Paris (APHP), Paris, France. LA - eng PT - Journal Article DEP - 20140527 PL - United States TA - Surgery JT - Surgery JID - 0417347 RN - Thyroid cancer, papillary SB - AIM SB - IM MH - Adult MH - Aged MH - Body Mass Index MH - Carcinoma/complications/*epidemiology/surgery MH - Female MH - France/epidemiology MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology/etiology MH - Obesity/*complications MH - Retrospective Studies MH - Thyroid Neoplasms/complications/*epidemiology/surgery MH - Thyroidectomy MH - Treatment Outcome EDAT- 2014/06/01 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/06/01 06:00 PHST- 2013/12/07 [received] PHST- 2014/04/14 [accepted] PHST- 2014/05/27 [aheadofprint] AID - S0039-6060(14)00190-1 [pii] AID - 10.1016/j.surg.2014.04.020 [doi] PST - ppublish SO - Surgery. 2014 Nov;156(5):1145-52. doi: 10.1016/j.surg.2014.04.020. Epub 2014 May 27. PMID- 24876728 OWN - NLM STAT- MEDLINE DA - 20140530 DCOM- 20150413 LR - 20150104 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 20 DP - 2014 May 28 TI - Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. PG - 6055-72 LID - 10.3748/wjg.v20.i20.6055 [doi] AB - Colorectal cancer (CRC) is one of the leading causes of cancer and cancer-related mortality worldwide. The disease has been traditionally a major health problem in industrial countries, however the CRC rates are increasing in the developing countries that are undergoing economic growth. Several environmental risk factors, mainly changes in diet and life style, have been suggested to underlie the rise of CRC in these populations. Diet and lifestyle impinge on nuclear receptors, on the intestinal microbiota and on crucial molecular pathways that are implicated in intestinal carcinogenesis. In this respect, the epidemiological transition in several regions of the world offers a unique opportunity to better understand CRC carcinogenesis by studying the disease phenotypes and their environmental and molecular associations in different populations. The data from these studies may have important implications for the global prevention and treatment of CRC. FAU - Bishehsari, Faraz AU - Bishehsari F AD - Faraz Bishehsari, Division of Gastroenterology, Robert H Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United States. FAU - Mahdavinia, Mahboobeh AU - Mahdavinia M AD - Faraz Bishehsari, Division of Gastroenterology, Robert H Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United States. FAU - Vacca, Michele AU - Vacca M AD - Faraz Bishehsari, Division of Gastroenterology, Robert H Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United States. FAU - Malekzadeh, Reza AU - Malekzadeh R AD - Faraz Bishehsari, Division of Gastroenterology, Robert H Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United States. FAU - Mariani-Costantini, Renato AU - Mariani-Costantini R AD - Faraz Bishehsari, Division of Gastroenterology, Robert H Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United States. LA - eng GR - MC_UP_A090_1006/Medical Research Council/United Kingdom GR - T32 CA079447/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 RN - 0 (Receptors, Cytoplasmic and Nuclear) SB - IM MH - Colorectal Neoplasms/*epidemiology/*prevention & control/*therapy MH - Developing Countries MH - Diet MH - Environment MH - Epigenesis, Genetic MH - Food Habits MH - Global Health MH - Humans MH - Intestines/microbiology MH - Life Style MH - Microbiota MH - Obesity/complications MH - Phenotype MH - Receptors, Cytoplasmic and Nuclear/metabolism MH - Risk Factors PMC - PMC4033445 OID - NLM: PMC4033445 OTO - NOTNLM OT - Colorectal cancer OT - Developing countries OT - Diet OT - Environment OT - Gut microbiota OT - Nuclear receptors EDAT- 2014/05/31 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/05/31 06:00 PHST- 2013/09/29 [received] PHST- 2014/02/20 [revised] PHST- 2014/04/15 [accepted] AID - 10.3748/wjg.v20.i20.6055 [doi] PST - ppublish SO - World J Gastroenterol. 2014 May 28;20(20):6055-72. doi: 10.3748/wjg.v20.i20.6055. PMID- 24866433 OWN - NLM STAT- MEDLINE DA - 20140705 DCOM- 20150330 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 21 IP - 8 DP - 2014 Aug TI - Shorter dinner-to-bed time is associated with gastric cardia adenocarcinoma risk partly in a reflux-dependent manner. PG - 2615-9 LID - 10.1245/s10434-014-3628-3 [doi] AB - BACKGROUND: Gastric cancer remains the second cause of cancer-related death worldwide. The aim of this study was to investigate the effects of shorter dinner-to-bed time, post-dinner walk, and obesity on gastric cardia adenocarcinoma (GCA) risk. METHODS: The study subjects consisted of 146 GCA patients and 166 healthy controls roughly matched by gender and age. Conditional logistic regression was used to calculated odds ratio (OR) and 95 % confidence intervals (CIs). RESULTS: The adjusted ORs of GCA for subjects with shorter dinner-to-bed time were 4.18 (95 % CI 2.10-8.33) compared with those with longer dinner-to-bed time. What is more, when reflux symptom was added into the multivariate models, risk estimate for shorter dinner-to-bed time decreased greatly, but still remained statistically significant (p = 0.007). Post-dinner walk was associated with a significantly decreased GCA risk (adjusted OR 0.54; 95 % CI 0.31-0.94). When subjects were analyzed according to post-dinner walk, the adjusted OR of GCA for shorter dinner-to-bed time relative to longer dinner-to-bed time was much higher for non-walking subjects (adjusted OR 20.21) than walking subjects (adjusted OR 1.39). We further found a significant interaction between shorter dinner-to-bed time and post-dinner walk regarding the risk of GCA (adjusted OR 0.07; p = 0.001). CONCLUSIONS: We found that shorter dinner-to-bed time was associated with significantly increased GCA risk, partly depending on reflux symptoms, while post-dinner walk was related to a significantly decreased GCA risk and could greatly attenuate the GCA risk attributable to shorter dinner-to-bed time. FAU - Song, Qingxu AU - Song Q AD - Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, People's Republic of China. FAU - Wang, Jianbo AU - Wang J FAU - Jia, Yibin AU - Jia Y FAU - Wang, Chuan AU - Wang C FAU - Wang, Nana AU - Wang N FAU - Tan, Bingxu AU - Tan B FAU - Ma, Wei AU - Ma W FAU - Guan, Shanghui AU - Guan S FAU - Jiang, Dong AU - Jiang D FAU - Cheng, Yufeng AU - Cheng Y LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140528 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Adenocarcinoma/*etiology/pathology MH - Cardia/*pathology MH - Case-Control Studies MH - Female MH - Follow-Up Studies MH - Gastroesophageal Reflux/*complications MH - Humans MH - Male MH - *Meals MH - Middle Aged MH - Neoplasm Staging MH - Obesity/*complications MH - Prognosis MH - Risk Factors MH - Stomach Neoplasms/*etiology/pathology MH - Time Factors MH - *Walking EDAT- 2014/05/29 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/05/29 06:00 PHST- 2013/12/04 [received] PHST- 2014/05/28 [aheadofprint] AID - 10.1245/s10434-014-3628-3 [doi] PST - ppublish SO - Ann Surg Oncol. 2014 Aug;21(8):2615-9. doi: 10.1245/s10434-014-3628-3. Epub 2014 May 28. PMID- 24858413 OWN - NLM STAT- MEDLINE DA - 20140818 DCOM- 20150413 IS - 1881-2090 (Electronic) IS - 0023-5679 (Linking) VI - 60 IP - 3-4 DP - 2014 TI - Production of ghrelin by the stomach of patients with gastric cancer. PG - 99-104 AB - Poor nutrition and weight loss are important factors contributing to poor quality of life (QOL) after gastrectomy in patients with gastric cancer. Ghrelin is a hormone produced by the stomach that, plays a role in appetite increase and fat storage. The present study aims to clarify the location of ghrelin mRNA in the stomach, changes in blood ghrelin concentrations after gastrectomy and whether or not they are associated with the reconstruction method in patients with gastric cancer. We collected seven normal mucosa samples from different parts of six totally resected stomachs with gastric cancer. We extracted RNA from the normal mucosa, synthesized cDNA from total RNA (1 mug), and then quantified ghrelin mRNA using quantitative real-time polymerase chain reaction (Q-PCR). Ghrelin blood concentrations were measured using enzyme-linked immunosorbent assay (ELISA) kits in 74 patients with gastric cancer (total gastrectomy (TG), n=23; distal gastrectomy (DG), n=30; proximal gastrectomy (PG), n=11; pylorus preserving gastrectomy (PPG), n=10). In order, the ghrelin gene was expressed most frequently in the gastric body, followed by the fornix, cardia, antrum and pylorus ring. Blood ghrelin concentrations after surgery similarly changed in all groups. The average blood ghrelin concentrations were significantly higher in the DG and PPG groups than in the TG group on postoperative days (POD) 1, 7, 30, 90 and 180. However, blood ghrelin concentrations did not significantly differ between the DG and TG groups on POD 270 and 360. Cells that produce ghrelin are supposed to be located mostly in the fundic gland of the stomach. We speculate that the production of ghrelin from other organs increases from around nine months after total gastrectomy. Therefore, evaluating the nutritional status and the weight of patients at nine months after total gastrectomy is important to help these patients improve their QOL. FAU - Kizaki, Junya AU - Kizaki J AD - Department of Surgery, Kurume University School of Medicine. FAU - Aoyagi, Keishiro AU - Aoyagi K FAU - Sato, Takahiro AU - Sato T FAU - Kojima, Masayasu AU - Kojima M FAU - Shirouzu, Kazuo AU - Shirouzu K LA - eng PT - Comparative Study PT - Journal Article DEP - 20140526 PL - Japan TA - Kurume Med J JT - The Kurume medical journal JID - 2985210R RN - 0 (GHRL protein, human) RN - 0 (Ghrelin) RN - 0 (RNA, Messenger) RN - 0 (Tumor Markers, Biological) SB - IM MH - Adult MH - Aged MH - Body Mass Index MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Gastrectomy/methods MH - Gastric Mucosa/chemistry MH - Ghrelin/blood/*genetics MH - Humans MH - Male MH - Middle Aged MH - Nutritional Status MH - RNA, Messenger/analysis MH - Real-Time Polymerase Chain Reaction MH - Stomach/*chemistry/pathology/surgery MH - Stomach Neoplasms/blood/*genetics/pathology/surgery MH - Time Factors MH - Treatment Outcome MH - Tumor Markers, Biological/blood/*genetics EDAT- 2014/05/27 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/05/27 06:00 PHST- 2014/05/26 [aheadofprint] AID - DN/JST.JSTAGE/kurumemedj/MS63012 [pii] PST - ppublish SO - Kurume Med J. 2014;60(3-4):99-104. Epub 2014 May 26. PMID- 24855125 OWN - NLM STAT- MEDLINE DA - 20140813 DCOM- 20150410 IS - 1460-2091 (Electronic) IS - 0305-7453 (Linking) VI - 69 IP - 9 DP - 2014 Sep TI - Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. PG - 2556-62 LID - 10.1093/jac/dku150 [doi] AB - OBJECTIVES: Information on the efficacy of extended meropenem administration in neutropenic patients is scarce. Our objective was to determine whether the administration of meropenem in a 4 h extended infusion (EI) leads to a better clinical outcome in patients with febrile neutropenia than the conventional short infusion (SI). METHODS: This was a retrospective observational study. The subjects were neutropenic patients who presented with fever after receiving haematopoietic stem-cell transplantation or induction chemotherapy for acute myeloid leukaemia. The primary endpoint was the success of treatment after 5 days of meropenem therapy, defined as follows: the disappearance of fever leading to a maintained (>/= 24 h) feverless state; the resolution or improvement of the clinical signs and symptoms of infection; the absence of persistent or breakthrough bacteraemia; and no additional antibiotics prescribed because of an unsatisfactory clinical evolution. RESULTS: Eighty-eight patients received meropenem (1 g/8 h) in SI and 76 received the same dose in EI. Treatment success on day 5 was superior in the EI group [52/76 (68.4%) versus 36/88 (40.9%); P<0.001]. Meropenem administered in EI was independently associated with success (OR 3.13, 95% CI 1.61-6.10). Fewer additional antibiotics were prescribed in the EI group during the first 5 days of treatment [20/76 (26.3%) versus 44/88 (50.0%); P=0.002]. Using Kaplan-Meier survival analysis a more prompt defervescence and a faster decrease in C-reactive protein concentration were observed in the EI group (P=0.021 and P=0.037, respectively). There were no significant differences in the length of hospital stay and in the mortality rate. CONCLUSIONS: Meropenem administration in EI results in a better clinical outcome for febrile neutropenia episodes, with fewer additional antibiotics needed. CI - (c) The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. FAU - Feher, Csaba AU - Feher C AD - Department of Infectious Diseases, Hospital Clinic, Barcelona, Spain cfeher@clinic.ub.es. FAU - Rovira, Montserrat AU - Rovira M AD - Department of Haematology and Bone Marrow Transplant Unit, Hospital Clinic, Barcelona, Spain August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. FAU - Soriano, Alex AU - Soriano A AD - Department of Infectious Diseases, Hospital Clinic, Barcelona, Spain August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain University of Barcelona, Barcelona, Spain. FAU - Esteve, Jordi AU - Esteve J AD - Department of Haematology and Bone Marrow Transplant Unit, Hospital Clinic, Barcelona, Spain August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. FAU - Martinez, Jose Antonio AU - Martinez JA AD - Department of Infectious Diseases, Hospital Clinic, Barcelona, Spain August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. FAU - Marco, Francesc AU - Marco F AD - Microbiology Service, Hospital Clinic, Barcelona, Spain Barcelona Centre for International Health Research (CRESIB), Hospital Clinic-University of Barcelona, Barcelona, Spain. FAU - Carreras, Enric AU - Carreras E AD - Department of Haematology and Bone Marrow Transplant Unit, Hospital Clinic, Barcelona, Spain August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. FAU - Martinez, Carmen AU - Martinez C AD - Department of Haematology and Bone Marrow Transplant Unit, Hospital Clinic, Barcelona, Spain August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. FAU - Fernandez-Aviles, Francesc AU - Fernandez-Aviles F AD - Department of Haematology and Bone Marrow Transplant Unit, Hospital Clinic, Barcelona, Spain August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. FAU - Suarez-Lledo, Maria AU - Suarez-Lledo M AD - Department of Haematology and Bone Marrow Transplant Unit, Hospital Clinic, Barcelona, Spain August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. FAU - Mensa, Josep AU - Mensa J AD - Department of Infectious Diseases, Hospital Clinic, Barcelona, Spain August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20140522 PL - England TA - J Antimicrob Chemother JT - The Journal of antimicrobial chemotherapy JID - 7513617 RN - 0 (Anti-Bacterial Agents) RN - 0 (Antineoplastic Agents) RN - 0 (Thienamycins) RN - FV9J3JU8B1 (meropenem) SB - IM MH - Adult MH - Anti-Bacterial Agents/*administration & dosage MH - Antineoplastic Agents/adverse effects MH - Febrile Neutropenia/*drug therapy MH - Female MH - Hematopoietic Stem Cell Transplantation/adverse effects MH - Humans MH - Infusions, Intravenous/*methods MH - Leukemia, Myeloid, Acute/*complications/therapy MH - Male MH - Middle Aged MH - Retrospective Studies MH - Thienamycins/*administration & dosage MH - Treatment Outcome OTO - NOTNLM OT - neutropenic fever OT - prolonged antibiotic infusion OT - β-lactams EDAT- 2014/05/24 06:00 MHDA- 2015/04/11 06:00 CRDT- 2014/05/24 06:00 PHST- 2014/05/22 [aheadofprint] AID - dku150 [pii] AID - 10.1093/jac/dku150 [doi] PST - ppublish SO - J Antimicrob Chemother. 2014 Sep;69(9):2556-62. doi: 10.1093/jac/dku150. Epub 2014 May 22. PMID- 24851067 OWN - NLM STAT- MEDLINE DA - 20140522 DCOM- 20150409 IS - 2005-6648 (Electronic) IS - 1226-3303 (Linking) VI - 29 IP - 3 DP - 2014 May TI - Follicular and Hurthle cell carcinoma of the thyroid in iodine-sufficient area: retrospective analysis of Korean multicenter data. PG - 325-33 LID - 10.3904/kjim.2014.29.3.325 [doi] AB - BACKGROUND/AIMS: Follicular thyroid carcinoma (FTC) and Hurthle cell carcinoma (HCC) of the thyroid are relatively uncommon thyroid malignancies in iodine-sufficient areas. In this study we evaluated the clinical behavior, prognostic factors and treatment outcomes of FTC and HCC in Korea. METHODS: This multicenter study included 483 patients with FTC and 80 patients with HCC who underwent an initial surgery between 1995 and 2006 in one of the four tertiary referral hospitals in Korea. We evaluated clinicopathological factors associated with distant metastases and recurrence during a median of 6 years of follow-up. RESULTS: HCC patients were significantly older (49 years vs. 43 years; p < 0.001) and had more lymphovascular invasions (22% vs. 14%; p = 0.03) compared with FTC patients. Distant metastases were confirmed in 40 patients (8%) in the FTC group and in two patients (3%) in the HCC group (p = 0.07). Distant metastases were significantly associated with older age, widely invasive cancer and extrathyroidal invasion. Only 14 patients (3%) had recurrent disease and there was no significant difference between FTC and HCC groups (p = 0.38). Recurrence was associated with larger tumor size and cervical lymph node metastasis. CONCLUSIONS: HCC patients were older and had more lymphovascular invasions than FTC patients. However, FTC and HCC patients had similar initial clinicopathological features. Older age, wide invasiveness and extrathyroidal invasion were independent risk factors for predicting distant metastases in FTC and HCC patients. FAU - Kim, Won Gu AU - Kim WG AD - Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Kim, Tae Yong AU - Kim TY AD - Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Kim, Tae Hyuk AU - Kim TH AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. FAU - Jang, Hye Won AU - Jang HW AD - Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jo, Young Suk AU - Jo YS AD - Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. FAU - Park, Young Joo AU - Park YJ AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. FAU - Kim, Sun Wook AU - Kim SW AD - Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kim, Won Bae AU - Kim WB AD - Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Shong, Minho AU - Shong M AD - Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. FAU - Park, Do Joon AU - Park do J AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. FAU - Chung, Jae Hoon AU - Chung JH AD - Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Shong, Young Kee AU - Shong YK AD - Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Cho, Bo Youn AU - Cho BY AD - Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20140429 PL - Korea (South) TA - Korean J Intern Med JT - The Korean journal of internal medicine JID - 8712418 RN - 9679TC07X4 (Iodine) RN - Thyroid cancer, Hurthle cell SB - IM CIN - Korean J Intern Med. 2014 May;29(3):305-6. PMID: 24851064 MH - Adenocarcinoma, Follicular/*epidemiology/secondary/surgery MH - Adult MH - Age Factors MH - *Diet MH - Female MH - Humans MH - *Iodine MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - *Nutritional Status MH - Republic of Korea/epidemiology MH - Retrospective Studies MH - Risk Factors MH - Tertiary Care Centers MH - Thyroid Neoplasms/*epidemiology/pathology/surgery MH - Thyroidectomy MH - Time Factors MH - Treatment Outcome PMC - PMC4028522 OID - NLM: PMC4028522 OTO - NOTNLM OT - Distant metastases OT - Follicular adenocarcinoma OT - Hurthle cell thyroid cancer OT - Iodine OT - Prognosis EDAT- 2014/05/23 06:00 MHDA- 2015/04/10 06:00 CRDT- 2014/05/23 06:00 PHST- 2013/04/30 [received] PHST- 2013/07/22 [revised] PHST- 2013/09/01 [accepted] PHST- 2014/04/29 [epublish] AID - 10.3904/kjim.2014.29.3.325 [doi] PST - ppublish SO - Korean J Intern Med. 2014 May;29(3):325-33. doi: 10.3904/kjim.2014.29.3.325. Epub 2014 Apr 29. PMID- 24851064 OWN - NLM STAT- MEDLINE DA - 20140522 DCOM- 20150409 IS - 2005-6648 (Electronic) IS - 1226-3303 (Linking) VI - 29 IP - 3 DP - 2014 May TI - Clinical implications of follicular and Hurthle cell carcinoma in an iodine-sufficient area. PG - 305-6 LID - 10.3904/kjim.2014.29.3.305 [doi] FAU - Shin, Dong Yeob AU - Shin DY AD - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. FAU - Jo, Young Suk AU - Jo YS AD - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. LA - eng PT - Comment PT - Editorial DEP - 20140429 PL - Korea (South) TA - Korean J Intern Med JT - The Korean journal of internal medicine JID - 8712418 RN - 9679TC07X4 (Iodine) RN - Thyroid cancer, Hurthle cell SB - IM CON - Korean J Intern Med. 2014 May;29(3):325-33. PMID: 24851067 MH - Adenocarcinoma, Follicular/*epidemiology MH - *Diet MH - Female MH - Humans MH - *Iodine MH - Male MH - *Nutritional Status MH - Thyroid Neoplasms/*epidemiology PMC - PMC4028519 OID - NLM: PMC4028519 EDAT- 2014/05/23 06:00 MHDA- 2015/04/10 06:00 CRDT- 2014/05/23 06:00 PHST- 2014/04/05 [received] PHST- 2014/04/07 [accepted] PHST- 2014/04/29 [epublish] AID - 10.3904/kjim.2014.29.3.305 [doi] PST - ppublish SO - Korean J Intern Med. 2014 May;29(3):305-6. doi: 10.3904/kjim.2014.29.3.305. Epub 2014 Apr 29. PMID- 24842106 OWN - NLM STAT- MEDLINE DA - 20140725 DCOM- 20150331 LR - 20150402 IS - 1878-5875 (Electronic) IS - 1357-2725 (Linking) VI - 53 DP - 2014 Aug TI - Mitophagy mechanisms and role in human diseases. PG - 127-33 LID - 10.1016/j.biocel.2014.05.010 [doi] LID - S1357-2725(14)00168-X [pii] AB - Mitophagy is a process of mitochondrial turnover through lysosomal mediated autophagy activities. This review will highlight recent studies that have identified mediators of mitophagy in response to starvation, loss of mitochondrial membrane potential or perturbation of mitochondrial integrity. Furthermore, we will review evidence of mitophagy dysfunction in various human diseases and discuss the potential for therapeutic interventions that target mitophagy processes. CI - Copyright (c) 2014 Elsevier Ltd. All rights reserved. FAU - Redmann, Matthew AU - Redmann M AD - Center for Free Radical Biology, University of Alabama at Birmingham, USA; Department of Pathology, University of Alabama at Birmingham, USA. FAU - Dodson, Matthew AU - Dodson M AD - Center for Free Radical Biology, University of Alabama at Birmingham, USA; Department of Pathology, University of Alabama at Birmingham, USA. FAU - Boyer-Guittaut, Michael AU - Boyer-Guittaut M AD - Universite de Franche-Comte, Laboratoire de Biochimie, EA3922, SFR IBCT FED4234, Sciences et Techniques, 16 route de Gray, 25030 Besancon Cedex, France. FAU - Darley-Usmar, Victor AU - Darley-Usmar V AD - Center for Free Radical Biology, University of Alabama at Birmingham, USA; Department of Pathology, University of Alabama at Birmingham, USA. FAU - Zhang, Jianhua AU - Zhang J AD - Center for Free Radical Biology, University of Alabama at Birmingham, USA; Department of Pathology, University of Alabama at Birmingham, USA; Department of Veterans Affairs, Birmingham VA Medical Center, AL 35294, USA. Electronic address: zhanja@uab.edu. LA - eng GR - R01 NS064090/NS/NINDS NIH HHS/United States GR - R01-NS064090/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Review DEP - 20140516 PL - Netherlands TA - Int J Biochem Cell Biol JT - The international journal of biochemistry & cell biology JID - 9508482 SB - IM MH - Heart Diseases/*genetics/metabolism/pathology MH - Humans MH - Membrane Potential, Mitochondrial MH - Mitochondrial Degradation/*genetics MH - Neoplasms/*genetics/metabolism/pathology MH - Parkinson Disease/*genetics/metabolism/pathology PMC - PMC4111979 MID - NIHMS598951 OID - NLM: NIHMS598951 [Available on 08/01/15] OID - NLM: PMC4111979 [Available on 08/01/15] OTO - NOTNLM OT - Cancer OT - Heart disease OT - Mitochondria OT - Mitophagy OT - Parkinson's disease EDAT- 2014/05/21 06:00 MHDA- 2015/04/01 06:00 CRDT- 2014/05/21 06:00 PMCR- 2015/08/01 00:00 PHST- 2013/12/24 [received] PHST- 2014/04/10 [revised] PHST- 2014/05/11 [accepted] PHST- 2014/05/16 [aheadofprint] AID - S1357-2725(14)00168-X [pii] AID - 10.1016/j.biocel.2014.05.010 [doi] PST - ppublish SO - Int J Biochem Cell Biol. 2014 Aug;53:127-33. doi: 10.1016/j.biocel.2014.05.010. Epub 2014 May 16. PMID- 24835673 OWN - NLM STAT- MEDLINE DA - 20140616 DCOM- 20150416 IS - 1879-2472 (Electronic) IS - 0049-3848 (Linking) VI - 134 IP - 1 DP - 2014 Jul TI - Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. PG - 93-5 LID - 10.1016/j.thromres.2014.04.028 [doi] LID - S0049-3848(14)00242-4 [pii] AB - INTRODUCTION: Patients with cancer-associated thrombosis are at a high risk of developing recurrent events despite anticoagulant therapy. Escalation of the dose of low molecular weight heparin (LMWH) has been suggested as a potential treatment option to manage these patients. We sought to confirm the benefit and risk of this management strategy in patients with recurrent cancer-associated thrombosis. MATERIAL AND METHODS: A retrospective cohort study of consecutive cancer outpatients seen for management of a symptomatic recurrent cancer-associated thrombosis while on anticoagulation was undertaken. Objectively confirmed episodes of recurrent thrombosis were treated with either dose escalation of LMWH or initiation of therapeutic dose of LMWH in patients already anticoagulated with LMWH or vitamin K antagonist (VKA) respectively. Included patients were followed for a minimum of 3 months after the index recurrent event. RESULTS: Fifty-five cancer patients with a recurrent venous thromboembolism (VTE) despite anticoagulation were included. At the time of the recurrence, 89% of patients were on LMWH. The median time between the initial cancer-associated thrombosis to the index recurrent event was 2.3 months (range 0.1 to 30.4 months). Four patients (7.3%; 95% CI: 2.0 to 17.6%) had a second recurrent VTE during the 3-month follow-up period. Three patients (5.5%; 95% CI 1.1 to 15.1%) had major bleeding complications after dose escalation of LMWH. There were no recurrent fatal VTE or major bleeding episodes. CONCLUSION: Escalating the dose of LMWH seems effective and safe for managing patients with recurrent cancer-associated thrombosis despite anticoagulant therapy. CI - Copyright (c) 2014 Elsevier Ltd. All rights reserved. FAU - Ihaddadene, Ryma AU - Ihaddadene R AD - Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario Canada. FAU - Le Gal, Gregoire AU - Le Gal G AD - Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario Canada; Departement de Medecine Interne, EA3878, University of Brest, Brest, France. FAU - Delluc, Aurelien AU - Delluc A AD - Departement de Medecine Interne, EA3878, University of Brest, Brest, France. FAU - Carrier, Marc AU - Carrier M AD - Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario Canada; Institut de Recherche de l'Hopital Montfort, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: mcarrier@ottawahospital.on.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140502 PL - United States TA - Thromb Res JT - Thrombosis research JID - 0326377 RN - 0 (Anticoagulants) RN - 0 (Heparin, Low-Molecular-Weight) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Anticoagulants/*therapeutic use MH - Cohort Studies MH - Dose-Response Relationship, Drug MH - Female MH - Heparin, Low-Molecular-Weight/*therapeutic use MH - Humans MH - Male MH - Middle Aged MH - Neoplasms/*blood/pathology MH - Retrospective Studies MH - Risk Assessment MH - Venous Thromboembolism/*drug therapy/pathology MH - Young Adult OTO - NOTNLM OT - Hemorrhage OT - Heparin OT - Low molecular weight OT - Neoplasm OT - Venous thromboembolism OT - Venous thrombosis EDAT- 2014/05/20 06:00 MHDA- 2015/04/17 06:00 CRDT- 2014/05/20 06:00 PHST- 2014/02/13 [received] PHST- 2014/03/25 [revised] PHST- 2014/04/25 [accepted] PHST- 2014/05/02 [aheadofprint] AID - S0049-3848(14)00242-4 [pii] AID - 10.1016/j.thromres.2014.04.028 [doi] PST - ppublish SO - Thromb Res. 2014 Jul;134(1):93-5. doi: 10.1016/j.thromres.2014.04.028. Epub 2014 May 2. PMID- 24832769 OWN - NLM STAT- MEDLINE DA - 20140708 DCOM- 20150408 IS - 1868-8500 (Electronic) IS - 1868-8497 (Linking) VI - 5 IP - 4 DP - 2014 Aug TI - Can non-thyroid illness syndrome predict mortality in lung cancer patients? A prospective cohort study. PG - 240-6 LID - 10.1007/s12672-014-0183-0 [doi] AB - This study aims to evaluate the incidence of non-thyroid illness syndrome (NTIS) among patients diagnosed as lung cancer and its association with the stage of the disease, Eastern Cooperative Oncology Group (ECOG) performance score, nutritional parameters, and survival. We enrolled 120 patients that 71 of them with newly diagnosed and staged non-small cell lung cancer and 49 of them small-cell lung cancer. The cases were examined for thyroid function tests, ECOG performance score, and nutritional evaluation before treatment. Also, cases were evaluated for their overall survival rates. NTIS was identified in 30 (42 %) of the 71 non-small cell lung cancer patients and 22 (44 %) of the 49 small-cell lung cancer patients. NTIS was more frequent among advanced stage of cases. Serum albumin level, cholesterol level, lymphocyte level, and body mass index were detected to be significantly low and ECOG performance score was significantly high in cases with NTIS when compared to cases without NTIS. NTIS was found to be negatively correlated with body mass index, ECOG performance score, and serum albumin level, and it was positively correlated with disease stage. NTIS was detected significantly as a poor prognostic factor for lung cancer. NTIS was frequently seen in cases with non-small cell lung cancer and small-cell lung cancer. NTIS can be used as a predictor of poor prognosis for lung cancer patients. FAU - Yasar, Zehra Asuk AU - Yasar ZA AD - Department of Chest Diseases, Abant Izzet Baysal University School of Medicine, Golkoy-Bolu, Turkey, zehraasuk@hotmail.com. FAU - Kirakli, Cenk AU - Kirakli C FAU - Yilmaz, Ufuk AU - Yilmaz U FAU - Ucar, Zeynep Zeren AU - Ucar ZZ FAU - Talay, Fahrettin AU - Talay F LA - eng PT - Journal Article DEP - 20140516 PL - United States TA - Horm Cancer JT - Hormones & cancer JID - 101518427 SB - IM MH - Aged MH - Carcinoma, Non-Small-Cell Lung/mortality MH - Cohort Studies MH - Euthyroid Sick Syndromes/*mortality MH - Female MH - Humans MH - Incidence MH - Lung Neoplasms/*mortality MH - Male MH - Middle Aged MH - Prospective Studies MH - Small Cell Lung Carcinoma/mortality MH - Turkey/epidemiology EDAT- 2014/05/17 06:00 MHDA- 2015/04/09 06:00 CRDT- 2014/05/17 06:00 PHST- 2014/03/11 [received] PHST- 2014/05/05 [accepted] PHST- 2014/05/16 [aheadofprint] AID - 10.1007/s12672-014-0183-0 [doi] PST - ppublish SO - Horm Cancer. 2014 Aug;5(4):240-6. doi: 10.1007/s12672-014-0183-0. Epub 2014 May 16. PMID- 24828952 OWN - NLM STAT- MEDLINE DA - 20140729 DCOM- 20150420 IS - 1751-2980 (Electronic) IS - 1751-2972 (Linking) VI - 15 IP - 8 DP - 2014 Aug TI - Underlying liver disease influences volumetric changes in the spared hemiliver after selective internal radiation therapy with 90Y in patients with hepatocellular carcinoma. PG - 444-50 LID - 10.1111/1751-2980.12162 [doi] AB - OBJECTIVE: Hypertrophy of the contralateral liver lobe after treatment with yttrium-90 ((90)Y) microspheres has recently been reported. This study aimed to quantify left hepatic lobe hypertrophy after right-sided radioembolization for hepatocellular carcinoma (HCC) and to identify pretreatment predictive factors of hypertrophy in an Asian population. METHODS: A retrospective review of patients with inoperable HCC undergoing selective internal radiation treatment (SIRT) with (90)Y microspheres at a single institution from January 2008 to January 2012 was performed. Only patients who had treatment delivered via the right hepatic artery alone were included. RESULTS: In all, 17 patients fulfilling the study criteria were identified. The mean percentage of left-lobe hypertrophy was 34.2% +/- 34.9% (range 19.0-106.5%) during a median of 5-month follow-up. Patients with hepatitis B were found to experience a significantly greater degree of hypertrophy than those with hepatitis C or alcoholic liver cirrhosis. There were no cases of acute liver failure after the administration of SIRT in this study and none of the patients developed disease in the contralateral lobe over the study period. CONCLUSIONS: Administration of unilobar SIRT to the right liver lobe in patients with HCC resulted in a significant degree of contralateral left lobe hypertrophy. Patients with hepatitis B experienced a greater degree of hypertrophy than those with hepatitis C or alcoholic liver cirrhosis. CI - (c) 2014 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd. FAU - Teo, Jin Yao AU - Teo JY AD - Department of General Surgery, Singapore General Hospital, Singapore. FAU - Goh, Brian Kim Poh AU - Goh BK FAU - Cheah, Foong Koon AU - Cheah FK FAU - Allen, John Carson AU - Allen JC FAU - Lo, Richard Hoau Gong AU - Lo RH FAU - Ng, David Chee Eng AU - Ng DC FAU - Goh, Anthony Soon Whatt AU - Goh AS FAU - Khor, Andrew Yu Keat AU - Khor AY FAU - Sim, Hui Shan AU - Sim HS FAU - Ng, Jia Jun AU - Ng JJ FAU - Chow, Pierce Kah-Hoe AU - Chow PK LA - eng PT - Journal Article PL - Australia TA - J Dig Dis JT - Journal of digestive diseases JID - 101302699 RN - 0 (Yttrium Radioisotopes) SB - IM MH - Adult MH - Aged MH - Brachytherapy/adverse effects/methods MH - Carcinoma, Hepatocellular/*radiotherapy/virology MH - Female MH - Hepatitis B, Chronic/complications MH - Hepatitis C, Chronic/complications MH - Humans MH - Hypertrophy/etiology/virology MH - Liver/pathology MH - Liver Cirrhosis, Alcoholic/complications MH - Liver Neoplasms/*radiotherapy/virology MH - Male MH - Microspheres MH - Middle Aged MH - Retrospective Studies MH - Risk Factors MH - Yttrium Radioisotopes/adverse effects/*therapeutic use OTO - NOTNLM OT - hepatitis B OT - hepatocellular carcinoma OT - hypertrophy OT - liver cirrhosis OT - selective internal radiation therapy EDAT- 2014/05/16 06:00 MHDA- 2015/04/22 06:00 CRDT- 2014/05/16 06:00 AID - 10.1111/1751-2980.12162 [doi] PST - ppublish SO - J Dig Dis. 2014 Aug;15(8):444-50. doi: 10.1111/1751-2980.12162. PMID- 24820216 OWN - NLM STAT- MEDLINE DA - 20140806 DCOM- 20150330 IS - 1476-5365 (Electronic) IS - 0268-3369 (Linking) VI - 49 IP - 8 DP - 2014 Aug TI - The skinny on obesity and plasma cell myeloma: a review of the literature. PG - 1009-15 LID - 10.1038/bmt.2014.71 [doi] AB - Despite tremendous advances in treatments for myeloma in the past decade, the disease remains incurable in the majority of patients. Here, we review recent data demonstrating an association between obesity and increased risk of myeloma development. This may be due to the pro-inflammatory cytokine profile caused by obesity. Currently, there are no screening or prevention strategies for myeloma, but we propose that obesity-associated inflammatory pathways, or obesity itself, may be amenable to intervention, thereby preventing the transition from pre-malignancy to myeloma. In addition, we suggest that the morbidity, mortality and the significant costs associated with myeloma treatment could be reduced by addressing modifiable risk factors, and that research efforts should explore this novel hypothesis. FAU - Carson, K R AU - Carson KR AD - Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA. FAU - Bates, M L AU - Bates ML AD - Department of Pediatrics, Critical Care Division and the John Rankin Laboratory of Pulmonary Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. FAU - Tomasson, M H AU - Tomasson MH AD - Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA. LA - eng PT - Journal Article PT - Review DEP - 20140512 PL - England TA - Bone Marrow Transplant JT - Bone marrow transplantation JID - 8702459 SB - IM MH - Humans MH - *Multiple Myeloma/epidemiology/etiology/metabolism MH - *Obesity/complications/epidemiology/metabolism MH - *Precancerous Conditions/epidemiology/etiology/metabolism MH - Risk Factors EDAT- 2014/05/14 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/05/14 06:00 PHST- 2014/02/11 [received] PHST- 2014/02/17 [accepted] PHST- 2014/05/12 [aheadofprint] AID - bmt201471 [pii] AID - 10.1038/bmt.2014.71 [doi] PST - ppublish SO - Bone Marrow Transplant. 2014 Aug;49(8):1009-15. doi: 10.1038/bmt.2014.71. Epub 2014 May 12. PMID- 24819040 OWN - NLM STAT- MEDLINE DA - 20140721 DCOM- 20150331 IS - 1538-7836 (Electronic) IS - 1538-7836 (Linking) VI - 12 IP - 7 DP - 2014 Jul TI - Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. PG - 1116-20 LID - 10.1111/jth.12605 [doi] AB - INTRODUCTION: Treatment of acute venous thromboembolism (VTE) in cancer patients is challenging, owing to a high risk of recurrent VTE and bleeding complications. The anticoagulants of choice are low molecular weight heparins (LMWHs), because of a proven higher efficacy than vitamin K antagonists (VKAs) and a similar bleeding profile. The recently introduced new oral anticoagulants (NOACs) have the potential to be alternative options for these patients, as these drugs share practical advantages with LMWH, are administered orally, and had similar efficacy to VKAs but a lower bleeding risk in phase 3 studies in the general VTE population. METHODS: A systematic literature search was performed to identify phase 3 trials investigating NOACs for the treatment of VTE. The efficacy outcome was recurrent VTE, and the safety outcome was major and clinically relevant non-major bleeding. Pooled incidence rates and risk ratios (RRs) were calculated for cancer patients and non-cancer patients separately. RESULTS AND DISCUSSION: Five studies were included, with 19 060 patients, of whom 973 (5.1%) had active cancer. The pooled incidence rates of recurrent VTE were 4.1% (95% confidence interval [CI] 2.6-6.0) in cancer patients treated with NOACs, and 6.1% (95% CI 4.1-8.5) in patients treated with VKAs (RR 0.66, 95% CI 0.38-1.2). The pooled incidence rates of major or non-major clinically relevant bleeding were 15% (95% CI 12-18) in cancer patients treated with NOACs, and 16% (95% CI 9.9-22) in patients treated with VKAs (RR 0.94, 95% CI 0.70-1.3). These results form a solid basis for the initiation of a head-to-head comparison of NOACs with LMWH in cancer patients. CI - (c) 2014 International Society on Thrombosis and Haemostasis. FAU - van der Hulle, T AU - van der Hulle T AD - Department of Thrombosis and Hemostasis, LUMC, Leiden, The Netherlands. FAU - den Exter, P L AU - den Exter PL FAU - Kooiman, J AU - Kooiman J FAU - van der Hoeven, J J M AU - van der Hoeven JJ FAU - Huisman, M V AU - Huisman MV FAU - Klok, F A AU - Klok FA LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20140619 PL - England TA - J Thromb Haemost JT - Journal of thrombosis and haemostasis : JTH JID - 101170508 RN - 0 (Anticoagulants) RN - 0 (Heparin, Low-Molecular-Weight) RN - 0 (Morpholines) RN - 0 (Thiophenes) RN - 9NDF7JZ4M3 (rivaroxaban) SB - IM CIN - J Thromb Haemost. 2014 Dec;12(12):2136-8. PMID: 25280347 CIN - J Thromb Haemost. 2014 Dec;12(12):2138-9. PMID: 25322961 MH - Acute Disease MH - Administration, Oral MH - Anticoagulants/*therapeutic use MH - Hemorrhage MH - Heparin, Low-Molecular-Weight/therapeutic use MH - Humans MH - Morpholines/therapeutic use MH - Neoplasms/*complications/therapy MH - Randomized Controlled Trials as Topic MH - Recurrence MH - Risk MH - Thiophenes/therapeutic use MH - Treatment Outcome MH - Venous Thrombosis/*complications/*drug therapy OTO - NOTNLM OT - anticoagulants OT - hemorrhage OT - neoplasms OT - treatment outcome OT - venous thromboembolism EDAT- 2014/05/14 06:00 MHDA- 2015/04/01 06:00 CRDT- 2014/05/14 06:00 PHST- 2014/04/01 [received] PHST- 2014/05/04 [accepted] PHST- 2014/06/19 [aheadofprint] AID - 10.1111/jth.12605 [doi] PST - ppublish SO - J Thromb Haemost. 2014 Jul;12(7):1116-20. doi: 10.1111/jth.12605. Epub 2014 Jun 19. PMID- 24817302 OWN - NLM STAT- MEDLINE DA - 20140512 DCOM- 20150402 IS - 2284-0729 (Electronic) IS - 1128-3602 (Linking) VI - 18 IP - 8 DP - 2014 TI - The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report. PG - 1247-58 LID - 7301 [pii] AB - AIM: We retrospectively investigated the relationship between IVS14+1 G > A genotype of the dihydropyrimidine dehydrogenase (DPD) gene with plasma concentration of 5-fluorouracil (5-FU) as well as adverse reactions in 80 patients with locally advanced or metastatic colorectal cancer. PATIENTS AND METHODS: Eighty patients with un-resectable locally advanced or metastatic colorectal cancer were treated with Folfox-6 regimen, which repeated every two weeks for at least three cycles. Single nucleotide polymorphisms for DPD gene were analyzed before chemotherapy by high-resolution melting (HRM) analysis. The plasma concentration of fluorouracil was measured by high performance liquid chromatography (HPLC) after continuous infusion of fluorouracil over 12 h in each cycle. The average values of plasma concentrations in each cycle were calculated, and the factors related to plasma concentration of 5-FU were screened by stepwise regression. RESULTS: All patients were divided into three groups according to the predictive confidence interval of plasma concentration of 5-FU, and the average plasma concentrations of fluorouracil in each cycle of these three groups were less than or equal to 26.83 mg/L, 26.83-40.62 mg/L, and more than 40.62 mg/L, respectively. Stepwise regression analysis showed that the plasma concentration of fluorouracil was associated with myelosuppression, hand-foot syndrome, diarrhea, overall survival (OS) and DPD genotype. In efficacy, the median progression-free survival PFS (mPFS) and OS (mOS) of group 2 and group 3 were both significantly higher than those of group 1. CONCLUSIONS: Among the advanced colorectal cancer patients receiving fluorouracil-based chemotherapy, those with plasma concentration of 5-FU above 26.83 mg/L can obtain better survival; for patients with heterozygous DPD IVS14+1 mutation, 5-FU dose should be appropriately reduced according to last plasma concentration to reduce adverse reactions, while the homozygous ones should avoid application of 5-FU and its derivatives. FAU - Cai, X AU - Cai X AD - Department of Oncology, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai, China. yzwlw_submit@sina.com. FAU - Fang, J-M AU - Fang JM FAU - Xue, P AU - Xue P FAU - Song, W-F AU - Song WF FAU - Hu, J AU - Hu J FAU - Gu, H-L AU - Gu HL FAU - Yang, H-Y AU - Yang HY FAU - Wang, L-W AU - Wang LW LA - eng PT - Journal Article PL - Italy TA - Eur Rev Med Pharmacol Sci JT - European review for medical and pharmacological sciences JID - 9717360 RN - 0 (Organoplatinum Compounds) RN - EC 1.3.1.2 (Dihydrouracil Dehydrogenase (NADP)) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Folfox protocol SB - IM MH - Adenocarcinoma/blood/*drug therapy/mortality/pathology MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/blood/*pharmacokinetics MH - Chromatography, High Pressure Liquid MH - Colorectal Neoplasms/blood/*drug therapy/mortality/pathology MH - Dihydrouracil Dehydrogenase (NADP)/*genetics/metabolism MH - *Drug Monitoring/methods MH - Female MH - Fluorouracil/administration & dosage/adverse effects/blood/*pharmacokinetics MH - Heterozygote MH - Homozygote MH - Humans MH - Individualized Medicine MH - Leucovorin/administration & dosage MH - Male MH - Middle Aged MH - Organoplatinum Compounds/administration & dosage MH - Patient Selection MH - Pharmacogenetics MH - Phenotype MH - *Polymorphism, Single Nucleotide MH - Retrospective Studies MH - Risk Factors MH - Treatment Outcome EDAT- 2014/05/13 06:00 MHDA- 2015/04/04 06:00 CRDT- 2014/05/13 06:00 PST - ppublish SO - Eur Rev Med Pharmacol Sci. 2014;18(8):1247-58. PMID- 24816030 OWN - NLM STAT- MEDLINE DA - 20140721 DCOM- 20150402 IS - 1399-3046 (Electronic) IS - 1397-3142 (Linking) VI - 18 IP - 5 DP - 2014 Aug TI - Scurvy: a new problem for patients with chronic GVHD involving mucous membranes; an easy problem to resolve. PG - 524-6 LID - 10.1111/petr.12285 [doi] AB - Vitamin C deficiency in developed countries is typically observed in patients with unique clinical conditions such as cystic fibrosis or anorexia nervosa, or in patients on long-term tube feeds. We report here a clinical observation in six pediatric and adolescent patients (median age 17.5 yr, range 9.8-23.5 yr) with chronic GVHD with mucous membrane involvement found to be vitamin C deficient. These patients' baseline serum vitamin C levels ranged from <0.12 to 0.94 mg/dL (normal value 0.20-1.90 mg/dL), with a mean level 0.56 +/- 0.36 mg/dL and a median level 0.6 mg/dL. Among these patients, signs and symptoms of mucositis failed to respond to standard chronic GVHD therapy. After receiving treatment with 2000 mg of ascorbic acid by mouth, daily patients displayed increased serum vitamin C levels. Clinically, this correlated with a remarkable improvement in patients' mucositis and ability to eat. CI - (c) 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Kletzel, Morris AU - Kletzel M AD - Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. FAU - Powers, Kim AU - Powers K FAU - Hayes, Meghan AU - Hayes M LA - eng PT - Journal Article DEP - 20140512 PL - Denmark TA - Pediatr Transplant JT - Pediatric transplantation JID - 9802574 RN - PQ6CK8PD0R (Ascorbic Acid) RN - VB0R961HZT (Prednisone) SB - IM MH - Administration, Oral MH - Adolescent MH - Adult MH - Ascorbic Acid/blood/*therapeutic use MH - Ascorbic Acid Deficiency/complications MH - Child MH - Chronic Disease MH - Graft vs Host Disease/*complications MH - Humans MH - Leukemia, Myeloid, Acute/complications/therapy MH - Mucositis/*therapy MH - Mucous Membrane/*pathology MH - Myelodysplastic Syndromes/complications/therapy MH - Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications/therapy MH - Prednisone/therapeutic use MH - Scurvy/*complications/*therapy MH - Stem Cell Transplantation MH - Young Adult OTO - NOTNLM OT - chronic graft vs. host disease OT - mucositis OT - scurvy EDAT- 2014/05/13 06:00 MHDA- 2015/04/04 06:00 CRDT- 2014/05/13 06:00 PHST- 2014/04/11 [accepted] PHST- 2014/05/12 [aheadofprint] AID - 10.1111/petr.12285 [doi] PST - ppublish SO - Pediatr Transplant. 2014 Aug;18(5):524-6. doi: 10.1111/petr.12285. Epub 2014 May 12. PMID- 24803822 OWN - NLM STAT- MEDLINE DA - 20140507 DCOM- 20150409 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 17 DP - 2014 May 7 TI - Prognostic analysis and comparison of colon cancer in Han and Hui patients. PG - 5082-6 LID - 10.3748/wjg.v20.i17.5082 [doi] AB - AIM: To investigate the relevant prognostic factors and their differences between colorectal cancer (CRC) patients of Chinese Han and Hui ethnicities in the Beijing region. METHODS: A retrospective analysis of 880 patients diagnosed with CRC at Xuanwu Hospital, Capital Medical University between September 2001 and September 2011 was performed. Among the 880 patients, 398 and 482 were Hui and Han, respectively. Characteristics including sex, age, diet, tumor size, primary tumor site, Dukes' stage and degree of differentiation were analyzed for their influence on prognosis. Data on dietary structures were recorded through a questionnaire survey conducted during the patient's first visit, return visit or follow-up checkups. RESULTS: Among patients with colon cancer, the 5-year survival rate for patients of Hui ethnicity was lower than that for Han patients (P = 0.025). Six risk factors (age of onset, dietary structure, tumor size, Dukes' stage, location of cancer and degree of differentiation) in both Han and Hui patients were identified as prognostic factors (P < 0.05). Multivariate analysis showed that age of onset (P = 0.002), diet (P = 0.000), Dukes' stage (P = 0.000) and degree of differentiation (P = 0.000) are prognostic factors affecting both ethnic groups. Comparison of prognostic factors between Han and Hui patients with CRC showed that dietary structure was a statistically significant factor, and diet varied significantly between the two ethnic groups. CONCLUSION: Dietary structure has a significant influence on colon cancer prognosis among Han and Hui patients with colon cancer in Beijing, which may cause a difference in their survival rates. FAU - Zhang, Mei AU - Zhang M AD - Mei Zhang, Qu-Chuan Zhao, Yan-Peng Liu, Lei Yang, Hong-Ming Zhu, Jagadish K Chhetri, Department of Gastroenterology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. FAU - Zhao, Qu-Chuan AU - Zhao QC AD - Mei Zhang, Qu-Chuan Zhao, Yan-Peng Liu, Lei Yang, Hong-Ming Zhu, Jagadish K Chhetri, Department of Gastroenterology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. FAU - Liu, Yan-Peng AU - Liu YP AD - Mei Zhang, Qu-Chuan Zhao, Yan-Peng Liu, Lei Yang, Hong-Ming Zhu, Jagadish K Chhetri, Department of Gastroenterology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. FAU - Yang, Lei AU - Yang L AD - Mei Zhang, Qu-Chuan Zhao, Yan-Peng Liu, Lei Yang, Hong-Ming Zhu, Jagadish K Chhetri, Department of Gastroenterology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. FAU - Zhu, Hong-Ming AU - Zhu HM AD - Mei Zhang, Qu-Chuan Zhao, Yan-Peng Liu, Lei Yang, Hong-Ming Zhu, Jagadish K Chhetri, Department of Gastroenterology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. FAU - Chhetri, Jagadish K AU - Chhetri JK AD - Mei Zhang, Qu-Chuan Zhao, Yan-Peng Liu, Lei Yang, Hong-Ming Zhu, Jagadish K Chhetri, Department of Gastroenterology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. LA - eng PT - Comparative Study PT - Journal Article PL - China TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 SB - IM MH - Adult MH - Age of Onset MH - Aged MH - Aged, 80 and over MH - *Asian Continental Ancestry Group MH - Cell Differentiation MH - China/epidemiology MH - Colonic Neoplasms/*ethnology/mortality/*pathology MH - Diet/adverse effects/*ethnology MH - Female MH - Food Habits/*ethnology MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Staging MH - Predictive Value of Tests MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Time Factors MH - Tumor Burden PMC - PMC4009544 OID - NLM: PMC4009544 OTO - NOTNLM OT - Colon cancer OT - Colorectal cancer OT - Han patients OT - Hui patients OT - Multivariate analysis OT - Prognosis EDAT- 2014/05/08 06:00 MHDA- 2015/04/10 06:00 CRDT- 2014/05/08 06:00 PHST- 2014/02/17 [received] PHST- 2014/02/27 [revised] PHST- 2014/03/12 [accepted] AID - 10.3748/wjg.v20.i17.5082 [doi] PST - ppublish SO - World J Gastroenterol. 2014 May 7;20(17):5082-6. doi: 10.3748/wjg.v20.i17.5082. PMID- 24803815 OWN - NLM STAT- MEDLINE DA - 20140507 DCOM- 20150409 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 17 DP - 2014 May 7 TI - Dietary habits of colorectal neoplasia patients in comparison to their first-degree relatives. PG - 5025-30 LID - 10.3748/wjg.v20.i17.5025 [doi] AB - AIM: To compare the dietary habits between colorectal neoplasia patients, their first-degree relatives, and unrelated controls. METHODS: From July 2008 to April 2011, we collected epidemiological data relevant to colorectal cancer from patients with colorectal neoplasias, their first-degree relatives, and also from a control group consisting of people referred for colonoscopy with a negative family history of colorectal cancer and without evidence of neoplasia after colonoscopic examination. The first-degree relatives were divided into two groups following the colonoscopic examination: (1) patients with neoplasia or (2) patients without neoplasia. Dietary habits of all groups were compared. A chi (2) test was used to assess the association between two dichotomous categorical variables. RESULTS: The study groups consisted of 242 patients with colorectal neoplasias (143 men, 99 women; mean age: 64 +/- 12 years) and 160 first-degree relatives (66 men, 94 women; mean age: 48 +/- 11 years). Fifty-five of the first-degree relatives were found to have a neoplastic lesion upon colonoscopy, while the remaining 105 were without neoplasia. The control group contained 123 individuals with a negative family history for neoplastic lesions (66 men, 57 women; mean age: 54 +/- 12 years). Two hypotheses were tested. In the first, the dietary habits of first-degree relatives with neoplasia were more similar to those of patients with neoplasia, while the dietary habits of first-degree relatives without neoplasia were similar to those of the control group. In the second, no sex-related differences in dietary habits were expected between the particular groups. Indeed, no significant differences were observed in the dietary habits between the groups of patients, controls and first-degree relatives with/without neoplastic lesions. Nevertheless, statistically significant sex-related differences were observed in all groups, wherein women had healthier dietary habits than men. CONCLUSION: In all groups examined, women had healthier dietary habits than men. Modification of screening guidelines according to sex may improve the efficiency of screening programs. FAU - Kajzrlikova, Ivana Mikoviny AU - Kajzrlikova IM AD - Ivana Mikoviny Kajzrlikova, Petr Vitek, Josef Chalupa, Beskydy Gastrocentre, Department of Internal Medicine, Hospital Frydek-Mistek, 73818 Frydek-Mistek, Czech Republic. FAU - Vitek, Petr AU - Vitek P AD - Ivana Mikoviny Kajzrlikova, Petr Vitek, Josef Chalupa, Beskydy Gastrocentre, Department of Internal Medicine, Hospital Frydek-Mistek, 73818 Frydek-Mistek, Czech Republic. FAU - Chalupa, Josef AU - Chalupa J AD - Ivana Mikoviny Kajzrlikova, Petr Vitek, Josef Chalupa, Beskydy Gastrocentre, Department of Internal Medicine, Hospital Frydek-Mistek, 73818 Frydek-Mistek, Czech Republic. FAU - Dite, Petr AU - Dite P AD - Ivana Mikoviny Kajzrlikova, Petr Vitek, Josef Chalupa, Beskydy Gastrocentre, Department of Internal Medicine, Hospital Frydek-Mistek, 73818 Frydek-Mistek, Czech Republic. LA - eng PT - Comparative Study PT - Journal Article PL - China TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 SB - IM MH - Adult MH - Aged MH - Case-Control Studies MH - Chi-Square Distribution MH - Colonoscopy MH - Colorectal Neoplasms/epidemiology/pathology/*psychology MH - Czech Republic/epidemiology MH - *Diet MH - Family/*psychology MH - Female MH - *Food Habits MH - Humans MH - Male MH - Middle Aged MH - Patients/*psychology MH - Sex Factors PMC - PMC4009536 OID - NLM: PMC4009536 OTO - NOTNLM OT - Colorectal neoplasms OT - Family OT - Food habits OT - Mass screening OT - Risk factors EDAT- 2014/05/08 06:00 MHDA- 2015/04/10 06:00 CRDT- 2014/05/08 06:00 PHST- 2013/10/27 [received] PHST- 2014/01/12 [revised] PHST- 2014/02/17 [accepted] AID - 10.3748/wjg.v20.i17.5025 [doi] PST - ppublish SO - World J Gastroenterol. 2014 May 7;20(17):5025-30. doi: 10.3748/wjg.v20.i17.5025. PMID- 24797965 OWN - NLM STAT- MEDLINE DA - 20140506 DCOM- 20150413 IS - 1898-4002 (Electronic) IS - 1896-1126 (Linking) VI - 59 IP - 1 DP - 2014 Mar TI - Anorexia-cachexia syndrome in pancreatic cancer: recent advances and new pharmacological approach. PG - 1-6 LID - 10.1016/j.advms.2013.11.001 [doi] LID - S1896-1126(14)00006-6 [pii] AB - About 80% of all pancreatic ductal adenocarcinoma patients suffer from a wasting syndrome referred to as the "cancer anorexia-cachexia syndrome" (CACS) characterized by abnormally low weight, weakness and loss of skeletal muscle mass with or without loss of body fat, which directly impacts overall survival, quality of life, and physical activity. The aim of this review was to examine recent findings about CACS' pathophysiology and to describe the current pharmacological approaches. In recent years many efforts were made to improve our knowledge of CACS; currently we know that cachexia arises from a complex and multifactorial interaction between various mechanisms including inflammation, anorexia/malnutrition, alterations of protein and lipid metabolism; consequently its management requires multidisciplinary and multipharmacological approach that should address the different causes underlying this clinical event. On these premises, several drugs have been proposed starting from the first pharmacological treatment based on progestational agents or corticosteroids; most of them are in the preclinical phase, but some have already reached the clinical experimentation stage. In conclusion, to date, there is no standard effective treatment and further studies are needed to unravel the basic mechanisms underlying CACS and to develop newer therapeutic strategies with the hope to improve the quality of life of pancreatic cancer patients. CI - Copyright (c) 2014 Medical University of Bialystok. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved. FAU - Ronga, Ilaria AU - Ronga I AD - Internal Medicine Unit 3, Cardarelli Hospital, Napoli, Italy. FAU - Gallucci, Fernando AU - Gallucci F AD - Internal Medicine Unit 3, Cardarelli Hospital, Napoli, Italy. FAU - Riccardi, Ferdinando AU - Riccardi F AD - Oncology Unit, Cardarelli Hospital, Napoli, Italy. FAU - Uomo, Generoso AU - Uomo G AD - Internal Medicine Unit 3, Cardarelli Hospital, Napoli, Italy. Electronic address: gene.uomo@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20140315 PL - Netherlands TA - Adv Med Sci JT - Advances in medical sciences JID - 101276222 SB - IM MH - Anorexia/etiology/*prevention & control MH - Cachexia/etiology/*prevention & control MH - Humans MH - Pancreatic Neoplasms/*complications MH - Quality of Life OTO - NOTNLM OT - Anorexia OT - Cachexia OT - Corticosteroids OT - Megestrol OT - Pancreatic adenocarcinoma OT - Thalidomide EDAT- 2014/05/07 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/05/07 06:00 PHST- 2013/10/14 [received] PHST- 2013/11/20 [accepted] PHST- 2014/03/15 [aheadofprint] AID - S1896-1126(14)00006-6 [pii] AID - 10.1016/j.advms.2013.11.001 [doi] PST - ppublish SO - Adv Med Sci. 2014 Mar;59(1):1-6. doi: 10.1016/j.advms.2013.11.001. Epub 2014 Mar 15. PMID- 24794790 OWN - NLM STAT- MEDLINE DA - 20140726 DCOM- 20150407 IS - 1878-3562 (Electronic) IS - 1590-8658 (Linking) VI - 46 IP - 8 DP - 2014 Aug TI - Clinical nutrition guidelines of the French Speaking Society of Clinical Nutrition and Metabolism (SFNEP): Summary of recommendations for adults undergoing non-surgical anticancer treatment. PG - 667-74 LID - 10.1016/j.dld.2014.01.160 [doi] LID - S1590-8658(14)00210-2 [pii] AB - Up to 50% of patients with cancer suffer from weight loss and undernutrition (as called cachexia) even though it is rarely screened or properly handled. Patients' prognosis and quality of life could be greatly improved by simple and inexpensive means encompassing nutritional status assessment and effective nutritional care. These guidelines aim to give health professionals and patients practical and up-to-date advice to manage nutrition in the principal situations encountered during the cancer course according to the type of tumour and treatment (i.e. radio and/or chemotherapy). Specific suggestions are made for palliative and elderly patients because of specific risks of undernutrition and related comorbidities in this subset. Levels of evidence and grades of recommendations are detailed as stated by current literature and consensus opinion of clinical experts in each field. CI - Copyright (c) 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. CN - French Speaking Society of Clinical Nutrition and Metabolism (SFNEP) LA - eng PT - Journal Article PT - Practice Guideline DEP - 20140501 PL - Netherlands TA - Dig Liver Dis JT - Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver JID - 100958385 RN - 0 (Antioxidants) RN - 0 (Dietary Proteins) SB - IM MH - Adult MH - Antioxidants/adverse effects MH - Cachexia/etiology/*prevention & control MH - Dietary Proteins/administration & dosage MH - Dietary Supplements/adverse effects MH - Directive Counseling MH - Energy Intake MH - Humans MH - Neoplasms/complications/*therapy MH - Nutrition Assessment MH - *Nutrition Policy MH - Nutritional Status OTO - NOTNLM OT - Clinical practice OT - Evidence-based OT - Nutritional care OT - Oncology IR - Senesse P FIR - Senesse, Pierre IR - Bachmann P FIR - Bachmann, Patrick IR - Bensadoun RJ FIR - Bensadoun, Rene-Jean IR - Besnard I FIR - Besnard, Isabelle IR - Bourdel-Marchasson I FIR - Bourdel-Marchasson, Isabelle IR - Bouteloup C FIR - Bouteloup, Corinne IR - Crenn P FIR - Crenn, Pascal IR - Goldwasser F FIR - Goldwasser, Francois IR - Guerin O FIR - Guerin, Olivier IR - Latino-Martel P FIR - Latino-Martel, Paule IR - Meuric J FIR - Meuric, Jocelyne IR - May-Levin F FIR - May-Levin, Francoise IR - Michallet M FIR - Michallet, Mauricette IR - Vasson MP FIR - Vasson, Marie-Paule IR - Hebuterne X FIR - Hebuterne, Xavier EDAT- 2014/05/06 06:00 MHDA- 2015/04/08 06:00 CRDT- 2014/05/06 06:00 PHST- 2013/12/20 [received] PHST- 2014/01/28 [accepted] PHST- 2014/05/01 [aheadofprint] AID - S1590-8658(14)00210-2 [pii] AID - 10.1016/j.dld.2014.01.160 [doi] PST - ppublish SO - Dig Liver Dis. 2014 Aug;46(8):667-74. doi: 10.1016/j.dld.2014.01.160. Epub 2014 May 1. PMID- 24764664 OWN - NLM STAT- MEDLINE DA - 20140425 DCOM- 20150413 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 15 DP - 2014 Apr 21 TI - Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. PG - 4263-75 LID - 10.3748/wjg.v20.i15.4263 [doi] AB - Colorectal liver metastasis (CLM) is common worldwide. Targeted therapies with monoclonal antibodies have been proven effective in numerous clinical trials, and are now becoming standards for patients with CLM. The development and application of anti-epidermal growth factor receptor (anti-EGFR) and anti-vascular endothelial growth factor (anti-VEGF) antibodies represents significant advances in the treatment of this disease. However, new findings continue to emerge casting doubt on the efficacy of this approach. The Kirsten rat sarcoma viral oncogene (KRAS) has been proven to be a crucial predictor of the success of anti-EGFR treatment in CLM. Whereas a recent study summarized several randomized controlled trials, and showed that patients with the KRAS G13D mutation significantly benefited from the addition of cetuximab in terms of progress-free survival (PFS, 4.0 mo vs 1.9 mo, HR = 0.51, P = 0.004) and overall survival (OS, 7.6 mo vs 5.7 mo, HR = 0.50, P = 0.005). Some other studies also reported that the KRAS G13D mutation might not be absolutely predictive of non-responsiveness to anti-EGFR therapy. At the same time, "new" RAS mutations, including mutations in neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) and exons 3 and 4 of KRAS, have been suggested to be predictors of a poor treatment response. This finding was first reported by the update of the PRIME trial. The update showed that for patients with non-mutated KRAS exon 2 but other RAS mutations, panitumumab-fluorouracil, leucovorin, and oxaliplatin (FOLFOX)4 treatment led to inferior PFS (HR = 1.28, 95%CI: 0.79-2.07) and OS (HR = 1.29, 95%CI: 0.79-2.10), which was consistent with the findings in patients with KRAS mutations in exon 2. Then, the update of the PEAK trial and the FIRE-III trial also supported this finding, which would reduce candidates for anti-EGFR therapy but enhance the efficacy. In first-line targeted combination therapy, the regimens of cetuximab plus FOLFOX was called into question because of the inferior prognosis in the COIN trial and the NORDIC-VII trial. Also, bevacizumab plus oxaliplatin-based chemotherapy was questioned because of the NO16966 trial. By the update and further analysis of the COIN trial and the NORDIC-VII trial, cetuximab plus FOLFOX was reported to be reliable again. But bevacizumab plus oxaliplatin-based chemotherapy was still controversial. In addition, some trials have reported that bevacizumab is not suitable for conversion therapy. The results of the FIRE-III trial showed that cetuximab led to a significant advantage over bevacizumab in response rate (72% vs 63%, P = 0.017) for evaluable population. With the balanced allocation of second-line treatment, the FIRE-III trial was expected to provide evidence for selecting following regimens after first-line progression. There is still no strong evidence for the efficacy of targeted therapy as a preoperative treatment for resectable CLM or postoperative treatment for resected CLM, although the combined regimen is often administered based on experience. Combination therapy with more than one targeted agent has been proven to provide no benefit, and even was reported to be harmful as first-line treatment by four large clinical trials. However, recent studies reported positive results of erlotinib plus bevacizumab for maintenance treatment. The mechanism of antagonism between different targeted agents deserves further study, and may also provide greater understanding of the development of resistance to targeted agents. FAU - Feng, Qing-Yang AU - Feng QY AD - Qing-Yang Feng, Ye Wei, Jing-Wen Chen, Wen-Ju Chang, Le-Chi Ye, De-Xiang Zhu, Jian-Min Xu, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Wei, Ye AU - Wei Y AD - Qing-Yang Feng, Ye Wei, Jing-Wen Chen, Wen-Ju Chang, Le-Chi Ye, De-Xiang Zhu, Jian-Min Xu, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Chen, Jing-Wen AU - Chen JW AD - Qing-Yang Feng, Ye Wei, Jing-Wen Chen, Wen-Ju Chang, Le-Chi Ye, De-Xiang Zhu, Jian-Min Xu, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Chang, Wen-Ju AU - Chang WJ AD - Qing-Yang Feng, Ye Wei, Jing-Wen Chen, Wen-Ju Chang, Le-Chi Ye, De-Xiang Zhu, Jian-Min Xu, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Ye, Le-Chi AU - Ye LC AD - Qing-Yang Feng, Ye Wei, Jing-Wen Chen, Wen-Ju Chang, Le-Chi Ye, De-Xiang Zhu, Jian-Min Xu, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Zhu, De-Xiang AU - Zhu DX AD - Qing-Yang Feng, Ye Wei, Jing-Wen Chen, Wen-Ju Chang, Le-Chi Ye, De-Xiang Zhu, Jian-Min Xu, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Xu, Jian-Min AU - Xu JM AD - Qing-Yang Feng, Ye Wei, Jing-Wen Chen, Wen-Ju Chang, Le-Chi Ye, De-Xiang Zhu, Jian-Min Xu, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. LA - eng PT - Journal Article PT - Review PL - China TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 RN - 0 (KRAS protein, human) RN - 0 (Organoplatinum Compounds) RN - 0 (Proto-Oncogene Proteins) RN - 0 (Vascular Endothelial Growth Factor A) RN - EC 2.7.10.1 (Receptor, Epidermal Growth Factor) RN - EC 3.6.5.2 (ras Proteins) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Folfox protocol SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Clinical Trials as Topic MH - Colorectal Neoplasms/pathology/*therapy MH - Disease-Free Survival MH - Exons MH - Fluorouracil/therapeutic use MH - Humans MH - Leucovorin/therapeutic use MH - Liver Neoplasms/*secondary/*therapy MH - Mutation MH - Organoplatinum Compounds/therapeutic use MH - Practice Guidelines as Topic MH - Proto-Oncogene Proteins/metabolism MH - Randomized Controlled Trials as Topic MH - Receptor, Epidermal Growth Factor/*antagonists & inhibitors MH - Treatment Outcome MH - Vascular Endothelial Growth Factor A/*antagonists & inhibitors MH - ras Proteins/metabolism PMC - PMC3989962 OID - NLM: PMC3989962 OTO - NOTNLM OT - Chemotherapy OT - Colorectal cancer OT - Liver metastases OT - Oncology OT - Targeted therapy EDAT- 2014/04/26 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/04/26 06:00 PHST- 2013/09/26 [received] PHST- 2014/02/07 [revised] PHST- 2014/02/20 [accepted] AID - 10.3748/wjg.v20.i15.4263 [doi] PST - ppublish SO - World J Gastroenterol. 2014 Apr 21;20(15):4263-75. doi: 10.3748/wjg.v20.i15.4263. PMID- 24764659 OWN - NLM STAT- MEDLINE DA - 20140425 DCOM- 20150413 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 15 DP - 2014 Apr 21 TI - Role of cetuximab in first-line treatment of metastatic colorectal cancer. PG - 4208-19 LID - 10.3748/wjg.v20.i15.4208 [doi] AB - The treatment of metastatic colorectal cancer (mCRC) has evolved considerably in the last decade, currently allowing most mCRC patients to live more than two years. Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor play an important role in the current treatment of these patients. However, only antibodies directed against EGFR have a predictive marker of response, which is the mutation status of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS). Cetuximab has been shown to be effective in patients with KRAS wild-type mCRC. The CRYSTAL study showed that adding cetuximab to FOLFIRI (regimen of irinotecan, infusional fluorouracil and leucovorin) significantly improved results in the first-line treatment of KRAS wild-type mCRC. However, results that evaluate the efficacy of cetuximab in combination with oxaliplatin-based chemotherapy in this setting are contradictory. On the other hand, recent advances in the management of colorectal liver metastases have improved survival in these patients. Adding cetuximab to standard chemotherapy increases the response rate in patients with wild-type KRAS and can thus increase the resectability rate of liver metastases in this group of patients. In this paper we review the different studies assessing the efficacy of cetuximab in the first-line treatment of mCRC. FAU - Sotelo, Miguel Jhonatan AU - Sotelo MJ AD - Miguel Jhonatan Sotelo, Beatriz Garcia-Paredes, Carlos Aguado, Javier Sastre, Eduardo Diaz-Rubio, Center affiliate to the "Red Tematica de Investigacion Cooperativa (RD12/0036/006)", Instituto Carlos III, Spanish Ministry of Economy and Competitivity. Oncology Department, Hospital Clinico San Carlos, 28040 Madrid, Spain. FAU - Garcia-Paredes, Beatriz AU - Garcia-Paredes B AD - Miguel Jhonatan Sotelo, Beatriz Garcia-Paredes, Carlos Aguado, Javier Sastre, Eduardo Diaz-Rubio, Center affiliate to the "Red Tematica de Investigacion Cooperativa (RD12/0036/006)", Instituto Carlos III, Spanish Ministry of Economy and Competitivity. Oncology Department, Hospital Clinico San Carlos, 28040 Madrid, Spain. FAU - Aguado, Carlos AU - Aguado C AD - Miguel Jhonatan Sotelo, Beatriz Garcia-Paredes, Carlos Aguado, Javier Sastre, Eduardo Diaz-Rubio, Center affiliate to the "Red Tematica de Investigacion Cooperativa (RD12/0036/006)", Instituto Carlos III, Spanish Ministry of Economy and Competitivity. Oncology Department, Hospital Clinico San Carlos, 28040 Madrid, Spain. FAU - Sastre, Javier AU - Sastre J AD - Miguel Jhonatan Sotelo, Beatriz Garcia-Paredes, Carlos Aguado, Javier Sastre, Eduardo Diaz-Rubio, Center affiliate to the "Red Tematica de Investigacion Cooperativa (RD12/0036/006)", Instituto Carlos III, Spanish Ministry of Economy and Competitivity. Oncology Department, Hospital Clinico San Carlos, 28040 Madrid, Spain. FAU - Diaz-Rubio, Eduardo AU - Diaz-Rubio E AD - Miguel Jhonatan Sotelo, Beatriz Garcia-Paredes, Carlos Aguado, Javier Sastre, Eduardo Diaz-Rubio, Center affiliate to the "Red Tematica de Investigacion Cooperativa (RD12/0036/006)", Instituto Carlos III, Spanish Ministry of Economy and Competitivity. Oncology Department, Hospital Clinico San Carlos, 28040 Madrid, Spain. LA - eng PT - Journal Article PT - Review PL - China TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antineoplastic Agents) RN - 0 (KRAS protein, human) RN - 0 (Ligands) RN - 0 (Organoplatinum Compounds) RN - 0 (Proto-Oncogene Proteins) RN - 0 (Tumor Markers, Biological) RN - 0 (Vascular Endothelial Growth Factor A) RN - 04ZR38536J (oxaliplatin) RN - EC 2.7.10.1 (Receptor, Epidermal Growth Factor) RN - EC 3.6.5.2 (ras Proteins) RN - PQX0D8J21J (cetuximab) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - XT3Z54Z28A (Camptothecin) RN - IFL protocol SB - IM MH - Antibodies, Monoclonal, Humanized/*therapeutic use MH - Antineoplastic Agents/*therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Camptothecin/analogs & derivatives/therapeutic use MH - Clinical Trials as Topic MH - Colorectal Neoplasms/*drug therapy MH - Fluorouracil/therapeutic use MH - Humans MH - Leucovorin/therapeutic use MH - Ligands MH - Liver Neoplasms/secondary MH - Mutation MH - Neoplasm Metastasis MH - Organoplatinum Compounds/therapeutic use MH - Proto-Oncogene Proteins/genetics/metabolism MH - Receptor, Epidermal Growth Factor/metabolism MH - Treatment Outcome MH - Tumor Markers, Biological/metabolism MH - Vascular Endothelial Growth Factor A/metabolism MH - ras Proteins/genetics/metabolism PMC - PMC3989957 OID - NLM: PMC3989957 OTO - NOTNLM OT - Cetuximab OT - Colorectal liver metastases OT - Elderly patients OT - First-line OT - Metastatic colorectal cancer EDAT- 2014/04/26 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/04/26 06:00 PHST- 2013/09/20 [received] PHST- 2014/01/01 [revised] PHST- 2014/02/17 [accepted] AID - 10.3748/wjg.v20.i15.4208 [doi] PST - ppublish SO - World J Gastroenterol. 2014 Apr 21;20(15):4208-19. doi: 10.3748/wjg.v20.i15.4208. PMID- 24755745 OWN - NLM STAT- MEDLINE DA - 20140423 DCOM- 20150407 IS - 1598-9992 (Print) IS - 1598-9992 (Linking) VI - 63 IP - 4 DP - 2014 Apr TI - Prognostic factors for metastatic colorectal cancer after first-line chemotherapy with FOLFOX-4 or FOLFIRI regimen. PG - 209-15 AB - BACKGROUND/AIMS: Information on prognostic factors for metastatic colorectal cancer is an important basis for planning the treatment and predicting the outcomes of the patients; however, it has not been well established. The aim of this study was to identify factors that predict results of chemotherapy and to establish a plan for treatment of patients whose tumors are inoperable due to metastatic colorectal cancer. METHODS: We conducted a retrospective review of records from 75 patients treated for colorectal cancer in Kosin University Gospel Hospital, from October 2004 to September 2008. Patients with inoperable tumors due to metastasis at the time of diagnosis who were treated with oxaliplatin or irinotecan as the first-line treatment were included in this study. We investigated the factors that might have an effect on overall survival. RESULTS: A total of 75 patients were included in this study. Results of univariate analysis showed that hemoglobin (Hb) >/=10 g/dL at the time of diagnosis, no increase in CEA on the follow-up examination after chemotherapy, chemotherapy plus surgery, and better response to chemotherapy were significant prognostic factors. Results of multivariate analysis showed that Hb >/=10 g/dL at the time of diagnosis (p<0.001), surgery after chemotherapy (p=0.001), and better response to chemotherapy (p=0.014) were significant prognostic factors. CONCLUSIONS: In this study, Hb >/=10 g/dL at the time of diagnosis, surgery after chemotherapy, and better response to chemotherapy were significant prognostic factors for metastatic colorectal cancer. FAU - Kim, Jae Hyun AU - Kim JH AD - Department of Gastroenterology, Kosin University Gospel Hospital, 262 Gamcheon-ro, Seo-gu, Busan 602-702, Korea. FAU - Choi, Pyoung Rak AU - Choi PR AD - Department of Gastroenterology, Kosin University Gospel Hospital, 262 Gamcheon-ro, Seo-gu, Busan 602-702, Korea. FAU - Park, Seun Ja AU - Park SJ AD - Department of Gastroenterology, Kosin University Gospel Hospital, 262 Gamcheon-ro, Seo-gu, Busan 602-702, Korea. FAU - Park, Moo In AU - Park MI AD - Department of Gastroenterology, Kosin University Gospel Hospital, 262 Gamcheon-ro, Seo-gu, Busan 602-702, Korea. FAU - Moon, Won AU - Moon W AD - Department of Gastroenterology, Kosin University Gospel Hospital, 262 Gamcheon-ro, Seo-gu, Busan 602-702, Korea. FAU - Kim, Sung Eun AU - Kim SE AD - Department of Gastroenterology, Kosin University Gospel Hospital, 262 Gamcheon-ro, Seo-gu, Busan 602-702, Korea. FAU - Lee, Gyu Won AU - Lee GW AD - Department of Gastroenterology, Kosin University Gospel Hospital, 262 Gamcheon-ro, Seo-gu, Busan 602-702, Korea. LA - eng PT - Journal Article PL - Korea (South) TA - Korean J Gastroenterol JT - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi JID - 101189416 RN - 0 (Hemoglobins) RN - 0 (Organoplatinum Compounds) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - XT3Z54Z28A (Camptothecin) RN - Folfox protocol RN - IFL protocol SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Camptothecin/*analogs & derivatives/therapeutic use MH - Colorectal Neoplasms/*diagnosis/*drug therapy/mortality/surgery MH - Female MH - Fluorouracil/administration & dosage/therapeutic use MH - Hemoglobins/analysis MH - Humans MH - Kaplan-Meier Estimate MH - Leucovorin/administration & dosage/therapeutic use MH - Male MH - Middle Aged MH - Neoplasm Metastasis MH - Odds Ratio MH - Organoplatinum Compounds/therapeutic use MH - Prognosis MH - Retrospective Studies EDAT- 2014/04/24 06:00 MHDA- 2015/04/08 06:00 CRDT- 2014/04/24 06:00 AID - 201404183 [pii] PST - ppublish SO - Korean J Gastroenterol. 2014 Apr;63(4):209-15. PMID- 24731156 OWN - NLM STAT- MEDLINE DA - 20140723 DCOM- 20150331 IS - 1557-9077 (Electronic) IS - 1050-7256 (Linking) VI - 24 IP - 8 DP - 2014 Aug TI - Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas. PG - 1289-96 LID - 10.1089/thy.2013.0695 [doi] AB - BACKGROUND: Most current guidelines suggest one or two weeks of low iodine diet (LID) before radioactive iodine ablation therapy (RAIT) to increase its efficacy in differentiated thyroid cancer (DTC) patients after total thyroidectomy. LID duration is particularly important for patients living in iodine excess areas. However, there is no standardized LID protocol and there are limited reports regarding the relationship between LID and ablation outcome. Therefore, we aimed to evaluate the optimal LID duration and define clinical features that affect ablation outcome. METHODS: A total of 202 papillary thyroid cancer patients with total thyroidectomy preparing for RAIT were enrolled. All patients had undergone two weeks of LID before (131)I administration. Morning spot urine specimens were obtained twice (one week or two weeks after LID, respectively) from each patient. Urine iodine excretion (UIE) values were used to evaluate LID efficacy. Successful ablation was defined using two definitions: (i) no visible uptake on a follow-up diagnostic (131)I scans, and (ii) no visible uptake on a follow-up diagnostic (131)I scans and stimulated serum thyroglobulin (Tg) levels <1 ng/mL. RESULTS: The UIE median values after LID for one and two weeks were lower than 50 mug/L, and the median UIE values were not significantly different according to the LID duration. Based on the first criterion for successful ablation, 175 of the 195 patients were successfully ablated. There were no significant differences in mean and median UIE levels between the ablated and non-ablated groups after LID for two weeks. The rate of ablation did not differ between the mild and moderate iodine deficient groups. Based on the second criterion for successful ablation, 149 of 188 patients were successfully ablated. The ablation success rate did not differ between UIE levels. When we analyzed clinical factors that affect ablation outcome, serum Tg level at the time of ablation was the only significant variable in multivariate logistic analysis. CONCLUSION: Strict LID for one week was sufficient to achieve target UIE values for RAIT preparation, even in iodine-rich areas. FAU - Lee, Minkyung AU - Lee M AD - 1 Department of Nuclear Medicine, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei College of Medicine , Seoul, Korea. FAU - Lee, Yu Kyung AU - Lee YK FAU - Jeon, Tae Joo AU - Jeon TJ FAU - Chang, Hang Seok AU - Chang HS FAU - Kim, Bup-Woo AU - Kim BW FAU - Lee, Yong Sang AU - Lee YS FAU - Park, Cheong Soo AU - Park CS FAU - Ryu, Young Hoon AU - Ryu YH LA - eng PT - Journal Article DEP - 20140605 PL - United States TA - Thyroid JT - Thyroid : official journal of the American Thyroid Association JID - 9104317 RN - 0 (Antibodies) RN - 0 (Iodine Radioisotopes) RN - 9010-34-8 (Thyroglobulin) RN - 9679TC07X4 (Iodine) SB - IM MH - Adult MH - Aged MH - Antibodies/blood MH - Cell Differentiation MH - *Diet MH - Female MH - Humans MH - Iodine/*therapeutic use MH - Iodine Radioisotopes/*therapeutic use MH - Male MH - Middle Aged MH - Practice Guidelines as Topic MH - Quality of Life MH - Thyroglobulin/blood/immunology MH - Thyroid Neoplasms/*radiotherapy MH - Thyroidectomy/methods MH - Treatment Outcome MH - Young Adult EDAT- 2014/04/16 06:00 MHDA- 2015/04/01 06:00 CRDT- 2014/04/16 06:00 PHST- 2014/06/05 [aheadofprint] AID - 10.1089/thy.2013.0695 [doi] PST - ppublish SO - Thyroid. 2014 Aug;24(8):1289-96. doi: 10.1089/thy.2013.0695. Epub 2014 Jun 5. PMID- 24729313 OWN - NLM STAT- MEDLINE DA - 20140801 DCOM- 20150330 IS - 1522-2683 (Electronic) IS - 0173-0835 (Linking) VI - 35 IP - 15 DP - 2014 Aug TI - Proteomic characterization of pediatric craniopharyngioma intracystic fluid by LC-MS top-down/bottom-up integrated approaches. PG - 2172-83 LID - 10.1002/elps.201300578 [doi] AB - The combination of top-down and bottom-up platforms was utilized for the LC-MS proteomic characterization of the intracystic fluid of adamantinomatous craniopharyngioma pediatric brain tumor disease. Proteins and peptides characterization was achieved by high-resolution LC-ESI-LTQ-Orbitrap-MS analysis while low-resolution LC-ESI-IT-MS was applied for the complete screening of the samples and the evaluation of the protein distribution within patients. Top-down analyses were applied to liquid/liquid extracted samples while bottom-up analyses were performed after trypsin digestion of both untreated and pretreated samples. The two proteomic approaches were complementary for the characterization of the proteome of craniopharyngioma intracystic fluid. Proteins and peptides involved in inflammation, mineralization processes and lipid transport were identified, in agreement with the calcium flecks, cholesterol granules and bone residues characteristic of this fluid. Apolipoprotein A-I, A-II, C-I and J, hemoglobin fragments, ubiquitin, alpha-2-HS-glycoprotein or fetuin A, alpha-1-antichymotrypsin, vitamin D binding protein, and alpha-1-acid glycoprotein were characterized. These data could be relevant for the comprehension of the processes involved in the pathogenesis of the disease and the development of the cyst and could contribute to the individuation of therapeutic targets for the reduction of the cyst volume delaying and/or avoiding invasive surgical treatments. CI - (c) 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. FAU - Martelli, Claudia AU - Martelli C AD - Facolta di Medicina, Istituto di Biochimica e Biochimica Clinica, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Iavarone, Federica AU - Iavarone F FAU - Vincenzoni, Federica AU - Vincenzoni F FAU - Rossetti, Diana Valeria AU - Rossetti DV FAU - D'Angelo, Luca AU - D'Angelo L FAU - Tamburrini, Gianpiero AU - Tamburrini G FAU - Caldarelli, Massimo AU - Caldarelli M FAU - Di Rocco, Concezio AU - Di Rocco C FAU - Messana, Irene AU - Messana I FAU - Castagnola, Massimo AU - Castagnola M FAU - Desiderio, Claudia AU - Desiderio C LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140620 PL - Germany TA - Electrophoresis JT - Electrophoresis JID - 8204476 RN - 0 (Peptide Fragments) RN - 0 (Proteome) RN - EC 3.4.21.4 (Trypsin) SB - IM MH - Adolescent MH - Child MH - Child, Preschool MH - Chromatography, High Pressure Liquid MH - Craniopharyngioma/*chemistry MH - Cyst Fluid/*chemistry MH - Female MH - Humans MH - Male MH - Mass Spectrometry MH - Peptide Fragments/analysis MH - Pituitary Neoplasms/*chemistry MH - Proteome/*analysis MH - Proteomics/*methods MH - Trypsin OTO - NOTNLM OT - Brain tumor OT - Craniopharyngioma OT - Intracystic fluid OT - MS OT - Proteomics EDAT- 2014/04/15 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/04/15 06:00 PHST- 2013/11/21 [received] PHST- 2014/03/21 [revised] PHST- 2014/04/04 [accepted] PHST- 2014/06/20 [aheadofprint] AID - 10.1002/elps.201300578 [doi] PST - ppublish SO - Electrophoresis. 2014 Aug;35(15):2172-83. doi: 10.1002/elps.201300578. Epub 2014 Jun 20. PMID- 24720758 OWN - NLM STAT- MEDLINE DA - 20140703 DCOM- 20150330 LR - 20150419 IS - 1557-7465 (Electronic) IS - 1079-9907 (Linking) VI - 34 IP - 7 DP - 2014 Jul TI - The altered tight junctions: an important gateway of bacterial translocation in cachexia patients with advanced gastric cancer. PG - 518-25 LID - 10.1089/jir.2013.0020 [doi] AB - Tight junctions (TJs) are the structural basis for the intestinal epithelium barrier. Increased intestinal permeability caused by variations in TJ proteins may result in bacterial translocation (BT). There is increasing evidence that BT might contribute to the occurrence and development of cancer cachexia, but the details are not known. Aims, we undertook further investigations into the pathway of BT in cancer cachexia. RESULTS: BT-positive patients had a higher level of claudins-2 (CL-2, P=0.035) and a lower level of occludin (P=0.038) and Zonula occluden-1 (P=0.01) than BT-negative patients. Moreover, the levels of IL-6, TNF-alpha, and IFN-gamma in BT-positive cachexia patients were higher compared with BT-negative cachexia patients (P<0.001, P=0.01, P<0.001) and BT-positive noncachexia patients (P<0.001, P=0.025, P<0.001). In the BT-positive cachexia patients, the local concentration of IL-6, TNF-alpha, and IFN-gamma, in the middle colic vein, was higher than in the peripheral venous (P=0.04, P=0.03, P=0.038). In addition, endotoxin was detected within the small intestinal wall, and the concentration of endotoxin decreased from the mucosal side to the serosal side gradually in BT-positive patients. This study suggests that the altered TJs could be an important gateway of BT in gastric cancer cachexia and local cytokines could play a more important role than systemic cytokines in the process. FAU - Jiang, Yingjian AU - Jiang Y AD - 1 Department of General Surgery, The Affiliated Hospital of Medical College, Qingdao University , Qingdao, P.R. China . FAU - Guo, Chuanyou AU - Guo C FAU - Zhang, Dianliang AU - Zhang D FAU - Zhang, Jian AU - Zhang J FAU - Wang, Xiaojie AU - Wang X FAU - Geng, Changxin AU - Geng C LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140410 PL - United States TA - J Interferon Cytokine Res JT - Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research JID - 9507088 SB - IM MH - *Bacterial Translocation MH - Cachexia/*complications/*microbiology MH - Cell Membrane Permeability/physiology MH - Electrophoresis, Gel, Two-Dimensional MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Stomach Neoplasms/*complications/*microbiology MH - Tight Junctions/chemistry/*pathology/physiology PMC - PMC4080858 OID - NLM: PMC4080858 [Available on 07/01/15] EDAT- 2014/04/12 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/04/12 06:00 PMCR- 2015/07/01 00:00 PHST- 2014/04/10 [aheadofprint] AID - 10.1089/jir.2013.0020 [doi] PST - ppublish SO - J Interferon Cytokine Res. 2014 Jul;34(7):518-25. doi: 10.1089/jir.2013.0020. Epub 2014 Apr 10. PMID- 24719122 OWN - NLM STAT- MEDLINE DA - 20140410 DCOM- 20150422 IS - 1976-2437 (Electronic) IS - 0513-5796 (Linking) VI - 55 IP - 3 DP - 2014 May TI - Expression of glycolysis-related proteins in solid papillary carcinoma of the breast according to basement membrane status. PG - 576-83 LID - 10.3349/ymj.2014.55.3.576 [doi] AB - PURPOSE: The aim of this study was to investigate the differences of expression in glycolysis-related proteins such as Glut-1, carbonic anhydrase (CA) IX, and monocarboxylate transporter (MCT) 4 according to the myoepithelial cell (MEC) and basement membrane (BM) status in solid papillary carcinoma (SPC) of the breast. MATERIALS AND METHODS: Immunohistochemical evaluation of Glut-1, CAIX, and MCT4, as well as p63 and type IV collagen, were performed on 23 SPC cases. RESULTS: Six and nine cases of SPC showed the presence and absence of myoepithelial cells, respectively, and eight cases belonged to the borderline status (p63-positive MEC on some areas of the outer tumor surface but not in others). BM was partially or completely absent in 14 cases and present in nine cases. SPC lacking BM more frequently showed high expression of CAIX than SPC with BM (p=0.037). CONCLUSION: In SPC of the breast, a strong expression of CAIX seems to be associated with an increasing degree of loss of BM, which can be interpreted as BM degradation due to the induction of extracellular acidity with increasing expression of CAIX. FAU - Kwon, Ji Eun AU - Kwon JE AD - Department of Pathology, Ajou University College of Medicine, Suwon, Korea. FAU - Jung, Woo-Hee AU - Jung WH AD - Department of Pathology, Yonsei University College of Medicine, Seoul, Korea. FAU - Koo, Ja Seung AU - Koo JS AD - Department of Pathology, Yonsei University College of Medicine, Seoul, Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140401 PL - Korea (South) TA - Yonsei Med J JT - Yonsei medical journal JID - 0414003 RN - 0 (Excitatory Amino Acid Transporter 2) RN - 0 (Monocarboxylic Acid Transporters) RN - 0 (Muscle Proteins) RN - 0 (SLC16A4 protein, human) RN - 0 (Tumor Markers, Biological) SB - IM MH - Adult MH - Aged MH - Basement Membrane/*metabolism MH - Breast Neoplasms/*metabolism MH - Carcinoma, Papillary/*metabolism MH - Excitatory Amino Acid Transporter 2/metabolism MH - Female MH - Glycolysis MH - Humans MH - Immunohistochemistry MH - Middle Aged MH - Monocarboxylic Acid Transporters/metabolism MH - Muscle Proteins/metabolism MH - Tumor Markers, Biological/*metabolism PMC - PMC3990068 OID - NLM: PMC3990068 OTO - NOTNLM OT - Basement membrane OT - breast OT - metabolism OT - myoepithelial cell OT - solid papillary carcinoma EDAT- 2014/04/11 06:00 MHDA- 2015/04/23 06:00 CRDT- 2014/04/11 06:00 PHST- 2013/07/08 [received] PHST- 2013/10/15 [revised] PHST- 2013/10/16 [accepted] PHST- 2014/04/01 [epublish] AID - 201405576 [pii] AID - 10.3349/ymj.2014.55.3.576 [doi] PST - ppublish SO - Yonsei Med J. 2014 May;55(3):576-83. doi: 10.3349/ymj.2014.55.3.576. Epub 2014 Apr 1. PMID- 24710566 OWN - NLM STAT- MEDLINE DA - 20140702 DCOM- 20150417 IS - 1476-5365 (Electronic) IS - 0268-3369 (Linking) VI - 49 IP - 7 DP - 2014 Jul TI - Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. PG - 907-12 LID - 10.1038/bmt.2014.63 [doi] AB - Modern treatment strategies have increased life expectancy in multiple myeloma, but little is known about the endocrine, metabolic and nutritional status of long-term survivors. We performed endocrine, metabolic, bone, body composition and nutritional evaluations in 32 patients with intensively-treated, advanced but stable, myeloma a median duration of 6 years from diagnosis and three lines of intensive treatment, including at least one haematopoietic SCT procedure. All patients were off active treatment. There was a high prevalence of endocrine dysfunction: hypothyroidism (9%), hypogonadism (65% males) and elevated prolactin (19%). Adrenocortical function was preserved despite large cumulative corticosteroid pretreatment. Biochemical markers were consistent with postmenopausal status in all females and infertility in males. Nutritionally, 59% were vitamin D insufficient/deficient, reduced serum folate in 25% and vitamin B12 in 6%. Total body DEXA scanning confirmed 'sarcopenic-obesity' in 65%, but reduced bone density was seen in a minority. We conclude that potentially correctable endocrine, metabolic and nutritional abnormalities are prevalent in heavily-treated patients with stable multiple myeloma. Preservation of bone supports the efficacy of bisphosphonate treatment from diagnosis, but sarcopenic-obesity may contribute to frailty. Ultimately, multi-system screening and appropriate interventions may optimise quality of long-term survival and further studies are warranted. FAU - Greenfield, D M AU - Greenfield DM AD - Department of Clinical Oncology, Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Boland, E AU - Boland E AD - Academic Unit of Supportive Care, University of Sheffield, Sheffield, UK. FAU - Ezaydi, Y AU - Ezaydi Y AD - Department of Clinical Haematology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Ross, R J M AU - Ross RJ AD - Academic Unit of Diabetes, Endocrinology and Reproduction, University of Sheffield, Sheffield, UK. FAU - Ahmedzai, S H AU - Ahmedzai SH AD - Academic Unit of Supportive Care, University of Sheffield, Sheffield, UK. FAU - Snowden, J A AU - Snowden JA AD - Department of Clinical Haematology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. CN - Late Effects Group LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140407 PL - England TA - Bone Marrow Transplant JT - Bone marrow transplantation JID - 8702459 SB - IM EIN - Bone Marrow Transplant. 2014 Jul;49(7):995 MH - Adult MH - Aged MH - Body Composition MH - Cross-Sectional Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Multiple Myeloma/immunology/*metabolism/pathology/*therapy MH - Nutritional Status IR - Coleman R FIR - Coleman, Robert IR - Eiser C FIR - Eiser, Christine IR - Ledger W FIR - Ledger, William IR - Jivraj S FIR - Jivraj, Shehnaaz EDAT- 2014/04/09 06:00 MHDA- 2015/04/18 06:00 CRDT- 2014/04/09 06:00 PHST- 2012/09/26 [received] PHST- 2014/01/30 [revised] PHST- 2014/02/02 [accepted] PHST- 2014/04/07 [aheadofprint] AID - bmt201463 [pii] AID - 10.1038/bmt.2014.63 [doi] PST - ppublish SO - Bone Marrow Transplant. 2014 Jul;49(7):907-12. doi: 10.1038/bmt.2014.63. Epub 2014 Apr 7. PMID- 24702121 OWN - NLM STAT- MEDLINE DA - 20141020 DCOM- 20150423 IS - 1651-226X (Electronic) IS - 0284-186X (Linking) VI - 53 IP - 10 DP - 2014 Oct TI - Self-reported taste and smell alterations in patients under investigation for lung cancer. PG - 1405-12 LID - 10.3109/0284186X.2014.895035 [doi] AB - This study of patients under investigation for lung cancer (LC) aims to: 1) examine the prevalence of self-reported taste and smell alterations (TSAs) and their relationships with demographic and clinical characteristics; and 2) explore nutritional importance of TSAs by examining their associations with patient-reported weight loss, symptoms interfering with food intake, and changes in food intake. METHODS: Patients were recruited consecutively during investigation for LC from one university hospital in Sweden. Patient-reported information on TSAs, demographics, six-month weight history, symptoms interfering with food intake, and changes in food intake was obtained. Relationships between TSAs and other variables were examined using two-tailed significance tests. In addition, putative explanatory factors for weight loss were explored in those patients diagnosed with LC, since a relationship between TSAs and weight loss was found in this group. RESULTS: The final sample consisted of 215 patients, of which 117 were diagnosed with primary LC within four months of study inclusion and 98 did not receive a cancer diagnosis. The 38% prevalence of TSAs was identical in both groups, and were generally reported as mild and not interfering with food intake. However, a statistically significant relationship between TSAs and weight loss was found among patients with LC, with a median weight change of - 5.5% and a higher frequency of weight loss >/= 10%. Patients with LC and weight loss >/= 10%, had higher frequency of reporting TSAs, of decreased food intake and of >/= 1 symptom interfering with food intake compared with those with less weight loss. CONCLUSION: TSAs, although relatively mild, were present in 38% of patients with and without LC. Relationships between TSAs and weight loss were found among patients with LC, but not fully explained by decreased food intake. This highlights the complexity of cancer-related weight loss. FAU - Belqaid, Kerstin AU - Belqaid K AD - Medical Management Centre, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet , Stockholm , Sweden. FAU - Orrevall, Ylva AU - Orrevall Y FAU - McGreevy, Jenny AU - McGreevy J FAU - Mansson-Brahme, Eva AU - Mansson-Brahme E FAU - Wismer, Wendy AU - Wismer W FAU - Tishelman, Carol AU - Tishelman C FAU - Bernhardson, Britt-Marie AU - Bernhardson BM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140404 PL - England TA - Acta Oncol JT - Acta oncologica (Stockholm, Sweden) JID - 8709065 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - *Eating MH - Female MH - Humans MH - Lung Neoplasms/*complications/diagnosis MH - Male MH - Middle Aged MH - Olfaction Disorders/epidemiology/*etiology MH - Patient Selection MH - Prevalence MH - *Self Report MH - Smoking/epidemiology MH - Taste Disorders/epidemiology/*etiology MH - *Weight Loss PMC - PMC4220986 OID - NLM: PMC4220986 EDAT- 2014/04/08 06:00 MHDA- 2015/04/24 06:00 CRDT- 2014/04/08 06:00 PHST- 2014/04/04 [aheadofprint] AID - 10.3109/0284186X.2014.895035 [doi] PST - ppublish SO - Acta Oncol. 2014 Oct;53(10):1405-12. doi: 10.3109/0284186X.2014.895035. Epub 2014 Apr 4. PMID- 24699907 OWN - NLM STAT- MEDLINE DA - 20140806 DCOM- 20150330 LR - 20150423 IS - 1619-7089 (Electronic) IS - 1619-7070 (Linking) VI - 41 IP - 9 DP - 2014 Sep TI - The value of (1)(8)F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors. PG - 1756-66 LID - 10.1007/s00259-014-2756-0 [doi] AB - PURPOSE: Our objective was to determine how positron emission tomography (PET)/CT had been used in the clinical treatment of malignant peripheral nerve sheath tumor (MPNST) patients at The University of Texas MD Anderson Cancer Center. METHODS: We reviewed a database of MPNST patients referred to MD Anderson Cancer Center during 1995-2011. We enrolled 47 patients who underwent PET/CT imaging. Disease stage was based on conventional imaging and PET/CT findings using National Comprehensive Cancer Network (NCCN) guidelines. Treatment strategies based on PET/CT and conventional imaging were determined by chart review. The maximum and mean standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), change in SUVmax, change in MTV, and change in TLG were calculated from the PET/CT studies before and after treatment. Response prediction was based on imaging studies performed before and after therapy and categorized as positive or negative for residual tumor. Clinical outcome was determined from chart review. RESULTS: PET/CT was performed for staging in 16 patients, for restaging in 29 patients, and for surveillance in 2 patients. Of the patients, 88 % were correctly staged with PET/CT, whereas 75 % were correctly staged with conventional imaging. The sensitivity to detect local recurrence and distant metastasis at restaging was 100 and 100 % for PET/CT compared to 86 and 83 % for conventional imaging, respectively. PET/CT findings resulted in treatment changes in 31 % (5/16) and 14 % (4/29) of patients at staging and restaging, respectively. Recurrence, MTV, and TLG were prognostic factors for survival, whereas SUVmax and SUVmean were not predictive. For 21 patients who had imaging studies performed both before and after treatment, PET/CT was better at predicting outcome (overall survival, progression-free survival) than conventional imaging. A decreasing SUVmax >/= 30 % and decrease in TLG and MTV were significant predictors for overall and progression-free survival. CONCLUSION: PET/CT is valuable in MPNST management because of its high accuracy in staging and high sensitivity and accuracy in restaging as well as improvements in treatment planning. MTV from baseline staging studies is predictive of survival. Additionally, change in SUVmax, TLG, and MTV accurately predicted outcomes after treatment. FAU - Khiewvan, Benjapa AU - Khiewvan B AD - Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, P.O. Box 301402, Unit 1483,1515 Holcombe Blvd., Houston, TX, 77230-1402, USA. FAU - Macapinlac, Homer A AU - Macapinlac HA FAU - Lev, Dina AU - Lev D FAU - McCutcheon, Ian E AU - McCutcheon IE FAU - Slopis, John M AU - Slopis JM FAU - Al Sannaa, Ghadah AU - Al Sannaa G FAU - Wei, Wei AU - Wei W FAU - Chuang, Hubert H AU - Chuang HH LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P30 CA016672/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20140404 PL - Germany TA - Eur J Nucl Med Mol Imaging JT - European journal of nuclear medicine and molecular imaging JID - 101140988 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Child MH - Female MH - Fluorodeoxyglucose F18/*diagnostic use MH - Glycolysis MH - Humans MH - Male MH - Middle Aged MH - *Multimodal Imaging MH - Neurilemmoma/*diagnosis/metabolism/pathology/*therapy MH - *Positron-Emission Tomography MH - Retrospective Studies MH - Sensitivity and Specificity MH - *Tomography, X-Ray Computed MH - Treatment Outcome MH - Tumor Burden MH - Young Adult EDAT- 2014/04/05 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/04/05 06:00 PHST- 2013/11/04 [received] PHST- 2014/03/04 [accepted] PHST- 2014/04/04 [aheadofprint] AID - 10.1007/s00259-014-2756-0 [doi] PST - ppublish SO - Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1756-66. doi: 10.1007/s00259-014-2756-0. Epub 2014 Apr 4. PMID- 24679035 OWN - NLM STAT- MEDLINE DA - 20140331 DCOM- 20150410 IS - 1699-5198 (Electronic) IS - 0212-1611 (Linking) VI - 29 IP - 4 DP - 2014 TI - Dietary intake and nutritional status in cancer patients; comparing adults and older adults. PG - 907-12 LID - 10.3305/nh.2014.29.4.7131 [doi] AB - OBJECTIVE: Evaluate the nutrient intake and nutritional status of food in cancer patients admitted to a university hospital, with comparison of adult and older adult age category. METHODS: Cross-sectional study. This study involved cancer patients admitted to a hospital in 2010. Dietary habits were collected using a Brazilian food frequency questionnaire. Participants were divided in two groups: adults or older adults and in 4-cancer category: hematologic, lung, gastrointestinal and others. Body Mass Index evaluated nutritional status. RESULTS: A total of 86 patients with a mean age of 56.5 years, with 55% males and 42% older adults were evaluated. The older adult category had a higher frequency of being underweight (24.4% vs 16.3%, p < 0.01) and a lower frequency of being overweight (7% vs. 15.1%, p < 0.01) than adults. Both, adult and older adults had a high frequency of smoking, alcohol consumption and physical inactivity. The older adults had lower consumption of calories, intake of iron and folic acid. Inadequacy of vitamin intake was observed in both groups; respectively, 52%, 43%, 95%, 76% and 88% for Vitamin A, C, D, E and folic acid. The older adults had a higher folic acid and calcium inadequacy than the adults (97% vs 82%, p <0.01; 88% vs 72%, p < 0.01). There was no association of micronutrient intake with cancer, nor with nutritional status. CONCLUSION: The food intake, macro and micronutrients ingestion is insufficient among cancer individuals. Food intake of older adults was inferior, when compared to the adult category. There was a high prevalence of BMI excess in the adult group and a worst nutritional status in the older adult category. CI - Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved. FAU - Gomez Valiente da Silva, Henyse AU - Gomez Valiente da Silva H AD - Universidade do Estado de Rio de Janeiro-UERJ. Brazil.. henyse@uol.com.br. FAU - Fonseca de Andrade, Camila AU - Fonseca de Andrade C AD - Universidade do Estado de Rio de Janeiro-UERJ. Brazil.. FAU - Bello Moreira, Annie Seixas AU - Bello Moreira AS AD - Universidade do Estado de Rio de Janeiro-UERJ. Brazil.. LA - eng PT - Comparative Study PT - Journal Article DEP - 20140401 PL - Spain TA - Nutr Hosp JT - Nutricion hospitalaria JID - 9100365 SB - IM MH - Adult MH - Aged MH - *Aging MH - Cross-Sectional Studies MH - *Diet MH - *Eating MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasms/*physiopathology MH - Nutrition Assessment MH - *Nutritional Status OAB - Publisher: Abstract available from the publisher. OABL- spa EDAT- 2014/04/01 06:00 MHDA- 2015/04/11 06:00 CRDT- 2014/04/01 06:00 AID - 10.3305/nh.2014.29.4.7131 [doi] PST - epublish SO - Nutr Hosp. 2014 Apr 1;29(4):907-12. doi: 10.3305/nh.2014.29.4.7131. PMID- 24668337 OWN - NLM STAT- MEDLINE DA - 20140416 DCOM- 20150417 IS - 1477-9234 (Electronic) IS - 1477-9226 (Linking) VI - 43 IP - 19 DP - 2014 May 21 TI - Dinuclear zinc(II) complexes containing (benzimidazol-2-yl)benzene that overcome drug resistance in hepatocellular carcinoma cells through induction of mitochondria fragmentation. PG - 6973-6 LID - 10.1039/c4dt00198b [doi] AB - Herein we demonstrated that dinuclear zinc complexes could overcome drug resistance in R-HepG2 drug resistance hepatocellular carcinoma cells through induction of mitochondria-mediated apoptosis or by triggering mitochondria fragmentation, depletion of the membrane potential and intracellular ATP levels. FAU - Xie, Qiang AU - Xie Q AD - Department of Chemistry, Jinan University, Guangzhou 510632, China. tchentf@jnu.edu.cn. FAU - Liu, Shenggui AU - Liu S FAU - Li, Xiaoling AU - Li X FAU - Wu, Qiong AU - Wu Q FAU - Luo, Zuandi AU - Luo Z FAU - Fu, Xiaoyan AU - Fu X FAU - Cao, Wenqiang AU - Cao W FAU - Lan, Guoqiang AU - Lan G FAU - Li, Dan AU - Li D FAU - Zheng, Wenjie AU - Zheng W FAU - Chen, Tianfeng AU - Chen T LA - eng PT - Journal Article DEP - 20140326 PL - England TA - Dalton Trans JT - Dalton transactions (Cambridge, England : 2003) JID - 101176026 RN - 0 (Benzimidazoles) RN - 0 (Coordination Complexes) RN - 8L70Q75FXE (Adenosine Triphosphate) RN - E24GX49LD8 (benzimidazole) RN - J41CSQ7QDS (Zinc) RN - J64922108F (Benzene) SB - IM MH - Adenosine Triphosphate/metabolism MH - Apoptosis/drug effects MH - Benzene/*chemistry MH - Benzimidazoles/chemistry MH - Carcinoma, Hepatocellular/metabolism/pathology MH - Coordination Complexes/chemical synthesis/*chemistry/toxicity MH - Crystallography, X-Ray MH - Drug Resistance, Neoplasm/drug effects MH - Hep G2 Cells MH - Humans MH - Liver Neoplasms/metabolism/pathology MH - Membrane Potential, Mitochondrial/drug effects MH - Mitochondria/drug effects/*metabolism MH - Molecular Conformation MH - Zinc/*chemistry EDAT- 2014/03/29 06:00 MHDA- 2015/04/18 06:00 CRDT- 2014/03/27 06:00 PHST- 2014/03/26 [aheadofprint] PHST- 2014/04/15 [epublish] AID - 10.1039/c4dt00198b [doi] PST - ppublish SO - Dalton Trans. 2014 May 21;43(19):6973-6. doi: 10.1039/c4dt00198b. Epub 2014 Mar 26. PMID- 24639190 OWN - NLM STAT- MEDLINE DA - 20140705 DCOM- 20150330 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 21 IP - 8 DP - 2014 Aug TI - Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study. PG - 2636-41 LID - 10.1245/s10434-013-3438-z [doi] AB - BACKGROUND: Results concerning the side effects of oxaliplatin associated with fluorouracil and leucovorin (FOLFOX) in older patients are controversial. The objective of this study was to assess the use and the toxicity of FOLFOX in patients aged 70 years and older as administered in current practice. METHODS: Among 305 stage III colon cancers registered in a well-defined population in Burgundy between 2004 and 2009, 210 had adjuvant chemotherapy, including 156 with FOLFOX. The cumulated rates of toxicity were calculated by using the Kaplan-Meier method. The risks of overall toxicity and of severe toxicity (grade 3 or 4) in patients less than 70 years and in older patients were compared by using a Cox model. RESULTS: There was no difference between the group of the patients less than 70 years and the older age group for the cumulative incidence of hematologic, neurologic, digestive, and general toxicity. There was also no difference between the two groups for the severity of side effects (grade 3 or 4, 31.4 vs. 39.0 %; p = 0.576). The multivariate analysis indicated after adjustment on sex and the Charlson comorbidity score that there was no difference between the two age groups for toxicity (hazard ratio = 1.28; 95 % CI 0.68-2.41; p = 0.439). CONCLUSIONS: Cancer registries can be used to evaluate the toxicity of chemotherapy at the population level. Tolerance to the FOLFOX regimen among elderly patients did not significantly differ from that in younger patients. This treatment should be considered regardless of patients' age alone, but consideration should be given to the capacity of patients to tolerate adverse events. FAU - Hamza, Samia AU - Hamza S AD - Digestive Cancer Registry of Burgundy, INSERM U866, University Hospital, University of Burgundy, Dijon, France. FAU - Bouvier, Anne-Marie AU - Bouvier AM FAU - Rollot, Fabien AU - Rollot F FAU - Lepage, Come AU - Lepage C FAU - Faivre, Jean AU - Faivre J FAU - Bedenne, Laurent AU - Bedenne L LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140318 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 0 (Organoplatinum Compounds) RN - 04ZR38536J (oxaliplatin) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) SB - IM MH - Adenocarcinoma/*drug therapy/mortality/pathology MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/*adverse effects MH - Cohort Studies MH - Colonic Neoplasms/*drug therapy/mortality/pathology MH - Digestive System Diseases/chemically induced/*epidemiology MH - Female MH - Fluorouracil/administration & dosage MH - Follow-Up Studies MH - France/epidemiology MH - Hematologic Diseases/chemically induced/*epidemiology MH - Humans MH - Incidence MH - Leucovorin/administration & dosage MH - Male MH - Neoplasm Staging MH - Nervous System Diseases/chemically induced/*epidemiology MH - Organoplatinum Compounds/administration & dosage MH - Prognosis MH - Survival Rate EDAT- 2014/03/19 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/03/19 06:00 PHST- 2013/06/22 [received] PHST- 2014/03/18 [aheadofprint] AID - 10.1245/s10434-013-3438-z [doi] PST - ppublish SO - Ann Surg Oncol. 2014 Aug;21(8):2636-41. doi: 10.1245/s10434-013-3438-z. Epub 2014 Mar 18. PMID- 24629850 OWN - NLM STAT- MEDLINE DA - 20140721 DCOM- 20150330 IS - 2152-2669 (Electronic) IS - 2152-2669 (Linking) VI - 14 IP - 4 DP - 2014 Aug TI - The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation. PG - 291-6 LID - 10.1016/j.clml.2014.02.001 [doi] LID - S2152-2650(14)00043-3 [pii] AB - INTRODUCTION/BACKGROUND: Mucositis is a common complication of high-dose melphalan (HDM) used before autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Mucositis rates are influenced by previous chemotherapy (CT) exposure. We examined the effect of induction therapy before ASCT on ASCT mucositis rates. PATIENTS AND METHODS: Patients undergoing first 200 mg/m(2) HDM ASCT were assessed. Those receiving < 200 mg/m(2), or those with previous ASCT were excluded. Patients were evaluated depending on type of induction therapy (CT, immunomodulatory drug [IMiD], or proteasome inhibitor [PI]) before ASCT. A case record review was performed and data collected on response to induction, rates of Grade 3/4 mucositis, and days of total parenteral nutrition (TPN) or parenteral opiate analgesia. RESULTS: One hundred twenty-eight patients with ASCT were assessed. Induction therapy was CT- (n = 62), IMiD- (n = 51), or PI-based (n = 15) therapy. Patient characteristics were overall similar, including median age, MM stage, and CD34(+) cell dose. IMiD-based therapy patients had lower rates of mucositis (33% vs. 53%; P = .03) and less opiate requirements (10% vs. 31%; P = .02) compared with those treated with CT. Rates of mucositis and opiate use in the PI group were not different to the CT cohorts (33% vs. 53%; P = .6 and 13% vs. 31%; P = .13), likely due to concurrent anthracycline exposure. TPN usage was similar (CT, 42%; IMiD, 35%; and PI, 20%), as was neutropenia duration and antibiotic usage. CONCLUSION: Patients treated with IMiD-based regimens before HDM ASCT had significantly lower rates of mucositis than those treated with CT-based therapy. There were too few patients who received PI therapy to evaluate the effect. CI - Copyright (c) 2014 Elsevier Inc. All rights reserved. FAU - Fleming, Shaun AU - Fleming S AD - The Royal Melbourne Hospital, Victoria, Australia. Electronic address: flemsha@gmail.com. FAU - Harrison, Simon J AU - Harrison SJ AD - Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; University of Melbourne, Victoria, Australia. FAU - Blombery, Piers AU - Blombery P AD - Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. FAU - Joyce, Trish AU - Joyce T AD - Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. FAU - Stokes, Kerrie AU - Stokes K AD - Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. FAU - Seymour, John F AU - Seymour JF AD - Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; University of Melbourne, Victoria, Australia. FAU - Prince, H Miles AU - Prince HM AD - Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; University of Melbourne, Victoria, Australia. FAU - Ritchie, David AU - Ritchie D AD - The Royal Melbourne Hospital, Victoria, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; University of Melbourne, Victoria, Australia. LA - eng PT - Journal Article DEP - 20140215 PL - United States TA - Clin Lymphoma Myeloma Leuk JT - Clinical lymphoma, myeloma & leukemia JID - 101525386 RN - 0 (Anthracyclines) RN - 0 (Steroids) RN - Q41OR9510P (Melphalan) SB - IM MH - Adult MH - Aged MH - Anthracyclines/administration & dosage/adverse effects MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Female MH - Hematopoietic Stem Cell Transplantation/adverse effects MH - Humans MH - *Induction Chemotherapy MH - Male MH - Melphalan/therapeutic use MH - Middle Aged MH - Multiple Myeloma/*complications/diagnosis/*drug therapy/mortality/therapy MH - Neoplasm Staging MH - Retrospective Moral Judgment MH - Severity of Illness Index MH - Steroids/administration & dosage/adverse effects MH - Stomatitis/diagnosis/*etiology MH - Transplantation Conditioning MH - Transplantation, Autologous MH - Treatment Outcome OTO - NOTNLM OT - Autologus transplantation OT - Mucositis OT - Myeloma OT - Novel therapy OT - Supportive Care EDAT- 2014/03/19 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/03/18 06:00 PHST- 2013/09/22 [received] PHST- 2014/02/06 [revised] PHST- 2014/02/11 [accepted] PHST- 2014/02/15 [aheadofprint] AID - S2152-2650(14)00043-3 [pii] AID - 10.1016/j.clml.2014.02.001 [doi] PST - ppublish SO - Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):291-6. doi: 10.1016/j.clml.2014.02.001. Epub 2014 Feb 15. PMID- 24627603 OWN - NLM STAT- MEDLINE DA - 20140314 DCOM- 20150406 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 10 DP - 2014 Mar 14 TI - Effect of branched-chain amino acids in patients receiving intervention for hepatocellular carcinoma. PG - 2673-80 LID - 10.3748/wjg.v20.i10.2673 [doi] AB - AIM: To investigate the usefulness of branched-chain amino acids (BCAA) before transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). METHODS: We investigated the usefulness of pre-intervention with BCAAs by comparing patients treated with BCAAs at 12.45 g/d orally for at least 2 wk before TACE or RFA and those not receiving such pretreatment. A total of 270 patients with hepatocellular carcinoma complicated by cirrhosis were included in the study. Mean changes from baseline (Delta) in serum albumin (Alb), C-reactive protein (CRP), and transaminase levels, as well as peak body temperature were also determined and compared at days 2, 5, and 10 after the start of TACE or RFA. RESULTS: In patients who underwent TACE or RFA, BCAA pre-intervention significantly suppressed the development of post- intervention hypoalbuminemia and reduced inflammatory reactions during the subsequent clinical course. After TACE, the DeltaAlb peaked on day 2, remained constantly lower in BCAA-treated patients, compared to the control group, and was -0.13 +/- 0.42 g/dL in BCAA-treated patients and -0.33 +/- 0.51 g/dL in untreated patients on day 10. The DeltaCRP was also significantly lower in BCAA-treated patients on days 2, 5 and 10 after TACE. Like the trends noted after TACE, a similar tendency was noted as to the DeltaAlb and DeltaCRP after RFA. The changes in serum Alb level were inversely correlated with CRP changes; therefore, a possible involvement of the anti-inflammatory effect of BCAAs was inferred as a factor contributory to the suppression of decrease in serum Alb level. CONCLUSION: Pre-intervention with BCAAs may hasten the recovery of serum Alb level and mitigate post-operative complications in patients undergoing TACE or RFA. FAU - Ishihara, Tomoaki AU - Ishihara T AD - Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan. FAU - Iwasa, Motoh AU - Iwasa M AD - Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan. FAU - Tanaka, Hideaki AU - Tanaka H AD - Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan. FAU - Kaito, Masahiko AU - Kaito M AD - Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan. FAU - Ikoma, Jiro AU - Ikoma J AD - Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan. FAU - Shibata, Toshiya AU - Shibata T AD - Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan. FAU - Takei, Yoshiyuki AU - Takei Y AD - Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan. LA - eng PT - Journal Article PL - China TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 RN - 0 (ALB protein, human) RN - 0 (Amino Acids, Branched-Chain) RN - 0 (Serum Albumin) RN - 9007-41-4 (C-Reactive Protein) RN - EC 2.6.1.- (Transaminases) SB - IM MH - Administration, Oral MH - Aged MH - Aged, 80 and over MH - Amino Acids, Branched-Chain/*administration & dosage MH - Body Temperature Regulation/drug effects MH - C-Reactive Protein/metabolism MH - Carcinoma, Hepatocellular/blood/pathology/*therapy MH - *Catheter Ablation/adverse effects MH - *Chemoembolization, Therapeutic/adverse effects MH - *Dietary Supplements MH - Drug Administration Schedule MH - Female MH - Humans MH - Hypoalbuminemia/blood/etiology/*prevention & control MH - Liver Neoplasms/blood/pathology/*therapy MH - Male MH - Retrospective Studies MH - Serum Albumin/metabolism MH - Time Factors MH - Transaminases/blood MH - Treatment Outcome PMC - PMC3949276 OID - NLM: PMC3949276 OTO - NOTNLM OT - Branched-chain amino acids OT - Cirrhosis OT - Hepatocellular carcinoma OT - Hypoalbuminemia OT - Radiofrequency ablation OT - Transarterial chemoembolization EDAT- 2014/03/15 06:00 MHDA- 2015/04/07 06:00 CRDT- 2014/03/15 06:00 PHST- 2013/07/02 [received] PHST- 2013/08/09 [revised] PHST- 2013/12/12 [accepted] AID - 10.3748/wjg.v20.i10.2673 [doi] PST - ppublish SO - World J Gastroenterol. 2014 Mar 14;20(10):2673-80. doi: 10.3748/wjg.v20.i10.2673. PMID- 24616571 OWN - NLM STAT- MEDLINE DA - 20140311 DCOM- 20150408 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 8 DP - 2014 Feb 28 TI - Sequencing of treatment in metastatic colorectal cancer: where to fit the target. PG - 1993-2004 LID - 10.3748/wjg.v20.i8.1993 [doi] AB - Colorectal cancer is a lethal disease if not discovered early. Even though appropriate screening and preventive strategies are in place in many countries, a significant number of patients are still diagnosed at late stages of the disease. The management of metastatic colorectal cancer remains a significant clinical challenge to oncologists worldwide. While cytotoxic regimens constitute the main treatment of choice in this patient population, addition of the five biologics (bevacizumab, cetuximab, aflibercept, panitumumab and regorafenib) to these regimens has improved clinical outcomes. The most commonly used cytotoxic regimens include doublet combinations (FOLFOX/XELOX or FOLFIRI). Many clinical trials have been published and others are underway to compare the biologic agents with one another in order to prove the superiority of one regimen over another. Metastatic colorectal cancer patients have many treatment options; however, the optimal use and sequence of targeted agents remain to be determined. This review entails concise and updated clinical data on the management of metastatic colorectal cancer. The aim of the review is to determine where to fit the five biologic targets into the treatment algorithm of metastatic colorectal cancer patients and to derive treatment sequences that would achieve best clinical outcome based on the current available data. FAU - Temraz, Sally AU - Temraz S AD - Sally Temraz, Deborah Mukherji, Ali Shamseddine, Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center (AUBMC), Riad El Solh 110 72020, Beirut, Lebanon. FAU - Mukherji, Deborah AU - Mukherji D AD - Sally Temraz, Deborah Mukherji, Ali Shamseddine, Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center (AUBMC), Riad El Solh 110 72020, Beirut, Lebanon. FAU - Shamseddine, Ali AU - Shamseddine A AD - Sally Temraz, Deborah Mukherji, Ali Shamseddine, Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center (AUBMC), Riad El Solh 110 72020, Beirut, Lebanon. LA - eng PT - Journal Article PT - Review PL - China TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 RN - 0 (Angiogenesis Inhibitors) RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Organoplatinum Compounds) RN - 0 (Phenylurea Compounds) RN - 0 (Pyridines) RN - 0 (Recombinant Fusion Proteins) RN - 0 (panitumumab) RN - 15C2VL427D (aflibercept) RN - 24T2A1DOYB (regorafenib) RN - 2S9ZZM9Q9V (bevacizumab) RN - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor) RN - PQX0D8J21J (cetuximab) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - XT3Z54Z28A (Camptothecin) RN - Folfox protocol RN - IFL protocol SB - IM MH - Algorithms MH - Angiogenesis Inhibitors/administration & dosage MH - Antibodies, Monoclonal/administration & dosage MH - Antibodies, Monoclonal, Humanized/administration & dosage MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Camptothecin/analogs & derivatives/therapeutic use MH - Clinical Trials as Topic MH - Colorectal Neoplasms/*therapy MH - Disease Progression MH - *Drug Administration Schedule MH - Fluorouracil/therapeutic use MH - Humans MH - Leucovorin/therapeutic use MH - Neoplasm Metastasis MH - Organoplatinum Compounds/therapeutic use MH - Phenylurea Compounds/administration & dosage MH - Pyridines/administration & dosage MH - Receptors, Vascular Endothelial Growth Factor/administration & dosage MH - Recombinant Fusion Proteins/administration & dosage PMC - PMC3934469 OID - NLM: PMC3934469 OTO - NOTNLM OT - Anti-epithelial growth factor receptor OT - Anti-vascular endothelial growth factor OT - Chemotherapy OT - Metastatic colorectal cancer OT - Treatment sequence EDAT- 2014/03/13 06:00 MHDA- 2015/04/09 06:00 CRDT- 2014/03/12 06:00 PHST- 2013/09/25 [received] PHST- 2013/12/01 [revised] PHST- 2014/01/14 [accepted] AID - 10.3748/wjg.v20.i8.1993 [doi] PST - ppublish SO - World J Gastroenterol. 2014 Feb 28;20(8):1993-2004. doi: 10.3748/wjg.v20.i8.1993. PMID- 24614259 OWN - NLM STAT- MEDLINE DA - 20140421 DCOM- 20150409 IS - 1759-5037 (Electronic) IS - 1759-5029 (Linking) VI - 10 IP - 5 DP - 2014 May TI - Thyroid gland. BMI may predict risk of papillary thyroid cancer. PG - 252 LID - 10.1038/nrendo.2014.27 [doi] FAU - Sargent, Jennifer AU - Sargent J LA - eng PT - Comment PT - Journal Article DEP - 20140311 PL - England TA - Nat Rev Endocrinol JT - Nature reviews. Endocrinology JID - 101500078 SB - IM CON - Thyroid. 2014 Jun;24(6):966-74. PMID: 24555500 MH - Carcinoma/*etiology MH - Female MH - Humans MH - Male MH - Obesity/*complications MH - Thyroid Neoplasms/*etiology EDAT- 2014/03/13 06:00 MHDA- 2015/04/10 06:00 CRDT- 2014/03/12 06:00 PHST- 2014/03/11 [aheadofprint] AID - nrendo.2014.27 [pii] AID - 10.1038/nrendo.2014.27 [doi] PST - ppublish SO - Nat Rev Endocrinol. 2014 May;10(5):252. doi: 10.1038/nrendo.2014.27. Epub 2014 Mar 11. PMID- 24610400 OWN - NLM STAT- MEDLINE DA - 20140809 DCOM- 20150331 IS - 1941-6636 (Electronic) VI - 45 IP - 3 DP - 2014 Sep TI - Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis. PG - 298-306 LID - 10.1007/s12029-014-9594-y [doi] AB - PURPOSE: Whether the survival benefit of perioperative FOLFOX in patients with liver metastases of colorectal cancer (LMCRC) is provided by preoperative chemotherapy (CT), postoperative CT, or both remains unclear. This study aimed to evaluate, in patients with resectable LMCRC, the survival impact of preoperative and postoperative separately. METHODS: Between 2000 and 2010, the 179 patients (126 men, age 61 +/- 11 years) with initially resectable LMCRC, who underwent liver resection (LR) and were offered pre- and/or postoperative FOLFOX were included. Twenty-four (13%) patients did not receive CT, 27(15%) patients received only preoperative CT, 71 (40%) patients received only postoperative CT, and 57 (32%) patients received both pre- and postoperative CT. RESULTS: Operative morbidity and mortality rates were 19 and 0.6%, respectively. At 1, 3, and 5 years, OS and DFS rates were 97, 66, 46 and 60, 32, and 24%, respectively. Postoperative FOLFOX was an independent predictor of increased OS (HR = 0.55 [95% CI, 0.35-0.87] p = 0.01) and DFS (HR = 0.54 [0.36-0.82] p = 0.0017), whereas the synchronous onset of the metastasis and the presence of radiographically occult liver metastases were independent predictors of poorer OS. Alternatively, preoperative FOLFOX had no significant influence on OS (HR = 0.96 [0.57-1.60] p = 0.83) or DFS (HR = 1.05 [0.66-1.66] p = 0.87). CONCLUSIONS: The survival benefit of FOLFOX in patients with resectable LMCRC may be provided by postoperative rather than preoperative administration. FAU - Faron, Matthieu AU - Faron M AD - Department of Digestive Surgery, AP-HP Hopital Saint Antoine, 184, rue du Faubourg Saint Antoine, Paris, 75012, France. FAU - Chirica, Mircea AU - Chirica M FAU - Tranchard, Hadrien AU - Tranchard H FAU - Balladur, Pierre AU - Balladur P FAU - de Gramont, Aimery AU - de Gramont A FAU - Afchain, Pauline AU - Afchain P FAU - Andre, Thierry AU - Andre T FAU - Paye, Francois AU - Paye F LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - J Gastrointest Cancer JT - Journal of gastrointestinal cancer JID - 101479627 RN - 0 (Organoplatinum Compounds) RN - 04ZR38536J (oxaliplatin) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Folfox protocol SB - IM MH - Adenocarcinoma/drug therapy/radiography/*secondary/surgery MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use MH - *Chemotherapy, Adjuvant MH - Colorectal Neoplasms/drug therapy/*pathology/surgery MH - Disease-Free Survival MH - Drug Administration Schedule MH - Drug Evaluation MH - False Negative Reactions MH - Female MH - Fluorouracil/administration & dosage MH - Follow-Up Studies MH - *Hepatectomy MH - Humans MH - Kaplan-Meier Estimate MH - Leucovorin/administration & dosage MH - Liver Neoplasms/drug therapy/pathology/radiography/*secondary/surgery MH - Male MH - Middle Aged MH - *Neoadjuvant Therapy MH - Organoplatinum Compounds/administration & dosage MH - Postoperative Care MH - Preoperative Care MH - Retrospective Studies MH - Treatment Outcome EDAT- 2014/03/13 06:00 MHDA- 2015/04/01 06:00 CRDT- 2014/03/11 06:00 AID - 10.1007/s12029-014-9594-y [doi] PST - ppublish SO - J Gastrointest Cancer. 2014 Sep;45(3):298-306. doi: 10.1007/s12029-014-9594-y. PMID- 24608701 OWN - NLM STAT- MEDLINE DA - 20140310 DCOM- 20150406 IS - 1532-8457 (Electronic) IS - 1043-4542 (Linking) VI - 31 IP - 2 DP - 2014 Mar-Apr TI - Exploring parental factors related to weight management in survivors of childhood central nervous system tumors. PG - 84-94 LID - 10.1177/1043454213518112 [doi] AB - Childhood central nervous system tumor survivors (CCNSTS) are at risk for adverse health issues. Little research has been conducted to explore the role of parental factors in weight management to mitigate adverse health outcomes. We conducted 9 group interviews (n=20) with CCNSTS, their parents, and health care providers to ascertain parental factors that may influence weight management practices in CCNSTS. Three main themes were identified: parenting style, parent-child connectedness, and food and physical activity (PA) environment. Although most parents adopted an authoritative parenting style related to diet and PA practices, some adopted a permissive parenting style. Participants expressed high levels of connection that may hinder the development of peer relationships and described the food and PA environments that promote or hinder weight management through parental modeling of healthy eating and PA and access to healthy food and activities. Weight management interventions for CCNSTS may experience greater benefit from using a family-focused approach, promoting positive food and PA environments, parental modeling of healthy eating and exercise, and partnering with youth to adopt weight management behaviors. FAU - Santa Maria, Diane AU - Santa Maria D AD - 1The University of Texas School of Public Health, Houston, TX, USA. FAU - Swartz, Maria C AU - Swartz MC FAU - Markham, Christine AU - Markham C FAU - Chandra, Joya AU - Chandra J FAU - McCurdy, Sheryl AU - McCurdy S FAU - Basen-Engquist, Karen AU - Basen-Engquist K LA - eng GR - CA 016672/CA/NCI NIH HHS/United States GR - R25T CA057730/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - J Pediatr Oncol Nurs JT - Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses JID - 8917825 SB - IM SB - N MH - Adolescent MH - Adult MH - *Body Weight MH - Central Nervous System Neoplasms/*physiopathology MH - Child MH - Humans MH - *Parent-Child Relations MH - *Survivors OTO - NOTNLM OT - central nervous system (CNS) tumors OT - childhood cancer survivors OT - neoplasms OT - parent–child relationship OT - weight management EDAT- 2014/03/13 06:00 MHDA- 2015/04/07 06:00 CRDT- 2014/03/11 06:00 AID - 1043454213518112 [pii] AID - 10.1177/1043454213518112 [doi] PST - ppublish SO - J Pediatr Oncol Nurs. 2014 Mar-Apr;31(2):84-94. doi: 10.1177/1043454213518112. PMID- 24587663 OWN - NLM STAT- MEDLINE DA - 20140303 DCOM- 20150408 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 7 DP - 2014 Feb 21 TI - Intravenous iron supplementation may be superior to observation in acute isovolemic anemia after gastrectomy for cancer. PG - 1852-7 LID - 10.3748/wjg.v20.i7.1852 [doi] AB - AIM: To determine whether the application of post-operative intravenous (IV)-iron for acute isovolemic anemia after gastrectomy for cancer may be effective. METHODS: Among 2078 gastric cancer patients who underwent surgery between February 2007 and August 2009 at the National Cancer Center Korea, 368 patients developed post-operative anemia [hemoglobin-(Hb)-level < 9 g/dL] within the first postoperative week. Patients requiring transfusions were excluded. IV-iron was administered to 63 patients (iron group). Sixty patients were observed without treatment (observation group). The clinical outcomes of the groups were compared concerning clinicopathologic data, morbidity, and changes in Hb levels using Fisher's exact test, Student's t-test and the Z-test. RESULTS: The initial Hb level was higher in the iron group than in the observation group (7.3 +/- 1.0 g/dL vs 8.4 +/- 0.5 g/dL, P < 0.001). The slope of the changes in the Hb level was significantly higher in the iron group than in the observation group (0.648 +/- 0.054 vs 0.349 +/- 0.038, P < 0.001). The Hb level 1 and 3 mo post-operatively increased from 10.7 +/- 1.3 to 11.9 +/- 1.3 g/dL in the iron group (P = 0.033) and from 10.1 +/- 1.0 to 10.8 +/- 1.4 g/dL in the observation group (P < 0.001). The postoperative hospital stay was significantly longer in the iron group than in the observation group (10.5 +/- 6.8 d vs 7.6 +/- 5.5 d, P = 0.011). There were no significant differences in the major and surgical complications between the groups (6.3% vs 13.3%, P = 0.192; 9.5% vs 3.3%, P = 0.164). CONCLUSION: IV-iron supplementation may be an effective treatment for post-operative isovolemic post-gastrectomy anemia and may be a better alternative than observation. FAU - Yoon, Hong Man AU - Yoon HM AD - Hong Man Yoon, Young-Woo Kim, Daniel Reim, Bang Wool Eom, Ji Yeon Park, Keun Won Ryu, Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang-si 410-769, South Korea. FAU - Kim, Young-Woo AU - Kim YW AD - Hong Man Yoon, Young-Woo Kim, Daniel Reim, Bang Wool Eom, Ji Yeon Park, Keun Won Ryu, Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang-si 410-769, South Korea. FAU - Nam, Byung Ho AU - Nam BH AD - Hong Man Yoon, Young-Woo Kim, Daniel Reim, Bang Wool Eom, Ji Yeon Park, Keun Won Ryu, Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang-si 410-769, South Korea. FAU - Reim, Daniel AU - Reim D AD - Hong Man Yoon, Young-Woo Kim, Daniel Reim, Bang Wool Eom, Ji Yeon Park, Keun Won Ryu, Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang-si 410-769, South Korea. FAU - Eom, Bang Wool AU - Eom BW AD - Hong Man Yoon, Young-Woo Kim, Daniel Reim, Bang Wool Eom, Ji Yeon Park, Keun Won Ryu, Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang-si 410-769, South Korea. FAU - Park, Ji Yeon AU - Park JY AD - Hong Man Yoon, Young-Woo Kim, Daniel Reim, Bang Wool Eom, Ji Yeon Park, Keun Won Ryu, Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang-si 410-769, South Korea. FAU - Ryu, Keun Won AU - Ryu KW AD - Hong Man Yoon, Young-Woo Kim, Daniel Reim, Bang Wool Eom, Ji Yeon Park, Keun Won Ryu, Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang-si 410-769, South Korea. LA - eng PT - Journal Article PL - China TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 RN - 0 (Hemoglobins) RN - E1UOL152H7 (Iron) SB - IM MH - Administration, Intravenous MH - Aged MH - Anemia/*complications/*therapy MH - Case-Control Studies MH - *Dietary Supplements MH - Female MH - Gastrectomy/*adverse effects MH - Hemoglobins/chemistry MH - Humans MH - Iron/*therapeutic use MH - Male MH - Middle Aged MH - Neoplasms/blood/*complications/*surgery MH - Postoperative Period MH - Republic of Korea MH - Retrospective Studies MH - Treatment Outcome PMC - PMC3930984 OID - NLM: PMC3930984 OTO - NOTNLM OT - Acute isovolemic anemia OT - Gastrectomy OT - Gastric cancer OT - Intravenous iron OT - Observation EDAT- 2014/03/04 06:00 MHDA- 2015/04/09 06:00 CRDT- 2014/03/04 06:00 PHST- 2013/08/05 [received] PHST- 2013/11/20 [revised] PHST- 2013/12/12 [accepted] AID - 10.3748/wjg.v20.i7.1852 [doi] PST - ppublish SO - World J Gastroenterol. 2014 Feb 21;20(7):1852-7. doi: 10.3748/wjg.v20.i7.1852. PMID- 24587620 OWN - NLM STAT- MEDLINE DA - 20140303 DCOM- 20150408 IS - 2219-2840 (Electronic) IS - 1007-9327 (Linking) VI - 20 IP - 6 DP - 2014 Feb 14 TI - A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. PG - 1438-49 LID - 10.3748/wjg.v20.i6.1438 [doi] AB - Helicobacter pylori (H. pylori) affects nearly half of the world's population and, thus, is one of the most frequent and persistent bacterial infections worldwide. H. pylori is associated with peptic ulcer disease, gastric ulcers, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. Various diagnostic methods exist to detect infection, and the choice of one method or another depends on several factors, such as accessibility, advantages and disadvantages of each method, cost, and the age of patients. Once H. pylori infection is diagnosed, the clinician decides whether treatment is necessity, according to the patient's clinical condition. Typically, eradication of H. pylori is recommended for treatment and prevention of the infection. Cure rates with the standard triple therapy are acceptable, and effective quadruple therapies, sequential therapies, and concomitant therapies have been introduced as key alternatives to treat H. pylori infection. In this work, we review the main diagnostic methods used to identify H. pylori infection and to confirm eradication of infection. In addition, key factors related to treatment are reviewed. FAU - Garza-Gonzalez, Elvira AU - Garza-Gonzalez E AD - Elvira Garza-Gonzalez, Hector Jesus Maldonado-Garza, Francisco Javier Bosques-Padilla, Servicio de Gastroenterologia y Departamento de Patologia Clinica, Hospital Universitario "Dr. Jose Eleuterio Gonzalez" Universidad Autonoma de Nuevo Leon, Monterrey 64460, Mexico. FAU - Perez-Perez, Guillermo Ignacio AU - Perez-Perez GI AD - Elvira Garza-Gonzalez, Hector Jesus Maldonado-Garza, Francisco Javier Bosques-Padilla, Servicio de Gastroenterologia y Departamento de Patologia Clinica, Hospital Universitario "Dr. Jose Eleuterio Gonzalez" Universidad Autonoma de Nuevo Leon, Monterrey 64460, Mexico. FAU - Maldonado-Garza, Hector Jesus AU - Maldonado-Garza HJ AD - Elvira Garza-Gonzalez, Hector Jesus Maldonado-Garza, Francisco Javier Bosques-Padilla, Servicio de Gastroenterologia y Departamento de Patologia Clinica, Hospital Universitario "Dr. Jose Eleuterio Gonzalez" Universidad Autonoma de Nuevo Leon, Monterrey 64460, Mexico. FAU - Bosques-Padilla, Francisco Javier AU - Bosques-Padilla FJ AD - Elvira Garza-Gonzalez, Hector Jesus Maldonado-Garza, Francisco Javier Bosques-Padilla, Servicio de Gastroenterologia y Departamento de Patologia Clinica, Hospital Universitario "Dr. Jose Eleuterio Gonzalez" Universidad Autonoma de Nuevo Leon, Monterrey 64460, Mexico. LA - eng PT - Journal Article PT - Review PL - China TA - World J Gastroenterol JT - World journal of gastroenterology : WJG JID - 100883448 RN - 0 (Anti-Bacterial Agents) RN - 8W8T17847W (Urea) RN - EC 3.5.1.5 (Urease) RN - H1250JIK0A (Clarithromycin) SB - IM MH - Anti-Bacterial Agents/therapeutic use MH - Biopsy MH - Breath Tests MH - Clarithromycin/pharmacology MH - Drug Resistance, Bacterial MH - Helicobacter Infections/*diagnosis/*drug therapy/*microbiology MH - Helicobacter pylori/*drug effects MH - Humans MH - Lymphoma, B-Cell, Marginal Zone/microbiology MH - Peptic Ulcer/microbiology MH - Probiotics/therapeutic use MH - Reproducibility of Results MH - Stomach Neoplasms/microbiology MH - Stomach Ulcer/microbiology MH - Treatment Outcome MH - Urea/metabolism MH - Urease/metabolism PMC - PMC3925853 OID - NLM: PMC3925853 OTO - NOTNLM OT - Concomitant therapy OT - Diagnosis OT - Helicobacter pylori OT - Hybrid therapy OT - Sequential therapy OT - Treatment EDAT- 2014/03/04 06:00 MHDA- 2015/04/09 06:00 CRDT- 2014/03/04 06:00 PHST- 2013/09/27 [received] PHST- 2013/11/15 [revised] PHST- 2014/01/06 [accepted] AID - 10.3748/wjg.v20.i6.1438 [doi] PST - ppublish SO - World J Gastroenterol. 2014 Feb 14;20(6):1438-49. doi: 10.3748/wjg.v20.i6.1438. PMID- 24584196 OWN - NLM STAT- MEDLINE DA - 20140729 DCOM- 20150330 IS - 1473-5709 (Electronic) IS - 0959-8278 (Linking) VI - 23 IP - 5 DP - 2014 Sep TI - Knowledge of oral cancer, preventive attitudes, and behaviors of primary care physicians in Turkey. PG - 464-8 LID - 10.1097/CEJ.0000000000000020 [doi] AB - Oral cancers (OCs) have a high mortality rate because of their typically late diagnosis. Primary care physicians play a vital role in early detection. In this study, we evaluated the family physicians' (FPs) knowledge, preventive attitudes, and behaviors in terms of OCs. A semistructured questionnaire consisting of 50 questions was prepared and distributed to 200 FPs. Questions were grouped under four main headings: demographic characteristics, general protective attitudes against OCs, risk factors, and daily practices while performing the necessary examinations and referrals. Of 200 FPs, 164 responded to the questionnaire (82% response rate). The mean age of the study participants was 34.8 +/- 8.4 years and the mean duration of practice was 10 +/- 8.1 years. One-third of the physicians (29.9%, n=49) stated that they did not inquire about the amount of tobacco use. In terms of alcohol use, 45.7% (n=75) and 56.7% (n=93) did not ask about past alcohol consumption or the amount of alcohol consumed, respectively. Moreover, 69.5% (n=114) believed that they did not receive adequate smoking cessation training and 79.9% (n=131) stated that they did not receive any alcohol cessation training. To decrease morbidity and mortality associated with OCs, primary care physicians should be trained to ask their patients about high-risk behaviors, provide counseling and education on tobacco and alcohol-abuse cessation, and provide oral examinations. FAU - Tanriover, Ozlem AU - Tanriover O AD - aDepartment of Family Medicine, Faculty of Medicine, Yeditepe University bDepartment of Public Health, Faculty of Medicine, Medipol University cDepartment of Public Health, School of Medicine, Marmara University, Istanbul, Turkey. FAU - Hidiroglu, Seyhan AU - Hidiroglu S FAU - Save, Dilsad AU - Save D FAU - Akan, Hulya AU - Akan H FAU - Ay, Pinar AU - Ay P FAU - Karavus, Melda AU - Karavus M FAU - Hayran, Osman AU - Hayran O LA - eng PT - Journal Article PL - England TA - Eur J Cancer Prev JT - European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) JID - 9300837 SB - IM MH - Adult MH - Alcohol Drinking/adverse effects/prevention & control MH - *Attitude of Health Personnel MH - Clinical Competence/*statistics & numerical data MH - Counseling MH - Female MH - Follow-Up Studies MH - *Health Behavior MH - *Health Knowledge, Attitudes, Practice MH - Humans MH - Male MH - Medical History Taking MH - Middle Aged MH - Mouth Neoplasms/etiology/*prevention & control MH - *Physician's Practice Patterns MH - Physicians, Primary Care/*psychology MH - Questionnaires MH - Risk-Taking MH - Smoking/adverse effects/prevention & control MH - Turkey MH - Young Adult EDAT- 2014/03/04 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/03/04 06:00 AID - 10.1097/CEJ.0000000000000020 [doi] PST - ppublish SO - Eur J Cancer Prev. 2014 Sep;23(5):464-8. doi: 10.1097/CEJ.0000000000000020. PMID- 24569179 OWN - NLM STAT- MEDLINE DA - 20140402 DCOM- 20150413 IS - 1873-5134 (Electronic) IS - 0738-3991 (Linking) VI - 95 IP - 2 DP - 2014 May TI - Self-efficacy for temptations is a better predictor of weight loss than motivation and global self-efficacy: evidence from two prospective studies among overweight/obese women at high risk of breast cancer. PG - 254-8 LID - 10.1016/j.pec.2014.01.015 [doi] LID - S0738-3991(14)00050-0 [pii] AB - OBJECTIVES: Identifying predictors of weight loss could help to triage people who will benefit most from programs and identify those who require additional support. The present research was designed to address statistical, conceptual and operational difficulties associated with the role of self-efficacy in predicting weight loss. METHODS: In Study 1, 115 dieting overweight/obese women at high risk of breast cancer were weighed and completed questionnaires assessing motivation, global self-efficacy and self-efficacy for temptations. The main outcome measure was weight, measured 3-months post-baseline. Study 2 was identical (n=107), except changes in psychological variables were computed, and used to predict weight 6-months post-baseline. RESULTS: In Study 1, self-efficacy for temptations was a significant predictor of weight loss at 3-month follow-up. In Study 2, improved self-efficacy for temptations between baseline and four-weeks was predictive of lower weight at 6 months. CONCLUSION: The key finding was that self-efficacy for temptations, as opposed to motivation and global self-efficacy, was predictive of subsequent weight loss. PRACTICE IMPLICATIONS: The implication is that augmenting dieters' capability for dealing with temptations might boost the impact of weight loss programs. CI - Copyright (c) 2014 Elsevier Ireland Ltd. All rights reserved. FAU - Armitage, Christopher J AU - Armitage CJ AD - University of Manchester, UK. Electronic address: chris.armitage@manchester.ac.uk. FAU - Wright, Claire L AU - Wright CL AD - University of Chester, UK. FAU - Parfitt, Gaynor AU - Parfitt G AD - University of South Australia, Australia. FAU - Pegington, Mary AU - Pegington M AD - University Hospital South Manchester, UK. FAU - Donnelly, Louise S AU - Donnelly LS AD - University Hospital South Manchester, UK. FAU - Harvie, Michelle N AU - Harvie MN AD - University Hospital South Manchester, UK. LA - eng GR - 2005MAY06/Breast Cancer Campaign/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140203 PL - Ireland TA - Patient Educ Couns JT - Patient education and counseling JID - 8406280 SB - N MH - Adult MH - Breast Neoplasms/*psychology MH - Female MH - Health Behavior MH - Humans MH - *Intention MH - Middle Aged MH - *Motivation MH - Obesity/psychology MH - Overweight/*psychology MH - Predictive Value of Tests MH - Prospective Studies MH - Questionnaires MH - *Self Efficacy MH - *Weight Loss OTO - NOTNLM OT - Intention OT - Obese OT - Overweight OT - Self-efficacy OT - Weight loss EDAT- 2014/02/27 06:00 MHDA- 2015/04/14 06:00 CRDT- 2014/02/27 06:00 PHST- 2013/09/12 [received] PHST- 2014/01/07 [revised] PHST- 2014/01/26 [accepted] PHST- 2014/02/03 [aheadofprint] AID - S0738-3991(14)00050-0 [pii] AID - 10.1016/j.pec.2014.01.015 [doi] PST - ppublish SO - Patient Educ Couns. 2014 May;95(2):254-8. doi: 10.1016/j.pec.2014.01.015. Epub 2014 Feb 3. PMID- 24559008 OWN - NLM STAT- MEDLINE DA - 20140224 DCOM- 20150406 IS - 1699-5198 (Electronic) IS - 0212-1611 (Linking) VI - 29 IP - 3 DP - 2014 TI - The Inflammatory-Nutritional Index; assessing nutritional status and prognosis in gastrointestinal and lung cancer patients. PG - 629-34 LID - 10.3305/nh.2014.29.3.7195 [doi] AB - OBJECTIVE: To evaluate the prognostic capacity of the Inflammatory-Nutritional Index (INI) in gastrointestinal and lung cancer patients. METHODS: Longitudinal study, including patients from a chemotherapy service in Brazil, between July 2008 and May 2010. INI (Albumin/CRP) and nutritional status (by Subjective Global Assessment - SGA) were evaluated. Risk INI was defined as lower than 0.35. The mean follow-up of survival was 1.6 year. Statistical analyses were performed using Stata 11.1. RESULTS: 74 patients participated in the study, mean age 63.4, most of them male (58%) and presenting gastrointestinal cancer (71%). Malnutrition was identified in 87% of the patients (22% severely malnourished). The mean INI was 2.67 and 54% of the patients had INI levels considered as risk. During the follow-up there were 49 deaths (66%). The median survival time for INI risk patients was significantly shorter than for normal INI ones (p = 0,002). It took 0.78 year for the INI risk subsample to decline 50%, while it took 2.78 year for the normal INI subsample. INI risk and severe malnutrition were independent predictors for poor survival. CONCLUSION: The INI showed prognostic capacity in this sample and may be a useful tool, based on routinely available blood tests, to assess cancer patients. CI - Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved. FAU - Pastore, Carla Alberici AU - Pastore CA AD - Post-Graduate Program on Health and Behavior-Catholic University of Pelotas, Brazil. Nutrition College-Federal University of Pelotas. Brazil.. pastorecarla@yahoo.com.br. FAU - Orlandi, Silvana Paiva AU - Orlandi SP AD - Nutrition College-Federal University of Pelotas. Brazil.. FAU - Gonzalez, Maria Cristina AU - Gonzalez MC AD - Post-Graduate Program on Health and Behavior-Catholic University of Pelotas, Brazil.. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140301 PL - Spain TA - Nutr Hosp JT - Nutricion hospitalaria JID - 9100365 SB - IM MH - Aged MH - Female MH - Gastrointestinal Neoplasms/*physiopathology MH - Humans MH - Inflammation/*physiopathology MH - Longitudinal Studies MH - Lung Neoplasms/*physiopathology MH - Male MH - Malnutrition/etiology/physiopathology MH - Middle Aged MH - *Nutritional Status MH - Prognosis OAB - Publisher: Abstract available from the publisher. OABL- spa EDAT- 2014/02/25 06:00 MHDA- 2015/04/07 06:00 CRDT- 2014/02/25 06:00 AID - 10.3305/nh.2014.29.3.7195 [doi] PST - epublish SO - Nutr Hosp. 2014 Mar 1;29(3):629-34. doi: 10.3305/nh.2014.29.3.7195. PMID- 24530096 OWN - NLM STAT- MEDLINE DA - 20140512 DCOM- 20150410 IS - 1532-3080 (Electronic) IS - 0960-9776 (Linking) VI - 23 IP - 3 DP - 2014 Jun TI - The effect of molecular subtype and body mass index on neo-adjuvant chemotherapy in breast cancer patients. PG - 264-72 LID - 10.1016/j.breast.2013.11.008 [doi] LID - S0960-9776(13)00297-X [pii] AB - The aim of the present study was to analyze the effect of subtype and body mass index (BMI) on neo-adjuvant chemotherapy (NAC) and postoperative prognosis. Two-hundred and forty nine patients who underwent surgery after NAC were included. A multivariate analysis and survival analysis were used to clarify the relationship between BMI, subtype, and NAC. In the logistic regression model, the pCR rate had a significant relationship with the subtype and tumor stage. In the non-pCR group, more overweight patients had significantly a worse disease-free survival (DFS) compared to normal range patients (Log lank test, p < 0.05). In the Cox proportional hazards model, subtype and tumor stage were significantly associated with decreased DFS. In conclusion, patients with the ER (+), HER (-) type and a high BMI had a high risk for recurrence when they achieved non-pCR after NAC. CI - Copyright (c) 2014 Elsevier Ltd. All rights reserved. FAU - Iwase, Toshiaki AU - Iwase T AD - Division of Breast Surgery, Chiba Cancer Center Hospital, 666-2, Nitona-Cho, Chuo-Ku, Chiba, Japan. FAU - Nakamura, Rikiya AU - Nakamura R AD - Division of Breast Surgery, Chiba Cancer Center Hospital, 666-2, Nitona-Cho, Chuo-Ku, Chiba, Japan. Electronic address: rikiya@graduate.chiba-u.jp. FAU - Yamamoto, Naohito AU - Yamamoto N AD - Division of Breast Surgery, Chiba Cancer Center Hospital, 666-2, Nitona-Cho, Chuo-Ku, Chiba, Japan. FAU - Yoshi, Atushi AU - Yoshi A AD - Division of Breast Surgery, Chiba Cancer Center Hospital, 666-2, Nitona-Cho, Chuo-Ku, Chiba, Japan. FAU - Itami, Makiko AU - Itami M AD - Division of Diagnostic Pathology, Chiba Cancer Center Hospital, Chiba, Japan. FAU - Miyazaki, Masaru AU - Miyazaki M AD - Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Japan. LA - eng PT - Journal Article DEP - 20140212 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - 0 (Receptors, Cell Surface) SB - IM MH - Adult MH - Body Mass Index MH - Breast/pathology MH - *Breast Neoplasms/classification/epidemiology/metabolism/pathology/therapy MH - Chemotherapy, Adjuvant/*methods MH - Disease-Free Survival MH - Female MH - Humans MH - Japan/epidemiology MH - Mastectomy/statistics & numerical data MH - Middle Aged MH - Neoadjuvant Therapy/*methods MH - *Neoplasm Recurrence, Local/diagnosis/epidemiology MH - Neoplasm Staging MH - *Obesity/epidemiology MH - Prognosis MH - Proportional Hazards Models MH - Receptors, Cell Surface/analysis MH - Risk Assessment MH - Risk Factors OTO - NOTNLM OT - Body mass index OT - Breast neoplasms OT - Neoadjuvant therapy EDAT- 2014/02/18 06:00 MHDA- 2015/04/11 06:00 CRDT- 2014/02/18 06:00 PHST- 2013/04/15 [received] PHST- 2013/08/06 [revised] PHST- 2013/11/18 [accepted] PHST- 2014/02/12 [aheadofprint] AID - S0960-9776(13)00297-X [pii] AID - 10.1016/j.breast.2013.11.008 [doi] PST - ppublish SO - Breast. 2014 Jun;23(3):264-72. doi: 10.1016/j.breast.2013.11.008. Epub 2014 Feb 12. PMID- 24528363 OWN - NLM STAT- MEDLINE DA - 20140217 DCOM- 20150406 IS - 1699-5198 (Electronic) IS - 0212-1611 (Linking) VI - 29 IP - 2 DP - 2014 TI - Scored Patient-Generated Subjective Global Assessment, albumin and transferrin for nutritional assessment of gastrostomy fed head or neck cancer patients. PG - 420-6 LID - 10.3305/nh.2014.29.2.7066 [doi] AB - INTRODUCTION: Gastrostomy fed head or neck cancer patients frequently have impaired speech capacities. Enteral feeding teams frequently depend on laboratorial or anthropometrical parameters for nutritional assessment. AIMS: In these patients, this study aimed to evaluate: (1) the practicability of Scored - Patient-Generated Subjective Global Assessment (PG-SGA); (2) their nutritional status using the Scored-PG-SGA; (3) association of serum albumin and transferrin values to the nutritional status rating using PG-SGA. METHODS: On adult outpatients with head or neck cancer under prolonged (> 1 month) gastrostomy feeding, Scored-PGSGA, albumin and transferrin were evaluated during the same appointment. RESULTS: Scored-PG-SGA was easily feasible in 42 patients, even in patients with speech difficulties. Twenty-five patients were moderately/severely undernourished (PG-SGA/B+C). Scored-PG-SGA rated 41 patients as >/= 2, thus needing nutritional/ pharmacologic intervention. Albumin was low in 13 patients. Transferrin was low in 19 patients. Average albumin and transferrin in moderately/severely undernourished patients (PG-SGA/B+C) was significantly lower than in well-nourished (PG-SGA/A). There was association between Scored- PG-SGA rating, albumin and transferrin. CONCLUSIONS: In PEG fed head or neck cancer patients, PGSGA was practicable and useful, even in patients with impaired speaking skills. Most patients displayed moderate/severe malnutrition (PG-SGA/B+C). Scored-PG-SGA rated 41 patients as needing for nutritional/pharmacological intervention. Scored-PG-SGA should be systematically included in the evaluation of these patients. In these patients, albumin and transferrin levels showed relation with Scored-PG-SGA and should be considered as nutritional biomarkers. CI - Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved. FAU - Correira Pereira, Marta Alexandra AU - Correira Pereira MA AD - GENE. Enteral Feeding Group. Hospital Garcia de Orta. Almada. Portugal.. carla.adriana.santos@hotmail.com. FAU - Santos, Carla Adriana AU - Santos CA AD - GENE. Enteral Feeding Group. Hospital Garcia de Orta. Almada. Portugal.. carla.adriana.santos@hotmail.com. FAU - Almeida Brito, Jose AU - Almeida Brito J AD - CiiEM. Centro de Investigacao Interdisciplinar Egas Moniz. Almada. Portugal.. carla.adriana.santos@hotmail.com. FAU - Fonseca, Jorge AU - Fonseca J AD - GENE. Enteral Feeding Group. Hospital Garcia de Orta. Almada. Portugal. CiiEM. Centro de Investigacao Interdisciplinar Egas Moniz. Almada. Portugal.. carla.adriana.santos@hotmail.com. LA - eng PT - Journal Article DEP - 20140201 PL - Spain TA - Nutr Hosp JT - Nutricion hospitalaria JID - 9100365 RN - 0 (Albumins) RN - 0 (Transferrins) SB - IM MH - Adult MH - Aged MH - Albumins/*analysis MH - Enteral Nutrition MH - Female MH - Gastrostomy/*methods MH - Head and Neck Neoplasms/complications/*metabolism MH - Humans MH - Male MH - Middle Aged MH - *Nutrition Assessment MH - Outpatients MH - Transferrins/*blood OAB - Publisher: Abstract available from the publisher. OABL- spa EDAT- 2014/02/18 06:00 MHDA- 2015/04/07 06:00 CRDT- 2014/02/18 06:00 AID - 10.3305/nh.2014.29.2.7066 [doi] PST - epublish SO - Nutr Hosp. 2014 Feb 1;29(2):420-6. doi: 10.3305/nh.2014.29.2.7066. PMID- 24468298 OWN - NLM STAT- MEDLINE DA - 20140719 DCOM- 20150330 IS - 1938-0666 (Electronic) IS - 1526-8209 (Linking) VI - 14 IP - 4 DP - 2014 Aug TI - Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels. PG - 291-6 LID - 10.1016/j.clbc.2013.12.008 [doi] LID - S1526-8209(13)00313-3 [pii] AB - INTRODUCTION: The efficacy of adjuvant endocrine treatment with aromatase inhibitors (AIs), inhibiting the conversion of androgens to estrogen in adipose tissue, might depend on the overall volume of adipose tissue. However, little evidence is available regarding the pharmacokinetic behavior of AIs in women with obesity. The aim of this study was to investigate the interaction between body mass index (BMI) and anastrozole treatment as well as estrogenic activity. PATIENTS AND METHODS: A total of 216 postmenopausal patients with early-stage breast cancer who were receiving AI treatment with anastrozole constituted the final sample included in the analysis. During a regular 3-month after-care check-up, sociodemographic and clinical data and BMI were assessed. Blood samples were collected during routine blood testing. Measurement of AI plasma levels was performed by liquid chromatography-tandem mass spectrometry. Follicle stimulating hormone (FSH) and estradiol were measured within the routine blood examination. RESULTS: A median anastrozole plasma concentration of 34.7 ng/mL (mean, 37.4), with a large interindividual variability, was observed (SD, 15.1; range, 5.4-86.5). After age adjustment, it was found that anastrozole plasma concentrations significantly increased with BMI (r = 0.241; P = .001). Anastrozole serum concentrations in women with obesity (BMI >/= 30) exceeded those of women with normal weight (BMI /=30 kg/m2. These results were not substantially altered after excluding the patients who were diagnosed with breast cancer in the first 2 years of follow-up. CONCLUSIONS: The increased risk of postmenopausal breast cancer among women with higher BMIs was confirmed in Japanese. A borderline-significant positive association between BMI and premenopausal breast cancer was observed, suggesting that body mass in Asian women might have opposite effects on breast cancer compared with Western women. FAU - Wada, K AU - Wada K AD - Department of Epidemiology and Preventive Medicine, Gifu University Graduate School of Medicine, Gifu. FAU - Nagata, C AU - Nagata C FAU - Tamakoshi, A AU - Tamakoshi A FAU - Matsuo, K AU - Matsuo K FAU - Oze, I AU - Oze I FAU - Wakai, K AU - Wakai K FAU - Tsuji, I AU - Tsuji I FAU - Sugawara, Y AU - Sugawara Y FAU - Mizoue, T AU - Mizoue T FAU - Tanaka, K AU - Tanaka K FAU - Iwasaki, M AU - Iwasaki M FAU - Inoue, M AU - Inoue M FAU - Tsugane, S AU - Tsugane S FAU - Sasazuki, S AU - Sasazuki S CN - Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't DEP - 20140110 PL - England TA - Ann Oncol JT - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO JID - 9007735 SB - IM MH - Body Mass Index MH - Breast Neoplasms/epidemiology/*etiology MH - Female MH - Humans MH - Incidence MH - Japan/epidemiology MH - Overweight/*complications/epidemiology MH - Postmenopause MH - Premenopause MH - Prospective Studies MH - Risk Factors OTO - NOTNLM OT - body mass index OT - breast cancer OT - cohort study OT - pooled analysis EDAT- 2014/01/15 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/01/14 06:00 PHST- 2014/01/10 [aheadofprint] AID - mdt542 [pii] AID - 10.1093/annonc/mdt542 [doi] PST - ppublish SO - Ann Oncol. 2014 Feb;25(2):519-24. doi: 10.1093/annonc/mdt542. Epub 2014 Jan 10. PMID- 24406425 OWN - NLM STAT- MEDLINE DA - 20140130 DCOM- 20150330 IS - 1569-8041 (Electronic) IS - 0923-7534 (Linking) VI - 25 IP - 2 DP - 2014 Feb TI - The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow-up of 414 patients. PG - 487-93 LID - 10.1093/annonc/mdt549 [doi] AB - BACKGROUND: The role of home parenteral nutrition (HPN) in incurable cachectic cancer patients unable to eat is extremely controversial. The aim of this study is to analyse which factors can influence the outcome. PATIENTS AND METHODS: We studied prospectively 414 incurable cachectic (sub)obstructed cancer patients receiving HPN and analysed the association between patient or clinical characteristics and surviving status. RESULTS: Median weight loss, versus pre-disease and last 6-month period, was 24% and 16%, respectively. Median body mass index was 19.5, median KPS was 60, median life expectancy was 3 months. Mean/median survival was 4.7/3.0 months; 50.0% and 22.9% of patients survived 3 and 6 months, respectively. At the multivariable analysis, the variables significantly associated with 3- and 6-month survival were Glasgow Prognostic Score (GPS) and KPS, and GPS, KPS and tumour spread, respectively. By the aggregation of the significant variables, it was possible to dissect several classes of patients with different survival probabilities. CONCLUSIONS: The outcome of cachectic incurable cancer patients on HPN is not homogeneous. It is possible to identify groups of patients with a >/=6-month survival (possibly longer than that allowed in starvation). The indications for HPN can be modulated on these clinical/biochemical indices. FAU - Bozzetti, F AU - Bozzetti F AD - Faculty of Medicine, University of Milan, Milan. FAU - Santarpia, L AU - Santarpia L FAU - Pironi, L AU - Pironi L FAU - Thul, P AU - Thul P FAU - Klek, S AU - Klek S FAU - Gavazzi, C AU - Gavazzi C FAU - Tinivella, M AU - Tinivella M FAU - Joly, F AU - Joly F FAU - Jonkers, C AU - Jonkers C FAU - Baxter, J AU - Baxter J FAU - Gramlich, L AU - Gramlich L FAU - Chicharro, L AU - Chicharro L FAU - Staun, M AU - Staun M FAU - Van Gossum, A AU - Van Gossum A FAU - Lo Vullo, S AU - Lo Vullo S FAU - Mariani, L AU - Mariani L LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20140109 PL - England TA - Ann Oncol JT - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO JID - 9007735 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Cachexia/etiology/mortality/*therapy MH - Carcinoma/complications/*mortality MH - Digestive System Neoplasms/complications/*mortality MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Logistic Models MH - Male MH - Middle Aged MH - *Parenteral Nutrition, Home MH - Prognosis MH - Prospective Studies MH - Young Adult OTO - NOTNLM OT - cancer cachexia OT - home parenteral nutrition OT - incurable cancer patient OT - malignant obstruction EDAT- 2014/01/11 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/01/11 06:00 PHST- 2014/01/09 [aheadofprint] AID - mdt549 [pii] AID - 10.1093/annonc/mdt549 [doi] PST - ppublish SO - Ann Oncol. 2014 Feb;25(2):487-93. doi: 10.1093/annonc/mdt549. Epub 2014 Jan 9. PMID- 24402990 OWN - NLM STAT- MEDLINE DA - 20140109 DCOM- 20150406 IS - 1930-613X (Electronic) IS - 0026-4075 (Linking) VI - 179 IP - 1 DP - 2014 Jan TI - Vitamin D and prostate cancer survival in veterans. PG - 81-4 LID - 10.7205/MILMED-D-12-00540 [doi] AB - Prostate cancer remains the second most commonly diagnosed cancer among the male population worldwide. Vitamin D deficiency has been linked to prostate cancer and its aggressiveness. Herein, we initiated a retrospective study to evaluate vitamin D status and monitoring in veterans with prostate cancer, and to examine the potential link between vitamin D and survival status and length of survival in this population. We found that veterans who were initially vitamin D deficient were significantly less likely to survive than those who were not initially deficient, and that both initial and follow-up vitamin D deficiency were associated with decreased likelihood of survival after prostate cancer diagnosis. We recommend that vitamin D deficiency be replaced in veterans with prostate cancer. CI - Reprint & Copyright (c) 2014 Association of Military Surgeons of the U.S. FAU - Der, Tatyana AU - Der T AD - Department of Internal Medicine, East Tennessee State University, P.O. Box 70622, Johnson City, TN 37614. FAU - Bailey, Beth A AU - Bailey BA AD - Department Family Medicine, East Tennessee State University, P.O. Box 70621, Johnson City, TN 37614. FAU - Youssef, Dima AU - Youssef D AD - Department of Internal Medicine, East Tennessee State University, P.O. Box 70622, Johnson City, TN 37614. FAU - Manning, Todd AU - Manning T AD - Mountain Home VAMC, Mountain Home, TN 37684. FAU - Grant, William B AU - Grant WB AD - Sunlight, Nutrition and Health Research Center, P.O. Box 641603, San Francisco, CA 94164-1603. FAU - Peiris, Alan N AU - Peiris AN AD - Department of Internal Medicine, East Tennessee State University, P.O. Box 70622, Johnson City, TN 37614. LA - eng PT - Journal Article PL - United States TA - Mil Med JT - Military medicine JID - 2984771R RN - 0 (Vitamins) RN - 1406-16-2 (Vitamin D) RN - 64719-49-9 (25-hydroxyvitamin D) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Humans MH - Male MH - Middle Aged MH - Prostatic Neoplasms/*blood/*mortality MH - Retrospective Studies MH - Survival Rate MH - United States/epidemiology MH - Veterans MH - Vitamin D/administration & dosage/*analogs & derivatives/blood MH - Vitamin D Deficiency/*blood MH - Vitamins/administration & dosage EDAT- 2014/01/10 06:00 MHDA- 2015/04/07 06:00 CRDT- 2014/01/10 06:00 AID - 10.7205/MILMED-D-12-00540 [doi] PST - ppublish SO - Mil Med. 2014 Jan;179(1):81-4. doi: 10.7205/MILMED-D-12-00540. PMID- 24321510 OWN - NLM STAT- MEDLINE DA - 20140704 DCOM- 20150406 IS - 1873-6513 (Electronic) IS - 0885-3924 (Linking) VI - 48 IP - 1 DP - 2014 Jul TI - The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy. PG - 13-25 LID - 10.1016/j.jpainsymman.2013.08.017 [doi] LID - S0885-3924(13)00612-X [pii] AB - CONTEXT: High body mass index (BMI) is linked to an increased risk of developing pancreatic cancer (PC). However, in patients with advanced PC (APC), especially those receiving palliative chemotherapy, the impact of BMI on survival has not been investigated fully. OBJECTIVES: To assess changes in BMI during the course of APC and their impact on patient survival, specifically for those receiving palliative chemotherapy. METHODS: Consecutive patients with APC, all of whom were treated with palliative chemotherapy, were enrolled during 2003-2010. Clinical characteristics and prognoses were analyzed. RESULTS: A total of 425 patients participated (median age, 60.1 years). At diagnosis of APC, patients' BMI distribution of patients was as follow: <18.5 (45, 10.6%); 18.5-19.9 (67, 15.8%); 20.0-22.4 (156, 36.7%); 22.5-24.9 (107, 25.2%); 25.0-29.9 (49, 11.5%); and >/= 30.0 (1, 0.2%). Median overall survival (OS) was 8.1 months (95% confidence interval 7.2, 9.1). Precancer BMI and baseline BMI (at diagnosis) had no impact on OS. Weight loss at diagnosis (precancer weight minus weight at diagnosis) and weight loss during first-line chemotherapy (both stipulated as BMI change >/= 1) were associated with shortened OS (hazard ratio, 1.300; P = 0.012 and hazard ratio, 1.367; P = 0.010, respectively). CONCLUSION: In patients with APC undergoing palliative chemotherapy, decreases in BMI at APC diagnosis and during chemotherapy are more hazardous for OS than precancer BMI or baseline BMI (at diagnosis) as absolute values. Further studies are needed to validate this finding and investigate strategies to maintain BMI during chemotherapy in this setting. CI - Copyright (c) 2014 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. FAU - Choi, Younak AU - Choi Y AD - Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kim, Tae-Yong AU - Kim TY AD - Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Lee, Kyung-hun AU - Lee KH AD - Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Han, Sae-Won AU - Han SW AD - Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Oh, Do-Youn AU - Oh DY AD - Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: ohdoyoun@snu.ac.kr. FAU - Im, Seock-Ah AU - Im SA AD - Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Kim, Tae-You AU - Kim TY AD - Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Bang, Yung-Jue AU - Bang YJ AD - Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. LA - eng PT - Journal Article DEP - 20131208 PL - United States TA - J Pain Symptom Manage JT - Journal of pain and symptom management JID - 8605836 SB - IM MH - Adenocarcinoma/diagnosis/*drug therapy/*physiopathology MH - Adult MH - Aged MH - Aged, 80 and over MH - *Body Mass Index MH - Factor Analysis, Statistical MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Obesity/complications MH - *Palliative Care MH - Pancreatic Neoplasms/diagnosis/*drug therapy/*physiopathology MH - Prognosis MH - Retrospective Studies MH - Survival Analysis MH - Weight Loss MH - Young Adult OTO - NOTNLM OT - Body mass index OT - advanced pancreatic cancer OT - chemotherapy OT - obesity OT - prognosis OT - survival EDAT- 2013/12/11 06:00 MHDA- 2015/04/07 06:00 CRDT- 2013/12/11 06:00 PHST- 2013/04/18 [received] PHST- 2013/08/07 [revised] PHST- 2013/08/13 [accepted] PHST- 2013/12/08 [aheadofprint] AID - S0885-3924(13)00612-X [pii] AID - 10.1016/j.jpainsymman.2013.08.017 [doi] PST - ppublish SO - J Pain Symptom Manage. 2014 Jul;48(1):13-25. doi: 10.1016/j.jpainsymman.2013.08.017. Epub 2013 Dec 8. PMID- 24257446 OWN - NLM STAT- MEDLINE DA - 20140423 DCOM- 20150416 IS - 1364-548X (Electronic) IS - 1359-7345 (Linking) VI - 50 IP - 40 DP - 2014 May 25 TI - Targeting cancer cells with folic acid-iminoboronate fluorescent conjugates. PG - 5261-3 LID - 10.1039/c3cc47534d [doi] AB - Herein we present the synthesis of fluorescent 2-acetylbenzeneboronic acids that undergo B-N promoted conjugation with lysozyme and N-(2-aminoethyl) folic acid (EDA-FA), generating conjugates that are selectively recognized and internalized by cancer cells that over-express folic acid receptors. FAU - Cal, Pedro M S D AU - Cal PM AD - Instituto de Investigacao do Medicamento (iMed.ULisboa), Faculdade de Farmacia, Universidade de Lisboa Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal. pedrogois@ff.ul.pt. FAU - Frade, Raquel F M AU - Frade RF FAU - Chudasama, Vijay AU - Chudasama V FAU - Cordeiro, Carlos AU - Cordeiro C FAU - Caddick, Stephen AU - Caddick S FAU - Gois, Pedro M P AU - Gois PM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131121 PL - England TA - Chem Commun (Camb) JT - Chemical communications (Cambridge, England) JID - 9610838 RN - 0 (Benzene Derivatives) RN - 0 (Boronic Acids) RN - 0 (Fluorescent Dyes) RN - 0 (Folate Receptor 1) RN - 935E97BOY8 (Folic Acid) RN - EC 3.2.1.17 (Muramidase) SB - IM MH - Benzene Derivatives/chemistry/*metabolism MH - Boronic Acids/chemistry/*metabolism MH - Carcinoma, Non-Small-Cell Lung/*metabolism MH - Endocytosis MH - Fluorescent Dyes/chemistry/*metabolism MH - Folate Receptor 1/*metabolism MH - Folic Acid/chemistry/*metabolism MH - Humans MH - Lung Neoplasms/metabolism MH - Molecular Structure MH - Muramidase/*metabolism MH - Tumor Cells, Cultured EDAT- 2013/11/22 06:00 MHDA- 2015/04/17 06:00 CRDT- 2013/11/22 06:00 PHST- 2013/11/21 [aheadofprint] PHST- 2014/04/22 [epublish] AID - 10.1039/c3cc47534d [doi] PST - ppublish SO - Chem Commun (Camb). 2014 May 25;50(40):5261-3. doi: 10.1039/c3cc47534d. Epub 2013 Nov 21. PMID- 24192216 OWN - NLM STAT- MEDLINE DA - 20140423 DCOM- 20150330 IS - 1477-0970 (Electronic) IS - 1352-4585 (Linking) VI - 20 IP - 6 DP - 2014 May TI - Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort. PG - 751-3 LID - 10.1177/1352458513509507 [doi] AB - Late Epstein-Barr virus infection and hypovitaminosis-D as environmental risk factors in the pathogenesis of multiple sclerosis are gaining great interest. We, therefore, tested for in-vivo interdependence between Epstein-Barr-virus (EBV)-status and 25-hydroxyvitamin D3 (25(OH)D3) -level in healthy young individuals from a United Kingdom (UK) autumn cohort. EBV-load was measured by quantitative polymerase chain reaction and 25(OH)D3 levels by isotope-dilution liquid chromatography-tandem mass spectrometry. This young, healthy UK autumn cohort showed surprisingly low levels of 25(OH)D3 (mean value: 40.5 nmol/L +/- 5.02). Furthermore, we found that low 25(OH)D3 levels did not impact on EBV load and anti-EBV nuclear antigen-1 (EBNA-1) titers. However, we observed a correlation between EBV load and EBNA-1 titers. These observations should be of value in the study of the potential relationship between hypovitaminosis-D and EBV-status in the pathophysiology of multiple sclerosis. FAU - Ramien, Caren AU - Ramien C AD - Department of Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, UK. FAU - Pachnio, Annette AU - Pachnio A FAU - Sisay, Sofia AU - Sisay S FAU - Begum, Jusnara AU - Begum J FAU - Leese, Alison AU - Leese A FAU - Disanto, Giulio AU - Disanto G FAU - Kuhle, Jens AU - Kuhle J FAU - Giovannoni, Gavin AU - Giovannoni G FAU - Rickinson, Alan AU - Rickinson A FAU - Ramagopalan, Sreeram V AU - Ramagopalan SV FAU - Moss, Paul AU - Moss P FAU - Meier, Ute-Christiane AU - Meier UC LA - eng GR - Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131105 PL - England TA - Mult Scler JT - Multiple sclerosis (Houndmills, Basingstoke, England) JID - 9509185 RN - 0 (Antibodies, Viral) RN - 0 (EBV-encoded nuclear antigen 1) RN - 0 (Epstein-Barr Virus Nuclear Antigens) RN - 1406-16-2 (Vitamin D) SB - IM MH - Adult MH - Antibodies, Viral/analysis MH - Avitaminosis/*immunology MH - Cohort Studies MH - Epstein-Barr Virus Infections/*immunology MH - Epstein-Barr Virus Nuclear Antigens/metabolism MH - Great Britain MH - Herpesvirus 4, Human/*immunology MH - Humans MH - Multiple Sclerosis/*immunology/*virology MH - Risk Factors MH - Seasons MH - Vitamin D/*metabolism MH - Young Adult OTO - NOTNLM OT - environment OT - immunology OT - infection EDAT- 2013/11/07 06:00 MHDA- 2015/03/31 06:00 CRDT- 2013/11/07 06:00 PHST- 2013/11/05 [aheadofprint] AID - 1352458513509507 [pii] AID - 10.1177/1352458513509507 [doi] PST - ppublish SO - Mult Scler. 2014 May;20(6):751-3. doi: 10.1177/1352458513509507. Epub 2013 Nov 5. PMID- 24170604 OWN - NLM STAT- MEDLINE DA - 20140102 DCOM- 20150411 IS - 2327-6924 (Electronic) IS - 2327-6886 (Linking) VI - 26 IP - 1 DP - 2014 Jan TI - Self-reported exercise and bone mineral density in prostate cancer patients receiving androgen deprivation therapy. PG - 40-8 LID - 10.1002/2327-6924.12066 [doi] AB - PURPOSE: Men with prostate cancer receiving androgen deprivation therapy (ADT) are at increased risk for decreased bone mineral density (BMD). This study evaluates the relationship between self-reported daily activity, endurance and resistance exercise, and BMD measured by dual-energy x-ray absorptiometry (DEXA) in prostate cancer patients receiving ADT. DATA SOURCES: We recruited 96 men treated with ADT for >/=9 months from urology and cancer practices. The Canadian Fitness Survey assessed daily activity and exercise. Data on demographic and lifestyle characteristics and calcium and vitamin D supplementation were collected. Blood was collected for analysis of 25-OH vitamin D. A DEXA scan was performed. CONCLUSIONS: A positive association between endurance exercise and DEXA T-scores of the hip was shown. Regression analysis showed endurance exercise of medium to heavy intensity (measured as energy expenditure in MET-hours/week) was associated with T-scores of the hip (beta = 0.048; 95% CI 0.003, 0.112; p = .040) but not with spinal T-scores after controlling for age, body mass index, and alcohol use. IMPLICATIONS FOR PRACTICE: Findings are cross-sectional, but if confirmed in prospective studies suggest that increased endurance exercise is a practical measure nurse practitioners can institute to prevent low bone density in the hip of men treated with ADT. CI - (c)2013 The Author(s) (c)2013 American Association of Nurse Practitioners. FAU - Mennen-Winchell, Lori J AU - Mennen-Winchell LJ AD - University Medical Center of Southern Nevada, Las Vegas, Nevada. FAU - Grigoriev, Victor AU - Grigoriev V FAU - Alpert, Patricia AU - Alpert P FAU - Dos Santos, Hildemar AU - Dos Santos H FAU - Tonstad, Serena AU - Tonstad S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130827 PL - United States TA - J Am Assoc Nurse Pract JT - Journal of the American Association of Nurse Practitioners JID - 101600770 RN - 0 (Androgen Antagonists) RN - 0 (Bone Density Conservation Agents) SB - N MH - Aged MH - Aged, 80 and over MH - Androgen Antagonists/*therapeutic use MH - *Bone Density MH - Bone Density Conservation Agents/therapeutic use MH - Cross-Sectional Studies MH - *Exercise MH - Humans MH - Life Style MH - Male MH - Middle Aged MH - Prostatic Neoplasms/complications/*drug therapy MH - Self Report OTO - NOTNLM OT - Androgen ablation therapy OT - cancer, bone mineral density OT - exercise EDAT- 2013/10/31 06:00 MHDA- 2015/04/12 06:00 CRDT- 2013/10/31 06:00 PHST- 2013/08/27 [aheadofprint] AID - 10.1002/2327-6924.12066 [doi] PST - ppublish SO - J Am Assoc Nurse Pract. 2014 Jan;26(1):40-8. doi: 10.1002/2327-6924.12066. Epub 2013 Aug 27. PMID- 24128069 OWN - NLM STAT- MEDLINE DA - 20140723 DCOM- 20150330 IS - 1029-2403 (Electronic) IS - 1026-8022 (Linking) VI - 55 IP - 8 DP - 2014 Aug TI - Nutritional assessment of patients with acute leukemia during induction chemotherapy: association with hospital outcomes. PG - 1743-50 LID - 10.3109/10428194.2013.853766 [doi] AB - Cancer-related malnutrition causes morbidity and reduced survival. The aim of this study was to evaluate the nutritional and inflammatory status of patients with acute leukemia in association with duration of neutropenic fever (DNF) and length of hospital stay (LHS) during induction chemotherapy. Fifty-five patients with acute lymphoblastic leukemia (ALL) (n = 28) and acute myeloid leukemia (AML) (n = 27) completed the study. There were significant differences between the two groups according to LHS and DNF (p = 0.022 and p = 0.012, respectively): both had a longer period in patients with AML. The patients were statistically different according to body mass index (BMI), pre-albumin, high-sensitivity C-reactive protein (hs-CRP) and patient-generated subjective global assessment (PG-SGA) score (p = 0.049, p = 0.028, p < 0.001, p = 0.030). In patients with ALL, serum albumin and pre-albumin levels were associated with LHS and DNF, respectively. Moreover, PG-SGA score was associated with DNF. In patients with AML, BMI and second pre-albumin level < 10 mg/dL were associated with DNF. Pre-albumin was the common indicator for chemotherapy-related complications in patients with both ALL and AML. Early nutritional assessment can help to find patients with acute leukemia who need nutritional support, and it may contribute to better outcome and less toxicity. FAU - Esfahani, Ali AU - Esfahani A AD - Hematology and Oncology Research Center. FAU - Ghoreishi, Zohreh AU - Ghoreishi Z FAU - Abedi Miran, Mahdi AU - Abedi Miran M FAU - Sanaat, Zohreh AU - Sanaat Z FAU - Ostadrahimi, Alireza AU - Ostadrahimi A FAU - Eivazi Ziaei, Jamal AU - Eivazi Ziaei J FAU - Ghayour Nahand, Mousa AU - Ghayour Nahand M FAU - Asghari Jafarabadi, Mohammad AU - Asghari Jafarabadi M FAU - Sorusheh, Yashar AU - Sorusheh Y FAU - Esmaili, Heidarali AU - Esmaili H LA - eng PT - Journal Article DEP - 20131114 PL - England TA - Leuk Lymphoma JT - Leukemia & lymphoma JID - 9007422 RN - 0 (Serum Albumin) RN - 0 (Transferrin) RN - 9007-41-4 (C-Reactive Protein) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols MH - Body Mass Index MH - C-Reactive Protein/metabolism MH - Cross-Sectional Studies MH - Febrile Neutropenia/etiology MH - Humans MH - Induction Chemotherapy MH - Length of Stay MH - Leukemia, Myeloid, Acute/*complications/drug therapy MH - Male MH - Malnutrition/*diagnosis/*etiology MH - Middle Aged MH - *Nutrition Assessment MH - Outcome Assessment (Health Care) MH - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*complications/drug therapy MH - Serum Albumin MH - Transferrin/metabolism MH - Young Adult OTO - NOTNLM OT - Acute myeloid leukemia OT - acute lymphoblastic leukemia OT - hospital stay OT - neutropenic fever OT - nutritional assessment OT - pre-albumin EDAT- 2013/10/17 06:00 MHDA- 2015/03/31 06:00 CRDT- 2013/10/17 06:00 PHST- 2013/11/14 [aheadofprint] AID - 10.3109/10428194.2013.853766 [doi] PST - ppublish SO - Leuk Lymphoma. 2014 Aug;55(8):1743-50. doi: 10.3109/10428194.2013.853766. Epub 2013 Nov 14. PMID- 24118332 OWN - NLM STAT- MEDLINE DA - 20140303 DCOM- 20150410 IS - 1365-2354 (Electronic) IS - 0961-5423 (Linking) VI - 23 IP - 2 DP - 2014 Mar TI - Complementary medicine use among cancer patients receiving radiotherapy and chemotherapy: methods, sources of information and the need for counselling. PG - 249-54 LID - 10.1111/ecc.12132 [doi] AB - Complementary medicine (CM) use is common among cancer patients. However, little is known about CM products that are utilised during radiotherapy and/or chemotherapy. Out of 62 cancer patients who completed a specialised survey, 35 (56%) consumed some type of CM during active anti-cancer therapy. Cancer patients reported the use of herbal teas (52%), vitamins and other dietary supplements (45%), vegetables and juices (39%), special diets (19%), herbal medicines, including Chinese medicines (19%) and 'immunomodulators' (3%). Most of patients (86%) consumed CM products every day. However, nearly 47% of CM users did not admit this to their oncologists. Majority of CM users (85%) were convinced that supplementary products increase the efficacy of standard anti-cancer therapy and prolong their survival. Information about CM was mainly obtained through internet sources (36%), books and brochures (25%). Although most CM users (82%) trusted the received information, 73% of them admitted that additional information about CM methods would be necessary. Patients would like to receive additional information through a specialised consultation (60%), but also from brochures (44%) and the internet (20%). Adequate counselling of patients is of paramount importance since some CM methods may cause significant side effects and decrease the efficacy of radiotherapy and/or chemotherapy. CI - (c) 2013 John Wiley & Sons Ltd. FAU - Pihlak, R AU - Pihlak R AD - Faculty of Medicine, University of Tartu, Tartu, Estonia; Haematology and Oncology Clinic, Department of Radiotherapy and Oncological Therapy, Tartu University Hospital, Tartu, Estonia. FAU - Liivand, R AU - Liivand R FAU - Trelin, O AU - Trelin O FAU - Neissar, H AU - Neissar H FAU - Peterson, I AU - Peterson I FAU - Kivistik, S AU - Kivistik S FAU - Lilo, K AU - Lilo K FAU - Jaal, J AU - Jaal J LA - eng PT - Journal Article DEP - 20130930 PL - England TA - Eur J Cancer Care (Engl) JT - European journal of cancer care JID - 9301979 RN - 0 (Antineoplastic Agents) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Vitamins) SB - N MH - Antineoplastic Agents/*therapeutic use MH - Beverages/utilization MH - Communication MH - Complementary Therapies/adverse effects/*utilization MH - Diet MH - Dietary Supplements/utilization MH - Drug Interactions MH - Drugs, Chinese Herbal/therapeutic use MH - Female MH - *Health Services Needs and Demand MH - Herb-Drug Interactions MH - Humans MH - Male MH - Middle Aged MH - Neoplasms/*therapy MH - *Patient Education as Topic MH - Physician-Patient Relations MH - *Radiotherapy MH - Vitamins/therapeutic use OTO - NOTNLM OT - chemotherapy OT - complementary medicine OT - counselling OT - information sources OT - radiotherapy EDAT- 2013/10/15 06:00 MHDA- 2015/04/11 06:00 CRDT- 2013/10/15 06:00 PHST- 2013/08/29 [accepted] PHST- 2013/09/30 [aheadofprint] AID - 10.1111/ecc.12132 [doi] PST - ppublish SO - Eur J Cancer Care (Engl). 2014 Mar;23(2):249-54. doi: 10.1111/ecc.12132. Epub 2013 Sep 30. PMID- 24118223 OWN - NLM STAT- MEDLINE DA - 20140129 DCOM- 20150402 IS - 1447-0756 (Electronic) IS - 1341-8076 (Linking) VI - 40 IP - 2 DP - 2014 Feb TI - Octreotide therapy for the management of refractory chylous ascites after a staging operation for endometrial adenocarcinoma. PG - 622-6 LID - 10.1111/jog.12183 [doi] AB - Chylous ascites after para-aortic lymphadenectomy is caused by a rupture in the retroperitoneal lymphatic channels. The incidence of postoperative chylous ascites is increasing as para-aortic lymphadenectomy for the management of gynecologic malignancies becomes more common. However, management of this condition remains unsatisfactory because some patients do not respond to conservative methods and have to undergo surgical intervention, even though they may be malnourished and immunosuppressed. We report the case of a patient who underwent a standard staging operation for endometrial cancer and experienced a large amount of lymphatic leakage, in spite of treatment with total parenteral nutrition and a low-fat diet for over 40 days. As a step-up approach, octreotide, a somatostatin analog, was added and the disease resolved completely. This case demonstrated that octreotide therapy is highly effective in refractory cases of chylous ascites where a large amount of leakage is observed and cases that are otherwise indicated for surgical intervention. CI - (c) 2013 The Authors. Journal of Obstetrics and Gynaecology Research (c) 2013 Japan Society of Obstetrics and Gynecology. FAU - Kim, Eun Ah AU - Kim EA AD - Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, College of Medicine, CHA University, Seongnam-si, Korea. FAU - Park, Hyun AU - Park H FAU - Jeong, Sang Geun AU - Jeong SG FAU - Lee, Chan AU - Lee C FAU - Lee, Joon Mo AU - Lee JM FAU - Park, Chong Taik AU - Park CT LA - eng PT - Case Reports PT - Journal Article DEP - 20131010 PL - Australia TA - J Obstet Gynaecol Res JT - The journal of obstetrics and gynaecology research JID - 9612761 RN - 0 (Antineoplastic Agents, Hormonal) RN - RWM8CCW8GP (Octreotide) SB - IM MH - Adenocarcinoma/*pathology MH - Adult MH - Antineoplastic Agents, Hormonal/*therapeutic use MH - Chylous Ascites/*drug therapy/etiology/therapy MH - Endometrial Neoplasms/*pathology MH - Female MH - Humans MH - Lymph Node Excision/*adverse effects MH - Neoplasm Staging MH - Octreotide/*therapeutic use MH - Parenteral Nutrition OTO - NOTNLM OT - chylous ascites OT - diet OT - lymphadenectomy OT - octreotide OT - parenteral nutrition EDAT- 2013/10/15 06:00 MHDA- 2015/04/04 06:00 CRDT- 2013/10/15 06:00 PHST- 2013/03/20 [received] PHST- 2013/05/11 [accepted] PHST- 2013/10/10 [aheadofprint] AID - 10.1111/jog.12183 [doi] PST - ppublish SO - J Obstet Gynaecol Res. 2014 Feb;40(2):622-6. doi: 10.1111/jog.12183. Epub 2013 Oct 10. PMID- 24072723 OWN - NLM STAT- MEDLINE DA - 20140423 DCOM- 20150330 IS - 1477-0970 (Electronic) IS - 1352-4585 (Linking) VI - 20 IP - 6 DP - 2014 May TI - Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. PG - 669-74 LID - 10.1177/1352458513505693 [doi] AB - BACKGROUND: Seasonal fluctuations in solar radiation and vitamin D levels could modulate the immune response against Epstein-Barr virus (EBV) infection and influence the subsequent risk of multiple sclerosis (MS). METHODS: Altogether 1660 MS patients and 3050 controls from Norway and Italy participating in the multinational case-control study of Environmental Factors In Multiple Sclerosis (EnvIMS) reported season of past infectious mononucleosis (IM). RESULTS: IM was generally reported more frequently in Norway (p=0.002), but was associated with MS to a similar degree in Norway (odds ratio (OR) 2.12, 95% confidence interval (CI) 1.64-2.73) and Italy (OR 1.72, 95% CI 1.17-2.52). For all participants, there was a higher reported frequency of IM during spring compared to fall (p<0.0005). Stratified by season of IM, the ORs for MS were 1.58 in spring (95% CI 1.08-2.31), 2.26 in summer (95% CI 1.46-3.51), 2.86 in fall (95% CI 1.69-4.85) and 2.30 in winter (95% CI 1.45-3.66). CONCLUSIONS: IM is associated with MS independently of season, and the association is not stronger for IM during spring, when vitamin D levels reach nadir. The distribution of IM may point towards a correlation with solar radiation or other factors with a similar latitudinal and seasonal variation. FAU - Lossius, Andreas AU - Lossius A AD - Institute of Clinical Medicine, University of Oslo, Norway. FAU - Riise, Trond AU - Riise T FAU - Pugliatti, Maura AU - Pugliatti M FAU - Bjornevik, Kjetil AU - Bjornevik K FAU - Casetta, Ilaria AU - Casetta I FAU - Drulovic, Jelena AU - Drulovic J FAU - Granieri, Enrico AU - Granieri E FAU - Kampman, Margitta T AU - Kampman MT FAU - Landtblom, Anne-Marie AU - Landtblom AM FAU - Lauer, Klaus AU - Lauer K FAU - Magalhaes, Sandra AU - Magalhaes S FAU - Myhr, Kjell-Morten AU - Myhr KM FAU - Pekmezovic, Tatjana AU - Pekmezovic T FAU - Wesnes, Kristin AU - Wesnes K FAU - Wolfson, Christina AU - Wolfson C FAU - Holmoy, Trygve AU - Holmoy T LA - eng PT - Controlled Clinical Trial PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20130926 PL - England TA - Mult Scler JT - Multiple sclerosis (Houndmills, Basingstoke, England) JID - 9509185 RN - 1406-16-2 (Vitamin D) SB - IM MH - Adult MH - Aged MH - Case-Control Studies MH - Epstein-Barr Virus Infections/*virology MH - Female MH - Humans MH - Infectious Mononucleosis/complications/*epidemiology/virology MH - Italy MH - Male MH - Middle Aged MH - Multiple Sclerosis/complications/*epidemiology/virology MH - Norway MH - Risk MH - *Seasons MH - Vitamin D/metabolism OTO - NOTNLM OT - Epstein-Barr virus OT - Multiple sclerosis OT - interaction OT - latitude OT - seasons OT - vitamin D EDAT- 2013/09/28 06:00 MHDA- 2015/03/31 06:00 CRDT- 2013/09/28 06:00 PHST- 2013/09/26 [aheadofprint] AID - 1352458513505693 [pii] AID - 10.1177/1352458513505693 [doi] PST - ppublish SO - Mult Scler. 2014 May;20(6):669-74. doi: 10.1177/1352458513505693. Epub 2013 Sep 26. PMID- 24062268 OWN - NLM STAT- MEDLINE DA - 20140219 DCOM- 20150413 IS - 0973-7693 (Electronic) IS - 0019-5456 (Linking) VI - 81 IP - 2 DP - 2014 Feb TI - Cushing syndrome. PG - 158-64 LID - 10.1007/s12098-013-1203-8 [doi] AB - Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. The most common cause of Cushing syndrome in children and adolescents is exogenous administration of glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension. Almost invariably, linear growth is severely diminished, a factor which may be useful in differentiating between childhood obesity and Cushing syndrome. Diagnostic approaches are based on distinguishing between adrenocorticotropic hormone (ACTH)-dependent and ACTH-independent etiologies, and consideration of the most likely diagnosis by age. Treatment modality is dependent upon etiology. After cure, important components of care include attention to linear growth, pubertal progression and body composition. FAU - Bista, Bibek AU - Bista B AD - Department of Pediatrics, Texas Tech University Health Sciences Center, 3601 - 4th Street, Mail Stop 9406, Lubbock, TX, 79430, USA. FAU - Beck, Nancy AU - Beck N LA - eng PT - Journal Article PT - Review DEP - 20130924 PL - India TA - Indian J Pediatr JT - Indian journal of pediatrics JID - 0417442 RN - 9002-60-2 (Adrenocorticotropic Hormone) RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - ACTH-Secreting Pituitary Adenoma/diagnosis/therapy MH - Adenoma/diagnosis/therapy MH - Adolescent MH - Adrenocorticotropic Hormone/blood MH - Body Composition MH - Cushing Syndrome/*diagnosis/physiopathology MH - Diagnosis, Differential MH - Fibrous Dysplasia, Polyostotic/diagnosis MH - Humans MH - Hydrocortisone/analysis MH - Obesity/diagnosis MH - Petrosal Sinus Sampling MH - Saliva/chemistry EDAT- 2013/09/26 06:00 MHDA- 2015/04/14 06:00 CRDT- 2013/09/25 06:00 PHST- 2013/04/04 [received] PHST- 2013/07/31 [accepted] PHST- 2013/09/24 [aheadofprint] AID - 10.1007/s12098-013-1203-8 [doi] PST - ppublish SO - Indian J Pediatr. 2014 Feb;81(2):158-64. doi: 10.1007/s12098-013-1203-8. Epub 2013 Sep 24. PMID- 23947403 OWN - NLM STAT- MEDLINE DA - 20140716 DCOM- 20150330 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 11 DP - 2013 TI - Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. PG - 191 LID - 10.1186/1479-5876-11-191 [doi] AB - BACKGROUND: Ascorbic acid (vitamin C, ascorbate) is a key water soluble antioxidant that, when administered in doses well above its recommended dietary allowance, may have preventative and therapeutic value against a number of pathologies. The intravenous administration of high dose ascorbate (IVC) has increased in popularity among complementary and alternative medicine practitioners: thousands of patients received IVC, at an average dose of 0.5 g/kg, without significant side effects. While IVC may have a variety of possible applications, it has generated the most interest for its potential use in treating cancer. METHODS: Medical records of patients with cancer treated with IVC at the Riordan Clinic were retrospectively reviewed. Cancer patients, for whom plasma ascorbate concentration data before and after treatment were available, along with C-reactive protein (CRP) measurements, were chosen for analysis. RESULTS: The results of the analysis can be summarized as follows. IVC produces peak plasma ascorbate concentrations on the order of ten millimolars with lower peak plasma concentrations obtained in cancer patients as compared to healthy subjects. Cancer patients who are deficient in vitamin C prior to therapy tend to achieve lower plasma levels post infusion. High inflammation or tumor burdens, as measured by CRP or tumor antigen levels, tend to lower peak plasma ascorbate levels after IVC. When compared to patients with localized tumors, patients with metastatic tumors tend to achieve lower post infusion plasma ascorbate concentrations. CONCLUSIONS: The data indicate that, while potentially therapeutic plasma ascorbate concentrations can be achieved with IVC, levels attained will vary based on tumor burden and degree of inflammation (among other factors). Evidence suggests that IVC may be able to modulate inflammation, which in turn might improve outcomes for cancer patients. IVC may serve as a safe, adjunctive therapy in clinical cancer care. FAU - Mikirova, Nina AU - Mikirova N FAU - Casciari, Joseph AU - Casciari J FAU - Riordan, Neil AU - Riordan N FAU - Hunninghake, Ronald AU - Hunninghake R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130815 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 RN - 0 (Tumor Markers, Biological) RN - 9007-41-4 (C-Reactive Protein) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Administration, Intravenous MH - Adult MH - Aged MH - Aged, 80 and over MH - Ascorbic Acid/*administration & dosage/blood/*therapeutic use MH - C-Reactive Protein/metabolism MH - Female MH - Humans MH - Inflammation/*blood/*drug therapy MH - Male MH - Middle Aged MH - Neoplasms/*blood/*drug therapy MH - Tumor Markers, Biological/metabolism PMC - PMC3751545 OID - NLM: PMC3751545 EDAT- 2013/08/21 06:00 MHDA- 2015/03/31 06:00 CRDT- 2013/08/17 06:00 PHST- 2013/04/23 [received] PHST- 2013/06/05 [accepted] PHST- 2013/08/15 [aheadofprint] AID - 1479-5876-11-191 [pii] AID - 10.1186/1479-5876-11-191 [doi] PST - epublish SO - J Transl Med. 2013 Aug 15;11:191. doi: 10.1186/1479-5876-11-191. PMID- 23931896 OWN - NLM STAT- MEDLINE DA - 20140717 DCOM- 20150419 IS - 1557-7716 (Electronic) IS - 1523-0864 (Linking) VI - 21 IP - 5 DP - 2014 Aug 10 TI - Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin. PG - 707-22 LID - 10.1089/ars.2012.5076 [doi] AB - AIMS: Efficient siRNA/drug codelivery carriers can offer great promises to cancer treatment on account of synergistic effect provided from cancer-associated gene and anticancer drugs. In this work, a redox-responsive drug/siRNA codelivery vehicle based on mesoporous silica nanoparticles was fabricated to simultaneously deliver siRNA and doxorubicin (Dox) in vitro and in vivo. RESULTS: The nanoparticle surface was functionalized with the adamantane (AD) units. Formation of stable host-guest complex between disulfide bond linked-AD and ethylenediamine-modified beta-cyclodextrin is capable of fully blocking drugs inside the nanopores, while amino groups can complex with siRNA via electrostatic interaction. Relatively high concentration of glutathione in biophysical environment provides natural reducing agent to trigger drug/siRNA release by cleaving pre-introduced disulfide bonds. B-cell lymphoma 2 (Bcl-2) siRNA was codelivered to silence Bcl-2 protein expression in HeLa cells, resulting in enhanced chemotherapy efficacy in vitro. In vivo delivery experiment carried out in transgenic zebrafish larvae indicates that the delivery of Dox inhibits the development of choroid plexus in a dose-dependent manner, leading to successful decrease of green fluorescence protein transcription in choroid plexus. Reduction of liver tumor was also demonstrated after injection of Dox-loaded nanoparticles. INNOVATION: We successfully demonstrated that functional nanoparticles could serve as an efficient carrier for the delivery of Bcl-2 siRNA and Dox in HeLa cells and in transgenic zebrafish larvae, leading to enhanced therapeutic efficacy. CONCLUSION: Enhanced cytotoxicity caused by simultaneous delivery of Bcl-2 siRNA and Dox was observed in HeLa cells. Drug-loaded nanoparticles were internalized in vivo, inhibiting the development of choroid plexus and the progression of liver tumor. FAU - Ma, Xing AU - Ma X AD - 1 Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University , Singapore, Singapore . FAU - Teh, Cathleen AU - Teh C FAU - Zhang, Quan AU - Zhang Q FAU - Borah, Parijat AU - Borah P FAU - Choong, Cleo AU - Choong C FAU - Korzh, Vladimir AU - Korzh V FAU - Zhao, Yanli AU - Zhao Y LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130928 PL - United States TA - Antioxid Redox Signal JT - Antioxidants & redox signaling JID - 100888899 RN - 0 (Antineoplastic Agents) RN - 0 (Drug Carriers) RN - 0 (RNA, Small Interfering) RN - 7631-86-9 (Silicon Dioxide) RN - 80168379AG (Doxorubicin) SB - IM MH - Antineoplastic Agents/*administration & dosage/chemistry/metabolism/pharmacology MH - Doxorubicin/*administration & dosage/metabolism/pharmacology MH - Drug Carriers/*chemistry MH - HeLa Cells MH - Humans MH - Nanoparticles/*chemistry MH - Neoplasms/*drug therapy/genetics/metabolism/pathology MH - Oxidation-Reduction MH - Particle Size MH - Porosity MH - RNA, Small Interfering/administration & dosage/*chemistry MH - Silicon Dioxide/*chemistry MH - Surface Properties EDAT- 2013/08/13 06:00 MHDA- 2015/04/22 06:00 CRDT- 2013/08/13 06:00 PHST- 2013/09/28 [aheadofprint] AID - 10.1089/ars.2012.5076 [doi] PST - ppublish SO - Antioxid Redox Signal. 2014 Aug 10;21(5):707-22. doi: 10.1089/ars.2012.5076. Epub 2013 Sep 28. PMID- 23895505 OWN - NLM STAT- MEDLINE DA - 20140723 DCOM- 20150330 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 14 DP - 2013 TI - A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial. PG - 237 LID - 10.1186/1745-6215-14-237 [doi] AB - BACKGROUND: The naturally-occurring omega (omega)-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid (EPA) reduces colorectal adenoma (polyp) number and size in patients with familial adenomatous polyposis. The safety profile and potential cardiovascular benefits associated with omega-3 PUFAs make EPA a strong candidate for colorectal cancer (CRC) chemoprevention, alone or in combination with aspirin, which itself has recognized anti-CRC activity. Colorectal adenoma number and size are recognized as biomarkers of future CRC risk and are established as surrogate end-points in CRC chemoprevention trials. DESIGN: The seAFOod Polyp Prevention Trial is a randomized, double-blind, placebo-controlled, 2x2 factorial 'efficacy' study, which will determine whether EPA prevents colorectal adenomas, either alone or in combination with aspirin. Participants are 55-73 year-old patients, who have been identified as 'high risk' (detection of >/=5 small adenomas or >/=3 adenomas with at least one being >/=10 mm in diameter) at screening colonoscopy in the English Bowel Cancer Screening Programme (BCSP). Exclusion criteria include the need for more than one repeat endoscopy within the three-month BCSP screening period, malignant change in an adenoma, regular use of aspirin or non-aspirin non-steroidal anti-inflammatory drugs, regular use of fish oil supplements and concomitant warfarin or anti-platelet agent therapy. Patients are randomized to either EPA-free fatty acid 1 g twice daily or identical placebo AND aspirin 300 mg once daily or identical placebo, for approximately 12 months. The primary end-point is the number of participants with one or more adenomas detected at routine one-year BCSP surveillance colonoscopy. Secondary end-points include the number of adenomas (total and 'advanced') per patient, the location (left versus right colon) of colorectal adenomas and the number of participants re-classified as 'intermediate risk' for future surveillance. Exploratory end-points include levels of bioactive lipid mediators such as omega-3 PUFAs, resolvin E1 and PGE-M in plasma, urine, erythrocytes and rectal mucosa in order to gain insights into the mechanism(s) of action of EPA and aspirin, alone and in combination, as well as to discover predictive biomarkers of chemopreventive efficacy. The recruitment target is 904 patients. TRIAL REGISTRATION: Current Controlled Trials ISRCTN05926847. FAU - Hull, Mark A AU - Hull MA FAU - Sandell, Anna C AU - Sandell AC FAU - Montgomery, Alan A AU - Montgomery AA FAU - Logan, Richard F A AU - Logan RF FAU - Clifford, Gayle M AU - Clifford GM FAU - Rees, Colin J AU - Rees CJ FAU - Loadman, Paul M AU - Loadman PM FAU - Whitham, Diane AU - Whitham D LA - eng SI - ISRCTN/ISRCTN05926847 GR - G0800800/Medical Research Council/United Kingdom GR - MC_G1002465/Medical Research Council/United Kingdom GR - Medical Research Council/United Kingdom PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20130729 PL - England TA - Trials JT - Trials JID - 101263253 RN - 0 (Anticarcinogenic Agents) RN - 0 (Tumor Markers, Biological) RN - AAN7QOV9EA (Eicosapentaenoic Acid) RN - R16CO5Y76E (Aspirin) SB - IM MH - Adenoma/diagnosis/metabolism/pathology/*prevention & control MH - Aged MH - Anticarcinogenic Agents/*therapeutic use MH - Aspirin/*therapeutic use MH - Clinical Protocols MH - *Colonoscopy MH - Colorectal Neoplasms/*diagnosis/metabolism/pathology/*prevention & control MH - Double-Blind Method MH - Drug Therapy, Combination MH - Eicosapentaenoic Acid/*therapeutic use MH - England MH - Female MH - Humans MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - *Research Design MH - Risk Assessment MH - Risk Factors MH - Sample Size MH - *State Medicine MH - Time Factors MH - Treatment Outcome MH - Tumor Markers, Biological/metabolism PMC - PMC3733694 OID - NLM: PMC3733694 EDAT- 2013/07/31 06:00 MHDA- 2015/03/31 06:00 CRDT- 2013/07/31 06:00 PHST- 2012/12/14 [received] PHST- 2013/07/19 [accepted] PHST- 2013/07/29 [aheadofprint] AID - 1745-6215-14-237 [pii] AID - 10.1186/1745-6215-14-237 [doi] PST - epublish SO - Trials. 2013 Jul 29;14:237. doi: 10.1186/1745-6215-14-237. PMID- 23855321 OWN - NLM STAT- MEDLINE DA - 20140725 DCOM- 20150330 IS - 1475-2891 (Electronic) IS - 1475-2891 (Linking) VI - 12 DP - 2013 TI - The presentation of metabolic dysfunction and the relationship with energy output in breast cancer survivors: a cross-sectional study. PG - 99 LID - 10.1186/1475-2891-12-99 [doi] AB - BACKGROUND: Breast cancer prognosis can be adversely influenced by obesity, physical inactivity and metabolic dysfunction. Interventions aimed at improving surrogate markers of breast cancer risk such as insulin resistance may result in improved breast cancer outcomes. The design of such interventions may be improved through increased understanding of metabolic presentation in this cohort. This cross-sectional study aimed to characterise the metabolic profile of breast cancer survivors relative to abdominal obesity and insulin resistance. A secondary aim was to compare measures of energy output across these groups. METHODS: Sixty-nine women (mean (SD) age 53.43 (9.39) years) who had completed adjuvant chemotherapy and radiotherapy for breast cancer were recruited. All measures were completed during one assessment conducted 3.1 (1.0) years post diagnosis. Body composition was measured by bioimpedance analysis and waist circumference (WC). Fasting (12 hour) blood samples were drawn to measure lipid profile, glucose, insulin, glycosylated haemoglobin A1c (HBA1c) and C-reactive protein (CRP). Insulin resistance was estimated by the homeostatic model assessment index (HOMA-IR)). Energy output was evaluated by resting metabolic rate (RMR) measured by indirect calorimetry and physical activity measured by accelerometry. Characteristics were compared across four groups (1. WC <80 cm, not insulin resistant; 2. WC 80-87.9 cm, not insulin resistant; 3. WC >88 cm, not insulin resistant; 4. WC >80 cm, insulin resistant) using ANOVA (p < 0.05). RESULTS: Group 4 was characterised by significant disturbances in measures of glucose metabolism (glucose, insulin, HOMA-IR and HBA1c) and raised CRP compared to other groups. Group 4 also displayed evidence of dyslipidemia and higher body composition values compared to Groups 1 and 2. Both absolute and adjusted RMR were significantly higher in the Group 4 versus all other groups. Physical activity levels were similar for all groups. CONCLUSIONS: The results from this study suggest that participants who were both centrally obese and insulin resistant showed evidence of dyslipidemia, low-grade inflammation and glucose dysregulation. Metabolic profiles of participants who were centrally obese only were not significantly different from lean participants. Consideration of baseline metabolic presentation may be useful when considering the therapeutic targets for future interventions in this cohort. FAU - Guinan, Emer M AU - Guinan EM FAU - Connolly, Elizabeth M AU - Connolly EM FAU - Kennedy, M John AU - Kennedy MJ FAU - Hussey, Juliette AU - Hussey J LA - eng PT - Journal Article DEP - 20130715 PL - England TA - Nutr J JT - Nutrition journal JID - 101152213 RN - 0 (Blood Glucose) RN - 0 (Hemoglobin A, Glycosylated) RN - 0 (Insulin) RN - 9007-41-4 (C-Reactive Protein) SB - IM MH - Adipose Tissue/metabolism MH - Adult MH - Basal Metabolism MH - Blood Glucose/metabolism MH - Body Composition MH - Body Mass Index MH - Body Weight MH - Breast Neoplasms/*blood/complications/metabolism MH - C-Reactive Protein MH - Cross-Sectional Studies MH - Electric Impedance MH - *Energy Metabolism MH - Female MH - Health Behavior MH - Hemoglobin A, Glycosylated MH - Humans MH - Insulin/blood MH - Insulin Resistance MH - Life Style MH - Middle Aged MH - Motor Activity MH - Obesity, Abdominal/*blood/complications MH - *Survivors MH - Waist Circumference PMC - PMC3717288 OID - NLM: PMC3717288 EDAT- 2013/07/17 06:00 MHDA- 2015/03/31 06:00 CRDT- 2013/07/17 06:00 PHST- 2013/01/16 [received] PHST- 2013/07/05 [accepted] PHST- 2013/07/15 [aheadofprint] AID - 1475-2891-12-99 [pii] AID - 10.1186/1475-2891-12-99 [doi] PST - epublish SO - Nutr J. 2013 Jul 15;12:99. doi: 10.1186/1475-2891-12-99. PMID- 23852670 OWN - NLM STAT- MEDLINE DA - 20140721 DCOM- 20150414 IS - 1097-0347 (Electronic) IS - 1043-3074 (Linking) VI - 36 IP - 8 DP - 2014 Aug TI - Toxicities and costs of placing prophylactic and reactive percutaneous gastrostomy tubes in patients with locally advanced head and neck cancers treated with chemoradiotherapy. PG - 1155-61 LID - 10.1002/hed.23426 [doi] AB - BACKGROUND: We compared dependence rates, complications, toxicities, and costs associated with prophylactic versus reactive percutaneous endoscopic gastrostomy (PEG) tube placement. METHODS: One hundred ninety-three patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy were retrospectively reviewed. RESULTS: The 1-year and 2-year actuarial PEG tube dependence rate of the entire cohort was 24% and 13%, respectively. There was no difference in the PEG tube dependence rates between those placed prophylactically versus reactively. Patients who received a PEG tube reactively had a significantly higher stricture rate (p = .03) and aspiration rate (p < .001) compared to the prophylactic group. There were significantly fewer hospitalizations in the prophylactic group compared to the reactive group (p = .003). When accounting for both PEG placement and hospitalizations, the prophylactic approach was found to be more cost effective. CONCLUSION: PEG tubes placed prophylactically were associated with lower rates of strictures, aspirations, hospitalizations, and costs compared to those placed reactively. CI - Copyright (c) 2013 Wiley Periodicals, Inc. FAU - Baschnagel, Andrew M AU - Baschnagel AM AD - Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan. FAU - Yadav, Siddhartha AU - Yadav S FAU - Marina, Ovidiu AU - Marina O FAU - Parzuchowski, Aaron AU - Parzuchowski A FAU - Lanni, Thomas B Jr AU - Lanni TB Jr FAU - Warner, Jillian N AU - Warner JN FAU - Parzuchowski, Jeanne S AU - Parzuchowski JS FAU - Ignatius, Renjitha T AU - Ignatius RT FAU - Akervall, Jan AU - Akervall J FAU - Chen, Peter Y AU - Chen PY FAU - Krauss, Daniel J AU - Krauss DJ LA - eng PT - Journal Article DEP - 20131127 PL - United States TA - Head Neck JT - Head & neck JID - 8902541 RN - Carcinoma, squamous cell of head and neck SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Squamous Cell/economics/*therapy MH - Chemoradiotherapy/*methods MH - Costs and Cost Analysis MH - Deglutition Disorders/economics/*prevention & control MH - Endoscopy, Gastrointestinal MH - Enteral Nutrition/*instrumentation MH - Female MH - Gastrostomy/economics/*methods MH - Head and Neck Neoplasms/economics/*therapy MH - Hospitalization MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - percutaneous endoscopic gastrostomy (PEG) tube OT - prophylactic PEG tube OT - reactive PEG tube EDAT- 2013/07/16 06:00 MHDA- 2015/04/15 06:00 CRDT- 2013/07/16 06:00 PHST- 2013/03/01 [received] PHST- 2013/04/26 [revised] PHST- 2013/06/26 [accepted] PHST- 2013/11/27 [aheadofprint] AID - 10.1002/hed.23426 [doi] PST - ppublish SO - Head Neck. 2014 Aug;36(8):1155-61. doi: 10.1002/hed.23426. Epub 2013 Nov 27. PMID- 23809011 OWN - NLM STAT- MEDLINE DA - 20130820 DCOM- 20150413 IS - 1601-0825 (Electronic) IS - 1354-523X (Linking) VI - 19 IP - 7 DP - 2013 Oct TI - SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. PG - 721-7 LID - 10.1111/odi.12146 [doi] AB - OBJECTIVE: Approximately 40% of patients receiving conditioning chemotherapy prior to autologous hematopoietic stem cell transplants (aHSCT) develop severe oral mucositis (SOM). Aside from disabling pain, ulcerative lesions associated with SOM predispose to poor health and economic outcomes. Our objective was to develop a probabilistic graphical model in which a cluster of single-nucleotide polymorphisms (SNPs) derived from salivary DNA could be used as a tool to predict SOM risk. METHODS: Salivary DNA was extracted from 153 HSCT patients and applied to Illumina BeadChips. Using sequential data analysis, we filtered extraneous SNPs, selected loci, and identified a predictive SNP network for OM risk. We then tested the predictive validity of the network using SNP array outputs from an independent HSCT cohort. RESULTS: We identified an 82-SNP Bayesian network (BN) that was related to SOM risk with a 10-fold cross-validation accuracy of 99.3% and an area under the ROC curve of 99.7%. Using samples from a small independent patient cohort (n = 16), we demonstrated the network's predictive validity with an accuracy of 81.2% in the absence of any false positives. CONCLUSIONS: Our results suggest that SNP-based BN developed from saliva-sourced DNA can predict SOM risk in patients prior to aHSCT. CI - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Sonis, St AU - Sonis S AD - Inform Genomics, Boston, MA, USA. ssonis@partners.org FAU - Antin, Jh AU - Antin J FAU - Tedaldi, Mw AU - Tedaldi M FAU - Alterovitz, G AU - Alterovitz G LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130628 PL - Denmark TA - Oral Dis JT - Oral diseases JID - 9508565 RN - 9007-49-2 (DNA) SB - D MH - Area Under Curve MH - Autografts/*transplantation MH - Bayes Theorem MH - Cohort Studies MH - DNA/genetics MH - Forecasting MH - Genome-Wide Association Study MH - *Hematopoietic Stem Cell Transplantation MH - Humans MH - Middle Aged MH - Models, Statistical MH - *Neural Networks (Computer) MH - Polymorphism, Single Nucleotide/*genetics MH - Predictive Value of Tests MH - ROC Curve MH - Reproducibility of Results MH - Saliva/chemistry MH - Stomatitis/*etiology/genetics MH - Transplantation Conditioning/*adverse effects OTO - NOTNLM OT - SNP OT - oral mucositis OT - risk prediction OT - stem cell transplant EDAT- 2013/07/03 06:00 MHDA- 2015/04/14 06:00 CRDT- 2013/07/02 06:00 PHST- 2013/04/03 [received] PHST- 2013/05/13 [accepted] PHST- 2013/06/28 [aheadofprint] AID - 10.1111/odi.12146 [doi] PST - ppublish SO - Oral Dis. 2013 Oct;19(7):721-7. doi: 10.1111/odi.12146. Epub 2013 Jun 28. PMID- 23383751 OWN - NLM STAT- MEDLINE DA - 20140122 DCOM- 20150406 IS - 1471-6712 (Electronic) IS - 0283-9318 (Linking) VI - 28 IP - 1 DP - 2014 Mar TI - Reflections on the process of translation and cultural adaptation of an instrument to investigate taste and smell changes in adults with cancer. PG - 204-11 LID - 10.1111/scs.12026 [doi] AB - Taste and smell changes are common and distressing symptoms in patients with cancer, which may contribute to decreased nutritional intake leading to malnutrition and reduced quality of life. Evidence-based knowledge available to healthcare staff regarding dietary counselling of patients with taste and smell changes is lacking. To be able to develop advice to patients, these symptoms need to be characterised and assessed. The Taste and Smell Survey (TSS) is a 16-item questionnaire in English, which has been used in Canada to investigate self-perceived changes in taste and smell reported by patients with cancer. As no equivalent instrument exists in Swedish, we therefore translated the TSS. This article describes and discusses experiences of using a 5-step process for translation and cultural adaptation of the TSS. Each of the five steps was found to elicit different, essential information contributing to the enhancement of the translation and building further upon refinements of the previous steps. Using a structured, multistep approach to translation and cultural adaptation, we have produced a robust instrument to investigate taste and smell changes specifically adapted for use in the Swedish language and culture. CI - (c) 2013 The Authors Scandinavian Journal of Caring Sciences (c) 2013 Nordic College of Caring Science. FAU - McGreevy, Jenny AU - McGreevy J AD - Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden; R & D unit, Stockholms Sjukhem Foundation, Stockholm, Sweden. FAU - Orrevall, Ylva AU - Orrevall Y FAU - Belqaid, Kerstin AU - Belqaid K FAU - Bernhardson, Britt-Marie AU - Bernhardson BM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130206 PL - Sweden TA - Scand J Caring Sci JT - Scandinavian journal of caring sciences JID - 8804206 SB - N MH - *Adaptation, Physiological MH - Adult MH - *Cultural Characteristics MH - Data Collection MH - Humans MH - Neoplasms/*physiopathology MH - Quality of Life MH - Smell/*physiology MH - Taste/*physiology OTO - NOTNLM OT - cancer OT - cultural adaptation OT - instrument OT - taste and smell OT - translation EDAT- 2013/02/07 06:00 MHDA- 2015/04/07 06:00 CRDT- 2013/02/07 06:00 PHST- 2012/09/20 [received] PHST- 2012/12/06 [accepted] PHST- 2013/02/06 [aheadofprint] AID - 10.1111/scs.12026 [doi] PST - ppublish SO - Scand J Caring Sci. 2014 Mar;28(1):204-11. doi: 10.1111/scs.12026. Epub 2013 Feb 6. PMID- 23357884 OWN - NLM STAT- MEDLINE DA - 20131210 DCOM- 20150413 IS - 1538-9804 (Electronic) IS - 0162-220X (Linking) VI - 37 IP - 1 DP - 2014 Jan-Feb TI - Factors relating to quality of life after esophagectomy for cancer patients in Taiwan. PG - 4-13 LID - 10.1097/NCC.0b013e318277dc53 [doi] AB - BACKGROUND: Little is known regarding the short-term quality of life (QoL) and predictive factors for QoL after esophagectomy for cancer in Eastern countries. OBJECTIVE: The aims of this study were to assess QoL and symptoms within 1 and 6 months after surgery for esophageal cancer (EC) and to identify factors predictive of QoL within 6 months after esophagectomy in Taiwan. METHODS: A longitudinal, prospective design was used, where convenience samples of 99 patients who had undergone esophagectomy for cancer were recruited from 2 medical centers in northern Taiwan. All participants responded to a questionnaire with a QLQ-C30 (Quality of Life Questionnaire-Cancer) core and a QLQ-OES18 (esophageal module of the European Organization for Research and Treatment [EORTC] QLQ-C30) module in structured interviews at baseline and 1 and 6 months after surgery. RESULTS: The results showed significant decline in social function and global QoL; fatigue, insomnia, eating problems, reflux, and dry mouth were major problems within 6 months. Body mass index, body weight loss before surgery, activity performance status, and anastomosis site showed no significant association with the function and symptom aspect of QoL. Surgical complications, advanced cancer, neoadjuvant therapy before surgery, and tumor location other than at the EC junction had significant deleterious effects on several aspects of QoL. CONCLUSIONS: This study describes the demographics of EC and short-term changes in QoL and also the predictive impact factor for QoL after surgery for EC. IMPLICATIONS FOR PRACTICE: Knowledge of risk factors for poor postoperative QoL would be useful for health providers in detecting and prioritizing problems and treatment options in a busy clinical site. FAU - Chang, Yu-Ling AU - Chang YL AD - Author Affiliations: Department of Nursing (Ms Chang) and Departments of Thoracic and Cardiovascular Surgery (Drs Wu and Hsieh), Chang Gung Memorial Hospital at Linkou; Graduate Institute of Clinical Medical Sciences (Ms Chang) and School of Nursing (Dr Tsai), Chang Gung University; and Department of Nursing, Chang Gung Memorial Hospital at Keelung (Dr Tsai), Taiwan. FAU - Tsai, Yun-Fang AU - Tsai YF FAU - Wu, Yi-Cheng AU - Wu YC FAU - Hsieh, Ming-Ju AU - Hsieh MJ LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - United States TA - Cancer Nurs JT - Cancer nursing JID - 7805358 SB - IM SB - N MH - Adenocarcinoma/*nursing MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Squamous Cell/*nursing MH - Eating Disorders/nursing MH - Esophageal Neoplasms/*nursing MH - Esophagectomy/*nursing MH - Fatigue/nursing MH - Female MH - Gastroesophageal Reflux/nursing MH - Humans MH - Longitudinal Studies MH - Male MH - Middle Aged MH - Prospective Studies MH - *Quality of Life MH - Questionnaires MH - Risk Assessment MH - Risk Factors MH - Sleep Initiation and Maintenance Disorders/nursing MH - Taiwan EDAT- 2013/01/30 06:00 MHDA- 2015/04/14 06:00 CRDT- 2013/01/30 06:00 AID - 10.1097/NCC.0b013e318277dc53 [doi] PST - ppublish SO - Cancer Nurs. 2014 Jan-Feb;37(1):4-13. doi: 10.1097/NCC.0b013e318277dc53. PMID- 23279745 OWN - NLM STAT- MEDLINE DA - 20140527 DCOM- 20150409 IS - 1743-7563 (Electronic) IS - 1743-7555 (Linking) VI - 10 IP - 2 DP - 2014 Jun TI - Endoscopic ultrasound in restaging and predicting pathological response for advanced gastric cancer patients after neoadjuvant chemotherapy. PG - e28-32 LID - 10.1111/ajco.12045 [doi] AB - AIM: To evaluate the role of endoscopic ultrasound (EUS) in restaging and predicting response after neoadjuvant chemotherapy in patients with advanced gastric cancer. METHODS: In all, 48 advanced gastric cancer patients were recruited from June 2007 to December 2010 after providing their written, informed consent. All patients underwent an EUS before and after three cycles of neoadjuvant chemotherapy (FOLFOX 6), and then a radical resection was performed 3-4 weeks after chemotherapy. The results of EUS were compared to the pathological results of the resected specimens. RESULTS: After chemotherapy, the overall sensitivity of EUS for T classification was 63 percent (T2: 44%, T3: 68%, T4: 90%), and overstaging (31%) was more frequent than understaging (6%). The sensitivity and specificity of EUS for N classification were 56 and 50 percent, respectively (N0: without lymph node metastasis, N1: with lymph node metastasis), with 15 percent overstaged and 32% understaged. EUS revealed that T and/or N downstaging occurred in 46 percent (22/48) of patients after chemotherapy, most of whom had a favorable pathological response to the chemotherapy compared with other patients without T and/or N downstaging. No T or N upstaging was observed after neoadjuvant chemotherapy. CONCLUSIONS: The accuracy of restaging by EUS for T and N classification was not as good as pathological data for locally advanced gastric cancer patients after neoadjuvant chemotherapy. However, T and/or N downstaging confirmed by EUS correlated well with the degree of pathological response to chemotherapy. CI - (c) 2012 Wiley Publishing Asia Pty Ltd. FAU - Guo, Tao AU - Guo T AD - Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China. FAU - Yao, Fang AU - Yao F FAU - Yang, Ai-ming AU - Yang AM FAU - Li, Xiao-yi AU - Li XY FAU - Zhong, Ding-rong AU - Zhong DR FAU - Wu, Dong-sheng AU - Wu DS FAU - Wu, Xi AU - Wu X FAU - Lu, Xing-hua AU - Lu XH LA - eng PT - Journal Article DEP - 20121221 PL - Australia TA - Asia Pac J Clin Oncol JT - Asia-Pacific journal of clinical oncology JID - 101241430 RN - 0 (Organoplatinum Compounds) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - Folfox protocol SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage MH - Cohort Studies MH - Endosonography/methods MH - Female MH - Fluorouracil/administration & dosage MH - Humans MH - Leucovorin/administration & dosage MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Staging MH - Organoplatinum Compounds/administration & dosage MH - Stomach Neoplasms/*drug therapy/pathology/surgery/*ultrasonography OTO - NOTNLM OT - endoscopic ultrasound OT - gastric cancer OT - neoadjuvant chemotherapy OT - pathological response OT - restaging EDAT- 2013/01/03 06:00 MHDA- 2015/04/10 06:00 CRDT- 2013/01/03 06:00 PHST- 2012/09/30 [accepted] PHST- 2012/12/21 [aheadofprint] AID - 10.1111/ajco.12045 [doi] PST - ppublish SO - Asia Pac J Clin Oncol. 2014 Jun;10(2):e28-32. doi: 10.1111/ajco.12045. Epub 2012 Dec 21. PMID- 23088731 OWN - NLM STAT- MEDLINE DA - 20140721 DCOM- 20150410 IS - 1442-2050 (Electronic) IS - 1120-8694 (Linking) VI - 27 IP - 5 DP - 2014 Jul TI - Tag single nucleotide polymorphisms of alcohol-metabolizing enzymes modify the risk of upper aerodigestive tract cancers: HapMap database analysis. PG - 493-503 LID - 10.1111/j.1442-2050.2012.01437.x [doi] AB - Although alcohol is associated with higher upper aerodigestive tract (UADT) cancer risk, only a small fraction of alcoholics develop cancers. There is a lack of evidence proving the association of tag single nucleotide polymorphisms of alcohol-metabolizing enzymes with cancer risk. The aim of this study was to determine the association of these genetic polymorphisms with UADT cancer risk in a Chinese population. It was a hospital-based case-control candidate gene study. The databases of the International HapMap Project were searched for haplotype tag single nucleotide polymorphisms of the genes alcohol dehydrogenase (ADH)1B, ADH1C, and aldehyde dehydrogenase (ALDH)2. The genotyping was performed by the Sequenom MassARRAY system. Totally, 120 head and neck squamous cell carcinoma, 138 esophageal squamous cell carcinoma patients, and 276 age- and gender-matched subjects were enrolled between June 2008 and June 2010.Minor alleles of ADH1B (rs1229984) and ALDH2(rs671) were not only associated with the risk of UADT cancers (odds ratio [OR] [95% confidence interval, CI]: 3.53 [2.14-5.80] and 2.59 [1.79-3.75], respectively) but also potentiated the carcinogenic effects of alcohol (OR [95% CI]: 53.44 [25.21-113.29] and 70.08 [33.65-145.95], respectively). Similar effects were observed for head/neck and esophageal cancer subgroups. Multivariate logistic regression analysis identified four significant risk factors, including habitual use of cigarettes, alcohol, betel quid, and lower body mass index (P < 0.001). The haplotypes GAGC (OR 1.61, 95% CI 1.08-2.40, P = 0.018) and CCAATG (OR 1.69, 95% CI 1.24-2.30, P < 0.001) on chromosomes 4 and 12, respectively, were associated with higher cancer risk. These findings suggested that risk allele or haplotype carriers who consume alcohol and other carcinogens should be advised to undergo endoscopy screening. The information can be used to determine the degree of susceptibility of each subject and can be combined with other environmental factors, like carcinogen consumption, in the screening analysis. CI - (c) 2012 Copyright the Authors. Journal compilation (c) 2012, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus. FAU - Chung, C-S AU - Chung CS AD - Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan. FAU - Lee, Y-C AU - Lee YC FAU - Liou, J-M AU - Liou JM FAU - Wang, C-P AU - Wang CP FAU - Ko, J-Y AU - Ko JY FAU - Lee, J-M AU - Lee JM FAU - Wu, M-S AU - Wu MS FAU - Wang, H-P AU - Wang HP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20121022 PL - United States TA - Dis Esophagus JT - Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus / I.S.D.E JID - 8809160 RN - EC 1.1.1.1 (ADH1B protein, human) RN - EC 1.1.1.1 (ADH1C protein, human) RN - EC 1.1.1.1 (Alcohol Dehydrogenase) RN - EC 1.2.1.3 (ALDH2 protein, human) RN - EC 1.2.1.3 (Aldehyde Dehydrogenase) SB - IM MH - Alcohol Dehydrogenase/*genetics MH - Alcohol Drinking/adverse effects MH - Aldehyde Dehydrogenase/*genetics MH - Areca/adverse effects MH - Body Mass Index MH - Carcinoma, Squamous Cell/epidemiology/genetics MH - Case-Control Studies MH - Databases, Nucleic Acid MH - Ethnic Groups/genetics MH - Female MH - *Genetic Predisposition to Disease MH - Genetics, Population MH - Haplotypes MH - Head and Neck Neoplasms/epidemiology/*genetics MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - *Polymorphism, Single Nucleotide MH - Risk Factors MH - Smoking/adverse effects MH - Taiwan/epidemiology OTO - NOTNLM OT - alcohol-metabolizing enzyme OT - cancer risk OT - genetic polymorphism OT - tag single nucleotide polymorphism OT - upper aerodigestive tract cancer EDAT- 2012/10/24 06:00 MHDA- 2015/04/11 06:00 CRDT- 2012/10/24 06:00 PHST- 2012/10/22 [aheadofprint] AID - 10.1111/j.1442-2050.2012.01437.x [doi] PST - ppublish SO - Dis Esophagus. 2014 Jul;27(5):493-503. doi: 10.1111/j.1442-2050.2012.01437.x. Epub 2012 Oct 22. PMID- 23009284 OWN - NLM STAT- MEDLINE DA - 20140721 DCOM- 20150410 IS - 1442-2050 (Electronic) IS - 1120-8694 (Linking) VI - 27 IP - 5 DP - 2014 Jul TI - Factors associated with the presence of multiple Lugol-voiding lesions in patients with esophageal squamous-cell carcinoma. PG - 457-62 LID - 10.1111/j.1442-2050.2012.01429.x [doi] AB - Multicentric squamous dysplasia of the esophagus is characterized by multiple Lugol-voiding lesions (LVLs) on Lugol chromoendoscopy. Multiple LVLs are associated with a very high risk of multiple cancers arising in the esophagus as well as the head and neck. To gain insight into the pathogenesis of multiple LVLs of the esophageal mucosa, we studied risk factors for the development of such lesions in 76 patients who had a current or previous diagnosis of esophageal squamous cell carcinoma. All patients underwent Lugol chromoendoscopy of the esophageal mucosa. The history of tobacco and alcohol use was documented. Polymorphisms of the aldehyde dehydrogenase type 2 (ALDH2) gene were identified by polymerase chain reaction using sequence-specific primers. Clinical factors related to multiple LVLs were analyzed. All patients with multiple LVLs were drinkers. On univariate analysis, male sex (odds ratio [OR] 15, 95% confidence interval [CI] 1.84-122.45: P = 0.011), presence of the ALDH2-2 allele (OR 4.5, 95% CI 1.55-13.24: P = 0.006), and smoking index >/=1000 (OR 2.6, 95% CI 1.02-6.6: P = 0.045) were associated with multiple LVLs. On multivariate analysis, male sex (OR 10.02, 95% CI 1.13-88.44: P = 0.038) and presence of the ALDH2-2 allele (OR 4.56, 95% CI 1.4-14.82: P = 0.012) were associated with multiple LVLs. Among drinkers, a daily alcohol intake of >/=100 g pure ethanol with the ALDH2-2 allele (OR 17.5, 95% CI 1.97-155.59: P = 0.01) and a daily alcohol intake of <100 g pure ethanol with the ALDH2-2 allele (OR 8.85, 95% CI 1.68-46.69: P = 0.01) more strongly correlated with multiple LVLs than did a daily alcohol intake of <100 g pure ethanol without the ALDH2-2 allele, whereas a daily alcohol intake of >/=100 g pure ethanol without the ALDH2-2 allele (OR 4.0, 95% CI 0.54-29.81: P = 0.18) did not. In conclusion, male sex and the ALDH2-2 allele are associated with an increased risk for multiple LVLs of the esophageal mucosa in patients with esophageal squamous cell carcinoma. Among drinkers with the ALDH2-2 allele, the risk of multiple LVLs increased in parallel to the daily alcohol intake. CI - (c) 2012 Copyright the Authors. Journal compilation (c) 2012, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus. FAU - Katada, C AU - Katada C AD - Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Muto, M AU - Muto M FAU - Tanabe, S AU - Tanabe S FAU - Higuchi, K AU - Higuchi K FAU - Sasaki, T AU - Sasaki T FAU - Azuma, M AU - Azuma M FAU - Ishido, K AU - Ishido K FAU - Katada, N AU - Katada N FAU - Sakuramoto, S AU - Sakuramoto S FAU - Yamashita, K AU - Yamashita K FAU - Masaki, T AU - Masaki T FAU - Nakayama, M AU - Nakayama M FAU - Okamoto, M AU - Okamoto M FAU - Koizumi, W AU - Koizumi W LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120925 PL - United States TA - Dis Esophagus JT - Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus / I.S.D.E JID - 8809160 RN - 0 (Coloring Agents) RN - 0 (Iodides) RN - EC 1.2.1.3 (ALDH2 protein, human) RN - EC 1.2.1.3 (Aldehyde Dehydrogenase) RN - T66M6Y3KSA (Lugol's solution) SB - IM MH - Aged MH - Alcohol Drinking/adverse effects MH - Aldehyde Dehydrogenase/genetics MH - Alleles MH - Carcinoma, Squamous Cell/*pathology MH - Coloring Agents/diagnostic use MH - Esophageal Neoplasms/*pathology MH - Esophagoscopy MH - Female MH - Humans MH - Iodides/diagnostic use MH - Male MH - Multivariate Analysis MH - Polymorphism, Genetic MH - Prospective Studies MH - Respiratory Mucosa/*pathology MH - Risk Factors MH - Sex Factors OTO - NOTNLM OT - ALDH2 OT - esophageal cancer OT - multiple LVL EDAT- 2012/09/27 06:00 MHDA- 2015/04/11 06:00 CRDT- 2012/09/27 06:00 PHST- 2012/09/25 [aheadofprint] AID - 10.1111/j.1442-2050.2012.01429.x [doi] PST - ppublish SO - Dis Esophagus. 2014 Jul;27(5):457-62. doi: 10.1111/j.1442-2050.2012.01429.x. Epub 2012 Sep 25. PMID- 22981782 OWN - NLM STAT- MEDLINE DA - 20130715 DCOM- 20150419 IS - 1532-8198 (Electronic) IS - 1092-9134 (Linking) VI - 17 IP - 4 DP - 2013 Aug TI - Phosphaturic mesenchymal tumor: a report of 6 patients treated at a single institution and comparison with reported series. PG - 319-21 LID - 10.1016/j.anndiagpath.2012.06.005 [doi] LID - S1092-9134(12)00095-0 [pii] AB - Osteogenic osteomalacia (OO)-associated phosphaturic mesenchymal tumors (PMTs) might represent a single histopathologic paraneoplastic entity. These tumors are largely misunderstood, ignored, or unknown by pathologists and clinicians. To elucidate the characteristics of OO-associated PMTs, we retrospectively analyzed the clinicopathologic features of PMTs from 6 patients, with either known OO or features suggestive of PMT-mixed connective tissue variant, who were studied and managed at a single center during the period from 1993 to 2011. Histologically, the tumor showed proliferation of spindle cells with focal areas of matrix production that showed distinct calcification, ossification, and osteoid-like matrix. Two patients had no evidence of disease and normal biochemical values; the other 2 patients each had multiple surgeries for multiple recurrences. In conclusion, PMT is histologically a benign lesion, with the malignant and metastatic variant being extremely rare. Infiltration of surrounding tissue is a frequent feature that is best managed with complete surgical removal of all involved tissue, which dramatically resolves the tumor-associated osteomalacia. CI - Published by Elsevier Inc. FAU - Fatani, Hanadi A AU - Fatani HA AD - Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. FAU - Sunbuli, Mohamad AU - Sunbuli M FAU - Lai, Stephen Y AU - Lai SY FAU - Bell, Diana AU - Bell D LA - eng PT - Journal Article DEP - 20120913 PL - United States TA - Ann Diagn Pathol JT - Annals of diagnostic pathology JID - 9800503 SB - IM MH - Aged MH - Aged, 80 and over MH - Bone Neoplasms/*pathology/radiography/surgery MH - Diagnosis, Differential MH - Female MH - Humans MH - Hypophosphatemia, Familial MH - Male MH - Mesenchymoma/*pathology/radiography/surgery MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Neoplasms, Connective and Soft Tissue/*pathology/radiography/surgery MH - Osteomalacia/*complications/pathology/surgery MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - Osteogenic osteomalacia OT - Paraneoplastic OT - Phosphaturic mesenchymal tumor EDAT- 2012/09/18 06:00 MHDA- 2015/04/22 06:00 CRDT- 2012/09/18 06:00 PHST- 2012/06/03 [received] PHST- 2012/06/29 [revised] PHST- 2012/06/29 [accepted] PHST- 2012/09/13 [aheadofprint] AID - S1092-9134(12)00095-0 [pii] AID - 10.1016/j.anndiagpath.2012.06.005 [doi] PST - ppublish SO - Ann Diagn Pathol. 2013 Aug;17(4):319-21. doi: 10.1016/j.anndiagpath.2012.06.005. Epub 2012 Sep 13.